U.S. patent application number 11/899343 was filed with the patent office on 2009-12-31 for novel human protein kinase, phosphatase, and protease family members and uses thereof.
This patent application is currently assigned to Millennium Pharmaceuticals Inc.. Invention is credited to Rory A. J. Curtis, Rosana Kapeller-Libermann, Rachel E. Meyers, Peter J. Olandt, Nadine Weich, Mark Williamson.
Application Number | 20090324608 11/899343 |
Document ID | / |
Family ID | 35610109 |
Filed Date | 2009-12-31 |
United States Patent
Application |
20090324608 |
Kind Code |
A1 |
Meyers; Rachel E. ; et
al. |
December 31, 2009 |
Novel human protein kinase, phosphatase, and protease family
members and uses thereof
Abstract
The invention provides isolated nucleic acids molecules,
designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436
nucleic acid molecules, which encode novel human protein kinase
family members, serine/threonine protein kinase family members,
serine/threonine phosphatase family members, prolyl oligopeptidase
family members, trypsin family members, trypsin serine protease
family members, and ubiquitin protease family members. The
invention also provides antisense nucleic acid molecules,
recombinant expression vectors containing 53070, 15985, 26583,
21953, m32404, 14089, or 23436 nucleic acid molecules, host cells
into which the expression vectors have been introduced, and
nonhuman transgenic animals in which a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 gene has been introduced or disrupted. The
invention still further provides isolated 53070, 15985, 26583,
21953, m32404, 14089, or 23436 proteins, fusion proteins, antigenic
peptides and anti-53070, 15985, 26583, 21953, m32404, 14089, or
23436 antibodies. Diagnostic methods utilizing compositions of the
invention are also provided.
Inventors: |
Meyers; Rachel E.; (Newton,
MA) ; Olandt; Peter J.; (Newton, MA) ;
Kapeller-Libermann; Rosana; (Chestnut Hill, MA) ;
Curtis; Rory A. J.; (Framingham, MA) ; Williamson;
Mark; (Saugus, MA) ; Weich; Nadine;
(Brookline, MA) |
Correspondence
Address: |
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
CAMBRIDGE
MA
02139
US
|
Assignee: |
Millennium Pharmaceuticals
Inc.
|
Family ID: |
35610109 |
Appl. No.: |
11/899343 |
Filed: |
September 5, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11636948 |
Dec 11, 2006 |
7282360 |
|
|
11899343 |
|
|
|
|
11151601 |
Jun 13, 2005 |
7198930 |
|
|
11636948 |
|
|
|
|
10170789 |
Jun 13, 2002 |
7070947 |
|
|
11151601 |
|
|
|
|
09797039 |
Feb 28, 2001 |
6730491 |
|
|
10170789 |
|
|
|
|
09882166 |
Jun 15, 2001 |
|
|
|
10170789 |
|
|
|
|
09934406 |
Aug 21, 2001 |
|
|
|
10170789 |
|
|
|
|
09861801 |
May 21, 2001 |
|
|
|
10170789 |
|
|
|
|
09801267 |
Mar 6, 2001 |
|
|
|
10170789 |
|
|
|
|
09829671 |
Apr 10, 2001 |
|
|
|
10170789 |
|
|
|
|
09961721 |
Sep 24, 2001 |
|
|
|
10170789 |
|
|
|
|
10045367 |
Nov 7, 2001 |
|
|
|
10170789 |
|
|
|
|
09801275 |
Mar 6, 2001 |
|
|
|
10170789 |
|
|
|
|
60186061 |
Feb 29, 2000 |
|
|
|
60212078 |
Jun 15, 2000 |
|
|
|
60226740 |
Aug 21, 2000 |
|
|
|
60205508 |
May 19, 2000 |
|
|
|
60187454 |
Mar 7, 2000 |
|
|
|
60197508 |
Apr 18, 2000 |
|
|
|
60235023 |
Sep 25, 2000 |
|
|
|
60246561 |
Nov 7, 2000 |
|
|
|
60187420 |
Mar 7, 2000 |
|
|
|
Current U.S.
Class: |
514/1.1 ;
435/184; 435/194; 435/212; 435/213; 435/320.1; 435/325; 435/375;
435/69.1; 514/1.2; 514/7.5; 530/387.9; 536/23.2 |
Current CPC
Class: |
C07K 16/40 20130101;
C12N 9/6427 20130101; C12Q 1/6886 20130101; C12N 9/1205 20130101;
C12N 9/16 20130101; C12Q 2600/106 20130101; A61K 38/00 20130101;
C12N 9/6472 20130101; C12N 9/6424 20130101; C12Q 2600/136 20130101;
C12Q 2600/156 20130101; C12N 9/48 20130101; C12N 9/12 20130101 |
Class at
Publication: |
424/158.1 ;
536/23.2; 435/320.1; 435/325; 435/194; 435/212; 435/213; 530/387.9;
435/69.1; 435/184; 435/375; 514/2; 435/6 |
International
Class: |
C12N 15/52 20060101
C12N015/52; C12N 15/85 20060101 C12N015/85; C12N 5/10 20060101
C12N005/10; C12N 9/12 20060101 C12N009/12; C12N 9/48 20060101
C12N009/48; C12N 9/76 20060101 C12N009/76; C07K 16/40 20060101
C07K016/40; C12P 21/02 20060101 C12P021/02; C12N 9/99 20060101
C12N009/99; A61K 38/02 20060101 A61K038/02; A61K 39/395 20060101
A61K039/395; C12Q 1/68 20060101 C12Q001/68 |
Claims
1. An isolated nucleic acid molecule selected from the group
consisting of: a) a nucleic acid comprising the nucleotide sequence
of SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42;
and b) a nucleic acid molecule which encodes a polypeptide
comprising the amino acid sequence of SEQ ID NO:2, 8, 15, 20, 25,
34, or 41.
2. The nucleic acid molecule of claim 1, further comprising vector
nucleic acid sequences.
3. The nucleic acid molecule of claim 1, further comprising nucleic
acid sequences encoding a heterologous polypeptide.
4. A host cell which contains the nucleic acid molecule of claim
1.
5. An isolated polypeptide comprising the amino acid sequence of
SEQ ID NO:2, 8, 15, 20, 25, 34, or 41.
6. The polypeptide of claim 5 further comprising heterologous amino
acid sequences.
7. An antibody or antigen-binding fragment thereof that selectively
binds to a polypeptide of claim 5.
8. A method for producing a polypeptide comprising the amino acid
sequence of SEQ ID NO:2, 8, 15, 20, 25, 34, or 41, the method
comprising culturing the host cell of claim 4 under conditions in
which the nucleic acid molecule is expressed.
9. A method for detecting the presence of a polypeptide of claim 5
in a sample, comprising: a) contacting the sample with a compound
which selectively binds to the polypeptide; and b) determining
whether the compound binds to the polypeptide in the sample.
10. The method of claim 9, wherein the compound which binds to the
polypeptide is an antibody.
11. A kit comprising a compound which selectively binds to a
polypeptide of claim 5 and instructions for use.
12. A method for detecting the presence of a nucleic acid molecule
of claim 1 in a sample, comprising the steps of: a) contacting the
sample with a nucleic acid probe or primer which selectively
hybridizes to the nucleic acid molecule; and b) determining whether
the nucleic acid probe or primer binds to a nucleic acid molecule
in the sample.
13. The method of claim 12, wherein the sample comprises mRNA
molecules and is contacted with a nucleic acid probe.
14. A kit comprising a compound which selectively hybridizes to a
nucleic acid molecule of claim 1 and instructions for use.
15. A method for identifying a compound which binds to a
polypeptide of claim 5 comprising the steps of: a) contacting a
polypeptide, or a cell expressing a polypeptide of claim 5 with a
test compound; and b) determining whether the polypeptide binds to
the test compound.
16. A method for modulating the activity of a polypeptide of claim
5, comprising contacting a polypeptide or a cell expressing a
polypeptide of claim 5 with a compound which binds to the
polypeptide in a sufficient concentration to modulate the activity
of the polypeptide.
17. A method of inhibiting aberrant activity of a 53070-, 15985-,
26583-, 21953-, m32404-, 14089-, or 23436-expressing cell,
comprising contacting a 53070-, 15985-, 26583-, 21953-, m32404-,
14089-, or 23436-expressing cell with a compound that modulates the
activity or expression of a polypeptide of claim 5, in an amount
which is effective to reduce or inhibit the aberrant activity of
the cell.
18. The method of claim 17, wherein the compound is selected from
the group consisting of a peptide, a phosphopeptide, a small
organic molecule, and an antibody.
19. A method of treating or preventing a disorder characterized by
aberrant activity of a 53070-, 15985-, 26583-, 21953-, m32404-,
14089-, or 23436-expressing cell, in a subject, comprising:
administering to the subject an effective amount of a compound that
modulates the activity or expression of a nucleic acid molecule of
claim 1, such that the aberrant activity of the 53070-, 15985-,
26583-, 21953-, m32404-, 14089-, or 23436-expressing cell is
reduced or inhibited.
Description
RELATED APPLICATIONS
[0001] The present application is a divisional of U.S. application
Ser. No. 11/636,948 (pending), which is a divisional of U.S.
application Ser. No. 11/151,601, filed Jun. 13, 2005 (now U.S. Pat.
No. 7,198,930), which is a divisional of U.S. application Ser. No.
10/170,789, filed Jun. 13, 2002, now U.S. Pat. No. 7,070,947, which
is a continuation-in-part of U.S. application Ser. No. 09/797,039,
filed Feb. 28, 2001, now U.S. Pat. No. 6,730,491, which claims the
benefit of U.S. Provisional Application Ser. No. 60/186,061, filed
Feb. 29, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/882,166, filed Jun. 15, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/212,078, filed
Jun. 15, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/934,406, filed Aug. 21, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/226,740, filed
Aug. 21, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/861,801, filed May 21, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/205,508, filed
May 19, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/801,267, filed Mar. 6, 2001, (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/187,454, filed
Mar. 7, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/829,671, filed Apr. 10, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/197,508, filed
Apr. 18, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/961,721, filed Sep. 24, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/235,023, filed
Sep. 25, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
10/045,367, filed Nov. 7, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/246,561, filed
Nov. 7, 2000 (abandoned). U.S. application Ser. No. 10/170,789 is
also a continuation-in-part of U.S. application Ser. No.
09/801,275, filed Mar. 6, 2001 (abandoned), which claims the
benefit of U.S. Provisional Application Ser. No. 60/187,420, filed
Mar. 7, 2000 (abandoned), the contents of each of which are
incorporated herein by reference.
[0002] The contents of the Sequence Listing are submitted herewith
on compact disc in duplicate. Each duplicate disc has a copy of the
file "sequence listing.txt" which is incorporated herein by this
reference. This file is 140 kilobytes and was created on Jun. 8,
2005. The compact disc copies were created on Aug. 31, 2007.
BACKGROUND OF THE INVENTION
[0003] The invention provides isolated polypeptide molecules and
nucleic acid molecules encoded the polypeptide molecules,
designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436
molecules, which encode novel kinase family molecules, phosphatase
family members, and protease family members, including prolyl
oligopeptidases, serine proteases, and ubiquitin carboxy terminal
hydrolases.
SUMMARY OF THE INVENTION
[0004] The present invention is based, in part, on the discovery of
novel protein kinase, serine/threonine protein kinase,
serine/threonine phosphatase, prolyl oligopeptidase, trypsin,
serine protease, and ubiquitin carboxy-terminal hydrolase family
members, referred to herein as "53070, 15985, 26583, 21953, m32404,
14089, and 23436". The nucleotide sequences of cDNAs encoding
53070, 15985, 26583, 21953, m32404, 14089, and 23436 are recited in
SEQ ID NO: 1, 7, 14, 19, 24, 33, and 40, respectively, and the
amino acid sequences of 53070, 15985, 26583, 21953, m32404, 14089,
and 23436 polypeptides are recited in SEQ ID NO:2, 8, 15, 20, 25,
34, and 41, respectively. In addition, the nucleotide sequences of
the coding regions are recited in SEQ ID NO: 3, 9, 16, 21, 26, 35,
and 42, respectively.
[0005] Accordingly, in one aspect, the invention features a nucleic
acid molecule that encodes a 53070 protein or polypeptide, e.g., a
biologically active portion of the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein. In a preferred embodiment the
isolated nucleic acid molecule encodes a polypeptide having the
amino acid sequence of SEQ ID NO:2, 8, 15, 20, 25, 34, and 41. In
other embodiments, the invention provides isolated 53070, 15985,
26583, 21953, m32404, 14089, or 23436 nucleic acid molecules having
the nucleotide sequence shown in SEQ ID NO: 1, 3, 7, 9, 14, 16, 19,
21, 24, 26, 33, 35, 40, or 42. In still other embodiments, the
invention provides nucleic acid molecules that are substantially
identical (e.g., naturally occurring allelic variants) to the
nucleotide sequence shown in SEQ ID NO: 1, 3, 7, 9, 14, 16, 19, 21,
24, 26, 33, 35, 40, or 42. In other embodiments, the invention
provides a nucleic acid molecule which hybridizes under a
stringency condition described herein to a nucleic acid molecule
comprising the nucleotide sequence of SEQ ID NO:1, 3, 7, 9, 14, 16,
19, 21, 24, 26, 33, 35, 40, or 42, wherein the nucleic acid encodes
a full length 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein or an active fragment thereof.
[0006] In a related aspect, the invention further provides nucleic
acid constructs that include a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 nucleic acid molecule described herein. In certain
embodiments, the nucleic acid molecules of the invention are
operatively linked to native or heterologous regulatory sequences.
Also included, are vectors and host cells containing the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules
of the invention e.g., vectors and host cells suitable for
producing 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid molecules and polypeptides.
[0007] In another related aspect, the invention provides nucleic
acid fragments suitable as primers or hybridization probes for the
detection of 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-encoding nucleic acids.
[0008] In still another related aspect, isolated nucleic acid
molecules that are antisense to a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 encoding nucleic acid molecule are
provided.
[0009] In another aspect, the invention features, 53070, 15985,
26583, 21953, m32404, 14089, and 23436 polypeptides, and
biologically active or antigenic fragments thereof that are useful,
e.g., as reagents or targets in assays applicable to treatment and
diagnosis of 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-mediated or -related disorders. In another embodiment, the
invention provides 53070, 15985, 26583, 21953, m32404, 14089, and
23436 polypeptides having a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity, respectively. Preferred polypeptides are
53070 proteins including at least one protein kinase domain, e.g.,
a serine/threonine kinase domain, and, preferably, having a 53070
activity, e.g., a 53070 activity as described herein.
[0010] Preferred polypeptides are 15985 proteins including at least
one protein kinase domain and at least one, preferably two
doublecortin repeats, and, preferably, having a 15985 activity,
e.g., a 15985 activity as described herein.
[0011] Preferred polypeptides are 26583 proteins including at least
one phosphatase catalytic domain, and, preferably, having a 26583
activity, e.g., a 26583 activity as described herein.
[0012] Preferred polypeptides are 21953 proteins including at least
one prolyl oligopeptidase domain, and, preferably, having a 21953
activity, e.g., a 21953 activity as described herein.
[0013] Preferred polypeptides are m32404 proteins including at
least one trypsin domain, e.g., polypeptides including m32404 amino
acids from about 35 to 268 or polypeptides including m32404 amino
acids from about 300-520, and, preferably, having an m32404
activity, e.g., an m32404 activity as described herein.
[0014] Preferred polypeptides are 14089 proteins including at least
one trypsin domain, and, preferably, having a 14089 activity, e.g.,
a 14089 activity as described herein.
[0015] Preferred polypeptides are 23436 polypeptides including at
least one ubiquitin carboxy-terminal hydrolase domain, and,
preferably, having a 23436 activity, e.g., a 23436
de-ubiquitinating activity as described herein.
[0016] In other embodiments, the invention provides 53070, 15985,
26583, 21953, m32404, 14089, and 23436 polypeptides, e.g., a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 polypeptide having the
amino acid sequence shown in SEQ ID NO:2, 8, 15, 20, 25, 34, or 41
an amino acid sequence that is substantially identical to the amino
acid sequence shown in SEQ ID NO:2, 8, 15, 20, 25, 34, and 41; or
an amino acid sequence encoded by a nucleic acid molecule having a
nucleotide sequence which hybridizes under a stringency condition
described herein to a nucleic acid molecule comprising the
nucleotide sequence of SEQ ID NO: 1, 3, 7, 9, 14, 16, 19, 21, 24,
26, 33, 35, 40, or 42, wherein the nucleic acid encodes a full
length 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
or an active fragment thereof.
[0017] In a related aspect, the invention further provides nucleic
acid constructs which include a 15985, 21953, m32404, or 23436
nucleic acid molecule described herein.
[0018] In a related aspect, the invention provides 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptides or fragments
operatively linked to non-53070, 15985, 26583, 21953, m32404,
14089, or 23436 polypeptides to form fusion proteins.
[0019] In another aspect, the invention provides a method of
evaluating a sample. The method includes: providing a sample;
detecting a 21953 polypeptide or nucleic acid in the sample; and,
optionally, comparing the level of expressed 21953 molecules to a
reference sample. For example, an increased level of 21953
molecules can be an indication that the sample includes cells
transiting from the G1 cell cycle phase to S phase. In other
examples, the level of 21953 molecules can be an indication that a
sample includes a proliferating cell, e.g., a proliferating lung,
breast, ovary, or colon cell; or a heart cell, a prostate cell, a
vascular cell (e.g., a smooth muscle or an endothelial cell), or a
brain cell.
[0020] In another aspect, the invention features antibodies and
antigen-binding fragments thereof, that react with, or more
preferably specifically bind 53070, 15985, 26583, 21953, m32404,
14089, or 23436 polypeptides or fragments thereof, e.g., the
protein kinase domain of a 53070 polypeptide, the C-terminal
non-kinase domain of a 53070 polypeptide, an epitope that includes
a phosphorylated amino acid residue, an extracellular domain of a
15985 polypeptide, trypsin domain of an m32404 polypeptide, a
trypsin domain of a 14089 polypeptide, or ubiquitin
carboxy-terminal hydrolase domain. In one embodiment, the
antibodies or antigen-binding fragment thereof competitively
inhibit the binding of a second antibody to a 53070 or 15985
polypeptide or a fragment thereof, e.g., the protein kinase domain
of 53070, the C-terminal non-kinase domain of 53070, an epitope
that includes a phosphorylated amino acid residue, or an
extracellular domain of a 15985 polypeptide.
[0021] In another aspect, the invention provides methods of
screening for compounds that modulate the expression or activity of
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptides or nucleic acids. In a preferred embodiment, a
screened compound alters the de-ubiquitinating activity of the
23436 polypeptide.
[0022] In still another aspect, the invention provides a method for
modulating 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide or nucleic acid expression or activity, e.g. using the
screened compounds. In certain embodiments, the methods involve
treatment of conditions related to aberrant activity or expression
of the 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptides or nucleic acids, such as conditions involving
aberrant or deficient cellular proliferation or differentiation;
cell migration; conditions involving cholesterol biosynthesis,
mitochondrial dysfunction, or aberrant cellular proliferation of a
26583 expressing cell, e.g., a lung cell, a breast cell, a colon
cell, a liver cell, or a brain cell; e.g., a cancer (e.g. a cancer
of the lung, breast, ovary, prostate, or colon), or conditions or
disorders of the cardiovascular (including vascular, e.g., a smooth
muscle or an endothelial cell), neuronal, or reproductive (e.g.,
prostatic) systems; as well as conditions involving the immune
response, and the blood clotting system, or tumor invasion or
metastasis; conditions involving aberrant or deficient proteolytic
cleavage; or proliferation or cellular differentiation of a
hematopoietic cell (e.g., a hematopoietic or an erythroid
disorder).
[0023] In one embodiment, a method for inhibiting abnormal
phosphorylation in a cell or a subject is provided. In other
embodiments, a method for enhancing phosphorylation in a cell or a
subject is provided. The method includes contacting a cell, or
administering to a subject, a modulator of 53070 polypeptide or
nucleic acid activity or expression, to thereby modulate, e.g.,
inhibit or enhance, the phosphorylation state in the cell or
subject.
[0024] The invention also provides assays for determining the
activity of or the presence or absence of 15985 polypeptides or
nucleic acid molecules in a biological sample, including for
disease diagnosis.
[0025] In yet another aspect, the invention provides methods for
inhibiting the proliferation or inducing the killing, of a
15985-expressing cell, e.g., a hyperproliferative 15985-expressing
cell. The method includes contacting the cell with an agent, e.g.,
a compound, (e.g., a compound identified using the methods
described herein) that modulates the activity, or expression, of
the 15985 polypeptide or nucleic acid. In a preferred embodiment,
the contacting step is effective in vitro or ex vivo. In other
embodiments, the contacting step is effected in vivo, e.g., in a
subject (e.g., a mammal, e.g., a human), as part of a therapeutic
or prophylactic protocol. In a preferred embodiment, the cell is a
hyperproliferative cell, e.g., a cell found in a solid tumor, a
soft tissue tumor, or a metastatic lesion. In other embodiments,
the hyperproliferative cell is an ovarian or a lung tumor cell.
[0026] In still another aspect, the invention features a method of
modulating (e.g., enhancing or inhibiting) the proliferation,
survival, and/or differentiation of a cell, e.g., a
26583-expressing cell, e.g., a lung cell, a breast cell, a colon
cell, a liver cell, or a brain cell. The method includes contacting
the cell with an agent that modulates the activity or expression of
a 26583 polypeptide or nucleic acid, in an amount effective to
modulate the proliferation and/or differentiation of the cell.
[0027] In a preferred embodiment, the 26583 polypeptide has an
amino acid sequence identical to, or substantially identical to,
SEQ ID NO:15. In other embodiments, the 26583 polypeptide is a
fragment of at least 15, 20, 50, 100, 150, 200, 213, 250, or more
contiguous amino acids of SEQ ID NO:15. In a preferred embodiment,
the 26583 polypeptide is a fragment of at least 213 contiguous
amino acids of SEQ ID NO:15.
[0028] In a preferred embodiment, the 26583 nucleic acid has a
nucleotide sequence identical to, or substantially identical to,
SEQ ID NO:14 or 16. In other embodiments, the 26583 nucleic acid is
a fragment of at least 50, 100, 150, 200, 250, 300, 350, 400, 450,
500, or more contiguous nucleotides of SEQ ID NO:14 or 16.
[0029] In a preferred embodiment, the agent modulates (e.g.,
increases or decreases) 26583 protein phosphatase activity, e.g.,
serine/threonine phosphatase activity.
[0030] In a preferred embodiment, the agent modulates (e.g.,
increases or decreases) expression of the 26583 nucleic acid by,
e.g., modulating transcription, mRNA stability, etc.
[0031] In a preferred embodiment, the cell, e.g., the
26583-expressing cell, is a lung cell, a breast cell, a colon cell,
a liver cell, or a brain cell, e.g., a neuron or glial cell.
[0032] In a preferred embodiment, the cell, e.g., the
26583-expressing cell, is a tumor cell, e.g., a lung, breast,
colon, liver, or brain tumor cell.
[0033] In a preferred embodiment, the cell, e.g., the
26583-expressing cell, is further contacted with a protein, e.g., a
cytokine or a hormone. Exemplary proteins include, but are not
limited to, G-CSF, GM-CSF, stem cell factor, interleukin-3 (IL-3),
IL-4, Flt-3 ligand, thrombopoietin, and erythropoietin. The protein
contacting step can occur before, at the same time, or after the
agent is contacted. The protein contacting step can be effected in
vitro or ex vivo. For example, the cell, e.g., the 26583-expressing
cell is obtained from a subject, e.g., a patient, and contacted
with the protein ex vivo. The treated cell can be re-introduced
into the subject. Alternatively, the protein contacting step can
occur in vivo.
[0034] In a preferred embodiment, the agent and the
26583-polypeptide or nucleic acid are contacted in vitro or ex
vivo.
[0035] In a preferred embodiment, the contacting step is effected
in vivo in a subject, e.g., as part of a therapeutic or
prophylactic protocol. Preferably, the subject is a human, e.g., a
patient with a metabolic disorder, e.g., a mitochondrial related
disorder or a cholesterol biosynthesis related disorder, or a
patient with a cell proliferation or differentiation disorder,
e.g., a tumor. For example, the subject can be a cancer patient,
e.g., a patient with a lung, breast, colon, liver, or brain tumor.
The subject can also be a patient with diabetes mellitus or a
neurodegenerative disorder (e.g., Parkinson's, Huntington's, or
Alzheimer's disease). In other embodiments, the subject is a
non-human animal, e.g., an experimental animal.
[0036] The contacting step(s) can be repeated.
[0037] In a preferred embodiment, the agent decreases the
proliferation and/or enhances the differentiation of the cell,
e.g., the 26583-expressing cell, e.g., the lung, breast, colon,
liver, or brain cell. Such agents can be used to treat or prevent
cancers, e.g., liver, breast, brain, colon, or lung carcinomas.
[0038] In yet another aspect, the invention features a method of
treating or preventing a disorder, e.g., a metabolic disorder,
e.g., a mitochondrial related disorder or a cholesterol
biosynthesis related disorder; or a cellular proliferation and/or
differentiation disorder, in a subject. The method includes
administering to the subject an effective amount of an agent that
modulates the activity or expression of a 26583 polypeptide or
nucleic acid such that the disorder is ameliorated or
prevented.
[0039] In a preferred embodiment, the 26583 polypeptide has an
amino acid sequence identical to, or substantially identical to,
SEQ ID NO:15. In other embodiments, the 26583 polypeptide is a
fragment of at least 15, 20, 50, 100, 150, or more contiguous amino
acids of SEQ ID NO:15. In a preferred embodiment, the 26583
polypeptide is a fragment of at least 213 contiguous amino acids of
SEQ ID NO:15.
[0040] In a preferred embodiment, the 26583 nucleic acid has a
nucleotide sequence identical to, or substantially identical to,
SEQ ID NO:14 or 16. In other embodiments, the 26583 nucleic acid is
a fragment of at least 50, 100, 150, 200, 250, 300, 350, 400, 450,
500, or more contiguous nucleotides of SEQ ID NO:14 or 16.
[0041] In a preferred embodiment, the agent modulates (e.g.,
increases or decreases) protein phosphatase activity.
[0042] In a preferred embodiment, the agent modulates (e.g.,
increases or decreases) expression of the 26583 nucleic acid by,
e.g., modulating transcription, mRNA stability, etc.
[0043] In preferred embodiments, the agent is a peptide, a
phosphopeptide, a small molecule, e.g., a member of a combinatorial
library, or an antibody, or any combination thereof. The antibody
can be conjugated to a therapeutic moiety selected from the group
consisting of a cytotoxin, a cytotoxic agent and a radioactive
metal ion.
[0044] In additional preferred embodiments, the agent is an
antisense, a ribozyme, or a triple helix molecule, or an 26583
nucleic acid, or any combination thereof.
[0045] In a preferred embodiment, the agent is administered in
combination with a cytotoxic agent.
[0046] In a preferred embodiment, the subject is a human, e.g., a
patient with a metabolic disorder, e.g., a mitochondrial related
disorder or a cholesterol biosynthesis related disorder, e.g.,
hypo- or hypercholesterolemia, diabetes mellitus, or a
neurodegenerative disorder (e.g., Parkinson's, Huntington's, or
Alzheimer's disease). The subject can also be a patient with a cell
proliferation or differentiation disorder, e.g., a tumor, e.g., a
patient with a lung, breast, colon, liver, or brain tumor. In other
embodiments, the subject is a non-human animal, e.g., an
experimental animal.
[0047] In a preferred embodiment, the agent decreases the
proliferation and/or enhances the differentiation of the cell,
e.g., the 26583-expressing cell, e.g., the lung, breast, colon,
liver, or brain cell. Such agents can be used to treat or prevent
cancers, e.g., liver, breast, brain, colon, or lung carcinomas.
[0048] In a preferred embodiment, the disorder is a metabolic
disorder, e.g., a cholesterol synthesis disorder, e.g., hypo- or
hypercholesterolemia; or a mitochondrial related disorder, e.g.,
diabetes mellitus, or Parkinson's, Huntington's, or Alzheimer's
disease.
[0049] In a preferred embodiment, the disorder is a cancer, e.g., a
lung, breast, colon, liver, or brain cancer.
[0050] In a preferred embodiment, the method further includes
administering an effective amount of a protein, e.g., a cytokine or
a hormone, to the subject. Exemplary proteins include, but are not
limited to, G-CSF, GM-CSF, stem cell factor, interleukin-3 (IL-3),
IL-4, Flt-3 ligand, thrombopoietin, and erythropoietin. The protein
can be administered before, at the same time or after,
administration of the agent.
[0051] The administration of the agent and/or protein can be
repeated.
[0052] In still another aspect, the invention features a method for
evaluating the efficacy of a treatment of a disorder, in a subject.
The method includes treating a subject with a protocol under
evaluation; assessing the expression of a 26583 nucleic acid or
26583 polypeptide, such that a change in the level of 26583 nucleic
acid or 26583 polypeptide after treatment, relative to the level
before treatment, is indicative of the efficacy of the treatment of
the disorder.
[0053] In a preferred embodiment, the disorder is a metabolic
disorder, e.g., a cholesterol synthesis disorder, e.g., hypo- or
hypercholesterolemia; or a mitochondrial related disorder, e.g.,
diabetes mellitus, or Parkinson's, Huntington's, or Alzheimer's
disease. In a preferred embodiment, the disorder is a cancer, e.g.,
a lung, breast, colon, liver, or brain cancer. In a preferred
embodiment, the subject is a human. In a preferred embodiment, the
subject is an experimental animal, e.g., an animal model for a
metabolic disorder or cancer.
[0054] In a preferred embodiment, the method can further include
treating the subject with a protein, e.g., a cytokine or a hormone.
Exemplary proteins include, but are not limited to, G-CSF, GM-CSF,
stem cell factor, interleukin-3 (IL-3), IL-4, Flt-3 ligand,
thrombopoietin, and erythropoietin.
[0055] The invention also features a method of diagnosing a
disorder, e.g., a metabolic disorder or a cell
proliferation/differentiation disorder, e.g., cancer, in a subject.
The method includes evaluating the expression or activity of a
26583 nucleic acid or a 26583 polypeptide, such that, a difference
in the level of 26583 nucleic acid or 26583 polypeptide relative to
a normal subject or a cohort of normal subjects is indicative of
the disorder.
[0056] In a preferred embodiment, the evaluating step occurs in
vivo. For example, by administering to the subject a detectably
labeled agent that interacts with the 26583 nucleic acid or
polypeptide, such that a signal is generated relative to the level
of activity or expression of the 26583 nucleic acid or
polypeptide.
[0057] In a preferred embodiment, the disorder is a metabolic
disorder, e.g., a cholesterol synthesis disorder, e.g., hypo- or
hypercholesterolemia; or a mitochondrial related disorder, e.g.,
diabetes mellitus, or Parkinson's, Huntington's, or Alzheimer's
disease. In a preferred embodiment, the disorder is a cancer, e.g.,
a lung, breast, colon, liver, or brain cancer.
[0058] The invention also provides assays for determining the
activity of or the presence or absence of 26583 polypeptides or
nucleic acid molecules in a biological sample, including for
disease diagnosis.
[0059] In further aspect, the invention provides assays for
determining the presence or absence of a genetic alteration in a
26583 polypeptide or nucleic acid molecule, including for disease
diagnosis.
[0060] In yet another aspect, the invention features a method for
identifying an agent, e.g., a compound, which modulates the
activity of a 26583 polypeptide, e.g., a 26583 polypeptide as
described herein, or the expression of a 26583 nucleic acid, e.g.,
a 26583 nucleic acid as described herein, including contacting the
26583 polypeptide or nucleic acid with a test agent (e.g., a test
compound); and determining the effect of the test compound on the
activity of the polypeptide or nucleic acid to thereby identify a
compound which modulates the activity of the polypeptide or nucleic
acid.
[0061] In a preferred embodiment, the activity of the 26583
polypeptide is a protein phosphatase activity.
[0062] In a preferred embodiment, the activity of the 26583
polypeptide is proliferation, differentiation, and/or survival of a
cell, e.g., a 26583-expressing cell, e.g., a lung, breast, colon,
liver, or brain cell.
[0063] In yet another aspect, the invention features a method of
treating or preventing a hematopoietic disorder, e.g., an
erythroid-associated disorder, in a subject. The method includes
administering to the subject an effective amount of an agent that
modulates the activity or expression of a 23436 polypeptide or
nucleic acid such that the hematopoietic disorder is ameliorated or
prevented. In preferred embodiments, the agent is a peptide, a
phosphopeptide, a small molecule, e.g., a member of a combinatorial
library, or an antibody, or any combination thereof. The antibody
can be conjugated to a therapeutic moiety selected from the group
consisting of a cytotoxin, a cytotoxic agent and a radioactive
metal ion.
[0064] In another aspect, the invention features a method of
modulating a hematopoietic disorder, e.g., an erythroid-associated
disorder or a disorder of erythropoiesis, comprising contacting a
hematopoietic cell, e.g., a blood cell, such as an erythroid cell
or erythroid-precursor, with a agent that increases or decreases
the activity or expression of a 23436 polypeptide or nucleic acid,
thereby (a) ameliorating or preventing the hematopoietic disorder
and/or (b) modulating the differentiation of the hematopoietic
cell, e.g., the blood cell.
[0065] The invention also provides assays for determining the
activity of or the presence or absence of 23436 polypeptides or
nucleic acid molecules in a biological sample, including for
disease diagnosis.
[0066] In one embodiment, the modulator of the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 is an agent as described herein.
[0067] In yet another aspect, the invention provides methods for
modulating, e.g., inhibiting or increasing, the activity or
expression of a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-expressing cell, e.g., a hyper-proliferative 53070-, 15985-,
26583-, 21953-, m32404-, 14089-, or 23436-expressing cell. The
method includes contacting the cell with an agent, e.g., a compound
(e.g., a compound identified using the methods described herein)
that modulates the activity, or expression, of the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptide or nucleic
acid.
[0068] Preferably, the methods inhibit the proliferation or induce
the killing of a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-,
or 23436-expressing cell, e.g., a hyper-proliferative 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-expressing
cell.
[0069] In a preferred embodiment, the contacting step is effective
in vitro or ex vivo. In other embodiments, the contacting step is
effected in vivo, e.g., in a subject (e.g., a mammal, e.g., a
human), as part of a therapeutic or prophylactic protocol.
[0070] In a preferred embodiment, the cell is a hyperproliferative
cell, e.g., a cell found in a solid tumor, a soft tissue tumor, or
a metastatic lesion. For example, the 21953-expressing cell is a
lung, breast, ovary, prostate, or colon cell. In a preferred
embodiment, the cell is lung cell.
[0071] In other embodiments, the 21953-expressing cell is a neural
cell (e.g., a neuronal or a glial cell), a vascular cell (e.g.,
smooth muscle or an endothelial cell), a heart cell, a prostatic
cell, or an immune cell. Preferably, the tumor is a sarcoma, a
carcinoma, or an adenocarcinoma. Preferably, the m32404-expressing
hyperproliferative cell is found in a cancerous or pre-cancerous
tissue, e.g., a cancerous or pre-cancerous tissue where an m32404
polypeptide or nucleic acid is expressed, e.g., breast, ovarian,
colon, liver, lung, kidney, or brain cancer. Most preferably, the
m32404-expressing hyperproliferative cell is found in a tumor from
the breast, ovary, colon, liver and lung.
[0072] In a preferred embodiment, the agent, e.g., the compound, is
an inhibitor of a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 polypeptide. Preferably, the inhibitor is chosen from a
peptide, a phosphopeptide, a small organic molecule, a small
inorganic molecule and an antibody (e.g., an antibody conjugated to
a therapeutic moiety selected from a cytotoxin, a cytotoxic agent
and a radioactive metal ion). In another preferred embodiment, the
agent, e.g., compound, is an inhibitor of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 nucleic acid, e.g., an antisense, a
ribozyme, or a triple helix molecule. The inhibitor can also be a
protease inhibitor or a derivative thereof, or a peptidomimetic,
e.g., a phosphonate analog of a peptide substrate such as a prolyl
peptide substrate. In another preferred embodiment, the compound is
an inhibitor of a 21953 nucleic acid, e.g., an antisense, a
ribozyme, or a triple helix molecule. The inhibitor can also be a
trypsin inhibitor or a derivative thereof, or a peptidomimetic,
e.g., a phosphonate analog of a peptide substrate.
[0073] In another embodiment, the agent, e.g., the compound, is
administered in combination with a cytotoxic agent. Examples of
cytotoxic agents include anti-microtubule agent, a topoisomerase I
inhibitor, a topoisomerase II inhibitor, an anti-metabolite, a
mitotic inhibitor, an alkylating agent, an intercalating agent, an
agent capable of interfering with a signal transduction pathway, an
agent that promotes apoptosis or necrosis, and radiation.
[0074] In another embodiment, the agent, e.g., compound, is an
activator of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide. Preferably, the activator is chosen from a peptide, a
phosphopeptide, a small organic molecule, a small inorganic
molecule and an antibody. In yet another embodiment, the compound
stimulates the expression of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 nucleic acid.
[0075] In another aspect, the invention features methods for
treating or preventing a disorder characterized by aberrant
cellular proliferation or differentiation of a 53070-, 15985-,
26583-, m32404-, 14089-, or 23436-expressing cell, in a subject.
Preferably, the method includes comprising administering to the
subject (e.g., a mammal, e.g., a human) an effective amount of a
compound (e.g., a compound identified using the methods described
herein) that modulates the activity, or expression, of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 polypeptide or nucleic
acid. In a preferred embodiment, the disorder is a cancerous or
pre-cancerous condition, e.g. in the case of 21953, relating to
proliferation of a lung, breast, ovary, prostate, or colon cell. In
another preferred embodiment, the disorder is an immune, a
neuronal, cardiovascular, reproductive disorder, e.g., a disorder
relating to aberrant processing of a polypeptide hormone.
Preferably, the cancer is found in a tissue where an m32404
polypeptide or nucleic acid is expressed, e.g., breast, ovarian,
colon, liver, lung, kidney, or brain cancer. Most preferably, the
cancer is found in the breast, ovary, colon, liver and lung.
[0076] In another aspect, the invention provides methods of
diagnosing or staging a disorder, e.g., proliferative disorder. The
method includes: (i) identifying a subject having, or at risk of
having, the disorder; (ii) obtaining a sample of a tissue or cell
affected with the disorder; (iii) contacting said sample or a
control sample with a labeled agent specific for a 15985
polypeptide or nucleic acid, e.g., a probe or a primer, under
conditions that allow interaction of the labeled agent and the
15985 nucleic acid, e.g., cDNA, mRNA, or 15985 protein to occur,
and (iv) detecting formation of a complex. A statistically
significant increase in the formation of the complex between the
labeled agent with respect to a reference, e.g., a control sample,
is indicative of the disorder or the stage of the disorder. The
level of 15985 nucleic acid or polypeptide expression can be
detected by any method described herein. Preferably, the labeled
agent is directly or indirectly labeled with a detectable substance
to facilitate detection of the bound or unbound binding agent.
Suitable detectable substances include various enzymes, prosthetic
groups, fluorescent materials, luminescent materials and
radioactive materials.
[0077] In a further aspect, the invention provides methods for
evaluating the efficacy of a treatment of a disorder, e.g., a
proliferative disorder or a differentiation disorder (e.g. in the
case of 21953, lung cancer, or a neuronal disorder). The method
includes: treating a subject, e.g., a patient or an animal, with a
protocol under evaluation (e.g., treating a subject with one or
more of: chemotherapy, radiation, and/or a compound identified
using the methods described herein); and evaluating the expression
of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic
acid or polypeptide before and after treatment. A change, e.g., a
decrease or increase, in the level of a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acid (e.g., mRNA) or polypeptide
after treatment, relative to the level of expression before
treatment, is indicative of the efficacy of the treatment of the
disorder. The level of 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 nucleic acid or polypeptide expression can be detected by
any method described herein.
[0078] The invention also provides assays for determining the
activity of or the presence or absence of m32404 polypeptides or
nucleic acid molecules in a biological sample, including for
disease diagnosis. Preferably, the biological sample includes a
cancerous or pre-cancerous cell or tissue. For example, the
cancerous tissue can be a solid tumor, a soft tissue tumor, or a
metastatic lesion. Preferably, the cancerous tissue is a sarcoma, a
carcinoma, or an adenocarcinoma. Preferably, the cancerous tissue
is from the breast, ovarian, colon, lung, liver, kidney, or
brain.
[0079] In a further aspect the invention provides assays for
determining the presence or absence of a genetic alteration in an
m32404 polypeptide or nucleic acid molecule in a sample, for, e.g.,
disease diagnosis. Preferably, the sample includes a cancer cell or
tissue. For example, the cancer can be a solid tumor, a soft tissue
tumor, or a metastatic lesion. Preferably, the cancer is a sarcoma,
a carcinoma, or an adenocarcinoma. Preferably, the cancer is a
breast, ovarian, colon, lung, liver, kidney, or brain cancer.
[0080] In a still further aspect, the invention provides methods
for evaluating the efficacy of a treatment of a disorder, e.g.,
proliferative disorder, e.g., cancer (e.g., breast, ovarian, colon,
liver or lung cancer). The method includes: treating a subject,
e.g., a patient or an animal, with a protocol under evaluation
(e.g., treating a subject with one or more of: chemotherapy,
radiation, and/or a compound identified using the methods described
herein); and evaluating the expression of an m32404 nucleic acid or
polypeptide before and after treatment. A change, e.g., a decrease
or increase, in the level of an m32404 nucleic acid (e.g., mRNA) or
polypeptide after treatment, relative to the level of expression
before treatment, is indicative of the efficacy of the treatment of
the disorder.
[0081] In a preferred embodiment, the disorder is a cancer of the
breast, ovary, colon, lung, or liver. The level of m32404 nucleic
acid or polypeptide expression can be detected by any method
described herein.
[0082] In a preferred embodiment, the evaluating step includes
obtaining a sample (e.g., a tissue sample, e.g., a biopsy, or a
fluid sample) from the subject, before and after treatment and
comparing the level of expressing of a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acid (e.g., mRNA) or polypeptide
before and after treatment.
[0083] In another aspect, the invention provides methods for
evaluating the efficacy of a therapeutic or prophylactic agent
(e.g., an anti-neoplastic agent). The method includes: contacting a
sample with an agent (e.g., a compound identified using the methods
described herein, a cytotoxic agent) and, evaluating the expression
of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid
or polypeptide in the sample before and after the contacting step.
A change, e.g., a decrease or increase, in the level of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid (e.g.,
mRNA) or polypeptide in the sample obtained after the contacting
step, relative to the level of expression in the sample before the
contacting step, is indicative of the efficacy of the agent. The
level of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid or polypeptide expression can be detected by any
method described herein. In a preferred embodiment, the sample
includes cells obtained from a cancerous tissue. The cancerous
tissue can include, for example in the case of 21953, cells of
lung, breast, ovary, prostate, or colon. In a preferred embodiment,
the sample includes cells obtained from a cancerous tissue where an
m32404 polypeptide or nucleic acid is obtained, e.g., a cancer of
the breast, ovary, colon, lung, or liver.
[0084] The invention also provides assays for determining the
activity of or the presence or absence of 14089 polypeptides or
nucleic acid molecules in a biological sample, including for
disease diagnosis.
[0085] In further aspect, the invention provides assays for
determining the presence or absence of a genetic alteration in a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptide or
nucleic acid molecule, including for disease diagnosis, or, in the
case of 23436, a disease susceptibility (e.g., susceptibility to
prostate cancer and/or brain cancer).
[0086] In a still further aspect, the 21953 invention features a
method of processing a polypeptide hormone precursor, e.g., in
vitro.
[0087] In another aspect, the invention features a two dimensional
array having a plurality of addresses, each address of the
plurality being positionally distinguishable from each other
address of the plurality, and each address of the plurality having
a unique capture probe, e.g., a nucleic acid or peptide sequence.
At least one address of the plurality has a capture probe that
recognizes a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecule. In one embodiment, the capture probe is a nucleic acid,
e.g., a probe complementary to a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acid sequence. In another
embodiment, the capture probe is a polypeptide, e.g., an antibody
specific for 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptides. Also featured is a method of analyzing a sample by
contacting the sample to the aforementioned array and detecting
binding of the sample to the array.
[0088] Other features and advantages of the invention will be
apparent from the following detailed description, and from the
claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0089] FIG. 1 depicts a hydropathy plot of human 53070. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. Numbers corresponding to positions in the amino acid sequence
of human 53070 are indicated. Polypeptides of the invention include
fragments which include: all or part of a hydrophobic sequence,
i.e., a sequence above the dashed line, e.g., the sequence from
about amino acid 63 to 73, from about 86 to 102, and from about 199
to 216 of SEQ ID NO:2; all or part of a hydrophilic sequence, i.e.,
a sequence below the dashed line, e.g., the sequence of from about
amino acid 103 to 119, from about 226 to 247, and from about 301 to
329 of SEQ ID NO:2.
[0090] FIG. 2 depicts an alignment of the protein kinase domain of
human 53070 with a consensus amino acid sequence derived from a
hidden Markov model (HMM) from PFAM. The upper sequence is the
consensus amino acid sequence (SEQ ID NO:4), while the lower amino
acid sequence corresponds to amino acids 12 to 272 of SEQ ID
NO:2.
[0091] FIG. 3 depicts an alignment of the serine/threonine protein
kinase domain of human 53070 with a consensus amino acid sequence
derived from a hidden Markov model (HMM) from SMART. The upper
sequence is the consensus amino acid sequence (SEQ ID NO:5), while
the lower amino acid sequence corresponds to amino acids 12 to 272
of SEQ ID NO:2.
[0092] FIG. 4 depicts a hydropathy plot of human 15985. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. The cysteine residues (cys) are indicated by short vertical
lines just below the hydropathy trace. The numbers corresponding to
the amino acid sequence of human 15985 are indicated. Polypeptides
of the invention include fragments which include: all or part of a
hydrophobic sequence, i.e., a sequence above the dashed line, e.g.,
the sequence from about amino acid 83 to 91, from about 465 to 472,
and from about 568 to 585 of SEQ ID NO:8; all or part of a
hydrophilic sequence, i.e., a sequence below the dashed line, e.g.,
the sequence of from about amino acid 8 to 20, from about 592 to
600, and from about 652 to 672 of SEQ ID NO:8; a sequence which
includes a Cys, or a glycosylation site.
[0093] FIG. 5 depicts an alignment of the protein kinase domain of
human 15985 with a consensus amino acid sequence derived from a
hidden Markov model (HMM) from PFAM. The upper sequence is the
consensus amino acid sequence (SEQ ID NO:10), while the lower amino
acid sequence corresponds to amino acids 394 to 651 of SEQ ID
NO:8.
[0094] FIGS. 6A-6B depicts an alignment of the doublecortin repeats
of human 15985 with a consensus amino acid sequence derived from a
hidden Markov model (HMM) from SMART. A. The upper sequence is the
consensus amino acid sequence (SEQ ID NO:11), while the lower amino
acid sequence corresponds to the first doublecortin repeat of human
15985, amino acids 67 to 158 of SEQ ID NO:8. B. The upper sequence
is the consensus amino acid sequence (SEQ ID NO:11), while the
lower amino acid sequence corresponds to the second doublecortin
repeat of human 15985, amino acids 192 to 280 of SEQ ID NO:8.
[0095] FIG. 7 depicts an alignment of the protein kinase domain of
human 15985 with a consensus amino acid sequence for
serine/threonine protein kinases derived from a hidden Markov model
(HMM) from SMART. The upper sequence is the consensus amino acid
sequence (SEQ ID NO:12), while the lower amino acid sequence
corresponds to the protein kinase domain of human 15985, amino
acids 394 to 651 of SEQ ID NO:8.
[0096] FIG. 8 depicts an alignment of the doublecortin repeats of
human 15985 with a consensus amino acid sequence derived from a
ProDom family PD024506 (ProDomain Release 2000.1). The lower
sequence is the consensus amino acid sequence (SEQ ID NO:13), while
the upper amino acid sequence corresponds to the doublecortin
repeats of human 15985, amino acids 42 to 291 of SEQ ID NO:8.
[0097] FIG. 9 depicts a hydropathy plot of human 26583. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. The cysteine residues (cys) are indicated by short vertical
lines just below the hydropathy trace. The numbers corresponding to
the amino acid sequence of human 26583 are indicated. Polypeptides
of the invention include fragments which include: all or part of a
hydrophobic sequence, i.e., a sequence above the dashed line, e.g.,
the sequence of 262-279; all or part of a hydrophilic sequence,
i.e., a sequence below the dashed line, e.g., the sequence of
60-70; a sequence which includes a Cys, or a glycosylation
site.
[0098] FIGS. 10A-10B depict alignments of human 26583 amino acid
sequence with a consensus amino acid sequence derived from protein
phosphatase 2C (PP2C) (FIG. 10A) and protein phosphatase 2C.sub.--4
(PP2C.sub.--4) (FIG. 10B). In FIG. 10A, the upper sequence is the
consensus amino acid sequence (SEQ ID NO:17) for PP2C, while the
lower amino acid sequence corresponds to amino acids 173 to 461 of
SEQ ID NO:15. In FIG. 10B, the upper sequence is the consensus
amino acid sequence (SEQ ID NO:18) for PP2C.sub.--4, while the
lower amino acid sequence corresponds to amino acids 99 to 522 of
SEQ ID NO:15.
[0099] FIG. 11 shows a bar graph depicting relative 26583 mRNA
expression as determined by TaqMan assays on mRNA derived from the
following tissue samples. Columns are numbered at five-column
intervals at the bottom of the Figure (i.e., columns 1-42), and
correspond to the following: columns 1-3, normal breast; columns
4-10, breast tumor; columns 11-13, normal lung; columns 14-20, lung
tumor; columns 21-23, normal colon; columns 24-31, colon tumor;
columns 32-35, colon metastases; columns 36-37, normal liver;
columns 38-39, normal brain; columns 40-42, brain tumor.
[0100] FIG. 12 depicts a hydropathy plot of human 21953. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. Numbers corresponding to positions in the amino acid sequence
of human 21953 are indicated.
[0101] FIG. 13 depicts an alignment of the prolyl oligopeptidase
domain of human 21953 with a consensus amino acid sequence derived
from a hidden Markov model for prolyl oligopeptidase domains. The
upper sequence is the consensus amino acid sequence (SEQ ID NO:22),
while the lower amino acid sequence corresponds to amino acids 672
to 744 of SEQ ID NO:20.
[0102] FIGS. 14A-14B depict an alignment of human dipeptidyl
peptidase IV (Accession Number P48147) (upper line, SEQ ID NO:23),
to the 21953 amino acid sequence. The * symbol indicates
identities, and the : or . symbols indicate similarities. The
alignment was generated by ClustalW (Thompson et al. (1994) Nucleic
Acids Res. 22:4673-4680).
[0103] FIG. 15 depicts a hydropathy plot of human m32404. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. The cysteine residues (cys) are indicated by short vertical
lines just below the hydropathy trace. The numbers corresponding to
the amino acid sequence of human m32404 are indicated. Polypeptides
of the invention include fragments which include: all or part of a
hydrophobic sequence, i.e., a sequence above the dashed line, e.g.,
the sequence from about amino acid 320 to 340, and from about
450-470, of SEQ ID NO:25; all or part of a hydrophilic sequence,
i.e., a sequence below the dashed line, e.g., the sequence from
about amino acid 30 to 60 of SEQ ID NO:25; a sequence which
includes a Cys, or a glycosylation site.
[0104] FIGS. 16A-16B depict alignments of the trypsin domains of
human m32404 with a consensus amino acid sequence derived from a
hidden Markov model (HMM) from PFAM. The upper sequence is the
consensus amino acid sequence (SEQ ID NO:27), while the lower amino
acid sequence corresponds to amino acids 45 to 268 of SEQ ID NO:25
(FIG. 16A) or upper sequence is the consensus amino acid sequence
(SEQ ID NO:28), while the lower amino acid sequence corresponds to
amino acids 311 to 520 of SEQ ID NO:25 (FIG. 16B).
[0105] FIGS. 17A-17B depict alignments of the trypsin domains of
human m32404 with a consensus amino acid sequence for a model
trypsin domain from SMART. The upper sequence is the consensus
amino acid sequence (SEQ ID NO:29), while the lower amino acid
sequence corresponds to amino acids 38 to 268 of SEQ ID NO:25 (FIG.
17A) or to amino acids 300 to 520 of SEQ ID NO:25 (FIG. 17B).
[0106] FIG. 18 depicts a hydropathy plot of human 14089. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. Cysteine (cys) residues are noted by short vertical lines
just below the hydropathy trace. The numbers corresponding to the
amino acid sequence of human 14089 are indicated. Polypeptides of
the invention include fragments that include: all or part of a
hydrophobic sequence, i.e., a sequence above the dashed line, e.g.,
the sequence from about amino acid 35 to 55, from about 58 to 70,
and from about 175 to 184 of SEQ ID NO:34; all or part of a
hydrophilic sequence, i.e., a sequence below the dashed line, e.g.,
the sequence of from about amino acid 71 to 79, from about 161 to
171, and from about 185 to 192 of SEQ ID NO:34; a sequence which
includes a Cys, or a glycosylation site.
[0107] FIGS. 19A-19B depict alignments of the trypsin domain of
human 14089 with a consensus amino acid sequence derived from a
hidden Markov model (HMM) from PFAM (3A) and SMART (3B). The upper
sequences are the consensus amino acid sequences (SEQ ID NO:36 and
SEQ ID NO:37), while the lower amino acid sequence corresponds to
amino acids 41 to 234 of SEQ ID NO:34 and amino acids 24 to 234 of
SEQ ID NO:34 (FIGS. 19A and 19B, respectively).
[0108] FIGS. 20A-20B depict a BLAST alignment of the serine
protease zymogen domain of human 14089 with a consensus amino acid
sequence derived from ProDomain No. 46 (Release 1999.2; see also
ProDom family PD00000046 (ProDomain Release 2000.1). FIG. 20A: The
lower sequence is the consensus amino acid sequence (SEQ ID NO:38),
while the upper amino acid sequence corresponds to the serine
protease zymogen domain of human 14089, about amino acids 72 to 234
of SEQ ID NO:34. FIG. 20B: The lower sequence is the consensus
amino acid sequence (SEQ ID NO:39), while the upper amino acid
sequence corresponds to the serine protease zymogen domain of human
14089, about amino acids 41 to 109 of SEQ ID NO:34.
[0109] FIG. 21 depicts a hydropathy plot of human 23436. Relative
hydrophobic residues are shown above the dashed horizontal line,
and relative hydrophilic residues are below the dashed horizontal
line. The cysteine residues (cys) are indicated by short vertical
lines just below the hydropathy trace. The numbers corresponding to
the amino acid sequence of human 23436 are indicated. Polypeptides
of the invention include fragments which include: all or part of a
hydrophobic sequence, i.e., a sequence above the dashed line, e.g.,
the sequence from about amino acid 103 to 114, from about 285 to
297, and from about 413 to 420 of SEQ ID NO:41; all or part of a
hydrophilic sequence, i.e., a sequence below the dashed line, e.g.,
the sequence of from about amino acid 76 to 87, from about 138 to
143, and from about 458 to 478 of SEQ ID NO:41; a sequence which
includes a Cys, or a glycosylation site.
[0110] FIGS. 22A-22B depict alignment of the ubiquitin
carboxy-terminal hydrolase (family 2) domain of human 23436 with
consensus amino acid sequences derived from a hidden Markov model
(HMM) from PFAM. The consensus sequence for the ubiquitin
carboxy-terminal hydrolase (family 2) domain comprises two
non-contiguous segments, UCH-1 and UCH-2. FIG. 22A depicts the
alignment of human 23436 with the UCH-1 segment of the ubiquitin
carboxy-terminal hydrolase (family 2) domain. The upper sequence is
the consensus amino acid sequence (SEQ ID NO:43), while the lower
amino acid sequence corresponds to amino acids 89 to 120 of SEQ ID
NO:41. FIG. 22B depicts the alignment of human 23436 with the UCH-2
segment of the ubiquitin carboxy-terminal hydrolase (family 2)
domain. The upper sequence is the consensus amino acid sequence
(SEQ ID NO:44), while the lower amino acid sequence corresponds to
amino acids 332 to 420 of SEQ ID NO:41.
[0111] FIG. 23 is a bar graph depicting relative 23436 mRNA
expression as determined by TaqMan assays on mRNA derived from
human hematological cell lines treated for various times with
transforming growth factor-.beta. (TGF-.beta.) and VPA. Erythroid
lineage precursors have elevated 23436 expression levels.
Expression is reduced by TGF-.beta. treatment.
[0112] FIG. 24 is a bar graph depicting relative 23436 mRNA
expression as determined by TaqMan assays on mRNA derived from
human hematological cells including neutrophils, platelets, blood
forming units (BFU), and TGF.beta.-treated hematopoietic
precursors. BFUs treated with erythropoietin (EPO) have elevated
23436 expression levels.
[0113] FIG. 25 is a bar graph depicting relative 23436 mRNA
expression as determined by TaqMan assays on mRNA derived from the
following cell types: (1) lung; (2) kidney; (3) fetal liver; (4)
grans.; (5) NHDF mock; (6) NHDF TGF; (7) NHLF mock; (8) NHLF TGF;
(9) NC Heps; (10) Pass Stell; (11) Liver CHT 339; (12) Liver NDR
191; (13) LF NDR 079; (14) Lymph Node; (15) Th0 046 6h; (16) Th1
046 6h; (17) Th2 046 6h; (18) CD8; (19) CD 14; (20) PBMC Rest; (21)
MBM MNC; (22) MPB CD34; (23) ABM CD34; (24) Cord Blood; (25)
Erythroid cells; (26) Megakaryocytes; (27) Neutrophil d14; (28)
CD15+/CD14- cells; (29) MBM CD11b-; (30) BM GPA; (31) VZV mock;
(32) VZV 18h; (33) VZV 72h; (34) K562; (35) NTC; (36) HL60; (37)
Molt4; (38) Hep3b Normal; and (39) Hep3b Hyp. Erythroid K562 cells
(34), erythroid cells (26), and fetal liver cells (3) have elevated
23436 mRNA expression levels.
[0114] FIG. 26 is a bar graph depicting relative 23436 mRNA
expression as determined by TaqMan assays on mRNA derived from the
following cell types: (1) Lung; (2) Colon 60; (3) Kidney 58; (4)
Liver NDR 200; (5) Fetal Liver 425; (6) Skeletal Muscle 167; (7)
mBone Marrow MNC LP139; (8) mBone Marrow CD34+ LP92; (9) mBone
Marrow CD34+ LP143; (10) mPB CD34+ LF70; (11) mPB CD34+ LP152; (12)
Bone Marrow CD34+ LF68; (13) Bone Marrow CD34+ LF154; (14) Cord
Blood CD34+ LP121; (15) Bone Marrow GPA+; (16) Bone Marrow GPA+
LP34-1; (17) Bone Marrow GPA Lo LP69; (18) Bone Marrow GPA Lo LP82;
(19) Bone Marrow CD41+ CD14- LP78; (20) mBone Marrow CD15+ LP15;
(21) mBone Marrow CD15+ CD11b- LP7-4; (22) mBone Marrow CD15+
CD11b+ LP15-2; (23) Bone Marrow CD15+ CD11b- LP23-2; (24) Bone
Marrow CD15+ CD34- LP27-2; (25) Bone Marrow CD 15+ CD34- LP41-1;
(26) Erythroid 24 hr LF90; (27) Erythroid 48 hr LF73; (28)
Erythroid 48 hr LF76; (29) Erythroid 48 hr LF90; (30) Erythroid d6
LP31-1; (31) Erythroid d7 LF24-5; (32) Erythroid d10 LP25-4; (33)
Erythroid d12 LF23-8; (34) Erythroid d12 LF24-10; (35) Erythroid
d14 GPA+ LP31-4; (36) Meg 48 hr LF76; (37) Meg 48 hr LF790; (38)
Meg d7 LP31-2; (39) Meg d12 LF102; (40) Meg d12 LF35; and (41) Meg
d14 LP31-5. Fetal Liver (5) and day 12 erythroid cells (33) and
(34) have elevated 23436 mRNA expression levels.
[0115] FIG. 27 is a bar graph depicting 23436 expression in human
prostate, hypothalamus, lung, bone marrow, differentiated
osteoblasts, and aorta cells as assessed by TaqMan analysis.
Elevated expression is observed in some prostate, hypothalamus, and
bone marrow cells. Relative expression levels were determined by
normalizing against a trachea control.
[0116] FIG. 28 is a bar graph depicting 23436 expression in human
liver, several hepatoma cell lines (HepG2) and ganglia, as assessed
by TaqMan analysis. Elevated expression is observed in hepatoma
cells (HepG2 cell line). Relative expression levels were determined
by normalizing against a trachea control.
[0117] FIG. 29 is a bar graph depicting 23436 expression as
determined by TaqMan assays on mRNA derived from the following cell
types: (1) brain; (2) brain cortex; (3) breast; (4) colon tumor;
(5) heart; (6) kidney; (7) liver norm; (8) liver fib; (9) lung
tumor; (10) ovary; (11) fetal liver; (12) mBM CD34+ LP92; (13) mBM
CD34+ LP143; (14) mPB CD34+ LF70; (15) mPB CD34+ LF162; (16) BM
CD34+ LF93; (17) BM CD34+ LP154; (18) Cord Blood CD34+ LF101; (19)
GPA+ High LP34-1; (20) GPA+ High 69; (21) GPA+ High 74; (22) GPA+
Low LP69; (23) GPA+ Low LP82; (24) Ery 24 hr LF102; (25) Ery 48h
LF87; (26) Ery 48h LF102; (27) Ery 48h LF72; (28) Ery d6 LP31-1;
(29) Ery d6 LF113; (30) Ery d7 LF24-5; (31) Ery d8 LF113; (32) Ery
d10 LP24-4; (33) Ery d12 LF23-8; (34) Ery d12 LF24-10; (35) Ery d12
LF113; (36) Ery d14 GPA+ LP31-4; (37) BFU d7 LP79; (38) BFU d7
LP95; (39) BFU d7+3 Epo LP81; and (40) BFU d7+3 Epo LP104.
DETAILED DESCRIPTION OF THE INVENTION
53070
[0118] Phosphate tightly associated with protein has been known
since the late nineteenth century. The occurrence of phosphorylated
proteins implies the existence of one or more protein kinases
capable of phosphorylating amino acid residues on proteins, and
also of protein phosphatases capable of hydrolyzing phosphorylated
amino acid residues on proteins.
[0119] Protein kinases play critical roles in the regulation of
biochemical and morphological changes associated with cellular
growth and division (D'Urso, G. et al. (1990) Science 250: 786-791;
Birchmeier. C. et al. (1993) Bioessays 15: 185-189). They serve as
growth factor receptors and signal transducers and have been
implicated in cellular transformation and malignancy (Hunter, T. et
al. (1992) Cell 70: 375-387; Posada, J. et al. (1992) Mol. Biol.
Cell 3: 583-592; Hunter, T. et al. (1994) Cell 79: 573-582). For
example, protein kinases have been shown to participate in the
transmission of signals from growth-factor receptors (Sturgill, T.
W. et al. (1988) Nature 344: 715-718; Gomez, N. et al. (1991)
Nature 353: 170-173), control of entry of cells into mitosis
(Nurse, P. (1990) Nature 344: 503-508; Maller, J. L. (1991) Curr.
Opin. Cell Biol. 3: 269-275) and regulation of actin bundling
(Husain-Chishti, A. et al. (1988) Nature 334: 718-721).
[0120] Protein kinases can be divided into two main groups based on
either amino acid sequence similarity or specificity for either
serine/threonine or tyrosine residues. A small number of
dual-specificity kinases are structurally like the
serine/threonine-specific group. Within the broad classification,
kinases can be further sub-divided into families whose members
share a higher degree of catalytic domain amino acid sequence
identity and also have similar biochemical properties. Most protein
kinase family members also share structural features outside the
kinase domain that reflect their particular cellular roles. These
include regulatory domains that control kinase activity or
interaction with other proteins (Hanks, S. K. et al. (1988) Science
241: 42-52).
[0121] The human 53070 sequence (see SEQ ID NO:1), which is
approximately 1704 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
1104 nucleotides, including the termination codon. The coding
sequence encodes a 367 amino acid protein (see SEQ ID NO:2).
[0122] Human 53070 contains the following regions or other
structural features:
[0123] a protein kinase domain (PFAM accession number PF00069)
located at about amino acid residues 12 to 272 of SEQ ID NO:2;
[0124] thirteen highly conserved amino acid residues typically
present in members of the protein kinase family, including a
glycine residue located at about amino acid residue 19 of SEQ ID
NO:2, a glycine residue located at about amino acid residue 21 of
SEQ ID NO:2, a valine residue located at about amino acid residue
26 of SEQ ID NO:2, a lysine residue located at about amino acid
residue 41 of SEQ ID NO:2, a glutamic acid residue located at about
amino acid residue 60 of SEQ ID NO:2, an aspartic acid residue
located at about amino acid residue 136 of SEQ ID NO:2, an
asparagine residue located at about amino acid residue 141 of SEQ
ID NO:2, an aspartic acid residue located at about amino acid
residue 154 of SEQ ID NO:2, a phenylalanine residue located at
about amino acid residue 155 of SEQ ID NO:2, a glutamic acid
residue located at about amino acid residue 185 of SEQ ID NO:2, an
aspartic acid residue located at about amino acid residue 198 of
SEQ ID NO:2, a glycine residue located at about amino acid residue
203 of SEQ ID NO:2, and an arginine residue located at about amino
acid residue 260 of SEQ ID NO:2;
[0125] one serine/threonine active site signature motif (PS00108),
located at about amino acid residues 132 to 144;
[0126] five predicted Protein Kinase C phosphorylation sites
(PS00005) located at about amino acid residues 31 to 33, 158 to
160, 166 to 168, 290 to 292, and 304 to 306 of SEQ ID NO:2;
[0127] three predicted Casein Kinase II phosphorylation sites
(PS00006) located at about amino acid residues 310 to 313, 326 to
329, and 349 to 352 of SEQ ID NO:2; and
[0128] one predicted N-myristylation sites (PS00008) from about
amino acid residues 15 to 20 of SEQ ID NO:2.
[0129] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to:
Sonnhammer et al. (1997) Protein 28:405-420;
[0130] The 53070 protein contains a significant number of
structural characteristics in common with members of the protein
kinase family, and in particular the serine/threonine protein
kinase subfamily. The term "family" when referring to the protein
and nucleic acid molecules of the invention means two or more
proteins or nucleic acid molecules having a common structural
domain or motif and having sufficient amino acid or nucleotide
sequence homology as defined herein. Such family members can be
naturally or non-naturally occurring and can be from either the
same or different species. For example, a family can contain a
first protein of human origin as well as other distinct proteins of
human origin, or alternatively, can contain homologues of non-human
origin, e.g., rat or mouse proteins. Members of a family can also
have common functional characteristics.
[0131] Protein kinase family members are characterized by a common
fold, which includes a small lobe associated primarily with binding
ATP and a large lobe associated primarily with binding substrate
peptides and catalyzing the transfer of phosphate from ATP to
substrate. Bases on sequence similarity, the kinase domain has been
divided into eleven distinct regions, or subdomains, and within
these eleven subdomains there are a large number of amino acid
residues that are considered "invariant", or highly conserved,
amongst members of the protein kinase family. As used herein, an
amino acid is "invariant" if it is present in the equivalent
position, as determined by a sequence alignment, in 95% or more of
the members of family. For example, in subdomain 1 of kinase domain
family members there are two invariant glycine residues and an
invariant valine residue; in subdomain 2 there is an invariant
lysine residue; in subdomain 3 there is an invariant glutamic acid
residue; in subdomain 6 there is an invariant aspartic acid residue
and an invariant asparagine residue; in subdomain 7 there are three
invariant residues adjacent to one another, consisting of the
sequence aspartic acid, phenylalanine, and glycine; in subdomain 8
there is an invariant glutamic acid residue; in subdomain 9 there
is an invariant aspartic acid residue and an invariant glycine; and
in subdomain 11 there is an invariant arginine residue. An
alignment of protein kinase family members that includes a
description of the eleven subdomains and the invariant residues
found within each subdomain can be found in Hanks et al. (1988),
Science 241:42-52, the contents of which are incorporated herein by
reference.
[0132] Structural analyses of the kinase domains of several
different proteins have been performed, and the function of the
invariant amino acid residues can be assigned accordingly. The
invariant glycines of subdomain 1 are part of a loop that anchors
the .theta.-phosphate of ATP, while the invariant valine of
subdomain 1 forms part of the adenine binding pocket. The invariant
lysine of subdomain 2 also helps the kinase domain bind ATP by
interacting with both the I- and .theta.-phosphate groups of ATP.
The invariant aspartic acid residue of subdomain 6 catalyzes the
transfer of the K-phosphate group of ATP to the substrate. The
invariant aspartic acid residue in subdomain 7 binds to a magnesium
ion which is required for the catalytic activity of the kinase
domain. And finally, the invariant aspartic acid of subdomain 9
stabilizes the position of the catalytic loop, located in subdomain
7. A more extensive description of the structures of protein kinase
domains and the function of the invariant residues can be found in
Taylor and Radzio-Andzelm (1994), Structure 2:345-55, the contents
of which are incorporated herein by reference.
[0133] A 53070 polypeptide can include a "protein kinase domain" or
regions homologous with a "protein kinase domain".
[0134] As used herein, the term "protein kinase domain" includes an
amino acid sequence of about 225 to 350 amino acid residues in
length and having a bit score for the alignment of the sequence to
the protein kinase domain profile (PFAM HMM) of at least 150.
Preferably, a protein kinase domain includes an amino acid sequence
of about 225 to 350 amino acid residues in length and having a bit
score for the alignment of the sequence to the serine/threonine
kinase domain profile (SMART HMM) of at least 150. Even more
preferably, a protein kinase domain includes at least about 230 to
325 amino acids, more preferably about 235 to 300 amino acid
residues, or about 240 to 280 amino acids and has a bit score for
the alignment of the sequence to the serine/threonine protein
kinase domain (SMART HMM) of at least 200, 250, 280, or greater.
The protein kinase domain (HMM) has been assigned the PFAM
identifier PF00069, and the serine/threonine protein kinase domain
(HMM) has been given the SMART identifier S_TKc. An alignment of
the protein kinase domain (amino acids 12 to 272 of SEQ ID NO:2) of
human 53070 with the PFAM consensus amino acid sequence (SEQ ID
NO:4) derived from a hidden Markov model is depicted in FIG. 2, and
with the SMART serine/threonine protein kinase domain consensus
amino acid sequence (SEQ ID NO:5) derived from a hidden Markov
model is depicted in FIG. 3.
[0135] In a preferred embodiment, a 53070 polypeptide or protein
has a "protein kinase domain" or a region which includes at least
about 230 to 325 more preferably about 235 to 300, or 240 to 280
amino acid residues and has at least about 85%, 90%, 95%, 99%, or
100% homology with a "protein kinase domain," e.g., the protein
kinase domain of human 53070 (e.g., residues 12 to 272 of SEQ ID
NO:2).
[0136] To identify the presence of a "protein kinase domain" in a
53070 protein sequence, and make the determination that a
polypeptide or protein of interest has a particular profile, the
amino acid sequence of the protein can be searched against the PFAM
database of HMMs (e.g., the PFAM database, release 2.1) using the
default parameters. For example, the hmmsf program, which is
available as part of the HMMER package of search programs, is a
family specific default program for MILPAT0063 and a score of 15 is
the default threshold score for determining a hit. Alternatively,
the threshold score for determining a hit can be lowered (e.g., to
8 bits). A description of the PFAM database can be found in
Sonhammer et al. (1997) Proteins 28(3):405-420 and a detailed
description of HMMs can be found, for example, in Gribskov et al.
(1990) Meth. Enzymol. 183:146-159; Gribskov et al. (1987) Proc.
Natl. Acad. Sci. USA 84:4355-4358; Krogh et al. (1994) J. Mol.
Biol. 235:1501-1531; and Stultz et al. (1993) Protein Sci.
2:305-314, the contents of which are incorporated herein by
reference. A search was performed against the HMM database
resulting in the identification of a "protein kinase domain" in the
amino acid sequence of human 53070 at about residues 12 to 272 of
SEQ ID NO:2 (see FIG. 2).
[0137] To identify the presence of a "serine/threonine protein
kinase domain" in a 53070 protein sequence, the amino acid sequence
of the protein can be searched against a SMART database (Simple
Modular Architecture Research Tool) of HMMs as described in Schultz
et al. (1998), Proc. Natl. Acad. Sci. USA 95:5857 and Schultz et
al. (200) Nucl. Acids Res 28:231. The database contains domains
identified by profiling with the hidden Markov models of the HMMer2
search program (R. Durbin et al. (1998) Biological sequence
analysis: probabilistic models of proteins and nucleic acids.
Cambridge University Press). The database also is extensively
annotated and monitored by experts to enhance accuracy. A search
was performed against the HMM database resulting in the
identification of a "serine/threonine protein kinase domain" in the
amino acid sequence of human 53070 at about residues 12 to 272 of
SEQ ID NO:2 (see FIG. 3).
[0138] In one embodiment, a 53070 protein includes at least one,
preferably two, three, four, five, six, seven, eight, nine, ten,
eleven, twelve, or even more preferably thirteen of the invariant
residues present in protein kinase family members, selected form
the group consisting of a glycine residue located at about amino
acid residue 19 of SEQ ID NO:2, a glycine residue located at about
amino acid residue 21 of SEQ ID NO:2, a valine residue located at
about amino acid residue 26 of SEQ ID NO:2, a lysine residue
located at about amino acid residue 41 of SEQ ID NO:2, a glutamic
acid residue located at about amino acid residue 60 of SEQ ID NO:2,
an aspartic acid residue located at about amino acid residue 136 of
SEQ ID NO:2, an asparagine residue located at about amino acid
residue 141 of SEQ ID NO:2, an aspartic acid residue located at
about amino acid residue 154 of SEQ ID NO:2, a phenylalanine
residue located at about amino acid residue 155 of SEQ ID NO:2, a
glutamic acid residue located at about amino acid residue 185 of
SEQ ID NO:2, an aspartic acid residue located at about amino acid
residue 198 of SEQ ID NO:2, a glycine residue located at about
amino acid residue 203 of SEQ ID NO:2, and an arginine residue
located at about amino acid residue 260 of SEQ ID NO:2.
[0139] In one embodiment, a 53070 protein includes at least one
serine/threonine protein kinase active-site signature motif
(PS00108), located at about amino acid residues 132 to 144 of SEQ
ID NO:2. As used herein, the term "serine/threonine protein kinase
active-site signature motif" includes a sequence of at least 8
amino acid residues defined by the sequence:
[LIVMFYC]-X-[HY]-X-D-[LIVMFY]-K-X-X-N-[LIVMFYCT]-[LIVMFYCT]-[LIVMFYCT]
(SEQ ID NO:6). A serine/threonine protein kinase active-site
signature motif, as defined, can be involved in the enzymatic
transfer of a phosphate moiety from ATP to an appropriate acceptor
molecule, e.g., a serine or threonine residue in a substrate
molecule. More preferably, a serine/threonine protein kinase
active-site signature motif includes 10 or, even more preferably,
13 amino acid residues. Serine/threonine protein kinase active-site
signature motifs have been given the PROSITE identifier
PS00108.
[0140] A 53070 family member can include at least one protein
kinase domain. Furthermore, a 53070 family member can include at
least one serine/threonine protein kinase active-site signature
motif (PS00108); at least one, two, three, four, preferably five
predicted protein kinase C phosphorylation sites (PS00005); at
least one, two, preferably three predicted casein kinase II
phosphorylation sites (PS00006); and at least one predicted
N-myristylation sites (PS00008).
[0141] As the 53070 polypeptides of the invention may modulate
53070-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for 53070-mediated or
related disorders, as described below.
[0142] As used herein, a "53070 activity", "biological activity of
53070" or "functional activity of 53070", refers to an activity
exerted by a 53070 protein, polypeptide or nucleic acid molecule.
For example, a 53070 activity can be an activity exerted by 53070
in a physiological milieu on, e.g., a 53070-responsive cell or on a
53070 substrate, e.g., a protein substrate. A 53070 activity can be
determined in vivo or in vitro. In one embodiment, a 53070 activity
is a direct activity, such as an association with a 53070 target
molecule. A "target molecule" or "binding partner" is a molecule
with which a 53070 protein binds or interacts in nature. In an
exemplary embodiment, 53070 is a protein kinase, e.g., a
serine/threonine protein kinase.
[0143] As used herein, the term "protein kinase" includes a protein
or polypeptide that is capable of modulating its own
phosphorylation state or the phosphorylation state of another
protein or polypeptide. Protein kinases can have a specificity for
(i.e., a specificity to phosphorylate) serine/threonine residues,
tyrosine residues, or both serine/threonine and tyrosine residues.
Specificity of a protein kinase for phosphorylation of either
tyrosine or serine/threonine can be predicted by the sequence of
two of the subdomains (VIb and VIII) in which different residues
are conserved in each class (as described in, for example, Hanks et
al. (1988) Science 241:42-52) the contents of which are
incorporated herein by reference). Preferably, the protein kinase
of the invention is a serine/threonine protein kinase.
[0144] A 53070 activity can also be an indirect activity, e.g., a
cellular signaling activity mediated by interaction of the 53070
protein with a 53070 substrate. Protein kinases play a role in
signaling pathways associated with cellular growth. For example,
protein kinases are involved in the regulation of signal
transmission from cellular receptors, e.g., growth-factor
receptors; entry of cells into mitosis; and the regulation of
cytoskeleton function, e.g., actin bundling. The features of the
53070 molecules of the present invention can provide similar
biological activities as protein kinase family members. For
example, the 53070 proteins of the present invention can have one
or more of the following activities: (1) the ability to bind to at
least one nucleoside tri-phosphate, e.g., ATP; (2) the ability to
auto-phosphorylate; (3) the ability to phosphorylate other
proteins; (4) the ability to phosphorylate serine or threonine
residues on other proteins; (5) the ability to alter the activity
or sub-cellular localization of a substrate molecule via
phosphorylation; (6) the ability to regulate the transmission of
signals from cellular receptors, e.g., growth factor receptors or
adhesion receptors; (7) the ability to modulate the entry of a cell
into mitosis; (8) the ability to regulate the process of cell
death; (9) the ability to regulate cell differentiation; (10) the
ability to regulate cell growth; (11) the ability to regulate actin
or tubulin dynamics; and/or (12) the ability to regulate cell shape
and motility.
[0145] Inhibition or over stimulation of the activity of protein
kinases involved in signaling pathways associated with cellular
growth or differentiation can lead to perturbed cellular growth or
function, which can in turn lead to cellular growth and/or
differentiation related disorders. As used herein, a "cellular
growth and/or differentiation disorder" includes a disorder,
disease, or condition characterized by a deregulation, e.g., an
upregulation or a downregulation, of cellular growth and/or
abnormal cellular behavior. Cellular growth deregulation may be due
to a deregulation of cellular proliferation, cell cycle
progression, cellular differentiation and/or cellular
hypertrophy.
[0146] Thus, the 53070 molecules can act as novel diagnostic
targets and therapeutic agents for controlling one or more of
cellular proliferative and/or differentiative disorders, disorders
associated with bone metabolism, immune disorders (e.g.,
inflammatory disorders), cardiovascular disorders, liver disorders,
viral diseases, pain or metabolic disorders.
[0147] Examples of cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, metastatic
disorders or hematopoietic neoplastic disorders, e.g., leukemias. A
metastatic tumor can arise from a multitude of primary tumor types,
including but not limited to those of prostate, colon, lung, breast
and liver origin.
[0148] As used herein, the terms "cancer", "hyperproliferative" and
"neoplastic" refer to cells having the capacity for autonomous
growth. Examples of such cells include cells having an abnormal
state or condition characterized by rapidly proliferating cell
growth. Hyperproliferative and neoplastic disease states may be
categorized as pathologic, i.e., characterizing or constituting a
disease state, or may be categorized as non-pathologic, i.e., a
deviation from normal but not associated with a disease state. The
term is meant to include all types of cancerous growths or
oncogenic processes, metastatic tissues or malignantly transformed
cells, tissues, or organs, irrespective of histopathologic type or
stage of invasiveness. "Pathologic hyperproliferative" cells occur
in disease states characterized by malignant tumor growth. Examples
of non-pathologic hyperproliferative cells include proliferation of
cells associated with wound repair.
[0149] The terms "cancer" or "neoplasms" include malignancies of
the various organ systems, such as affecting lung, breast, thyroid,
lymphoid, gastrointestinal, and genito-urinary tract, as well as
adenocarcinomas which include malignancies such as most colon
cancers, renal-cell carcinoma, prostate cancer and/or testicular
tumors, non-small cell carcinoma of the lung, cancer of the small
intestine and cancer of the esophagus.
[0150] The term "carcinoma" is art recognized and refers to
malignancies of epithelial or endocrine tissues including
respiratory system carcinomas, gastrointestinal system carcinomas,
genitourinary system carcinomas, testicular carcinomas, breast
carcinomas, prostatic carcinomas, endocrine system carcinomas, and
melanomas. Exemplary carcinomas include those forming from tissue
of the cervix, lung, prostate, breast, head and neck, colon and
ovary. The term also includes carcinosarcomas, e.g., which include
malignant tumors composed of carcinomatous and sarcomatous tissues.
An "adenocarcinoma" refers to a carcinoma derived from glandular
tissue or in which the tumor cells form recognizable glandular
structures.
[0151] The term "sarcoma" is art recognized and refers to malignant
tumors of mesenchymal derivation.
[0152] Additional examples of proliferative disorders include
hematopoietic neoplastic disorders. As used herein, the term
"hematopoietic neoplastic disorders" includes diseases involving
hyperplastic/neoplastic cells of hematopoietic origin. A
hematopoietic neoplastic disorder can arise from myeloid, lymphoid
or erythroid lineages, or precursor cells thereof. Preferably, the
diseases arise from poorly differentiated acute leukemias, e.g.,
erythroblastic leukemia and acute megakaryoblastic leukemia.
Additional exemplary myeloid disorders include, but are not limited
to, acute promyeloid leukemia (APML), acute myelogenous leukemia
(AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus,
L. (1991) Crit Rev. in Oncol./Hemotol. 11:267-97); lymphoid
malignancies include, but are not limited to acute lymphoblastic
leukemia (ALL) which includes B-lineage ALL and T-lineage ALL,
chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL),
hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM).
Additional forms of malignant lymphomas include, but are not
limited to non-Hodgkin lymphoma and variants thereof, peripheral T
cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous
T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF),
Hodgkin's disease and Reed-Sternberg disease.
[0153] The 53070 nucleic acid and protein of the invention can be
used to treat and/or diagnose a variety of immune disorders.
Examples of hematopoietic disorders or diseases include, but are
not limited to, autoimmune diseases (including, for example,
diabetes mellitus, arthritis (including rheumatoid arthritis,
juvenile rheumatoid arthritis, osteoarthritis, psoriatic
arthritis), multiple sclerosis, encephalomyelitis, myasthenia
gravis, systemic lupus erythematosis, autoimmune thyroiditis,
dermatitis (including atopic dermatitis and eczematous dermatitis),
psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer,
iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis,
asthma, allergic asthma, cutaneous lupus erythematosus,
scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal
reactions, erythema nodosum leprosum, autoimmune uveitis, allergic
encephalomyelitis, acute necrotizing hemorrhagic encephalopathy,
idiopathic bilateral progressive sensorineural hearing loss,
aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia,
polychondritis, Wegener's granulomatosis, chronic active hepatitis,
Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves'
disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior,
and interstitial lung fibrosis), graft-versus-host disease, cases
of transplantation, and allergy such as, atopic allergy.
[0154] Examples of disorders involving the heart or "cardiovascular
disorder" include, but are not limited to, a disease, disorder, or
state involving the cardiovascular system, e.g., the heart, the
blood vessels, and/or the blood. A cardiovascular disorder can be
caused by an imbalance in arterial pressure, a malfunction of the
heart, or an occlusion of a blood vessel, e.g., by a thrombus.
Examples of such disorders include hypertension, atherosclerosis,
coronary artery spasm, congestive heart failure, coronary artery
disease, valvular disease, arrhythmias, and cardiomyopathies.
[0155] The 53070 molecules of the invention may be used to treat,
prevent, and/or diagnose reproductive disorders, e.g., prostatic or
testicular disorders. As used herein, "a prostate disorder" refers
to an abnormal condition occurring in the male pelvic region
characterized by, e.g., male sexual dysfunction and/or urinary
symptoms. This disorder may be manifested in the form of
genitourinary inflammation (e.g., inflammation of smooth muscle
cells) as in several common diseases of the prostate including
prostatitis, benign prostatic hyperplasia and cancer, e.g.,
adenocarcinoma or carcinoma, of the prostate.
15985
[0156] Protein kinases are a large, diverse protein family.
Prominent among protein kinases in eukaryotes, are serine/threonine
protein kinases. These enzymes transfer a phosphate from ATP to the
hydroxyl of a serine or threonine side chain, where the phosphate
can remain stably attached. Serine/threonine protein kinases, also
called serine protein kinases, are frequently utilized in
signalling cascades as the activity of these enzymes can be finely
regulated by stimuli. A common stimulus is phosphorylation of the
serine protein kinase itself. Hence, signalling pathways, such as
the MAP protein kinase cascade, can contain multiple proteins
kinases which sequentially activate. This design has the advantages
of regulation, sensitivity, and amplification. Kinase cascades can
be activated locally, for example, near a signalling receptor on a
discrete region of the plasma membrane. An ultimate target of
protein kinases is the cytoskeleton and its associated proteins, as
it is often the object of signalling cascades to alter cell
morphology, or cell movement.
[0157] One important cytokeletal protein is doublecortin.
Doublecortin coassembles with microtubules in neurons of the brain.
Doublecortin was observed in vitro to stimulate the polymerization
of microtubules (Gleeson et al. (1999) Neuron 23:257-271).
Moreover, doublecortin colocalizes with microtubules in neurons
that are migrating in the central and peripheral nervous system
during embryonic and postnatal development (Gleeson, supra.).
Remarkably, defects in gene for doublecortin are the cause of
X-linked lissencephaly, also called Double Cortex Syndrome (Gleeson
et al. (1998) Cell 92:63-72). Patients with this disorder have
severe mental retardation, and intractable epilepsy. As result of
the failure of almost all cortical neurons to migrate completely to
their destination, the cerebral cortex is malformed, literally
"smooth brain" as a result. The doublecortin protein appears to be
critical to the neuronal migration process.
[0158] A feature of the doublecortin protein is two copies of a
short repeats of approximately 80 amino acids. Mutations in
affected individuals cluster in these repeats (Gleeson et al.
(1999) Ann. Neurol. 45:146-153; Sapir et al. (2000) Hum. Mol.
Genet. 9:703-712). These repeats in isolation can modulate the
properties of microtubules (Sapir, supra.). Interestingly, another
human protein, KIAA0369, has two copies of these noted doublecortin
repeats. KIAA0369 also contains a CAM kinase-like serine protein
kinase domain. KIAA0369 is highly expressed in the fetal and adult
brain (Sossey-Alaoui and Srivastava (1999) Genomics 56:121-126) and
may function in a calcium signaling pathway controlling neuronal
migration in the brain (see GenBank entry GI:6225242).
[0159] The human 15985 sequence (see SEQ ID NO:7), which is
approximately 3552 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
2301 nucleotides, including the termination codon. The coding
sequence encodes a 766 amino acid protein (see SEQ ID NO:8).
[0160] Human 15985 contains the following regions or other
structural features.
[0161] a protein kinase domain (PFAM Accession Number PF00069)
located at about amino acid residues 394 to 651 of SEQ ID NO:8;
[0162] a serine/threonine kinase active-site signature (Prosite
PS00108) located at about amino acid residues 511 to 523 of SEQ ID
NO:8;
[0163] two doublecortin repeats located at about amino acid
residues 67 to 158, and 192 to 280 of SEQ ID NO:8;
[0164] four predicted N-glycosylation sites (PS00001) at about
amino acids 164 to 167, 363 to 366, 619 to 622, and 681 to 684 of
SEQ ID NO:8;
[0165] nineteen predicted Protein Kinase C phosphorylation sites
(PS00005) at about amino acids 3 to 5, 23 to 25, 67 to 69, 93 to
95, 129 to 131, 173 to 175, 182 to 184, 312 to 314, 331 to 333, 334
to 336, 357 to 349, 416 to 418, 484 to 486, 488 to 490, 532 to 534,
623 to 625, 666 to 668, 710 to 712, and 760 to 762 of SEQ ID
NO:8;
[0166] eleven predicted Casein Kinase II phosphorylation sites
(PS00006) located at about amino acids 109 to 122, 133 to 136, 389
to 392, 416 to 419, 461 to 464, 488 to 491, 542 to 545, 623 to 626,
693 to 696, 724 to 727, and 739 to 742 of SEQ ID NO:8;
[0167] one predicted cAMP/cGMP-dependent protein kinase
phosphorylation sites (PS00004) located at about amino acids 130 to
133 of SEQ ID NO:8; and
[0168] ten predicted N-myristylation sites (PS00008) from about
amino acids 22 to 27, 32 to 37, 86 to 91, 172 to 177, 323 to 328,
346 to 351, 378 to 383, 643 to 648, 699 to 704, and 754 to 759 of
SEQ ID NO:8.
[0169] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to
Sonnhammer et al. (1997) Protein 28:405-420.
[0170] The 15985 protein contains a significant number of
structural characteristics in common with members of the protein
kinase family. The term "family" when referring to the protein and
nucleic acid molecules of the invention means two or more proteins
or nucleic acid molecules having a common structural domain or
motif and having sufficient amino acid or nucleotide sequence
homology as defined herein. Such family members can be naturally or
non-naturally occurring and can be from either the same or
different species. For example, a family can contain a first
protein of human origin as well as other distinct proteins of human
origin, or alternatively, can contain homologues of non-human
origin, e.g., rat or mouse proteins. Members of a family can also
have common functional characteristics.
[0171] Protein kinases have a catalytic protein kinase domain,
which contains both .alpha.-helical and .beta.-stranded structures.
In general, the domain has a smaller amino-terminal lobe whose
primarily function is to bind ATP, whereas the larger
carboxy-terminal lobe functions to recognize and bind peptide
substrates, and contributes catalytic side chains for phosphoryl
transfer. One hallmark of serine protein kinases is the active site
signature, Prosite PS00108,
[LIVMFYC]-X-[HY]-D-[LIVMFY]-K-X-X-N-[LIVMFYCT](3) wherein X
represents any amino acid and the number in parentheses indicates
the number of consecutive positions with a given profile of amino
acids.
[0172] Protein kinases play a role in signaling pathways associated
with cellular growth. For example, protein kinases are involved in
the regulation of signal transmission from cellular receptors,
e.g., growth-factor receptors; entry of cells into mitosis; and the
regulation of cytoskeleton function, e.g., actin bundling. Thus,
the molecules of the present invention may be involved in: 1) the
regulation of transmission of signals from cellular receptors,
e.g., cell growth factor receptors; 2) the modulation of the entry
of cells, e.g., precursor cells, into mitosis; 3) the modulation of
cellular differentiation; 4) the modulation of cell death; and 5)
the regulation of cytoskeleton function, e.g., actin bundling.
[0173] Inhibition or over stimulation of the activity of protein
kinases involved in signaling pathways associated with cellular
growth can lead to perturbed cellular growth, which can in turn
lead to cellular growth related disorders. As used herein, a
"cellular growth related disorder" includes a disorder, disease, or
condition characterized by a deregulation, e.g., an upregulation or
a downregulation, of cellular growth. Cellular growth deregulation
may be due to a deregulation of cellular proliferation, cell cycle
progression, cellular differentiation and/or cellular hypertrophy.
Examples of cellular growth related disorders include
cardiovascular disorders such as heart failure, hypertension,
atrial fibrillation, dilated cardiomyopathy, idiopathic
cardiomyopathy, or angina; proliferative disorders or
differentiative disorders such as cancer, e.g., melanoma, prostate
cancer, cervical cancer, breast cancer, colon cancer, or
sarcoma.
[0174] A 15985 polypeptide can include a "protein kinase domain" or
regions homologous with a "protein kinase domain".
[0175] As used herein, the term "protein kinase domain" includes an
amino acid sequence of about 200 to 500 amino acid residues in
length and having a bit score for the alignment of the sequence to
the protein kinase domain profile (Pfam HMM) of at least 300.
Preferably, a protein kinase domain includes at least about 200 to
500 amino acids, more preferably about 210 to 400 amino acid
residues, or about 230 to 280 amino acids and has a bit score for
the alignment of the sequence to the protein kinase domain (HMM) of
at least 345 or greater. The protein kinase domain (HMM) has been
assigned the PFAM Accession Number PF00069. An alignment of the
protein kinase domain (amino acids 394 to 651 of SEQ ID NO:8) of
human 15985 with a consensus amino acid sequence (SEQ ID NO:10)
derived from a hidden Markov model is depicted in FIG. 5.
[0176] In a preferred embodiment 15985 polypeptide or protein has a
"protein kinase domain" or a region which includes at least about
200 to 500 more preferably about 200 to 400 or 230 to 280 amino
acid residues and has at least about 50%, 60%, 70% 80% 90% 95%,
99%, or 100% homology with a "protein kinase domain," e.g., the
protein kinase domain of human 15985 (e.g., residues 394 to 651 of
SEQ ID NO:8). In addition, a 15985 polypeptide preferably includes
a serine protein kinase active site signature, e.g., the amino acid
sequence from about residues 511 to 523 of SEQ ID NO:8, including a
highly conserved aspartic acid, lysine, and asparagine at amino
acids 515, 517, and 520 of SEQ ID NO:8, respectively.
[0177] To identify the presence of a "protein kinase" domain in a
15985 protein sequence, and make the determination that a
polypeptide or protein of interest has a particular profile, the
amino acid sequence of the protein can be searched against the Pfam
database of HMMs (e.g., the Pfam database, release 2.1) using the
default parameters. For example, the hmmsf program, which is
available as part of the HMMER package of search programs, is a
family specific default program for MILPAT0063 and a score of 15 is
the default threshold score for determining a hit. Alternatively,
the threshold score for determining a hit can be lowered (e.g., to
8 bits). A description of the Pfam database can be found in
Sonhammer et al. (1997) Proteins 28(3):405-420 and a detailed
description of HMMs can be found, for example, in Gribskov et al.
(1990) Meth. Enzymol. 183:146-159; Gribskov et al. (1987) Proc.
Natl. Acad. Sci. USA 84:4355-4358; Krogh et al. (1994) J. Mol.
Biol. 235:1501-1531; and Stultz et al. (1993) Protein Sci.
2:305-314, the contents of which are incorporated herein by
reference. A search was performed against the HMM database
resulting in the identification of a "protein kinase" domain in the
amino acid sequence of human 15985 at about residues 394 to 651 of
SEQ ID NO:8 (see FIG. 5).
[0178] A doublecortin repeats family of proteins is characterized
by a common fold, as typified by the doublecortin and the KIAA0367
proteins. These repeats can modulate the activity and properties of
microtubules, especially microtubules in neuronal cells. A 15985
polypeptide can include at least one, preferably two "doublecortin
repeats" or regions homologous with a "doublecortin repeat".
[0179] As used herein, the term "doublecortin repeat" includes an
amino acid sequence of about 50 to 120 amino acid residues in
length and having a bit score for the alignment of the sequence to
the doublecortin repeat (HMM) of at least 250. Preferably, a
doublecortin repeat includes at least about 50 to 120 amino acids,
more preferably about 60 to 100 amino acid residues, or about 75 to
90 amino acids and has a bit score for the alignment of the
sequence to the doublecortin repeat (HMM) of at least 280 or
greater. An alignment of the doublecortin repeats (amino acids 67
to 158 and 192 to 280 of SEQ ID NO:8) of human 15985 with a
consensus amino acid sequence derived from a hidden Markov model is
depicted in FIG. 6A-6B.
[0180] In a preferred embodiment 15985 polypeptide or protein has a
"doublecortin repeat" or a region which includes at least about 50
to 120 more preferably about 60 to 100 or 75 to 90 amino acid
residues and has at least about 70% 80% 90% 95%, 99%, or 100%
homology with a "doublecortin repeat," e.g., the doublecortin
repeats of human 15985 (e.g., residues 67 to 158 and 192 to 280 of
SEQ ID NO:8).
[0181] To identify the presence of a "doublecortin repeat" in a
15985 protein sequence, and make the determination that a
polypeptide or protein of interest has a particular profile, the
amino acid sequence of the protein can be searched against a
database of HMMs (e.g., the SMART database, Washington University
School of Medicine) as described above. A search was performed
against the SMART database resulting in the identification of
"doublecortin repeats" in the amino acid sequence of human 15985 at
about residues 67 to 158 and 192 to 280 of SEQ ID NO:8 (see FIG.
4).
[0182] A 15985 family member can include at least one protein
kinase domain; and at least one, preferably two "doublecortin
repeats." Furthermore, a 15985 family member can include at least
one, two, three, four, five, six, seven, eight, nine, ten, eleven,
twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen,
and preferably nineteen predicted protein kinase C phosphorylation
sites (PS00005); at least one, two, three, four, five, six, seven,
eight, nine, ten, and preferably eleven predicted casein kinase II
phosphorylation sites (PS00006); at least one predicted
cAMP/cGMP-dependent protein kinase phosphorylation site (PS00004);
at least one, two, three, four, five, six, seven, eight, nine,
preferably ten predicted N-myristylation sites (PS00008), at least
one, two, three, preferably four predicted N-glycosylation sites
(PS000001); at least one protein kinase ATP-binding region
signature (PS00107), and at least one serine/threonine protein
kinase active-site signature (PS00108).
[0183] As the 15985 polypeptides of the invention may modulate
15985-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for 15985-mediated or
related disorders, as described below.
[0184] As used herein, a "15985 activity", "biological activity of
15985" or "functional activity of 15985", refers to an activity
exerted by a 15985 protein, polypeptide or nucleic acid molecule.
For example, a 15985 activity can be an activity exerted by 15985
in a physiological milieu on, e.g., a 15985-responsive cell or on a
15985 substrate, e.g., a protein substrate. A 15985 activity can be
determined in vivo or in vitro. In one embodiment, a 15985 activity
is a direct activity, such as an association with a 15985 target
molecule. A "target molecule" or "binding partner" is a molecule
with which a 15985 protein binds or interacts in nature. In an
exemplary embodiment, 15985 is a microtubule binding protein
[0185] A 15985 activity can also be an indirect activity, e.g., a
cellular signaling activity mediated by interaction of the 15985
protein with a 15985 receptor. The features of the 15985 molecules
of the present invention can provide similar biological activities
as protein kinase family members. For example, the 15985 proteins
of the present invention can have one or more of the following
activities: (1) the ability to bind a cytoskeletal protein, e.g., a
microtubule; (2) the ability to stimulate microtubule
polymerization; (3) the ability to phosphorylate a protein
substrates, e.g., a protein having a serine and/or threonine
residue; (4) the ability to bind to a nucleotide, e.g., an ATP
molecule; (5) the ability to modulate cellular migration, e.g.,
neuronal cell migration; (6) the ability to modulate neural
development and/or maintenance; (7) the ability to regulate the
transmission of signals from cellular receptors, e.g., cell growth
factor receptors; 8) the ability to modulate the entry of cells,
e.g., precursor cells, into mitosis; 9) the ability to modulate
cellular differentiation; and/or 10) the ability to modulate cell
death.
[0186] Based on the above-described sequence similarities, the
15985 molecules of the present invention are predicted regulate
cell migration, e.g., neuronal cell migration, inflammation, and
cellular growth and differentiation, e.g., cancer. Thus, the 15985
molecules can act as novel diagnostic targets and therapeutic
agents for controlling such disorders that can include neurological
and hematopoietic disorders, as well as cancer.
[0187] 15985 mRNA is expressed in tumors from the ovary and lung
(Example 7), as well as breast cancer cell lines (e.g., SkBr3
cells). Lower levels of expression are detected in cardiovascular
tissues and the brain (Example 7). Accordingly, molecules of the
invention may serve as tools to diagnose and/or treat disorders
involving aberrant activities of those cells in which they are
expressed disorders of the lung, breast or ovaries, e.g., cancers,
e.g., ovarian, breast, or lung cancers, as well as cardiovascular
or neurological disorders.
[0188] The 15985 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders, disorders
associated with bone metabolism, immune disorders (e.g.,
inflammatory disorders), cardiovascular disorders, liver disorders,
viral diseases, pain or metabolic disorders.
[0189] Examples of cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, metastatic
disorders or hematopoietic neoplastic disorders, e.g., leukemias. A
metastatic tumor can arise from a multitude of primary tumor types,
including but not limited to those of prostate, colon, lung, breast
and liver origin.
[0190] As used herein, the terms "cancer", "hyperproliferative" and
"neoplastic" refer to cells having the capacity for autonomous
growth. Examples of such cells include cells having an abnormal
state or condition characterized by rapidly proliferating cell
growth. Hyperproliferative and neoplastic disease states may be
categorized as pathologic, i.e., characterizing or constituting a
disease state, or may be categorized as non-pathologic, i.e., a
deviation from normal but not associated with a disease state. The
term is meant to include all types of cancerous growths or
oncogenic processes, metastatic tissues or malignantly transformed
cells, tissues, or organs, irrespective of histopathologic type or
stage of invasiveness. "Pathologic hyperproliferative" cells occur
in disease states characterized by malignant tumor growth. Examples
of non-pathologic hyperproliferative cells include proliferation of
cells associated with wound repair.
[0191] The terms "cancer" or "neoplasms" include malignancies of
the various organ systems, such as affecting lung, breast, thyroid,
lymphoid, gastrointestinal, and genito-urinary tract, as well as
adenocarcinomas which include malignancies such as most colon
cancers, renal-cell carcinoma, prostate cancer and/or testicular
tumors, non-small cell carcinoma of the lung, cancer of the small
intestine and cancer of the esophagus.
[0192] The term "carcinoma" is art recognized and refers to
malignancies of epithelial or endocrine tissues including
respiratory system carcinomas, gastrointestinal system carcinomas,
genitourinary system carcinomas, testicular carcinomas, breast
carcinomas, prostatic carcinomas, endocrine system carcinomas, and
melanomas. Exemplary carcinomas include those forming from tissue
of the cervix, lung, prostate, breast, head and neck, colon and
ovary. The term also includes carcinosarcomas, e.g., which include
malignant tumors composed of carcinomatous and sarcomatous tissues.
An "adenocarcinoma" refers to a carcinoma derived from glandular
tissue or in which the tumor cells form recognizable glandular
structures.
[0193] The term "sarcoma" is art recognized and refers to malignant
tumors of mesenchymal derivation.
[0194] Examples of cellular proliferative and/or differentiative
disorders of the colon include, but are not limited to,
non-neoplastic polyps, adenomas, familial syndromes, colorectal
carcinogenesis, colorectal carcinoma, and carcinoid tumors.
[0195] Examples of cellular proliferative and/or differentiative
disorders of the liver include, but are not limited to, nodular
hyperplasias, adenomas, and malignant tumors, including primary
carcinoma of the liver and metastatic tumors.
[0196] Examples of cellular proliferative and/or differentiative
disorders of the breast include, but are not limited to,
proliferative breast disease including, e.g., epithelial
hyperplasia, sclerosing adenosis, and small duct papillomas;
tumors, e.g., stromal tumors such as fibroadenoma, phyllodes tumor,
and sarcomas, and epithelial tumors such as large duct papilloma;
carcinoma of the breast including in situ (noninvasive) carcinoma
that includes ductal carcinoma in situ (including Paget's disease)
and lobular carcinoma in situ, and invasive (infiltrating)
carcinoma including, but not limited to, invasive ductal carcinoma,
invasive lobular carcinoma, medullary carcinoma, colloid (mucinous)
carcinoma, tubular carcinoma, and invasive papillary carcinoma, and
miscellaneous malignant neoplasms. Disorders in the male breast
include, but are not limited to, gynecomastia and carcinoma.
[0197] Examples of cellular proliferative and/or differentiative
disorders of the lung include, but are not limited to, bronchogenic
carcinoma, including paraneoplastic syndromes, bronchioloalveolar
carcinoma, neuroendocrine tumors, such as bronchial carcinoid,
miscellaneous tumors, and metastatic tumors; pathologies of the
pleura, including inflammatory pleural effusions, noninflammatory
pleural effusions, pneumothorax, and pleural tumors, including
solitary fibrous tumors (pleural fibroma) and malignant
mesothelioma.
[0198] Additional examples of proliferative disorders include
hematopoietic neoplastic disorders. As used herein, the term
"hematopoietic neoplastic disorders" includes diseases involving
hyperplastic/neoplastic cells of hematopoietic origin. A
hematopoietic neoplastic disorder can arise from myeloid, lymphoid
or erythroid lineages, or precursor cells thereof. Preferably, the
diseases arise from poorly differentiated acute leukemias, e.g.,
erythroblastic leukemia and acute megakaryoblastic leukemia.
Additional exemplary myeloid disorders include, but are not limited
to, acute promyeloid leukemia (APML), acute myelogenous leukemia
(AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus,
L. (1991) Crit Rev. in Oncol./Hemotol. 11:267-97); lymphoid
malignancies include, but are not limited to acute lymphoblastic
leukemia (ALL) which includes B-lineage ALL and T-lineage ALL,
chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL),
hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM).
Additional forms of malignant lymphomas include, but are not
limited to non-Hodgkin lymphoma and variants thereof, peripheral T
cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous
T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF),
Hodgkin's disease and Reed-Sternberg disease.
[0199] Examples of neurological disorders include, but are not
limited to, disorders involving neurons, and disorders involving
glia, such as astrocytes, oligodendrocytes, ependymal cells, and
microglia; cerebral edema, raised intracranial pressure and
herniation, and hydrocephalus; malformations and developmental
diseases, such as neural tube defects, forebrain anomalies,
posterior fossa anomalies, and syringomyelia and hydromyelia;
perinatal brain injury; cerebrovascular diseases, such as those
related to hypoxia, ischemia, and infarction, including
hypotension, hypoperfusion, and low-flow states--global cerebral
ischemia and focal cerebral ischemia--infarction from obstruction
of local blood supply, intracranial hemorrhage, including
intracerebral (intraparenchymal) hemorrhage, subarachnoid
hemorrhage and ruptured berry aneurysms, and vascular
malformations, hypertensive cerebrovascular disease, including
lacunar infarcts, slit hemorrhages, and hypertensive
encephalopathy; infections, such as acute meningitis, including
acute pyogenic (bacterial) meningitis and acute aseptic (viral)
meningitis, acute focal suppurative infections, including brain
abscess, subdural empyema, and extradural abscess, chronic
bacterial meningoencephalitis, including tuberculosis and
mycobacterioses, neurosyphilis, and neuroborreliosis (Lyme
disease), viral meningoencephalitis, including arthropod-borne
(Arbo) viral encephalitis, Herpes simplex virus Type 1, Herpes
simplex virus Type 2, Varicalla-zoster virus (Herpes zoster),
cytomegalovirus, poliomyelitis, rabies, and human immunodeficiency
virus 1, including HIV-1 meningoencephalitis (subacute
encephalitis), vacuolar myelopathy, A/DS-associated myopathy,
peripheral neuropathy, and AIDS in children, progressive multifocal
leukoencephalopathy, subacute sclerosing panencephalitis, fungal
meningoencephalitis, other infectious diseases of the nervous
system; transmissible spongiform encephalopathies (prion diseases);
demyelinating diseases, including multiple sclerosis, multiple
sclerosis variants, acute disseminated encephalomyelitis and acute
necrotizing hemorrhagic encephalomyelitis, and other diseases with
demyelination; degenerative diseases, such as degenerative diseases
affecting the cerebral cortex, including Alzheimer disease and Pick
disease, degenerative diseases of basal ganglia and brain stem,
including Parkinsonism, idiopathic Parkinson disease (paralysis
agitans), progressive supranuclear palsy, corticobasal
degeneration, multiple system atrophy, including striatonigral
degeneration, Shy-Drager syndrome, and olivopontocerebellar
atrophy, and Huntington disease; spinocerebellar degenerations,
including spinocerebellar ataxias, including Friedreich ataxia, and
ataxia-telanglectasia, degenerative diseases affecting motor
neurons, including amyotrophic lateral sclerosis (motor neuron
disease), bulbospinal atrophy (Kennedy syndrome), and spinal
muscular atrophy; inborn errors of metabolism, such as
leukodystrophies, including Krabbe disease, metachromatic
leukodystrophy, adrenoleukodystrophy, Pelizaeus-Merzbacher disease,
and Canavan disease, mitochondrial encephalomyopathies, including
Leigh disease and other mitochondrial encephalomyopathies; toxic
and acquired metabolic diseases, including vitamin deficiencies
such as thiamine (vitamin B.sub.1) deficiency and vitamin B.sub.12
deficiency, neurologic sequelae of metabolic disturbances,
including hypoglycemia, hyperglycemia, and hepatic encephatopathy,
toxic disorders, including carbon monoxide, methanol, ethanol, and
radiation, including combined methotrexate and radiation-induced
injury; tumors, such as gliomas, including astrocytoma, including
fibrillary (diffuse) astrocytoma and glioblastoma multiforme,
pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and brain
stem glioma, oligodendroglioma, and ependymoma and related
paraventricular mass lesions, neuronal tumors, poorly
differentiated neoplasms, including medulloblastoma, other
parenchymal tumors, including primary brain lymphoma, germ cell
tumors, and pineal parenchymal tumors, meningiomas, metastatic
tumors, paraneoplastic syndromes, peripheral nerve sheath tumors,
including schwannoma, neurofibroma, and malignant peripheral nerve
sheath tumor (malignant schwannoma), and neurocutaneous syndromes
(phakomatoses), including neurofibromotosis, including Type 1
neurofibromatosis (NF1) and TYPE 2 neurofibromatosis (NF2),
tuberous sclerosis, and Von Hippel-Lindau disease.
[0200] The 15985 nucleic acid and protein of the invention can be
used to treat and/or diagnose a variety of immune disorders.
Examples of immune disorders or diseases include, but are not
limited to, autoimmune diseases (including, for example, diabetes
mellitus, arthritis (including rheumatoid arthritis, juvenile
rheumatoid arthritis, osteoarthritis, psoriatic arthritis),
multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic
lupus erythematosis, autoimmune thyroiditis, dermatitis (including
atopic dermatitis and eczematous dermatitis), psoriasis, Sjogren's
Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis,
keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma,
cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis,
drug eruptions, leprosy reversal reactions, erythema nodosum
leprosum, autoimmune uveitis, allergic encephalomyelitis, acute
necrotizing hemorrhagic encephalopathy, idiopathic bilateral
progressive sensorineural hearing loss, aplastic anemia, pure red
cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's
granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome,
idiopathic sprue, lichen planus, Graves' disease, sarcoidosis,
primary biliary cirrhosis, uveitis posterior, and interstitial lung
fibrosis), graft-versus-host disease, cases of transplantation, and
allergy such as, atopic allergy.
[0201] 15985 is expressed at relatively high levels in normal vein
tissue. Thus, aberrant expression and/or activity of 15985
molecules may mediate disorders involving the blood vessels.
Disorders involving blood vessels include, but are not limited to,
responses of vascular cell walls to injury, such as endothelial
dysfunction and endothelial activation and intimal thickening;
vascular diseases including, but not limited to, congenital
anomalies, such as arteriovenous fistula, atherosclerosis, and
hypertensive vascular disease, such as hypertension; inflammatory
disease--the vasculitides, such as giant cell (temporal) arteritis,
Takayasu arteritis, polyarteritis nodosa (classic), Kawasaki
syndrome (mucocutaneous lymph node syndrome), microscopic
polyanglitis (microscopic polyarteritis, hypersensitivity or
leukocytoclastic anglitis), Wegener granulomatosis, thromboanglitis
obliterans (Buerger disease), vasculitis associated with other
disorders, and infectious arteritis; Raynaud disease; aneurysms and
dissection, such as abdominal aortic aneurysms, syphilitic (luetic)
aneurysms, and aortic dissection (dissecting hematoma); disorders
of veins and lymphatics, such as varicose veins, thrombophlebitis
and phlebothrombosis, obstruction of superior vena cava (superior
vena cava syndrome), obstruction of inferior vena cava (inferior
vena cava syndrome), and lymphangitis and lymphedema; tumors,
including benign tumors and tumor-like conditions, such as
hemangioma, lymphangioma, glomus tumor (glomangioma), vascular
ectasias, and bacillary angiomatosis, and intermediate-grade
(borderline low-grade malignant) tumors, such as Kaposi sarcoma and
hemangloendothelioma, and malignant tumors, such as angiosarcoma
and hemangiopericytoma; and pathology of therapeutic interventions
in vascular disease, such as balloon angioplasty and related
techniques and vascular replacement, such as coronary artery bypass
graft surgery.
[0202] As used herein, disorders involving the heart, or
"cardiovascular disease" or a "cardiovascular disorder" includes a
disease or disorder which affects the cardiovascular system, e.g.,
the heart, the blood vessels, and/or the blood. A cardiovascular
disorder can be caused by an imbalance in arterial pressure, a
malfunction of the heart, or an occlusion of a blood vessel, e.g.,
by a thrombus. A cardiovascular disorder includes, but is not
limited to disorders such as arteriosclerosis, atherosclerosis,
cardiac hypertrophy, ischemia reperfusion injury, restenosis,
arterial inflammation, vascular wall remodeling, ventricular
remodeling, rapid ventricular pacing, coronary microembolism,
tachycardia, bradycardia, pressure overload, aortic bending,
coronary artery ligation, vascular heart disease, valvular disease,
including but not limited to, valvular degeneration caused by
calcification, rheumatic heart disease, endocarditis, or
complications of artificial valves; atrial fibrillation, long-QT
syndrome, congestive heart failure, sinus node dysfunction, angina,
heart failure, hypertension, atrial fibrillation, atrial flutter,
pericardial disease, including but not limited to, pericardial
effusion and pericarditis; cardiomyopathies, e.g., dilated
cardiomyopathy or idiopathic cardiomyopathy, myocardial infarction,
coronary artery disease, coronary artery spasm, ischemic disease,
arrhythmia, sudden cardiac death, and cardiovascular developmental
disorders (e.g., arteriovenous malformations, arteriovenous
fistulae, raynaud's syndrome, neurogenic thoracic outlet syndrome,
causalgia/reflex sympathetic dystrophy, hemangioma, aneurysm,
cavernous angioma, aortic valve stenosis, atrial septal defects,
atrioventricular canal, coarctation of the aorta, ebsteins anomaly,
hypoplastic left heart syndrome, interruption of the aortic arch,
mitral valve prolapse, ductus arteriosus, patent foramen ovale,
partial anomalous pulmonary venous return, pulmonary atresia with
ventricular septal defect, pulmonary atresia without ventricular
septal defect, persistance of the fetal circulation, pulmonary
valve stenosis, single ventricle, total anomalous pulmonary venous
return, transposition of the great vessels, tricuspid atresia,
truncus arteriosus, ventricular septal defects). A cardiovasular
disease or disorder also can include an endothelial cell
disorder.
[0203] 15985 mRNA is expressed at relatively high levels in ovary
tumor and normal ovary tissue. Thus, aberrant expression and/or
activity of 15985 molecules may mediate disorders involving ovary
tissue, e.g. disorders involving the ovary. Disorders involving the
ovary include, for example, polycystic ovarian disease,
Stein-leventhal syndrome, Pseudomyxoma peritonei and stromal
hyperthecosis; ovarian tumors such as, tumors of coelomic
epithelium, serous tumors, mucinous tumors, endometeriod tumors,
clear cell adenocarcinoma, cystadenofibroma, brenner tumor, surface
epithelial tumors; germ cell tumors such as mature (benign)
teratomas, monodermal teratomas, immature malignant teratomas,
dysgerminoma, endodermal sinus tumor, choriocarcinoma; sex
cord-stomal tumors such as, granulosa-theca cell tumors,
thecoma-fibromas, androblastomas, hill cell tumors, and
gonadoblastoma; and metastatic tumors such as Krukenberg
tumors.
[0204] As 15985 mRNA is expressed in lung tissue, and therefore
aberrant expression and/or activity of 15985 molecules may mediate
disorders involving this tissue, e.g. disorders involving the lung.
Examples of disorders of the lung include, but are not limited to,
congenital anomalies; atelectasis; diseases of vascular origin,
such as pulmonary congestion and edema, including hemodynamic
pulmonary edema and edema caused by microvascular injury, adult
respiratory distress syndrome (diffuse alveolar damage), pulmonary
embolism, hemorrhage, and infarction, and pulmonary hypertension
and vascular sclerosis; chronic obstructive pulmonary disease, such
as emphysema, chronic bronchitis, bronchial asthma, and
bronchiectasis; diffuse interstitial (infiltrative, restrictive)
diseases, such as pneumoconioses, sarcoidosis, idiopathic pulmonary
fibrosis, desquamative interstitial pneumonitis, hypersensitivity
pneumonitis, pulmonary eosinophilia (pulmonary infiltration with
eosinophilia), Bronchiolitis obliterans-organizing pneumonia,
diffuse pulmonary hemorrhage syndromes, including Goodpasture
syndrome, idiopathic pulmonary hemosiderosis and other hemorrhagic
syndromes, pulmonary involvement in collagen vascular disorders,
and pulmonary alveolar proteinosis; complications of therapies,
such as drug-induced lung disease, radiation-induced lung disease,
and lung transplantation; tumors, such as bronchogenic carcinoma,
including paraneoplastic syndromes, bronchioloalveolar carcinoma,
neuroendocrine tumors, such as bronchial carcinoid, miscellaneous
tumors, and metastatic tumors; pathologies of the pleura, including
inflammatory pleural effusions, noninflammatory pleural effusions,
pneumothorax, and pleural tumors, including solitary fibrous tumors
(pleural fibroma) and malignant mesothelioma.
26583
[0205] Protein phosphatases are enzymes that reverse the actions of
protein kinases by cleaving phosphate from serine, threonine,
and/or tyrosine residues in proteins. The protein phosphatases are
divided into three groups according to catalytic function: (1)
protein phosphatases that dephosphorylate serine and threonine
residues; (2) protein phosphatases which dephosphorylate tyrosine
residues; and (3) protein phosphatases which dephosphorylate
serine, threonine and tyrosine residues.
[0206] Serine/threonine protein phosphatases are associated with
the regulation of cholesterol biosynthesis, glycogen metabolism,
muscle contractility, calcium ion channels, protein synthesis,
regulation of the G2 to M transition of the cell cycle, regulation
of glycolysis (6-phosphofructo-2-kinase and pyruvate kinase),
glycogenolysis (phosphorylase kinase subunit), gluconeogenesis
(fructose-2,6-bisphosphatase and pyruvate kinase), amino-acid
degradation (phenylalanine hydroxylase), lipid metabolism
(acetyl-CoA carboxylase), catecholamine synthesis (tyrosine
hydroxylase) and protein synthesis (elongation factor 2).
[0207] Protein tyrosine phosphatases (PTPs) are a family of
intracellular and integral membrane phosphatases that
dephosphorylate tyrosine residues in proteins. PTPs have been
identified in mammals, Drosophila and Schiz. pombe and are
implicated in the control of normal and neoplastic growth and
proliferation.
[0208] Generally, the balance of protein phosphorylation in a cell
depends on the level of protein kinase and protein phosphatase
activity. Protein phosphorylation is important for the regulation
of numerous metabolic processes such as cholesterol biosynthesis
and has been associated with cell cycle progression and
transformation of cells. Thus, protein phosphatases can serve as
positive or negative regulators of metabolic function as well as
cell growth and differentiation. Given the important biological
roles and properties of phosphatases, there exists a need for the
identification of novel genes encoding such proteins as well as for
the discovery of modulators of such molecules for use in regulating
a variety of normal and/or pathological cellular processes.
[0209] The human 26583 sequence (SEQ ID NO:14), which is
approximately 2838 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
1613 nucleotides (nucleotides 462 to 2075 of SEQ ID NO:14; SEQ ID
NO:16). The coding sequence encodes a 537 amino acid protein (SEQ
ID NO:15).
[0210] Human 26583 contains the following regions or other
structural features: a predicted serine/threonine catalytic domain
at residues 172-461; a predicted serine/threonine catalytic domain
at residues 99-523; one predicted N-glycosylation site (PS00001)
from about amino acids 105 to 108; five predicted Protein Kinase C
sites (PS00005) from about amino acids 95 to 97, 156 to 158, 182 to
184, 211 to 213 and 463 to 465 of SEQ ID NO:15; five predicted
Casein Kinase II phosphorylation sites (PS00006) from about amino
acids 172 to 175, 228 to 231, 371 to 374, 471 to 474 and 505 to 508
of SEQ ID NO:15; seven predicted N-myristoylation sites (PS00008)
from about amino acids 137 to 142, 148 to 153, 271 to 276, 303 to
308, 419 to 424, 456 to 461 and 531 to 536 of SEQ ID NO:15; one
amidation site (PS00009) at about amino acids 67 to 70 of SEQ ID
NO:15; and one protein phosphatase 2C signature (PS01037) from
about amino acids 139 to 147 of SEQ ID NO:15.
[0211] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to
Sonnhammer et al. (1997) Protein 28:405-420.
[0212] The 26583 protein contains a significant number of
structural characteristics in common with members of the
serine/threonine phosphatase family. The term "family" when
referring to the protein and nucleic acid molecules of the
invention means two or more proteins or nucleic acid molecules
having a common structural domain or motif and having sufficient
amino acid or nucleotide sequence homology as defined herein. Such
family members can be naturally or non-naturally occurring and can
be from either the same or different species. For example, a family
can contain a first protein of human origin as well as other
distinct proteins of human origin, or alternatively, can contain
homologues of non-human origin, e.g., rat or mouse proteins.
Members of a family can also have common functional
characteristics.
[0213] A 26583 polypeptide of the invention can include a
"serine/threonine phosphatase catalytic domain" or regions
homologous with a "serine/threonine phosphatase catalytic domain."
As used herein, the term "serine/threonine phosphatase catalytic
domain" refers to an amino acid sequence having about 200 to 450,
preferably about 150 to 350, more preferably about 100 to 300, and
even more preferably about 288 amino acid residues.
[0214] Based on structural similarities, members of the
serine/threonine phosphatase family have been classified into
various subfamilies, including four major types of protein
phosphatase catalytic subunits that dephosphorylate serine and
threonine residues. These enzymes are termed protein phosphatases
1, 2A, 2B, and 2C (PP1, PP2A, PP2B and PP2C, the human genome
symbols being PPP1, PPP2, PPP3 and PPM1 respectively). Protein
phosphatase PP1 appears to have pleiotropic actions in the
regulation of glycogen metabolism, muscle contractility, calcium
ion channels, protein synthesis and cell division. Protein
phosphatase 2A (PP2A) dephosphorylates enzymes involved in the
regulation of glycolysis (6-phosphofructo-2-kinase and pyruvate
kinase), glycogenolysis (phosphorylase kinase subunit),
gluconeogenesis (fructose-2,6-bisphosphatase and pyruvate kinase),
amino-acid degradation (phenylalanine hydroxylase), lipid
metabolism (acetyl-CoA carboxylase), catecholamine synthesis
(tyrosine hydroxylase) and protein synthesis (elongation factor 2).
The catalytic subunit has also been identified as a negative
regulator of the dephosphorylation and activation of p34cdc2
protein kinase in Xenopus and S. pombe and therefore as a
suppressor of the G2 to M transition of the cell cycle. Protein
phosphatase 2B (PP2B) is particularly abundant in brain where it
comprises up to 1% of total protein. The physiological roles of
PP2B may be to allow extracellular signals that act via Ca.sup.2+
to attenuate those that act through cyclic AMP. PP2B may be
involved in the regulation of ion channels in both neuronal and
non-neuronal cells. Protein phosphatase 4 (PP4) is required in late
G1 of the cell cycle for progression into S phase in yeast.
[0215] Protein phosphatase 2C (PP2C) may play a role in the
regulation of cholesterol biosynthesis, as PP2C possesses high
activity against hydroxymethylglutaryl-CoA reductase kinase, which
inactivates HMG-CoA reductase, the rate-limiting enzyme of this
pathway. Protein phosphatase 2C (PP2C) is a monomeric enzyme of
about 42 Kd that shows broad substrate specificity and is dependent
on divalent cations (mainly manganese and magnesium) for its
activity. At least three isozymes are known in mammals: PP2C-alpha,
-beta and -gamma. In yeast, there are at least four PP2C homologs:
phosphatase PTC1 that has weak tyrosine phosphatase activity in
addition to its activity on serines, phosphatases PTC2 and PTC3.
Isozymes of PP2C are also known from Arabidopsis thaliana (ABI1,
PPH1), Caenorhabditis elegans (FEM-2, F42G9.1, T23F11.1),
Leishmania chagasi and Paramecium tetraurelia. In Arabidopsis
thaliana, the kinase associated protein phosphatase (KAPP) is an
enzyme that dephosphorylates the Ser/Thr receptor-like kinase RLK5
and which contains a C-terminal PP2C domain. In addition, PP2C
appears to be significantly similar to the catalytic subunit of
pyruvate dehydrogenase phosphatase (EC 3.1.3.43) (PDPC) that
catalyzes dephosphorylation and concomitant reactivation of the
alpha subunit of the E1 component of the pyruvate dehydrogenase
complex. PDPC is a mitochondrial enzyme and, like PP2C, is
magnesium-dependent.
[0216] In addition, protein serine/threonine phosphatases may play
a role in signaling pathways associated with cellular growth. For
example, protein serine/threonine phosphatases can be involved in
the regulation of signal transmission from cellular receptors,
e.g., growth-factor receptors; entry of cells into mitosis. Thus,
the 26583 molecules of the present invention may be involved in:
(1) catalyzing the removal of a phosphate group attached to a
tyrosine residue in a protein; (2) the regulation of transmission
of signals from cellular receptors; (3) modulation of cellular
growth signaling mechanisms; (4) modulation of cell proliferation
or growth; (5) modulation of cell differentiation; (6) modulation
of cell survival; (7) modulation of transformation; (8) modulation
of apoptosis of a cell (e.g., a cancer cell); (9) modulation of
cholesterol biosynthesis; (10) modulation of glycogen metabolism;
(11) modulation of muscle contractility; (12) modulation of calcium
ion channel activity; (13) modulation of glycolysis,
glycogenolysis, or gluconeogenesis; (14) modulation of amino-acid
degradation; (15) modulation of lipid metabolism; and/or (16)
modulation of catecholamine synthesis.
[0217] In a preferred embodiment, a 26583 polypeptide or protein
has a "serine/threonine phosphatase catalytic domain" refers to an
amino acid sequence having about 200 to 450, preferably about 150
to 350, more preferably about 100 to 300, and even more preferably
about 288 amino acid residues and has at least about 70% 80% 90%
95%, 99%, or 100% homology with a "serine/threonine phosphatase
catalytic domain," e.g., the serine/threonine phosphatase catalytic
domain of human 26583.
[0218] Thus, a 26583 molecule of the present invention can be
identified based on the presence of a "serine/threonine phosphatase
catalytic domain" in the protein or corresponding nucleic acid
molecule. Preferably, a serine/threonine phosphatase catalytic
domain includes a protein domain having an amino acid sequence of
about 200 to 500 amino acid residues and having a bit score for the
alignment of the sequence to the fibroblast growth factor domain
(HMM) of at least 150. Preferably, a "serine/threonine phosphatase
catalytic domain" refers to an amino acid sequence having about 200
to 500, preferably about 250 to 400, more preferably about 250 to
350 amino acid residues and has a bit score for the alignment of
the sequence to a serine/threonine phosphatase catalytic domain
(HMM) of at least 100, 200, 250 or greater. An alignment of the
serine/threonine phosphatase of human 26583 (SEQ ID NO:15) with a
consensus amino acid sequence derived from a hidden Markov model is
depicted in FIGS. 10A-10B.
[0219] To identify the presence of a "serine/threonine phosphatase
catalytic domain" in a 26583 protein sequence and to make the
determination that a polypeptide or protein of interest has a
particular profile, the amino acid sequence of the protein can be
searched against a database of HMMs using the default parameters.
For example, the hmmsf program, which is available as part of the
HMMER package of search programs, is a family specific default
program for MILPAT0063 and a score of 15 is the default threshold
score for determining a hit. Alternatively, the threshold score for
determining a hit can be lowered (e.g., to 8 bits). A description
of the Pfam database can be found in Sonhammer et al. (1997)
Proteins 28(3):405-420 and a detailed description of HMMs can be
found, for example, in Gribskov et al. (1990) Meth. Enzymol.
183:146-159; Gribskov et al. (1987) Proc. Natl. Acad. Sci. USA
84:4355-4358; Krogh et al. (1994) J. Mol. Biol. 235:1501-1531; and
Stultz et al. (1993) Protein Sci. 2:305-314, the contents of which
are incorporated herein by reference. A search was performed
against the HMM database resulting in the identification of an
amino acid sequence of human 26583 that is homologous to a sequence
contained in PP2C at about residues 172 to 461 of SEQ ID NO:15 (see
FIG. 10A). The search further identified an amino acid sequence of
human 26583 that is homologous to a sequence contained in
PP2C.sub.--4 at about residues 99 to 523 of SEQ ID NO:15 (see FIG.
10B).
[0220] As the 26583 polypeptides of the invention may modulate
26583-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for 26583-mediated or
related disorders, as described below. As used herein, "26583
activity," "biological activity of 26583" or "functional activity
of 26583," refers to an activity exerted by a 26583 protein,
polypeptide or nucleic acid molecule on e.g., a 26583-responsive
cell or on a 26583 substrate, e.g., a protein substrate, as
determined in vivo or in vitro. In one embodiment, a 26583 activity
is a direct activity, such as an association with a 26583 target
molecule. A "target molecule" or "binding partner" is a molecule
with which a 26583 protein binds or interacts with in nature, e.g.,
a protein containing one or more serine/threonine residues. A 26583
activity also can be an indirect activity, e.g., a cellular
signaling activity mediated by interaction of the 26583 protein
with a 26583 receptor (e.g., a receptor that is a protein
serine/threonine kinase). For example, a 26583 protein of the
present invention can have one or more of the following activities:
(1) removal of phosphate moieties from phospho-serine/threonine
residues in proteins; (2) the regulation of transmission of signals
from cellular receptors; (3) modulation of cellular growth
signaling mechanisms; (4) modulation of cell proliferation; (5)
modulation of cell differentiation; (6) modulation of
transformation; (7) modulation of apoptosis (e.g., a cancer cell);
(8) modulation of cholesterol biosynthesis; (9) modulation of
glycogen metabolism; (10) modulation of muscle contractility; (11)
modulation of calcium ion channel activity; (12) modulation of
glycolysis, glycogenolysis and gluconeogenesis; (13) modulation of
amino-acid degradation; (14) modulation of lipid metabolism; and/or
(15) modulation of catecholamine synthesis.
[0221] As used herein, the term "cellular growth signaling
mechanism" includes the ability to interact with, e.g., bind to,
and remove a phospho-serine/threonine residue present in a protein,
e.g., a serine or threonine phosphorylated protein and modulate,
e.g., inhibit, one or more of: (1) induction of receptor
dimerization, (2) serine/threonine kinase activation, (3)
phosphorylation of signaling molecules, and/or (4) induction gene
expression; thereby regulating one or more of: (5) cell
proliferation, (6) cell differentiation, (7) cell survival, (8)
oncogenic transformation, (9) migration, and/or (10) apoptosis, of
a cell (e.g., a cancer cell), (11) modulation of cholesterol
biosynthesis, (12) modulation of glycogen metabolism, (13)
modulation of muscle contractility, (14) modulation of calcium ion
channel activity, (15) modulation of glycolysis, glycogenolysis and
gluconeogenesis, (16) modulation of amino-acid degradation, (17)
modulation of lipid metabolism and/or (18) modulation of
catecholamine synthesis.
[0222] Based on the above-described sequence similarities, a 26583
molecule of the present invention is predicted to have similar
biological activities as serine/threonine phosphatase family
members. Thus, the 26583 molecules can act as novel diagnostic
targets and therapeutic agents for controlling cellular
proliferative disorders or metabolic disorders such as those
associated with cholesterol biosynthesis or mitochondrial
dysfunction.
[0223] As used herein, a "cholesterol biosynthesis-associated
disorder" includes any disorder wherein the regulation of
cholesterol biosynthesis is affected by the presence or absence of
a 25583 activity of the invention. For example, the 26583 protein
of the present invention contains sequence homology to PP2C (see
FIG. 10A). PP2C possesses high activity against
hydroxymethylglutaryl-CoA reductase kinase, which inactivates
HMG-CoA reductase, the rate-limiting enzyme of the cholesterol
biosynthetic pathway. Thus, the present invention provides a means
for diagnosing and/or treating a cholesterol
biosynthesis-associated disorder such as, for example, hypo- or
hypercholesterolemia.
[0224] As previously noted, the 26583 protein of the present
invention contains sequence homology to PP2C (see FIG. 10A). PP2C
appears to be significantly similar to the catalytic subunit of
pyruvate dehydrogenase phosphatase (EC 3.1.3.43) (PDPC) that
catalyzes dephosphorylation and concomitant reactivation of the
alpha subunit of the E1 component of the pyruvate dehydrogenase
complex. PDPC is a mitochondrial enzyme and, like PP2C, is
magnesium-dependent. Thus, the present invention is additionally
useful as a means for diagnosing and/or treating disorders
associated with mitochondria. As used herein, a
"mitochondrial-associated disorder" includes any disorder related
to the function or dysfunction of mitochondria. For example,
diabetes mellitus has been associated with deficient mitochondrial
oxidative phosphorylation. Also, mitochondrial dysfunction has been
implicated in neuro-degenerative disorders, such as Parkinson's,
Huntington's and Alzheimer's diseases.
[0225] In addition, the 26583 molecules of the invention are useful
for diagnosing and/or treating cellular proliferative disorders. As
used herein, a "cellular proliferative disorder" includes a
disorder, disease, or condition characterized by a deregulated,
e.g., up-regulated or down-regulated, growth response. As used
herein, a "cellular differentiative disorder" includes a disorder,
disease, or condition characterized by aberrant cellular
differentiation. As used herein, metastatic refers to the ability
of a tumor cell to form implants at a site distant from the
original tumor. Thus, the 26583 molecules can act as novel
diagnostic targets and therapeutic agents for controlling cellular
proliferative and/or differentiative disorders.
[0226] Based on the above-described sequence similarities, the
26583 molecules of the present invention are predicted to have
similar biological activities as serine/threonine phosphatase
family members. Thus, the 26583 molecules can act as novel
diagnostic targets and therapeutic agents for controlling one or
more of cellular proliferative and/or differentiative disorders,
disorders associated with bone metabolism, immune or hematopoietic
disorders, cardiovascular disorders, liver disorders, viral
diseases, pain or metabolic disorders such as hypo- or
hypercholesterolemia, or disorders associated with mitochondrial
dysfunction.
[0227] In addition, the 26583 molecules of the invention may
modulate physiological and pathological processes in the cells or
tissues where they are expressed. For example, Taq Man studies
described herein show expression of 26583 in normal human breast,
lung, colon, liver, and brain tissue (FIG. 11). 26583 expression
can be modulated in samples of tumor tissue compared to normal
tissue. For example, 26583 expression in brain tumor samples can be
significantly higher than in normal brain tissue samples; and 26583
expression in lung tumor tissue can be higher than in normal lung
tissue (FIG. 11).
[0228] Examples of cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, metastatic
disorders or hematopoietic neoplastic disorders, e.g., leukemias. A
metastatic tumor can arise from a multitude of primary tumor types,
including but not limited to those of prostate, colon, lung, breast
and liver origin.
[0229] As used herein, the terms "cancer," "hyperproliferative" and
"neoplastic" refer to cells having the capacity for autonomous
growth, i.e., an abnormal state or condition characterized by
rapidly, proliferating cell growth. Hyperproliferative and
neoplastic disease states may be categorized as pathologic, i.e.,
characterizing or constituting a disease state, or may be
categorized as non-pathologic, i.e., a deviation from normal but
not associated with a disease state. The term is meant to include
all types of cancerous growths or oncogenic processes, metastatic
tissues or malignantly transformed cells, tissues, or organs,
irrespective of histopathologic type or stage of invasiveness.
"Pathologic hyperproliferative" cells occur in disease states
characterized by malignant tumor growth. Examples of non-pathologic
hyperproliferative cells include proliferation of cells associated
with wound repair.
[0230] The terms "cancer" or "neoplasms" include malignancies of
the various organ systems, such as affecting lung, breast, thyroid,
lymphoid, gastrointestinal, and genito-urinary tract, as well as
adenocarcinomas which include malignancies such as most colon
cancers, renal-cell carcinoma, prostate cancer and/or testicular
tumors, non-small cell carcinoma of the lung, cancer of the small
intestine and cancer of the esophagus.
[0231] The term "carcinoma" is art recognized and refers to
malignancies of epithelial or endocrine tissues including
respiratory system carcinomas, gastrointestinal system carcinomas,
genitourinary system carcinomas, testicular carcinomas, breast
carcinomas, prostatic carcinomas, endocrine system carcinomas, and
melanomas. Exemplary carcinomas include those forming from tissue
of the cervix, lung, prostate, breast, head and neck, colon and
ovary. The term also includes carcinosarcomas, e.g., which include
malignant tumors composed of carcinomatous and sarcomatous tissues.
An "adenocarcinoma" refers to a carcinoma derived from glandular
tissue or in which the tumor cells form recognizable glandular
structures.
[0232] The term "sarcoma" is art recognized and refers to malignant
tumors of mesenchymal derivation.
[0233] The 26583 nucleic acid and protein of the invention can be
used to treat and/or diagnose a variety of proliferative disorders.
Such disorders include hematopoietic neoplastic disorders. As used
herein, the term "hematopoietic neoplastic disorders" includes
diseases involving hyperplastic/neoplastic cells of hematopoietic
origin, e.g., arising from myeloid, lymphoid or erythroid lineages,
or precursor cells thereof. Preferably, the diseases arise from
poorly differentiated acute leukemias, e.g., erythroblastic
leukemia and acute megakaryoblastic leukemia. Additional exemplary
myeloid disorders include, but are not limited to, acute promyeloid
leukemia (APML), acute myelogenous leukemia (AML) and chronic
myelogenous leukemia (CML) (reviewed in Vaickus (1991) Crit Rev. in
Oncol./Hemotol. 11:267-97); lymphoid malignancies include, but are
not limited to acute lymphoblastic leukemia (ALL) which includes
B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia
(CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and
Waldenstrom's macroglobulinemia (WM). Additional forms of malignant
lymphomas include, but are not limited to non-Hodgkin lymphoma and
variants thereof, peripheral T cell lymphomas, adult T cell
leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large
granular lymphocytic leukemia (LGF), Hodgkin's disease and
Reed-Sternberg disease.
[0234] Aberrant expression and/or activity of 26583 molecules may
mediate disorders associated with bone metabolism. "Bone
metabolism" refers to direct or indirect effects in the formation
or degeneration of bone structures, e.g., bone formation, bone
resorption, etc., which may ultimately affect the concentrations in
serum of calcium and phosphate. This term also includes activities
mediated by 26583 molecules effects in bone cells, e.g.,
osteoclasts and osteoblasts, that may in turn result in bone
formation and degeneration. For example, 26583 molecules may
support different activities of bone resorbing osteoclasts, such as
the stimulation of differentiation of monocytes and mononuclear
phagocytes into osteoclasts. Accordingly, 26583 molecules that
modulate the production of bone cells can influence bone formation
and degeneration, and thus may be used to treat bone disorders.
Examples of such disorders include, but are not limited to,
osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis
fibrosa cystica, renal osteodystrophy, osteosclerosis,
anti-convulsant treatment, osteopenia, fibrogenesis-imperfecta
ossium, secondary hyperparathyrodism, hypoparathyroidism,
hyperparathyroidism, cirrhosis, obstructive jaundice, drug induced
metabolism, medullary carcinoma, chronic renal disease, rickets,
sarcoidosis, glucocorticoid antagonism, malabsorption syndrome,
steatorrhea, tropical sprue, idiopathic hypercalcemia and milk
fever.
[0235] Examples of immune disorders or diseases include, but are
not limited to, autoimmune diseases (including, for example,
diabetes mellitus, arthritis (including rheumatoid arthritis,
juvenile rheumatoid arthritis, osteoarthritis, psoriatic
arthritis), multiple sclerosis, encephalomyelitis, myasthenia
gravis, systemic lupus erythematosis, autoimmune thyroiditis,
dermatitis (including atopic dermatitis and eczematous dermatitis),
psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer,
iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis,
asthma, allergic asthma, cutaneous lupus erythematosus,
scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal
reactions, erythema nodosum leprosum, autoimmune uveitis, allergic
encephalomyelitis, acute necrotizing hemorrhagic encephalopathy,
idiopathic bilateral progressive sensorineural hearing loss,
aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia,
polychondritis, Wegener's granulomatosis, chronic active hepatitis,
Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves'
disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior,
and interstitial lung fibrosis), graft-versus-host disease, cases
of transplantation, and allergy such as, atopic allergy.
[0236] Examples of disorders involving the heart or "cardiovascular
disorder" include, but are not limited to, a disease, disorder, or
state involving the cardiovascular system, e.g., the heart, the
blood vessels, and/or the blood. A cardiovascular disorder can be
caused by an imbalance in arterial pressure, a malfunction of the
heart, or an occlusion of a blood vessel, e.g., by a thrombus.
Examples of such disorders include hypertension, atherosclerosis,
coronary artery spasm, congestive heart failure, coronary artery
disease, valvular disease, arrhythmias, and cardiomyopathies.
[0237] Disorders which may be treated or diagnosed by methods
described herein include, but are not limited to, disorders
associated with an accumulation in the liver of fibrous tissue,
such as that resulting from an imbalance between production and
degradation of the extracellular matrix accompanied by the collapse
and condensation of preexisting fibers. The methods described
herein can be used to diagnose or treat hepatocellular necrosis or
injury induced by a wide variety of agents including processes
which disturb homeostasis, such as an inflammatory process, tissue
damage resulting from toxic injury or altered hepatic blood flow,
and infections (e.g., bacterial, viral and parasitic). For example,
the methods can be used for the early detection of hepatic injury,
such as portal hypertension or hepatic fibrosis. In addition, the
methods can be employed to detect liver fibrosis attributed to
inborn errors of metabolism, for example, fibrosis resulting from a
storage disorder such as Gaucher's disease (lipid abnormalities) or
a glycogen storage disease, A1-antitrypsin deficiency; a disorder
mediating the accumulation (e.g., storage) of an exogenous
substance, for example, hemochromatosis (iron-overload syndrome)
and copper storage diseases (Wilson's disease), disorders resulting
in the accumulation of a toxic metabolite (e.g., tyrosinemia,
fructosemia and galactosemia) and peroxisomal disorders (e.g.,
Zellweger syndrome). Additionally, the methods described herein may
be useful for the early detection and treatment of liver injury
associated with the administration of various chemicals or drugs,
such as, for example, methotrexate, isonizaid, oxyphenisatin,
methyldopa, chlorpromazine, tolbutamide or alcohol, or which
represents a hepatic manifestation of a vascular disorder such as
obstruction of either the intrahepatic or extrahepatic bile flow or
an alteration in hepatic circulation resulting, for example, from
chronic heart failure, veno-occlusive disease, portal vein
thrombosis or Budd-Chiari syndrome.
[0238] Additionally, 26583 molecules may play an important role in
the etiology of certain viral diseases, including, but not limited
to, Hepatitis B, Hepatitis C, and Herpes Simplex Virus (HSV).
Modulators of 26583 activity could be used to control viral
diseases. The modulators can be used in the treatment and/or
diagnosis of viral infected tissue or virus-associated tissue
fibrosis, especially liver and liver fibrosis. Also, 26583
modulators can be used in the treatment and/or diagnosis of
virus-associated carcinoma, especially hepatocellular cancer.
[0239] Additionally, 26583 may play an important role in the
regulation of metabolism or pain disorders. Diseases of metabolic
imbalance include, but are not limited to, obesity, anorexia
nervosa, cachexia, lipid disorders or diabetes. Examples of pain
disorders include, but are not limited to, pain response elicited
during various forms of tissue injury, e.g., inflammation,
infection, and ischemia, usually referred to as hyperalgesia
(described in, for example, Fields, H. L. (1987) Pain, New
York:McGraw-Hill); pain associated with muscoloskeletal disorders,
e.g., joint pain; tooth pain; headaches; pain associated with
surgery; pain related to irritable bowel syndrome; or chest
pain.
21953
[0240] Prolyl oligopeptidases are a distinct sub-group of
endopeptidases that degrade a variety of proline-containing
peptides by cleaving the peptide bond at the carboxyl side of
proline residues. The natural substrates of prolyl oligopeptidases
include many biologically active peptides such as peptide messenger
molecules. For example, they are involved in the metabolism of
peptide hormones and neuropeptides. Prolyl oligopeptidases have few
naturally occurring inhibitors and their distinctive specificity
prevents them from interacting with .beta.-macroglobulin, unlike
the great majority of endopeptidases. The specificity of an
oligopeptidase depends on the three dimensional structure of its
active site, which includes a putative catalytic triad, which
contains aspartate, serine and histidine residues.
[0241] Examples of known prolyl oligopeptidases include human
prolyl oligopeptidase (Yoshimoto et al. Genebank AB020018), mouse
prolyl oligopeptidase (Ishino et al., J. Biochem. 123 (3), 540-545
(1998)), pig prolyl oligopeptidase (Rennix et al., Biochemistry,
30:2195-2203, 1991), rat dipeptidyl-peptidase IV (Ognata et al., J.
Biol. Chem, 264:3596-3601, 1989), F. meningosepticum prolyl
oligopeptidase (Yoshimoto et al., J. Biochem. 110:873-878, 1991),
and E. coli protease II (Kanatani et al., J. Biochemistry (Tokyo),
110: 315-320, 1991).
[0242] Prolyl oligopeptidases also control the activity of other
peptides present in body fluids such as bradykinin and angiotensin.
Bradykinin is a very potent vasodilator that increases the
permeability of post capillary venules and acts on endothelial
cells to activate phospholipase A2. Angiotensin causes contraction
of vascular smooth muscle, raising blood pressure and stimulating
aldosterone release from the adrenal glands. Other members of the
prolyl oligopeptidase family mediate the degradation of
neuropeptides such as substance P, thyrotropin releasing hormone,
hippocampal cholinergic neurostimulating peptide (HCNP),
neuropeptide Y (NPY), and neuropeptides derived from
pro-opiomelanocortin (POMC) and neurohypophyseal hormones.
[0243] The human 21953 sequence (see SEQ ID NO:19), which is
approximately 3143 nucleotides long, including untranslated
regions, contains a predicted methionine-initiated coding sequence
of about 2649 nucleotides, including the termination codon. The
coding sequence encodes a 882 amino acid protein (see SEQ ID
NO:20).
[0244] Human 21953 contains the following regions or other
structural features: a predicted prolyl oligopeptidase domain (PFAM
Accession PF00326) located at about amino acids 672-744 of SEQ ID
NO:20; two predicted cAMP phosphorylation sites and cGMP-dependent
protein kinase phosphorylation domains (Prosite Accession PS00004)
located at about amino acid residues 231 to 234 of SEQ ID NO:20 and
about amino acid residues 476-479 of SEQ ID NO:20; ten predicted
Protein Kinase C sites (PS00005) at about amino acids 52 to 54, 80
to 82, 115 to 117, 307 to 309, 312 to 314, 326 to 328, 551 to 553,
594 to 596, 776 to 778, and 850 to 852 of SEQ ID NO:20; 11
predicted Casein Kinase II sites (PS00006) located at about amino
133 to 136, 227 to 230, 293 to 296, 412 to 415, 443 to 446, 499 to
502, 530 to 533, 587 to 590, 603 to 606, 615 to 618, and 723 to 726
of SEQ ID NO:20; five predicted tyrosine phosphorylation sites
(PS00007) at about amino acids 29 to 36, 47 to 55, 308 to 315, 549
to 555, and 837 to 844 of SEQ ID NO:20; four predicted
N-myristylation sites (PS00008) from about amino 176 to 181, 741 to
746, 762 to 767 and 873 to 878 of SEQ ID NO:20 and one predicted
amidation site (PS00009) from about amino acid 642 to 645 of SEQ ID
NO:20.
[0245] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to
Sonnhammer et al. (1997) Protein 28:405-420.
[0246] The 21953 polypeptide contains a significant number of
structural characteristics in common with members of the human
prolyl oligopeptidase family. The term "family" when referring to
the protein and nucleic acid molecules of the invention means two
or more proteins or nucleic acid molecules having a common
structural domain or motif and having sufficient amino acid or
nucleotide sequence homology as defined herein. Such family members
can be naturally or non-naturally occurring and can be from either
the same or different species. For example, a family can contain a
first protein of human origin as well as other distinct proteins of
human origin, or alternatively, can contain homologues of non-human
origin, e.g., rat or mouse proteins. Members of a family can also
have common functional characteristics.
[0247] Polypeptide of the prolyl oligopeptidase family such as a
21953 polypeptide typically include an N-terminal seven-blade
.beta.-propeller domain and a C-terminal .alpha./.beta. hydrolase
domain. The N-terminal seven-blade .beta.-propeller domain can
include a "DPP IV N-terminal domain" or regions homologous with a
"DPP IV N-terminal domain." The C-terminal .alpha./.beta. hydrolase
domain, e.g., the C-terminal region of a 21953 polypeptide, can
include a "prolyl oligopeptidase domain" or regions homologous with
a "prolyl oligopeptidase domain". The "prolyl oligopeptidase
domain" can include a catalytic active site, which generally occurs
at the C-terminal region of the polypeptide chain, which is
involved in the hydrolysis of proline-containing peptide bonds. A
prolyl oligopeptidase can be soluble. An alignment of human
dipeptidyl peptidase IV (Accession Number P48147) to the 21953
amino acid sequence is depicted in FIGS. 14A-14B.
[0248] As used herein, the term "prolyl oligopeptidase domain"
includes an amino acid sequence of at least about 60 amino acid
residues in length and having a bit score for the alignment of the
sequence to the Pfam Hidden Markov Model (HMM) PF00326 of at least
10. Preferably, a prolyl oligopeptidase domain includes at least
about 30 to 180 amino acids, more preferably about 50 to 140 amino
acid residues, or about 60 to 80 amino acids and has a bit score
for the alignment of the sequence to the prolyl oligopeptidase
domain (HMM) of at least 10, 20, 30 or greater. An alignment of the
prolyl oligopeptidase domain (amino acids 672 to 744 of SEQ ID
NO:20) of human 21953 with a consensus amino acid sequence derived
from a hidden Markov model is depicted in FIG. 14A-14B. In a
preferred embodiment, a human 21953 polypeptide has a serine
peptidase active site, e.g., an active site that is nearly
identical to the Prosite signature PDOC00587. The active site can
have a conserved catalytic triad with a conserved serine, e.g., a
serine residue located at about amino acid 739 of SEQ ID NO:20, a
conserved aspartic acid, e.g., an aspartic acid residue located at
about amino acid 817 of SEQ ID NO:20, and a conserved histidine,
e.g., a histidine residue located at about amino acid 849 of SEQ ID
NO:20.
[0249] In a preferred embodiment 21953 polypeptide or protein has a
"prolyl oligopeptidase domain" or a region which includes at least
about 30-300, more preferably about 50-150, or 60-80 amino acid
residues and has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or
100% homology with a "prolyl oligopeptidase domain," e.g., the
prolyl oligopeptidase domain of human 21953 (e.g., residues 672-744
of SEQ ID NO:20).
[0250] To identify the presence of a "prolyl oligopeptidase" domain
in a 21953 protein sequence, and make the determination that a
polypeptide or protein of interest has a particular profile, the
amino acid sequence of the protein can be searched against a
database of HMMs (e.g., the Pfam database, release 2.1) using the
default parameters. For example, the hmmsf program, which is
available as part of the HMMER package of search programs, is a
family specific default program for MILPAT0063 and a score of 15 is
the default threshold score for determining a hit. Alternatively,
the threshold score for determining a hit can be lowered (e.g., to
8 bits). A description of the Pfam database can be found in
Sonhammer et al. (1997) Proteins 28(3):405-420 and a detailed
description of HMMs can be found, for example, in Gribskov et al.
(1990) Meth. Enzymol. 183:146-159; Gribskov et al. (1987) Proc.
Natl. Acad. Sci. USA 84:4355-4358; Krogh et al. (1994) J. Mol.
Biol. 235:1501-1531; and Stultz et al. (1993) Protein Sci.
2:305-314, the contents of which are incorporated herein by
reference. A search was performed against the HMM database
resulting in the identification of a "prolyl oligopeptidase domain"
domain in the amino acid sequence of human 21953 at about residues
672-744 of SEQ ID NO:20 (see FIG. 13).
[0251] In a preferred embodiment, a 21953 polypeptide includes an
N-terminal seven-blade .beta.-propeller domain, e.g., residues
about 88 to 663 of SEQ ID NO:20. The amino acid sequence of this
region can be aligned to the HMM profile for DPP IV N-terminal
domain or the human DPP IV amino acid sequence (P27487). As used
herein, the term "DPP IV N-terminal domain" refers to an amino acid
sequence at least 60% identical to residues about 88 to 663 of SEQ
ID NO:20.
[0252] A 21953 family member can include a prolyl oligopeptidase
domain and may also include a cAMP phosphorylation site and
cGMP-dependent protein kinase phosphorylation domain, a predicted
Protein Kinase C site, a predicted Casein Kinase II site, a
predicted tyrosine phosphorylation site, a predicted
N-myristylation site, and an amidation site.
[0253] As the 21953 polypeptides of the invention may modulate
21953-mediated activities, e.g., a dipeptidyl peptidase activity
such as a prolyl oligopeptidase activity, they may be useful for
developing novel diagnostic and therapeutic agents for
21953-mediated or related disorders, as described below. The 21953
polypeptide of the invention are highly expressed in tumors, for
example in breast and lung tumors. Further, 21953 polypeptide
expression is increased at the G1-S phase transition of the
mammalian cell cycle. Additional expression data for 21953
polypeptides are described below and in the Figures. Generally,
increased prolyl oligopeptidase activity has been detected in human
prostate, lung, and sigmoid tumors relative to healthy normal
tissue. Such increased activity can result from 21953 increased
expression.
[0254] As used herein, a "21953 activity", "biological activity of
21953" or "functional activity of 21953", refers to an activity
exerted by a 21953 protein, polypeptide or nucleic acid molecule
on, e.g., a 21953-responsive cell or on a 21953 substrate, e.g., a
oligopeptide substrate, as determined in vivo or in vitro. In one
embodiment, a 21953 activity is a direct activity, such as an
association with a 21953 target molecule. A "target molecule" or
"binding partner" is a molecule with which a 21953 protein binds or
interacts in nature. For example, the 21953 proteins of the present
invention can have one or more of the following activities: (1)
hydrolyzing peptide bonds at the carboxyl side of proline residues;
(2) mediating degradation of proline-containing peptides, e.g., a
prolyl endopeptidases activity; (3) processing of peptide factors
(e.g., peptide hormones, chemokines, cytokines, neuropeptides, and
vasoactive peptides); (4) processing N-terminal dipeptides of
unmodified N-termini wherein the penultimate residue is proline;
(5) modulating cell proliferation and/or modulating cell
differentiation (e.g., of a lung, breast, lymphoid, or colon cell);
(6) modulating the regulation of transmission of intracellular
signals, e.g., during immunological processes; (7) modulating
metabolism of neurotransmitters or neuropeptides; (8) modulating
neurodegeneration; or (9) modulating follicular development.
[0255] As used herein, a "dipetidyl peptidase activity" refers to a
catalytic activity that accelerates the scission of a peptide bond
between an amino acid sequence of less than four amino acids and
the remainder of the polypeptide. Preferably, the cleaved peptide
is a dipeptide having two amino acids. The catalytic activity can
be mediated by the side chain of a serine amino acid and
surrounding residues in the active site.
[0256] As used herein, a "prolyl endopeptidases activity" refers to
a catalytic activity that accelerates the scission of a peptide
bond adjacent to a proline amino acid in a peptide or polypeptide
chain. This catalytic activity has been detected, for example, in
primary human lung tumors, squamous cell lung carcinomas, and lung
adenocarcinomas. For example, squamous cell lung carcinomas and
lung adenocarcinomas showed significantly higher levels of prolyl
endopeptidases activity relative to normal lung parenchyma.
[0257] In accordance with the above-described sequence similarities
and observed polypeptide expression pattern, the 21953 molecules of
the present invention can have similar biological activities as
related prolyl oligopeptidase family members. Members of the prolyl
oligopeptidase family can play an important role in the metabolism
of a variety of proline containing peptides by cleaving prolyl
bonds. These peptides can be less than about 200, 150, 100, or 50
residues in length. Prolyl oligopeptidases are involved, e.g.,
alone or together with other factors, in the regulation, e.g.,
processing, activation, or degradation of biological factors, e.g.,
peptide hormones (such as growth hormone, insulin, prolactin,
adrenocorticotropic hormone, placental lactogen, calcitonin,
parathyroid hormone, and thyroid stimulating hormone); chemokines;
cytokines; neuropeptides; and vasoactive peptides.
[0258] As the 21953 mRNA is highly expressed, for example, in
cancerous tissues (e.g., lung and breast tumors), as well as normal
cardiovascular, neural, and prostatic tissues, the molecules of the
invention can be used to treat, prevent and/or diagnose disorders
involving aberrant activity of 21953-expressing cells. Accordingly,
the 21953 molecules can act as novel diagnostic targets and
therapeutic agents for controlling disorders associated with the
aberrant activity or degradation of peptide hormones, e.g.,
disorders associated with cell differentiation and proliferation
(e.g., a cancer of the lung, breast, ovary, and colon tissues),
immune function (e.g., T cell activities, e.g., lymphomas,
leukemias, and immune disorders), reproductive, neurological and
cardiovascular function.
[0259] As used herein, the terms "cancer", "hyperproliferative" and
"neoplastic" refer to cells having the capacity for autonomous
growth, i.e., an abnormal state or condition characterized by
rapidly proliferating cell growth. Hyperproliferative and
neoplastic disease states may be categorized as pathologic, i.e.,
characterizing or constituting a disease state, or may be
categorized as non-pathologic, i.e., a deviation from normal but
not associated with a disease state. The term is meant to include
all types of cancerous growths or oncogenic processes, metastatic
tissues or malignantly transformed cells, tissues, or organs,
irrespective of histopathologic type or stage of invasiveness.
"Pathologic hyperproliferative" cells occur in disease states
characterized by malignant tumor growth. Examples of non-pathologic
hyperproliferative cells include proliferation of cells associated
with wound repair.
[0260] Examples of cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, or metastatic
disorders. The 21953 molecules can act as novel diagnostic targets
and therapeutic agents for controlling lung cancer, breast cancer,
ovarian cancer, colon cancer, metastasis of such cancers and the
like. A metastatic tumor can arise from a multitude of primary
tumor types, including but not limited to those of lung, breast,
liver, colon and ovarian origin.
[0261] Examples of cellular proliferative and/or differentiative
disorders of the lung include, but are not limited to, squamous
cell lung carcinomas, small cell lung carcinoma, lung
adenocarcinomas, bronchogenic carcinoma, including paraneoplastic
syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors,
such as bronchial carcinoid, miscellaneous tumors, and metastatic
tumors; pathologies of the pleura, including inflammatory pleural
effusions, noninflammatory pleural effusions, pneumothorax, and
pleural tumors, including solitary fibrous tumors (pleural fibroma)
and malignant mesothelioma.
[0262] Examples of cellular proliferative and/or differentiative
disorders of the breast include, but are not limited to,
proliferative breast disease including, e.g., epithelial
hyperplasia, sclerosing adenosis, and small duct papillomas;
tumors, e.g., stromal tumors such as fibroadenoma, phyllodes tumor,
and sarcomas, and epithelial tumors such as large duct papilloma;
carcinoma of the breast including in situ (noninvasive) carcinoma
that includes ductal carcinoma in situ (including Paget's disease)
and lobular carcinoma in situ, and invasive (infiltrating)
carcinoma including, but not limited to, invasive ductal carcinoma,
invasive lobular carcinoma, medullary carcinoma, colloid (mucinous)
carcinoma, tubular carcinoma, and invasive papillary carcinoma, and
miscellaneous malignant neoplasms. Disorders in the male breast
include, but are not limited to, gynecomastia and carcinoma.
[0263] Examples of cellular proliferative and/or differentiative
disorders of the colon include, but are not limited to,
non-neoplastic polyps, adenomas, familial syndromes, colorectal
carcinogenesis, colorectal carcinoma, and carcinoid tumors.
[0264] Examples of cellular proliferative and/or differentiative
disorders of the liver include, but are not limited to, nodular
hyperplasias, adenomas, and malignant tumors, including primary
carcinoma of the liver and metastatic tumors.
[0265] Examples of cellular proliferative and/or differentiative
disorders of the ovary include, but are not limited to, ovarian
tumors such as, tumors of coelomic epithelium, serous tumors,
mucinous tumors, endometeriod tumors, clear cell adenocarcinoma,
cystadenofibroma, brenner tumor, surface epithelial tumors; germ
cell tumors such as mature (benign) teratomas, monodermal
teratomas, immature malignant teratomas, dysgerminoma, endodermal
sinus tumor, choriocarcinoma; sex cord-stomal tumors such as,
granulosa-theca cell tumors, thecoma-fibromas, androblastomas, hill
cell tumors, and gonadoblastoma; and metastatic tumors such as
Krukenberg tumors.
[0266] Additional examples of proliferative disorders include
hematopoietic neoplastic disorders. As used herein, the term
"hematopoietic neoplastic disorders" includes diseases involving
hyperplastic/neoplastic cells of hematopoietic origin, e.g.,
arising from myeloid, lymphoid or erythroid lineages, or precursor
cells thereof. Preferably, the diseases arise from poorly
differentiated acute leukemias, e.g., erythroblastic leukemia and
acute megakaryoblastic leukemia. Additional exemplary myeloid
disorders include, but are not limited to, acute promyeloid
leukemia (APML), acute myelogenous leukemia (AML) and chronic
myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit
Rev. in Oncol./Hemotol. 11:267-97); lymphoid malignancies include,
but are not limited to acute lymphoblastic leukemia (ALL) which
includes B-lineage ALL and T-lineage ALL, chronic lymphocytic
leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia
(HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of
malignant lymphomas include, but are not limited to non-Hodgkin
lymphoma and variants thereof, peripheral T cell lymphomas, adult T
cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL),
large granular lymphocytic leukemia (LGF), Hodgkin's disease and
Reed-Sternberg disease.
[0267] The 21953 nucleic acid and protein of the invention can be
used to treat and/or diagnose a variety of immune disorders, e.g.,
as a result of aberrant 21953 activity in T cells. Examples of
immune disorders or diseases include, but are not limited to,
autoimmune diseases (including, for example, diabetes mellitus,
arthritis (including rheumatoid arthritis, juvenile rheumatoid
arthritis, osteoarthritis, psoriatic arthritis), multiple
sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus
erythematosis, autoimmune thyroiditis, dermatitis (including atopic
dermatitis and eczematous dermatitis), psoriasis, Sjogren's
Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis,
keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma,
cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis,
drug eruptions, leprosy reversal reactions, erythema nodosum
leprosum, autoimmune uveitis, allergic encephalomyelitis, acute
necrotizing hemorrhagic encephalopathy, idiopathic bilateral
progressive sensorineural hearing loss, aplastic anemia, pure red
cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's
granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome,
idiopathic sprue, lichen planus, Graves' disease, sarcoidosis,
primary biliary cirrhosis, uveitis posterior, and interstitial lung
fibrosis), graft-versus-host disease, cases of transplantation, and
allergy such as, atopic allergy.
[0268] Examples of neuronal disorders include, but are not limited
to disorders involving neurons, and disorders involving glia, such
as astrocytes, oligodendrocytes, ependymal cells, and microglia;
cerebral edema, raised intracranial pressure and herniation, and
hydrocephalus; malformations and developmental diseases, such as
neural tube defects, forebrain anomalies, posterior fossa
anomalies, and syringomyelia and hydromyelia; perinatal brain
injury; transmissible spongiform encephalopathies (prion diseases);
demyelinating diseases, including multiple sclerosis, multiple
sclerosis variants, acute disseminated encephalomyelitis and acute
necrotizing hemorrhagic encephalomyelitis, and other diseases with
demyelination; degenerative diseases, such as degenerative diseases
affecting the cerebral cortex, including Alzheimer disease and Pick
disease, degenerative diseases of basal ganglia and brain stem,
including Parkinsonism, idiopathic Parkinson disease (paralysis
agitans), progressive supranuclear palsy, corticobasal
degeneration, multiple system atrophy, including striatonigral
degeneration, Shy-Drager syndrome, and olivopontocerebellar
atrophy, and Huntington disease; spinocerebellar degenerations,
including spinocerebellar ataxias, including Friedreich ataxia, and
ataxia-telanglectasia, degenerative diseases affecting motor
neurons, including amyotrophic lateral sclerosis (motor neuron
disease), bulbospinal atrophy (Kennedy syndrome), and spinal
muscular atrophy; tumors, such as gliomas, including astrocytoma,
including fibrillary (diffuse) astrocytoma and glioblastoma
multiforme, pilocytic astrocytoma, pleomorphic xanthoastrocytoma,
and brain stem glioma, oligodendroglioma, and ependymoma and
related paraventricular mass lesions, neuronal tumors, poorly
differentiated neoplasms, including medulloblastoma, other
parenchymal tumors, including primary brain lymphoma, germ cell
tumors, and pineal parenchymal tumors, meningiomas, metastatic
tumors, paraneoplastic syndromes, peripheral nerve sheath tumors,
including schwannoma, neurofibroma, and malignant peripheral nerve
sheath tumor (malignant schwannoma), and neurocutaneous syndromes
(phakomatoses), including neurofibromotosis, including Type 1
neurofibromatosis (NF1) and TYPE 2 neurofibromatosis (NF2),
tuberous sclerosis, and Von Hippel-Lindau disease.
[0269] The term "vascular disorder" includes disorders involving
aberrant activity (e.g., proliferation, metabolism, angiogenesis,
vascularization) of blood vessel-associated cells, e.g., smooth
muscle or endothelial cells. Examples of such disorders include but
are not limited to hypertension (e.g., arterial hypertension),
vascular restenosis, ischemic disease (e.g., atherosclerosis),
tumorigenesis, tumor metastasis, diabetic retinopathy,
endometriosis, Grave's disease. Aberrant vascular activity may also
affect cardiovascular function, and thus the molecules of the
invention can be used to treat, prevent and/or diagnose
cardiovascular disorders. Examples of cardiovascular disorders,
include but are not limited to, heart failure, cardiac hypertrophy,
left-sided heart failure, and right-sided heart failure; ischemic
heart disease, including but not limited to angina pectoris,
myocardial infarction, chronic ischemic heart disease, and sudden
cardiac death; hypertensive heart disease, including but not
limited to, systemic (left-sided) hypertensive heart disease and
pulmonary (right-sided) hypertensive heart disease; valvular heart
disease, including but not limited to, valvular degeneration caused
by calcification, such as calcific aortic stenosis, calcification
of a congenitally bicuspid aortic valve, and mitral annular
calcification, and myxomatous degeneration of the mitral valve
(mitral valve prolapse), rheumatic fever and rheumatic heart
disease, infective endocarditis, and noninfected vegetations, such
as nonbacterial thrombotic endocarditis and endocarditis of
systemic lupus erythematosus (Libman-Sacks disease), carcinoid
heart disease, and complications of artificial valves; myocardial
disease, including but not limited to dilated cardiomyopathy,
hypertrophic cardiomyopathy, restrictive cardiomyopathy, and
myocarditis; pericardial disease, including but not limited to,
pericardial effusion and hemopericardium and pericarditis,
including acute pericarditis and healed pericarditis, and
rheumatoid heart disease; neoplastic heart disease, including but
not limited to, primary cardiac tumors, such as myxoma, lipoma,
papillary fibroelastoma, rhabdomyoma, and sarcoma, and cardiac
effects of noncardiac neoplasms; congenital heart disease,
including but not limited to, left-to-right shunts--late cyanosis,
such as atrial septal defect, ventricular septal defect, patent
ductus arteriosus, and atrioventricular septal defect,
right-to-left shunts--early cyanosis, such as tetralogy of fallot,
transposition of great arteries, truncus arteriosus, tricuspid
atresia, and total anomalous pulmonary venous connection,
obstructive congenital anomalies, such as coarctation of aorta,
pulmonary stenosis and atresia, and aortic stenosis and atresia,
and disorders involving cardiac transplantation.
[0270] As used herein, "a prostate disorder" refers to an abnormal
condition occurring in the male pelvic region characterized by,
e.g., male sexual dysfunction and/or urinary symptoms. This
disorder may be manifested in the form of genitourinary
inflammation (e.g., inflammation of smooth muscle cells) as in
several common diseases of the prostate including prostatitis,
benign prostatic hyperplasia and cancer, e.g., adenocarcinoma or
carcinoma, of the prostate.
[0271] The 21953 nucleic acid and protein of the invention can be
used to treat and/or diagnose a variety of conditions, in addition
to the ones described above (see "Methods of Treatment" for
additional examples).
[0272] The presence of 21953 RNA or protein can also be used to
identify a cell or tissue, or other biological sample, as being
derived from breast, T-cell, kidney, liver, and aorta, or being of
human origin. Expression can also be used to diagnose or stage a
disorder, e.g., a cancer (e.g., a cancer of the lung or breast), or
a breast, lymphoid, lung, ovarian, or liver disorder. Expression
can be determined by evaluating RNA, e.g., by hybridization of a
21953 specific probe, or with a 21953 specific antibody.
m32404
[0273] Four major classes of proteases are known and are designated
by the principal functional group in their active site: serine,
thiol, carboxyl, and metallo. Serine proteases are characterized by
the presence of a unique serine residue that functions as a
nucleophile to cleave peptide bonds. In some cases, the serine
forms covalent adducts with substrates and inhibitors. The serine
functions with two other principal residues of the active site, a
histidine, and an acid, frequently aspartic acid. Together these
three residues compose the catalytic triad which is a signature of
the family. Serine proteases are divided into two major
evolutionary families. One family is represented by the bacterial
protease subtilisin. The other family is the trypsin-chymotrypsin
family and includes chymotrypsin, trypsin, and elastase. Members of
the trypsin-chymotrypsin serine protease family are involved in a
range of diverse cellular functions including, cell motility, cell
growth and differentiation, hormone production, organogenesis,
extracellular matrix regulation, blood clotting, and
complementation activation.
[0274] While the various serine proteases catalyze this reaction in
very similar ways, they differ in their preference for the amino
acid side chains immediately C-terminal to the cleave site. Trypsin
cleaves bonds only after lysine and arginine residues, whereas
chymotrypsin cleaves bonds after large hydrophobic residues. Some
members of the trypsin serine protease family play critical roles
in a variety of important biological events including regulating
cell proliferation, tumor growth, tumor invasion, metastasis,
development, and tissue remodeling.
[0275] The human m32404 sequence (see SEQ ID NO:24), which is
approximately 2219 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
1659 nucleotides, including the termination codon. The coding
sequence encodes a 552 amino acid protein (SEQ ID NO:25). The human
m32404 protein of SEQ ID NO:25 and FIG. 15 includes an
amino-terminal hydrophobic amino acid sequence, consistent with a
signal sequence, of about 23 amino acids (from amino acid 1 to
about amino acid 23 of SEQ ID NO:25), which upon cleavage results
in the production of a mature protein form. This mature protein
form is approximately 529 amino acid residues in length (from about
amino acid 24 to amino acid 552 of SEQ ID NO:25).
[0276] Human m32404 contains the following regions or other
structural features:
[0277] two trypsin domains (PFAM Accession PF00089) located at
about amino acid residues 45 to 268 and 311 to 520 of SEQ ID NO:25,
which include trypsin histidine and serine active sites located at
about amino acids 73-78 and 337-342, and 218-229, respectively, of
SEQ ID NO:25;
[0278] eight predicted Protein Kinase C phosphorylation sites
(PS00005) at about amino acids 4 to 6, 53 to 55, 96 to 98, 173 to
175, 246 to 248, 298 to 300, 422 to 424, and 504 to 506 of SEQ ID
NO:25;
[0279] six predicted Casein Kinase II phosphorylation sites
(PS00006) located at about amino acid 161 to 164, 348 to 351, 375
to 378, 496 to 499, 514 to 517, and 521 to 524 of SEQ ID NO:25;
[0280] two predicted N-glycosylation sites (PS00001) from about
amino acid 166 to 169 and 545 to 548 of SEQ ID NO:25; and
[0281] nine predicted N-myristylation sites (PS00008) from about
amino 20 to 25, 58 to 63, 64 to 69, 101 to 106, 126 to 131, 206 to
211, 297 to 302, 328 to 333, and 460 to 465 of SEQ ID NO:25.
[0282] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to
Sonnhammer et al. (1997) Protein 28:405-420.
[0283] The m32404 polypeptide contains a significant number of
structural characteristics in common with members of the trypsin
serine protease family (Rawlings and Barret (1993) Biochem J. 290:
205-218, and Meth. Enzymol. (1994) 244: 19-61, the contents of
which are hereby incorporated by reference in their entirety).
Based on the presence of the histidine-aspartate-serine catalytic
triad, the m32404 polypeptide appears to be a member of the serine
protease clan SA (Rawlings and Barret supra). The clan SA includes
the trypsin-chymotrypsin family (S1), the .alpha.-lytic
endopeptidase family (S2), and the Togavirus endopeptidase family
(S3).
[0284] The m32404 polypeptide seems to belong to the
trypsin-chymotrypsin family (S1). The prototype of this family is
chymotrypsin and the 3D structure of some of its members has been
resolved. The trypsin-chymotrypsin family (S1) includes such
members as: trypsin (forms I, II, III, IV, Va and Vb); trypsin-like
enzyme; hepsin; TMPRSS2; venombin; cercarial elastase; brachyurin;
Factor C; Proclotting enzyme; easter gene product; snake gene
product; stubble gene product; Vitellin-degrading endopeptidase;
hypodermin C; Serine proteases 1 and 2; achelase; chymotrypsin
(forms A, B, II, and 2); Proteinase RVV-V (forms .alpha. and
.gamma.); flavoboxin; venombin A; Crotalase; enteropeptidase;
acrosin; ancrod; seminin; semenogelase; tissue kallikrein; renal
kallikrein; submandibular kallikrein; 7S nerve growth factor
(chains .alpha. and .gamma.); epidermal growth factor-binding
protein (forms 1, 2, and 3); tonin; arginine esterase; pancreatic
elastase I; pancreatic elastase II (forms A and B); pancreatic
endopeptidase E (forms A and B); leukocyte elastase; medullasin;
azurocidin; cathepsin G; proteinase 3 (myeloblastin); chymase
(forms I and II); .gamma.-renin; tryptase (forms 1, 2, and 3);
granzyme A; natural killer cell protease 1; gilatoxin; granzymes B,
C, D, E, F, G and Y; carboxypeptidase A complex component III;
complement factors D, B, I; complement components C1r, C1s, and C2;
calcium-dependent serine protease; hypodermin A, B, and C;
haptoglobin (forms 1 and 2); haptoglobin-related protein; plasmin;
apolipoprotein (a); hepatocyte growth factor; medullasin; thrombin;
t-plasminogen activator; u-plasminogen activator; salivary
plasminogen activator; plasma kallikrein; coagulation factors VII,
IX, X, XI, and XII; and proteins C and Z, as well as as-yet
unidentified members.
[0285] Accordingly, the m32404 polypeptide contains a significant
number of structural characteristics in common with members of the
S1 family of the SA clan of serine-type proteases (also referred to
herein as "trypsin-chymotrypsin" or "trypsin" family members). The
term "family" when referring to the protein and nucleic acid
molecules of the invention means two or more proteins or nucleic
acid molecules having a common structural domain or motif and
having sufficient amino acid or nucleotide sequence homology as
defined herein. Such family members can be naturally or
non-naturally occurring and can be from either the same or
different species. For example, a family can contain a first
protein of human origin as well as other distinct proteins of human
origin, or alternatively, can contain homologues of non-human
origin, e.g., rat or mouse proteins. Members of a family can also
have common functional characteristics.
[0286] As used herein, a "trypsin-chymotrypsin family member"
typically contains a catalytic unit which is generally a
polypeptide sequence of about 100 to about 300 amino acids, more
preferably about 150 to about 250 amino acid residues, even more
preferably about 200 to about 230 amino acid residues, although
some members have N-terminal extensions of unrelated peptide
segments. The catalytic unit almost always forms the C-terminal
portion of the enzyme. These proteases typically cleave arginine or
lysine residues in a target protein.
[0287] Trypsin-chymotrypsin family members preferably have at least
one trypsin domain, comprising at least one histidine active site
residue, and at least one serine active site residue.
Trypsin-chymotrypsin family members can also include an aspartate
residue within the trypsin domain. These three residues act as a
"catalytic triad," with serine as nucleophile, aspartate as
electrophile, and histidine as base. The serine nucleophile
typically occurs in a signature motif characterized by Prosite
Motif PS00135 (also PDOC00124): G-[DE]-S-G-[GS]. Typically, a
trypsin domain additionally includes an activation and cleavage
site, Arg-Ile-Val-Gly-Gly (or "RIVGG"; SEQ ID NO:30), which is
present just N-terminal to the serine protease domain.
[0288] m32404 polypeptides contain structural features similar to
trypsin-chymotrypsin family members. For example, each of the two
trypsin domains of the m32404 polypeptide has a conserved histidine
residue present at about amino acid 77 and 341 of SEQ ID NO:25. The
histidine base typically occurs in a signature motif characterized
by Prosite Motif PS00134 (also PDOC00124):
[LIVM]-[ST]-A-[STAG]-H-C. An m32404 polypeptide also contains the
sequence LTAAHC (SEQ ID NO:31), which matches PS00134, at about
amino acids 73 to 78 and 337 to 342 of SEQ ID NO:25.
[0289] In addition, the m32404 polypeptide includes the sequence
GDSGG (SEQ ID NO:32), which matches PS00135, at about amino acids
222 to 226 of SEQ ID NO:25. The serine active site is located at
amino acid 224 of SEQ ID NO:25. The trypsin domains of the m32404
polypeptide additionally include eleven conserved cysteines, which
are present at about amino acids 62, 187, 209, 220, 249, 326, 342,
443, 463, 473, 501 of SEQ ID NO:25.
[0290] Trypsin-chymotrypsin family members occasionally function
intracellularly, but more generally, they act extracellularly.
Examples of such extracellular activity include release or
activation of growth factors, degradation of extracellular matrix,
coagulation, fibrinolysis, zymogen and growth hormone activation,
and complement activation. Trypsin-chymotrypsin family members have
been implicated in modulating tumor invasion and growth by, for
example, releasing or activating growth factors and/or digesting
extracellular matrix components.
[0291] An m32404 polypeptide includes at least one and preferably
two "trypsin domains" or at least one and preferably two regions
homologous with a "trypsin domain."
[0292] As used herein, the term "trypsin domain" (or a
"trypsin-chymotrypsin" domain) refers to a protein domain having an
amino acid sequence of from about 50 to about 350 amino acid
residues and having a bit score for the alignment of the sequence
to the trypsin domain (HMM) of at least 60. Preferably, a trypsin
domain includes at least about 100 to about 300 amino acids, more
preferably about 150 to about 250 amino acid residues, more
preferably about 200 to about 230 amino acids and has a bit score
for the alignment of the sequence to the trypsin domain (HMM) of at
least 80, preferably at least 90, more preferably at least 100, and
most preferably 110 or greater. The trypsin domain (HMM) has been
assigned the PFAM Accession (PF00089). Alignments of two trypsin
domains (from about amino acids 45 to 268 and from about amino
acids 311 to 520 of SEQ ID NO:25) of human m32404 with a consensus
amino acid sequence derived from a hidden Markov model (PFAM) are
depicted in FIGS. 16A and 16B. Alignments of the two trypsin
domains (from about amino acids 38 to about 268 and from about
amino acids 300 to 520 of SEQ ID NO:25) of human m32404 with a
consensus amino acid sequence derived from another hidden Markov
model (SMART) are depicted in FIGS. 17A and 17B.
[0293] In a preferred embodiment, an m32404 polypeptide or protein
has a "trypsin" domain or a region which includes at least about
100 to about 300 amino acids, more preferably about 150 to about
250 amino acid residues, or about 210 to about 235 amino acid
residues and has at least about 70%, 80%, 90%, 95%, 99%, or 100%
homology with a "trypsin domain," e.g., either trypsin domain of
human m32404 (e.g., residues about 45 to 268 and 311 to 520 of SEQ
ID NO:25). Preferably, the trypsin domain includes at least one
histidine active site residue, and at least one serine active site
residue. The trypsin domain can also include an aspartate residue,
thus forming a catalytic triad, with serine as nucleophile,
aspartate as electrophile, and histidine as base.
[0294] To identify the presence of a "trypsin" domain in an m32404
protein sequence, and make the determination that a polypeptide or
protein of interest has a particular profile, the amino acid
sequence of the protein can be searched against a database of HMMs
(e.g., the Pfam database, release 2.1) using the default
parameters. For example, the hmmsf program, which is available as
part of the HMMER package of search programs, is a family specific
default program for MILPAT0063 and a score of 15 is the default
threshold score for determining a hit. Alternatively, the threshold
score for determining a hit can be lowered (e.g., to 8 bits). A
description of the Pfam database can be found in Sonhammer et al.
(1997) Proteins 28(3):405-420 and a detailed description of HMMs
can be found, for example, in Gribskov et al. (1990) Meth. Enzymol.
183:146-159; Gribskov et al. (1987) Proc. Natl. Acad. Sci. USA
84:4355-4358; Krogh et al. (1994) J. Mol. Biol. 235:1501-1531; and
Stultz et al. (1993) Protein Sci. 2:305-314, the contents of which
are incorporated herein by reference. A search was performed
against the PFAM HMM database resulting in the identification of
two "trypsin domains" in the amino acid sequence of human m32404
from about residues 45 to 268 and 311 to 520 of SEQ ID NO:25 with a
bit score of 254 (see FIGS. 16A-16B).
[0295] To identify the presence of a "trypsin" domain in an m32404
protein sequence, and make the determination that a polypeptide or
protein of interest has a particular profile, the amino acid
sequence of the protein can also be searched against a SMART
database (Simple Modular Architecture Research Tool) of HMMs as
described in Schultz et al. (1998), Proc. Natl. Acad. Sci. USA
95:5857 and Schultz et al. (200) Nucl. Acids Res 28:231. The
database contains domains identified by profiling with the hidden
Markov models of the HMMer2 search program (R. Durbin et al. (1998)
Biological sequence analysis: probabilistic models of proteins and
nucleic acids. Cambridge University Press). The database also is
extensively annotated and monitored by experts to enhance accuracy.
A search was performed against the HMM database resulting in the
identification of two "trypsin" domains in the amino acid sequence
of human m32404 at about residues 38 to 268 and 300 to 520 of SEQ
ID NO:25 (see 3A-3B).
[0296] An m32404 family member can include one or more of a trypsin
domain, a signal peptide domain, an N-glycosylation site, a protein
kinase C phosphorylation site, a casein kinase II phosphorylation
site, or an N-myristoylation site.
[0297] As used herein, a "signal peptide" or "signal sequence"
refers to a peptide of about 15 to 30, preferably about 20 to 25,
more preferably, 23 amino acid residues in length which occurs at
the N-terminus of secretory and integral membrane proteins and
which contains a majority of hydrophobic amino acid residues. For
example, a signal sequence contains at least about 15 to 25 amino
acid residues, preferably about 20 to 25 amino acid residues, more
preferably about 23 amino acid residues, and has at least about
40-70%, preferably about 50-65%, and more preferably about 55-60%
hydrophobic amino acid residues (e.g., alanine, valine, leucine,
isoleucine, phenylalanine, tyrosine, tryptophan, or proline). Such
a "signal sequence", also referred to in the art as a "signal
peptide", serves to direct a protein containing such a sequence to
a lipid bilayer. For example, in one embodiment, an m32404 protein
contains a signal sequence of about amino acids 1 to 23 of SEQ ID
NO:25. The "signal sequence" is cleaved during processing of the
mature protein. The mature m32404 protein corresponds to amino
acids 24 to 552 of SEQ ID NO:25.
[0298] As the m32404 polypeptides of the invention may modulate
m32404-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for m32404-mediated or
related disorders, as described below.
[0299] As used herein, a "m32404 activity," "biological activity of
m32404" or "functional activity of m32404," refers to an activity
exerted by an m32404 protein, polypeptide or nucleic acid molecule
on e.g., an m32404-responsive cell or on an m32404 substrate, e.g.,
a protein substrate, as determined in vivo or in vitro. In one
embodiment, an m32404 activity is a direct activity, such as an
association with an m32404 target molecule. A "target molecule" or
"binding partner" is a molecule with which an m32404 protein binds
or interacts in nature. An m32404 activity can also be an indirect
activity, e.g., a cellular signaling activity mediated by
interaction of the m32404 protein with an m32404 receptor. For
example, the m32404 proteins of the present invention can have one
or more of the following activities: (1) modulate (e.g., stimulate
or inhibit) cellular proliferation (2) modulate cell
differentiation; (3) modulate tumorigenesis and/or tumor invasion;
(4) alter extracellular matrix composition; (5) catalyze
polypeptide growth factor activation and/or release; (6) regulate
the blood clotting cascade; (7) catalyze proteolytic cleavage of a
substrate, e.g., a protein substrate (e.g., cleavage at an arginine
or lysine residue); (8) catalyze the proteolytic activation of
signaling molecules, e.g., other proteases, growth factor
activation or release; or (9) regulate of cell motility or
attachment.
[0300] Based on the above-described sequence similarities, the
m32404 molecules of the present invention are predicted to have
similar biological activities as other trypsin family members, such
as hepsin proteases. Hepsin proteases are overexpressed in ovarian
tumors and hepatoma cells (Tanimoto, H. et al. (1997) Cancer Res.
57:2884-2887). Further in vitro studies have shown inhibition of
hepatoma cell proliferation using hepsin inhibitors (Torres-Rosado,
A. et al. (1993) Proc. Natl. Acad. Sci. USA 90: 7181-7185).
Accordingly, m32404 molecules are predicted to have peptidase
activity, and are predicted to regulate cell proliferation and
differentiation, to regulate coagulation (such as in blood
clotting), regulate organogenesis, control hormone production,
and/or modulate complement activation. Thus, the m32404 molecules
can serve as novel diagnostic targets and therapeutic agents for
controlling cell proliferation and differentiation disorders,
coagulation disorders, hormonal disorders, fertilization disorders,
and disorders of organogenesis and cell signaling.
[0301] The polypeptides and nucleic acids of the invention can also
be used to treat, prevent, and/or diagnose cancers and neoplastic
conditions in addition to the ones described above. As used herein,
the terms "cancer," "hyperproliferative" and "neoplastic" refer to
cells having the capacity for autonomous growth, i.e., an abnormal
state or condition characterized by rapidly proliferating cell
growth. Hyperproliferative and neoplastic disease states may be
categorized as pathologic, i.e., characterizing or constituting a
disease state, or may be categorized as non-pathologic, i.e., a
deviation from normal but not associated with a disease state. The
term is meant to include all types of cancerous growths or
oncogenic processes, metastatic tissues or malignantly transformed
cells, tissues, or organs, irrespective of histopathologic type or
stage of invasiveness. "Pathologic hyperproliferative" cells occur
in disease states characterized by malignant tumor growth. Examples
of non-pathologic hyperproliferative cells include proliferation of
cells associated with wound repair.
[0302] Examples of cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, or metastatic
disorders. The m32404 molecules can act as novel diagnostic targets
and therapeutic agents for controlling breast cancer, ovarian
cancer, colon cancer, lung cancer, metastasis of such cancers and
the like. A metastatic tumor can arise from a multitude of primary
tumor types, including but not limited to those of breast, lung,
liver, colon and ovarian origin.
[0303] Examples of cancers or neoplastic conditions, in addition to
the ones described above, include, but are not limited to, a
fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic
sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma,
gastric cancer, esophageal cancer, rectal cancer, pancreatic
cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of
the head and neck, skin cancer, brain cancer, squamous cell
carcinoma, sebaceous gland carcinoma, papillary carcinoma,
papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma,
bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's
tumor, cervical cancer, testicular cancer, small cell lung
carcinoma, non-small cell lung carcinoma, bladder carcinoma,
epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
craniopharyngioma, ependymoma, pinealoma, hemangioblastoma,
acoustic neuroma, oligodendroglioma, meningioma, melanoma,
neuroblastoma, retinoblastoma, leukemia, lymphoma, or Kaposi
sarcoma.
[0304] Examples of cellular proliferative and/or differentiative
disorders of the breast include, but are not limited to,
proliferative breast disease including, e.g., epithelial
hyperplasia, sclerosing adenosis, and small duct papillomas;
tumors, e.g., stromal tumors such as fibroadenoma, phyllodes tumor,
and sarcomas, and epithelial tumors such as large duct papilloma;
carcinoma of the breast including in situ (noninvasive) carcinoma
that includes ductal carcinoma in situ (including Paget's disease)
and lobular carcinoma in situ, and invasive (infiltrating)
carcinoma including, but not limited to, invasive ductal carcinoma,
invasive lobular carcinoma, medullary carcinoma, colloid (mucinous)
carcinoma, tubular carcinoma, and invasive papillary carcinoma, and
miscellaneous malignant neoplasms. Disorders in the male breast
include, but are not limited to, gynecomastia and carcinoma.
[0305] Examples of cellular proliferative and/or differentiative
disorders of the lung include, but are not limited to, bronchogenic
carcinoma, including paraneoplastic syndromes, bronchioloalveolar
carcinoma, neuroendocrine tumors, such as bronchial carcinoid,
miscellaneous tumors, and metastatic tumors; pathologies of the
pleura, including inflammatory pleural effusions, noninflammatory
pleural effusions, pneumothorax, and pleural tumors, including
solitary fibrous tumors (pleural fibroma) and malignant
mesothelioma.
[0306] Examples of cellular proliferative and/or differentiative
disorders of the colon include, but are not limited to,
non-neoplastic polyps, adenomas, familial syndromes, colorectal
carcinogenesis, colorectal carcinoma, and carcinoid tumors.
[0307] Examples of cellular proliferative and/or differentiative
disorders of the liver include, but are not limited to, nodular
hyperplasias, adenomas, and malignant tumors, including primary
carcinoma of the liver and metastatic tumors.
[0308] Examples of cellular proliferative and/or differentiative
disorders of the ovary include, but are not limited to, ovarian
tumors such as, tumors of coelomic epithelium, serous tumors,
mucinous tumors, endometeriod tumors, clear cell adenocarcinoma,
cystadenofibroma, brenner tumor, surface epithelial tumors; germ
cell tumors such as mature (benign) teratomas, monodermal
teratomas, immature malignant teratomas, dysgerminoma, endodermal
sinus tumor, choriocarcinoma; sex cord-stomal tumors such as,
granulosa-theca cell tumors, thecoma-fibromas, androblastomas, hill
cell tumors, and gonadoblastoma; and metastatic tumors such as
Krukenberg tumors.
[0309] Additional examples of proliferative disorders include
hematopoietic neoplastic disorders. As used herein, the term
"hematopoietic neoplastic disorders" includes diseases involving
hyperplastic/neoplastic cells of hematopoietic origin, e.g.,
arising from myeloid, lymphoid or erythroid lineages, or precursor
cells thereof. Preferably, the diseases arise from poorly
differentiated acute leukemias, e.g., erythroblastic leukemia and
acute megakaryoblastic leukemia. Additional exemplary myeloid
disorders include, but are not limited to, acute promyeloid
leukemia (APML), acute myelogenous leukemia (AML) and chronic
myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit
Rev. in Oncol./Hemotol. 11:267-97); lymphoid malignancies include,
but are not limited to acute lymphoblastic leukemia (ALL) which
includes B-lineage ALL and T-lineage ALL, chronic lymphocytic
leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia
(HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of
malignant lymphomas include, but are not limited to non-Hodgkin
lymphoma and variants thereof, peripheral T cell lymphomas, adult T
cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL),
large granular lymphocytic leukemia (LGF), Hodgkin's disease and
Reed-Sternberg disease.
14089
[0310] The human 14089 sequence (see SEQ ID NO:33), which is
approximately 957 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
726 nucleotides, including the termination codon (nucleotides
indicated as coding of SEQ ID NO:33; SEQ ID NO:35). The coding
sequence encodes a 241 amino acid protein (SEQ ID NO:34). The human
14089 protein of SEQ ID NO:34 includes an amino-terminal
hydrophobic amino acid sequence, consistent with a signal sequence,
of about 18 amino acids (from amino acid 1 to about amino acid 18
of SEQ ID NO:34), which upon cleavage results in the production of
a mature protein. This mature protein form is approximately 222
amino acid residues in length (from about amino acid 19 to amino
acid 241 of SEQ ID NO:34).
[0311] Human 14089 contains the following regions or other
structural features:
[0312] a trypsin domain (PFAM Accession Number PF00089) located at
about amino acid residues 24 to 234 or 41 to 234 of SEQ ID NO:34
(according to SMART and PFAM, respectively);
[0313] four predicted Casein Kinase II phosphorylation sites
(PS00006) located at about amino acids 96 to 99, 109 to 112, 126 to
129, and 210 to 213 of SEQ ID NO:34;
[0314] three predicted N-glycosylation sites (PS00001) from about
amino acids 11 to 14, 156 to 159, and 173 to 176 of SEQ ID
NO:34;
[0315] two predicted N-myristylation sites (PS00008) from about
amino acids 182 to 187 and 203 to 208 of SEQ ID NO:34;
[0316] one predicted amidation site (PS00009) from about amino
acids 185 to 188 of SEQ ID NO:34;
[0317] one predicted tyrosine kinase phosphorylation site (PS00007)
from about amino acids 108 to 116 of SEQ ID NO:34; or
[0318] one predicted serine protease, histidine active site
(PS00134) from about amino acids 52 to 57 of SEQ ID NO:34.
[0319] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to
Sonnhammer et al. (1997) Protein 28:405-420.
[0320] The 14089 polypeptide contains a significant number of
structural characteristics in common with members of the trypsin
serine protease family (Rawlings and Barret (1993) Biochem J. 290:
205-218, and Meth. Enzymol. (1994) 244: 19-61, the contents of
which are hereby incorporated by reference in their entirety).
Based on the presence of the histidine-aspartate-serine catalytic
triad, the 14089 polypeptide appears to be a member of the serine
protease clan SA (Rawlings and Barret, supra). The clan SA includes
the trypsin-chymotrypsin family (S1), the .alpha.-lytic
endopeptidase family (S2), and the Togavirus endopeptidase family
(S3).
[0321] The 14089 polypeptide seems to belong to the
trypsin-chymotrypsin family (S1). The prototype of this family is
chymotrypsin and the 3D structure of some of its members has been
resolved. The trypsin-chymotrypsin family (S1) includes such
members as: trypsin (forms I, II, III, IV, Va and Vb); trypsin-like
enzyme; hepsin; venombin; cercarial elastase; brachyurin; Factor C;
Proclotting enzyme; easter gene product; snake gene product;
stubble gene product; Vitellin-degrading endopeptidase; hypodermin
C; Serine proteases 1 and 2; achelase; chymotrypsin (forms A, B,
II, and 2); Proteinase RVV-V (forms .alpha. and .gamma.);
flavoboxin; venombin A; Crotalase; enteropeptidase; acrosin;
ancrod; seminin; semenogelase; tissue kallikrein; renal kallikrein;
submandibular kallikrein; 7S nerve growth factor (chains .alpha.
and .gamma.); epidermal growth factor-binding protein (forms 1, 2,
and 3); tonin; arginine esterase; pancreatic elastase I; pancreatic
elastase 11 (forms A and B); pancreatic endopeptidase E (forms A
and B); leukocyte elastase; medullasin; azurocidin; cathepsin G;
proteinase 3 (myeloblastin); chymase (forms I and II);
.gamma.-renin; tryptase (forms 1, 2, and 3); granzyme A; natural
killer cell protease 1; gilatoxin; granzymes B, C, D, E, F, G and
Y; carboxypeptidase A complex component III; complement factors D,
B, I; complement components C1r, C1s, and C2; calcium-dependent
serine protease; hypodermin A, B, and C; haptoglobin (forms 1 and
2); haptoglobin-related protein; plasmin; apolipoprotein (a);
hepatocyte growth factor; medullasin; thrombin; t-plasminogen
activator; u-plasminogen activator; salivary plasminogen activator;
plasma kallikrein; coagulation factors VII, IX, X, XI, and XII; and
proteins C and Z, as well as as-yet unidentified members.
[0322] The 14089 polypeptides can be homologous to the mouse
bodenin gene (GenBank Accession No. AJ001373). The mouse bodenin
gene is expressed in region of the brain such as the basal ganglia,
thalamus, cerebral cortex, and may play a role in the developing
and mature central nervous system. See, Faisst and Gruss, (1998)
Dev. Dyn. 212:293-303.
[0323] Accordingly, the 14089 polypeptide contains a significant
number of structural characteristics in common with members of the
S1 family of the SA clan of serine-type proteases (also referred to
herein as "trypsin-chymotrypsin" or "trypsin" family members). The
term "family" when referring to the protein and nucleic acid
molecules of the invention means two or more proteins or nucleic
acid molecules having a common structural domain or motif and
having sufficient amino acid or nucleotide sequence homology as
defined herein. Such family members can be naturally or
non-naturally occurring and can be from either the same or
different species. For example, a family can contain a first
protein of human origin as well as other distinct proteins of human
origin, or alternatively, can contain homologues of non-human
origin, e.g., rat or mouse proteins. Members of a family can also
have common functional characteristics.
[0324] As used herein, a "trypsin-chymotrypsin family member"
typically contains a catalytic unit that is generally a polypeptide
sequence of about 100 to about 300 amino acids, more preferably
about 150 to about 250, or about 170 to about 230 amino acid
residues, although some members have N-terminal extensions of
unrelated peptide segments. The catalytic unit typically forms the
C-terminal portion of the enzyme. These proteases typically cleave
arginine or lysine residues in a target protein.
[0325] Trypsin-chymotrypsin family members preferably have at least
one trypsin domain, comprising at least one histidine active site
residue, and at least one serine active site residue.
Trypsin-chymotrypsin family members can also include an aspartate
residue within the trypsin domain. These three residues act as a
"catalytic triad", with serine as nucleophile, aspartate as
electrophile, and histidine as base.
[0326] 14089 polypeptides contain structural features similar to
trypsin-chymotrypsin family members. For example, the trypsin
domain of the 14089 polypeptide has a conserved histidine residue
present at about amino acid 56 of SEQ ID NO:34, and a serine active
site located at amino acid 195 of SEQ ID NO:34. The trypsin domain
of the 14089 polypeptide additionally includes eight conserved
cysteines, which are present at about amino acids 40, 57, 133, 143,
165, 180, 191, 201, and 215 of SEQ ID NO:34. Eight of these
cysteines can form disulfide bonds together in an intramolecular
context. Preferably, the disulfide bonds are formed between
residues about 40 and 57, 133 and 201, 165 and 180, 191 and 215 of
SEQ ID NO:34.
[0327] In addition, the 14089 polypeptide includes an active site
serine at about residue 195 of SEQ ID NO:34. The histidine base
typically occurs in a signature motif characterized by Prosite
Motif PS00134: [LIVM]-[ST]-A-[STAG]-H-C. A 14089 polypeptide also
contains the sequence ITAAHC, which matches PS00134, at about amino
acids 52 to 57 of SEQ ID NO:34.
[0328] Trypsin-chymotrypsin family members occasionally function
intracellularly, but more generally, they act extracellularly.
Examples of such extracellular activity include release or
activation of growth factors, degradation of extracellular matrix,
coagulation, fibrinolysis, zymogen and growth hormone activation,
and complement activation. Trypsin-chymotrypsin family members have
been implicated in modulating tumor invasion and growth by, for
example, releasing or activating growth factors and/or digesting
extracellular matrix components. A 14089 polypeptide can include a
signal sequence, located at residues about 1 to 18 of SEQ ID NO:34,
which directs the polypeptide to the extracellular milieu.
[0329] A 14089 polypeptide includes at least one "trypsin domain"
or at least one region homologous with a "trypsin domain". As used
herein, the term "trypsin domain" (or a "trypsin-chymotrypsin"
domain) refers to a protein domain having an amino acid sequence of
from about 50 to about 350 amino acid residues and having a bit
score for the alignment of the sequence to the trypsin domain (HMM)
of at least 70. Preferably, a trypsin domain includes at least
about 100 to about 300 amino acids, more preferably about 150 to
about 250, or about 170 to about 220 amino acid residues and has a
bit score for the alignment of the sequence to the trypsin domain
(HMM) of at least 100, preferably at least 110, more preferably at
least 120 or greater. The trypsin domain (HMM) has been assigned
the PFAM Accession (PF00089). An alignment of the trypsin domain
(from about amino acids 41 to 234 of SEQ ID NO:34) of human 14089
with a consensus amino acid sequence derived from a hidden Markov
model (PFAM) is depicted in FIG. 19A. An alignment of the trypsin
domain (from about amino acids 24 to about 234 of SEQ ID NO:34) of
human 14089 with a consensus amino acid sequence derived from
another hidden Markov model (SMART) is depicted in FIG. 19B.
[0330] In a preferred embodiment, a 14089 polypeptide or protein
has a "trypsin" domain or a region which includes at least about
100 to about 300 amino acids, more preferably about 150 to about
250, or about 170 to about 220 amino acid residues and has at least
about 70%, 80%, 90%, 95%, 99%, or 100% homology with a "trypsin
domain," e.g., the trypsin domain of human 14089 (e.g., about
residues 224 to 234 or 241 to 234 of SEQ ID NO:34). Preferably, the
trypsin domain includes at least one histidine active site residue,
and at least one serine active site residue. The trypsin domain can
also include an aspartate residue, thus forming a catalytic triad,
with serine as nucleophile, aspartate as electrophile, and
histidine as base.
[0331] To identify the presence of a "trypsin" domain in a 14089
protein sequence, and make the determination that a polypeptide or
protein of interest has a particular profile, the amino acid
sequence of the protein can be searched against a database of HMMs
(e.g., the Pfam database, release 2.1) using the default
parameters. For example, the hmmsf program, which is available as
part of the HMMER package of search programs, is a family specific
default program for MILPAT0063 and a score of 15 is the default
threshold score for determining a hit. Alternatively, the threshold
score for determining a hit can be lowered (e.g., to 8 bits). A
description of the Pfam database can be found in Sonhammer et al.
(1997) Proteins 28(3):405-420 and a detailed description of HMMs
can be found, for example, in Gribskov et al. (1990) Meth. Enzymol.
183:146-159; Gribskov et al. (1987) Proc. Natl. Acad. Sci. USA
84:4355-4358; Krogh et al. (1994) J. Mol. Biol. 235:1501-1531; and
Stultz et al. (1993) Protein Sci. 2:305-314, the contents of which
are incorporated herein by reference. A search was performed
against the PFAM HMM database resulting in the identification of a
"trypsin domain" in the amino acid sequence of human 14089 at about
residues 41 to 234 of SEQ ID NO:34 with a bit score of 122.5 (see
FIGS. 18 and 20A-20B).
[0332] To identify the presence of a "trypsin" domain in a 14089
protein sequence, the amino acid sequence of the protein can also
be searched against a SMART database (Simple Modular Architecture
Research Tool) of HMMs as described in Schultz et al. (1998), Proc.
Natl. Acad. Sci. USA 95:5857 and Schultz et al. (200) Nucl. Acids
Res 28:231. The database contains domains identified by profiling
with the hidden Markov models of the HMMer2 search program (R.
Durbin et al. (1998) Biological sequence analysis: probabilistic
models of proteins and nucleic acids. Cambridge University Press).
The database also is extensively annotated and monitored by experts
to enhance accuracy. A search was performed against the HMM
database resulting in the identification of a "serine protease"
domain in the amino acid sequence of human 14089 at about residues
24 to 234 of SEQ ID NO:34 (see FIG. 18).
[0333] The sequence of interest can also be characterized using the
ProDom database. To perform this analysis, the amino acid sequence
of the protein is searched against a database of domains, e.g., the
ProDom database (Corpet et al. (1999), Nucl. Acids Res. 27:263-267)
The ProDom protein domain database consists of an automatic
compilation of homologous domains. Current versions of ProDom are
built using recursive PSI-BLAST searches (Altschul S F et al.
(1997) Nucleic Acids Res. 25:3389-3402; Gouzy et al. (1999)
Computers and Chemistry 23:333-340.) of the SWISS-PROT 38 and
TREMBL protein databases. The database automatically generates a
consensus sequence for each domain. A BLAST search was performed
against the HMM database resulting in the identification of a
"protease serine precursor signal hydrolase zymogen glycoprotein
family multigene factor" domain in the amino acid sequence of human
14089 at about residues 76 to 266 of SEQ ID NO:34 (see FIG.
20A-20B).
[0334] A 14089 family member can include at least one trypsin
domain and at least one serine protease, typsin family, histidine
active site. Furthermore, a 14089 family member can include at
least one, two, three, and preferably four predicted casein kinase
II phosphorylation sites (PS00006); at least one, and preferably
two predicted N-myristoylation sites (PS00008); at least one
predicted tyrosine kinase phosphorylation site (PS00007); at least
one amidation site (PS00009); and at least one or two, and
preferably three N-glycosylation sites (PS00001).
[0335] As the 14089 polypeptides of the invention may modulate
14089-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for 14089-mediated or
related disorders, as described below.
[0336] As used herein, a "14089 activity", "biological activity of
14089" or "functional activity of 14089", refers to an activity
exerted by a 14089 protein, polypeptide or nucleic acid molecule on
e.g., a 14089-responsive cell or on a 14089 substrate, e.g., a
protein substrate, as determined in vivo or in vitro. In one
embodiment, a 14089 activity is a direct activity, such as an
association with a 14089 target molecule. A "target molecule" or
"binding partner" is a molecule with which a 14089 protein binds or
interacts in nature, e.g., a substrate for proteolytic cleavage. A
14089 activity can also be an indirect activity, e.g., a cellular
signaling activity mediated by interaction of the 14089 protein
with a 14089 receptor. Based on the above-described sequence
similarities, the 14089 molecules of the present invention are
predicted to have similar biological activities as serine protease
family members. For example, the 14089 proteins of the present
invention can have one or more of the following activities: (1)
modulate (stimulate or inhibit) cellular proliferation (2) modulate
cell differentiation; (3) modulate tumorigenesis and tumor
invasion; (4) alter extracellular matrix composition; (5) catalyze
polypeptide growth factor activation and release; (6) regulate the
blood clotting cascade; (7) catalyze proteolytic cleavage of a
substrate, e.g., a protein substrate (e.g., cleavage at an arginine
or lysine residue; (8) catalyze the proteolytic activation of
signaling molecules, e.g., other proteases, growth factor
activation or release; or (9) regulate of cell motility or
attachment.
[0337] Based on the above-described sequence similarities, the
14089 molecules of the present invention are predicted to have
similar biological activities as other trypsin family members, such
as hepsin proteases. Hepsin proteases are overexpressed in ovarian
tumors and hepatoma cells (Tanimoto, H. et al. (1997) Cancer Res.
57:2884-2887). Further in vitro studies have shown inhibition of
hepatoma cell proliferation using hepsin inhibitors (Torres-Rosado,
A. et al. (1993) Proc. Natl. Acad. Sci. USA 90: 7181-7185). The
14089 molecules can serve as novel diagnostic targets and
therapeutic agents for controlling disorders of cell proliferation,
cell differentiation, organogenesis, coagulation, and cell
signaling.
[0338] Thus, the 14089 molecules can act as novel diagnostic
targets and therapeutic agents for controlling one or more of
cellular proliferative and/or differentiative disorders. Examples
of cellular proliferative and/or differentiative disorders include
cancer, e.g., carcinoma, sarcoma, metastatic disorders or
hematopoietic neoplastic disorders, e.g., leukemias. A metastatic
tumor can arise from a multitude of primary tumor types, including
but not limited to those of prostate, colon, lung, breast and liver
origin.
[0339] As used herein, the terms "cancer", "hyperproliferative" and
"neoplastic" refer to cells having the capacity for autonomous
growth, i.e., an abnormal state or condition characterized by
rapidly proliferating cell growth. Hyperproliferative and
neoplastic disease states may be categorized as pathologic, i.e.,
characterizing or constituting a disease state, or may be
categorized as non-pathologic, i.e., a deviation from normal but
not associated with a disease state. The term is meant to include
all types of cancerous growths or oncogenic processes, metastatic
tissues or malignantly transformed cells, tissues, or organs,
irrespective of histopathologic type or stage of invasiveness.
"Pathologic hyperproliferative" cells occur in disease states
characterized by malignant tumor growth. Examples of non-pathologic
hyperproliferative cells include proliferation of cells associated
with wound repair.
[0340] The terms "cancer" or "neoplasms" include malignancies of
the various organ systems, such as affecting lung, breast, thyroid,
lymphoid, gastrointestinal, and genito-urinary tract, as well as
adenocarcinomas which include malignancies such as most colon
cancers, renal-cell carcinoma, prostate cancer and/or testicular
tumors, non-small cell carcinoma of the lung, cancer of the small
intestine and cancer of the esophagus.
[0341] The term "carcinoma" is art recognized and refers to
malignancies of epithelial or endocrine tissues including
respiratory system carcinomas, gastrointestinal system carcinomas,
genitourinary system carcinomas, testicular carcinomas, breast
carcinomas, prostatic carcinomas, endocrine system carcinomas, and
melanomas. Exemplary carcinomas include those forming from tissue
of the cervix, lung, prostate, breast, head and neck, colon and
ovary. The term also includes carcinosarcomas, e.g., which include
malignant tumors composed of carcinomatous and sarcomatous tissues.
An "adenocarcinoma" refers to a carcinoma derived from glandular
tissue or in which the tumor cells form recognizable glandular
structures.
[0342] The term "sarcoma" is art recognized and refers to malignant
tumors of mesenchymal derivation.
[0343] Additional examples of proliferative disorders include
hematopoietic neoplastic disorders. As used herein, the term
"hematopoietic neoplastic disorders" includes diseases involving
hyperplastic/neoplastic cells of hematopoietic origin, e.g.,
arising from myeloid, lymphoid or erythroid lineages, or precursor
cells thereof. Preferably, the diseases arise from poorly
differentiated acute leukemias, e.g., erythroblastic leukemia and
acute megakaryoblastic leukemia. Additional exemplary myeloid
disorders include, but are not limited to, acute promyeloid
leukemia (APML), acute myelogenous leukemia (AML) and chronic
myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit
Rev. in Oncol./Hemotol. 11:267-97); lymphoid malignancies include,
but are not limited to acute lymphoblastic leukemia (ALL) which
includes B-lineage ALL and T-lineage ALL, chronic lymphocytic
leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia
(HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of
malignant lymphomas include, but are not limited to non-Hodgkin
lymphoma and variants thereof, peripheral T cell lymphomas, adult T
cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL),
large granular lymphocytic leukemia (LGF), Hodgkin's disease and
Reed-Sternberg disease.
23436
[0344] One post-translational mechanism of regulating protein
levels is the ubiquitin pathway. Ubiquitin is a highly conserved
polypeptide expressed in all eukaryotic cells. Ubiquitin is
covalently attached as a single molecule or as a conjugated form to
lysine residue(s) of target proteins by formation of an isopeptide
bond to the C-terminal glycine residue of ubiquitin. Most
ubiquitinated proteins are subsequently targeted to the 26S
proteasome, a multicatalytic protease, which cleaves the marked
protein into peptide fragments.
[0345] Of the various enzymes involved in the ubiquitin protein
degradation pathway, one type of enzyme, termed ubiquitin
carboxy-terminal hydrolase (also "UCH" or "ubiquitin protease"),
hydrolyzes the bond between ubiquitin and ubiquitin-tagged proteins
and the bond linking ubiquitin-ubiquitin conjugates. This activity
can provide a proofreading function, e.g., a function that reduces
protein degradation. These enzymes can include determinants for
substrate-specific recognition in order to selectively regulate
degradation of their preferred substrates. They can also associate
19S regulatory complex of the 26S proteasome.
[0346] The regulatory function of ubiquitin carboxy-terminal
hydrolases has been demonstrated for a number of cellular
processes. For example, in Drosophila the ubiquitin
carboxy-terminal hydrolase, fat facets (faf) is a regulator
important for eye development (Chen and Fischer (2000) Genetics
156:1829-36). In yeast, the ubiquitin carboxy-terminal hydrolase
UBP3 is associated with mating-type silencing (Moazed and Johnson
(1996) Cell 86:667-77). These findings suggest that ubiquitin
carboxy-terminal hydrolases exert a regulatory function by
controlling de-ubiquitination of substrates.
[0347] Ubiquitination and de-ubiquitination are important processes
through which protein levels and function are regulated in cells.
Ubiquitination has been implicated in regulating numerous cellular
processes including proliferation, differentiation, apoptosis
(programmed cell death), transcription, signal-transduction,
cell-cycle progression, receptor-mediated endocytosis, and
organelle biogenesis. The activity of an enzyme mediating substrate
de-ubiquitination or ubiquitin flux is key to the outcome of such
processes.
[0348] Levels of ubiquitination can be altered in the diseased
state. For example, in neuropathological conditions such as
Alzheimer's and Pick's disease abnormal amounts of ubiquitinated
proteins accumulate. In proliferative disorders, oncogenes (e.g.,
v-jun and v-fos) can be more resistant to ubiquitination in
comparison to their normal cell counterparts. The failure to
degrade oncogene protein products may contribute to their cell
transformation capability.
[0349] The human 23436 sequence (SEQ ID NO:40), which is
approximately 2446 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
1458 nucleotides, including the TAA termination codon (nucleotides
indicated as coding of SEQ ID NO:40; SEQ ID NO:42). The coding
sequence encodes a 485 amino acid protein (SEQ ID NO:41).
[0350] Human 23436 contains the following regions or other
structural features:
[0351] a ubiquitin carboxy-terminal hydrolase (family 2) domain
with a first segment (PFAM Accession Number PF00442) located at
about amino acid residues 89 to 120 of SEQ ID NO:41 and a second
segment (PFAM Accession Number PF00443) located at about amino acid
residues 332 to 420 of SEQ ID NO:41;
[0352] four predicted protein kinase C phosphorylation sites
(PS00005) at about amino acids 17 to 19, 158 to 160, 280 to 282,
and 398 to 400 of SEQ ID NO:41;
[0353] four predicted casein kinase II phosphorylation sites
(PS00006) located at about amino acids 123 to 126, 143 to 146, 191
to 194, and 445 to 448 of SEQ ID NO:41;
[0354] two predicted cAMP/cGMP-dependent protein kinase
phosphorylation sites (PS00004) located at about amino acids 84 to
87 and 458 to 461 of SEQ ID NO:41;
[0355] one predicted tyrosine kinase phosphorylation site (PS00007)
located at about amino acids 261 to 268;
[0356] two predicted N-glycosylation sites (PS00001) from about
amino acids 278 to 281 and 427 to 430 of SEQ ID NO:41;
[0357] one predicted amidation site (PS00009) from about amino
acids 378 to 381 of SEQ ID NO:41; and
[0358] three predicted N-myristylation sites (PS00008) from about
amino acids 50 to 55, 173 to 178, and 406 to 411 of SEQ ID
NO:41.
[0359] The ubiquitin carboxy-terminal hydrolase (family 2) domain
of 23436 protein also features a conserved catalytic cysteine at
about amino acid 98 of SEQ ID NO:41, and two conserved histidines
at about amino acids 344 and 353 of SEQ ID NO:41. The two conserved
histidines are contained within a ubiquitin specific carboxyl
terminal hydrolase family signature domain (Prosite motif PS00973)
located at about amino acid residues 336 to 354 (PFAM Accession
PS00973);
[0360] For general information regarding PFAM identifiers, PS
prefix and PF prefix domain identification numbers, refer to
Sonnhammer et al. (1997) Protein 28:405-420.
[0361] The 23436 protein contains a significant number of
characteristics in common with members of the ubiquitin
carboxy-terminal hydrolase family 2. The term "family" when
referring to the protein and nucleic acid molecules of the
invention means two or more proteins or nucleic acid molecules
having a common structural domain or motif and having sufficient
amino acid or nucleotide sequence homology as defined herein. Such
family members can be naturally or non-naturally occurring and can
be from either the same or different species. For example, a family
can contain a first protein of human origin as well as other
distinct proteins of human origin, or alternatively, can contain
homologues of non-human origin, e.g., rat or mouse proteins.
Members of a family can also have common functional
characteristics.
[0362] Proteins of the ubiquitin carboxy-terminal hydrolase family
2 are characterized by a common fold with characteristics cysteine
protease activity. The fold includes a conserved cysteine, e.g.,
the cysteine at about amino acid 98 of SEQ ID NO:41, which can be
the catalytic cysteine for the protease domain. The fold also
includes a conserved structural motif, characterized by the Prosite
signature Y-X-L-X-[SAG]-[LIVMFT]-X(2)-H-x-G-X(4,5)-G-H-Y (wherein X
is any amino acid; and numbers in parentheses indicate a repetition
of a feature for the indicated number of residues or a range of
residues; SEQ ID NO:45) which is located at about amino acids 336
to 354 of SEQ ID NO:41 and includes two conserved histidines, e.g.,
histidines at about amino acids 344 and 353 of SEQ ID NO:41. At
least one of these histidines can participate in catalysis.
[0363] A 23436 polypeptide or subsequence thereof can include a
"ubiquitin carboxy-terminal hydrolase domain," or a "ubiquitin
protease domain," or sequences homologous with a "ubiquitin
carboxy-terminal hydrolase or protease domain." As used herein the
phrases, "ubiquitin carboxy-terminal hydrolase," "ubiquitin
specific hydrolase," "ubiquitin hydrolase," "ubiquitin protease,"
or "ubiquitin specific protease" are used interchangeably and mean
a polypeptide with the ability to remove one or more ubiquitin
molecules from a protein that has one or more covalently attached
molecules of ubiquitin. For example, the definition includes
cleavage of conjugated forms of ubiquitin, e.g., at the peptide
bond following the carboxy-terminal glycine (e.g., whether or not
the ubiquitin conjugate is attached to a protein). In a preferred
embodiment, the ubiquitin carboxy-terminal hydrolase can cleave a
ubiquitin moiety from the .epsilon.-NH.sub.2 group of a lysine side
chain of a target protein.
[0364] As used herein, the term "ubiquitin carboxy-terminal
hydrolase domain" includes an amino acid sequence of about 300 to
450 amino acid residues in length and having a bit score for the
alignment of the sequence to the first ubiquitin carboxy-terminal
hydrolase (family 2) consensus (PFAM PF00442) of at least 20 and to
the second ubiquitin carboxy-terminal hydrolase (family 2)
consensus (PFAM PF00443) of at least 50. Preferably, a ubiquitin
carboxy-terminal hydrolase domain includes at least about 300 to
450 amino acids, more preferably about 320 to 440 amino acid
residues, or about 330 to 420 amino acids and has a bit score for
the alignment of the sequence to the second ubiquitin
carboxy-terminal hydrolase (family 2) domain consensus sequence
(HMM) of at least 50, 60, 70, 75 or greater. The ubiquitin
carboxy-terminal hydrolase (family 2) domain (MM) has been assigned
two non-contiguous consensus sequences PFAM Accession Numbers
PF00442 and PF00443. An alignment of the ubiquitin carboxy-terminal
hydrolase domain (amino acids 89 to 120 of SEQ ID NO:41) of human
23436 with the first ubiquitin carboxy-terminal hydrolase (family
2) consensus amino acid sequence (SEQ ID NO:43) derived from a
hidden Markov model is depicted in FIG. 22A and an alignment of the
ubiquitin carboxy-terminal hydrolase domain (amino acids 332 to 420
of SEQ ID NO:41) of human 23436 with the second ubiquitin
carboxy-terminal hydrolase (family 2) consensus amino acid sequence
(SEQ ID NO:44) derived from a hidden Markov model is depicted in
FIG. 22B.
[0365] In a preferred embodiment, 23436 polypeptide or protein has
a "ubiquitin carboxy-terminal hydrolase (family 2) domain" first
signature region (PF00442) which includes at least about 10 to 70
more preferably about 20 to 50 or 24 to 35 amino acid residues and
has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or 100% homology
with a "ubiquitin carboxy-terminal hydrolase (family 2) domain
UCH-1," e.g., the first signature region of the ubiquitin
carboxy-terminal hydrolase domain of human 23436 (e.g., residues 89
to 120 of SEQ ID NO:41). In a much preferred embodiment, the 23436
polypeptide includes a conserved catalytic cysteine at about
residue 98 of SEQ ID NO:41.
[0366] In another preferred embodiment, 23436 polypeptide or
protein has a "ubiquitin carboxy-terminal hydrolase (family 2)
domain" second signature region (PF00443) which includes at least
about 50 to 140 more preferably about 70 to 120, or 80 to 100 amino
acid residues and has at least about 50%, 60%, 70% 80% 90% 95%,
99%, or 100% homology with a "ubiquitin carboxy-terminal hydrolase
(family 2) domain UCH-2," e.g., the second signature region of the
ubiquitin carboxy-terminal hydrolase domain of human 23436 (e.g.,
residues 379 to 420 of SEQ ID NO:41). In a much preferred
embodiment, the 23436 polypeptide includes the two conserved
histidines at about amino acids 344 and 353 of SEQ ID NO:41.
[0367] To identify the presence of a "ubiquitin carboxy-terminal
hydrolase" domain in a 23436 protein sequence, and make the
determination that a polypeptide or protein of interest has a
particular profile, the amino acid sequence of the protein can be
searched against the Pfam database of HMMs (e.g., the Pfam
database, release 2.1) using the default parameters. For example,
the hmmsf program, which is available as part of the HMMER package
of search programs, is a family specific default program for
MILPAT0063 and a score of 15 is the default threshold score for
determining a hit. Alternatively, the threshold score for
determining a hit can be lowered (e.g., to 8 bits). A description
of the Pfam database can be found in Sonhammer et al. (1997)
Proteins 28(3):405-420 and a detailed description of HMMs can be
found, for example, in Gribskov et al. (1990) Meth. Enzymol.
183:146-159; Gribskov et al. (1987) Proc. Natl. Acad. Sci. USA
84:4355-4358; Krogh et al. (1994) J. Mol. Biol. 235:1501-1531; and
Stultz et al. (1993) Protein Sci. 2:305-314, the contents of which
are incorporated herein by reference. A search was performed
against the HMM database resulting in the identification of a
"ubiquitin carboxy-terminal hydrolase" domain in the amino acid
sequence of human 23436 at about residues 89 to 420 (e.g.,
particularly the segments 89 to 120 and 332 to 420) of SEQ ID
NO:41; see FIGS. 22A and 22B)).
[0368] A 23436 family member can include at least one ubiquitin
carboxy-terminal hydrolase domain. Furthermore, a 23436 family
member can include at least one, two, three, preferably four
protein kinase C phosphorylation sites (PS00005); at least one,
two, three, preferably four predicted casein kinase II
phosphorylation sites (PS00006); at least one tyrosine kinase
phosphorylation site (PS00009); at least one, preferably two cAMP
and cGMP protein kinase phosphorylation sites (PS00004); at least
one, preferably two N-glycosylation sites (PS00001); and at least
one, two, preferably three predicted N-myristylation sites
(PS00008).
[0369] As the 23436 polypeptides of the invention may modulate
23436-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for 23436-mediated or
related disorders, as described below.
[0370] As used herein, a "23436 activity", "biological activity of
23436" or "functional activity of 23436", refers to an activity
exerted by a 23436 protein, polypeptide or nucleic acid molecule.
For example, a 23436 activity can be an activity exerted by 23436
in a physiological milieu on, e.g., a 23436-responsive cell or on a
23436 substrate, e.g., a ubiquitinated protein substrate or a
ubiquitin-ubiquitin conjugate. A 23436 activity can be determined
in vivo or in vitro. In one embodiment, a 23436 activity is a
direct activity, such as an association with a 23436 target
molecule. A "target molecule" or "binding partner" is a molecule
with which a 23436 protein binds or interacts in nature. In a
preferred embodiment, the target molecule is a ubiquitinated
compound which is a substrate for 23436-mediated de-ubiquitination.
In an exemplary embodiment, 23436 is an enzyme that catalyzes the
removal of ubiquitin from a substrate, e.g., by hydrolyzing a
peptide bond.
[0371] A 23436 activity can also be an indirect activity, e.g.,
decreased degradation or increased stability of a protein due to
23436-mediated de-ubiquitination, or a cellular signaling activity
(e.g., proliferation, differentiation, apoptosis, etc.) that
results from or is mediated by the 23436 protein or a protein
de-ubiquitinated by 23436. For example, altered expression or
activity of a 23436 molecule can cause an inhibition or failure to
target proteins for degradation or, alternatively, excessive or
undesirable protein degradation, leading to accumulation of protein
in cells which, in turn, leads to a disorder of a tissue in which
23436 is normally expressed (e.g., the brain).
[0372] Based on the discovery disclosed herein, e.g., the
above-described sequence similarities, the 23436 molecules of the
present invention are predicted to have similar biological
activities as ubiquitin carboxy-terminal hydrolase family 2
members. Protein ubiquitination is important in
growth-factor-mediated cellular proliferation. The deubiquitinating
enzymes act as regulatory enzymes that couple extracellular
signaling to cell growth. 23436, which shows sequence similarity to
a deubiquitinating hydrolase is believed to negatively regulates
cytokine signaling in hematopoietic, e.g., erythroid, progenitors
resulting in the inhibition of hematopoietic progenitor growth.
Antagonists of this 23436 are expected to promote hematopoietic,
e.g., erythroid, cell proliferation and differentiation.
[0373] Accordingly, the 23436 proteins of the present invention can
have one or more of the following activities: (1) de-ubiquitinating
polypeptides that are ubiquitinated; (2) cleaving ubiquitin
conjugates (e.g., ubiquitin-tagged substrates, ubiquitin-tagged
peptide fragments, head to tail linked ubiquitin molecules); (3)
reversing targeting of a polypeptide to a proteasome (e.g., by
removing ubiquitin targeting signals); or (4) altering flux in the
ubiquitin pathway (e.g., by recycling ubiquitin from proteasome
digestions products). Hence, modulation of 23436 polypeptide
activity or expression are likely to influence degradation events,
and thereby regulate cellular activities related to cell
proliferation, cell signaling, cell death (e.g., apoptosis), cell
motility, receptor-mediated endocytosis, organelle biogenesis,
hematopoietic, e.g., erythroid, cell proliferation and
differentiation, and cytokine-mediated signaling events.
[0374] The molecules of the invention can be used to develop novel
agents or compounds to treat and/or diagnose disorders involving
aberrant activities of the cells in which 23436 nucleic acids and
polypeptides are expressed. 23436 mRNA is found primarily in
hematopoietic cells, and in particular, in cells of the erythroid
lineage (FIGS. 25-26), as well as prostate, hypothalamus, and
hepatoma cells. More specifically, high expression of 23436 was
detected in fetal liver, bone marrow, erythroid progenitor and
mature cells. Lower levels of expression were detected in the brain
(e.g., the cortex), kidney, ovary, human vascular endothelial cells
and hematopoietic progenitor cells. This pattern of expression
suggests a role for 23436 in the function and development of the
tissues in which it is expressed, and in particular in
hematopoietic cells.
[0375] As the 23436 polypeptides of the invention may modulate
23436-mediated activities, they may be useful as of for developing
novel diagnostic and therapeutic agents for 23436-mediated or
related disorders, e.g., blood cell-associated or
erythroid-associated disorders such as erythropoiesis, and other
hematopoietic disorders.
[0376] As used herein, the term "erythroid associated disorders"
include disorders involving aberrant (increased or deficient)
erythroblast proliferation, e.g., an erythroleukemia; aberrant
(increased or deficient) erythroblast differentiation, e.g., an
anemia; anemias such as, for example, drug- (chemotherapy-) induced
anemias, hemolytic anemias due to hereditary cell membrane
abnormalities, such as hereditary spherocytosis, hereditary
elliptocytosis, and hereditary pyropoikilocytosis; hemolytic
anemias due to acquired cell membrane defects, such as paroxysmal
nocturnal hemoglobinuria and spur cell anemia; hemolytic anemias
caused by antibody reactions, for example to the RBC antigens, or
antigens of the ABO system, Lewis system, Ii system, Rh system,
Kidd system, Duffy system, and Kell system; methemoglobinemia; a
failure of erythropoiesis, for example, as a result of aplastic
anemia, pure red cell aplasia, myelodysplastic syndromes,
sideroblastic anemias, and congenital dyserythropoietic anemia;
secondary anemia in non-hematolic disorders, for example, as a
result of chemotherapy, alcoholism, or liver disease; anemia of
chronic disease, such as chronic renal failure; and endocrine
deficiency diseases.
[0377] Agents that modulate 23436 polypeptide or nucleic acid
activity or expression can be used to treat anemias, in particular,
drug-induced anemias or anemias associated with cancer
chemotherapy, chronic renal failure, malignancies, adult and
juvenile rheumatoid arthritis, disorders of hemoglobin synthesis,
prematurity, and zidovudine treatment of IUV infection. A subject
receiving the treatment can be additionally treated with a second
agent, e.g., erythropoietin, to further ameliorate the
condition.
[0378] As used herein, the term "erythropoietin" or "EPO" refers to
a glycoprotein produced in the kidney, which is the principal
hormone responsible for stimulating red blood cell production
(erythrogenesis). EPO stimulates the division and differentiation
of committed erythroid progenitors in the bone marrow. Normal
plasma erythropoietin levels range from 0.01 to 0.03 Units/mL, and
can increase up to 100 to 1,000-fold during hypoxia or anemia.
Graber and Krantz (1978) Ann. Rev. Med. 29:51; Eschbach and Adamson
(1985) Kidney Intl. 28:1. Recombinant human erythropoietin (rHuEpo
or epoietin alpha) is commercially available as EPOGEN.RTM.
(epoietin alpha, recombinant human erythropoietin) (Amgen Inc.,
Thousand Oaks, Calif.) and as PROCRIT.RTM. (epoietin alpha,
recombinant human erythropoietin) (Ortho Biotech Inc., Raritan,
N.J.).
[0379] Another example of an erythroid-associated disorder is
erythrocytosis. Erythrocytosis, a disorder of red blood cell
overproduction caused by excessive and/or ectopic erythropoietin
production, can be caused by cancers, e.g., a renal cell cancer, a
hepatocarcinoma, and a central nervous system cancer. Diseases
associated with erythrocytosis include polycythemias, e.g.,
polycythemia vera, secondary polycythemia, and relative
polycythemia.
[0380] Aberrant expression or activity of the 23436 molecules may
be involved in neoplastic disorders. Accordingly, treatment,
prevention and diagnosis of cancer or neoplastic disorders related
to hematopoietic cells and, in particular, cells of the erythroid
lineage are also included in the present invention. Such neoplastic
disorders are exemplified by erythroid leukemias, or leukemias of
erythroid precursor cells, e.g., poorly differentiated acute
leukemias such as erythroblastic leukemia and acute
megakaryoblastic leukemia. Additional exemplary myeloid disorders
include, but are not limited to, acute promyeloid leukemia (APML),
acute myelogenous leukemia (AML) and chronic myelogenous leukemia
(CML) (reviewed in Vaickus, L. (1991) Crit Rev. in Oncol./Hemotol.
11:267-97). In particular, AML can include the uncontrolled
proliferation of CD34+ cells such as AML subtypes M1 and M2,
myeloblastic leukemias with and without maturation, and AML subtype
M6, erythroleukemia (Di Guglielmo's disease). Additional neoplastic
disorders include a myelodysplastic syndrome or preleukemic
disorder, e.g., oligoblastic leukemia, smoldering leukemia.
Additional cancers of the erythroid lineage include
erythroblastosis, and other relevant diseases of the bone
marrow.
[0381] The term "leukemia" or "leukemic cancer" is intended to have
its clinical meaning, namely, a neoplastic disease in which white
corpuscle maturation is arrested at a primitive stage of cell
development. The disease is characterized by an increased number of
leukemic blast cells in the bone marrow, and by varying degrees of
failure to produce normal hematopoietic cells. The condition may be
either acute or chronic. Leukemias are further typically
categorized as being either lymphocytic i.e., being characterized
by cells which have properties in common with normal lymphocytes,
or myelocytic (or myelogenous), i.e., characterized by cells having
some characteristics of normal granulocytic cells. Acute
lymphocytic leukemia ("ALL") arises in lymphoid tissue, and
ordinarily first manifests its presence in bone marrow. Acute
myelocytic leukemia ("AML") arises from bone marrow hematopoietic
stem cells or their progeny. The term acute myelocytic leukemia
subsumes several subtypes of leukemia: myeloblastic leukemia,
promyelocytic leukemia, and myelomonocytic leukemia. In addition,
leukemias with erythroid or megakaryocytic properties are
considered myelogenous leukemias as well.
[0382] The molecules of the invention may also modulate the
activity of neoplastic, non-hematopoietic tissues in which they are
expressed, e.g., liver and prostate. The 23436 molecules can act as
novel diagnostic targets and therapeutic agents for controlling one
or more of cellular proliferative and/or differentiative disorders.
Examples of such cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, or metastatic
disorders. A metastatic tumor can arise from a multitude of primary
tumor types, including but not limited to those of prostate and
liver origin.
[0383] As used herein, the terms "cancer", "hyperproliferative",
and "neoplastic" refer to cells having the capacity for autonomous
growth, i.e., an abnormal state or condition characterized by
rapidly proliferating cell growth. Hyperproliferative and
neoplastic disease states may be categorized as pathologic, i.e.,
characterizing or constituting a disease state, or may be
categorized as non-pathologic, i.e., a deviation from normal but
not associated with a disease state. The term is meant to include
all types of cancerous growths or oncogenic processes, metastatic
tissues or malignantly transformed cells, tissues, or organs,
irrespective of histopathologic type or stage of invasiveness.
"Pathologic hyperproliferative" cells occur in disease states
characterized by malignant tumor growth. Examples of non-pathologic
hyperproliferative cells include proliferation of cells associated
with wound repair.
[0384] The terms "cancer" or "neoplasms" include malignancies of
the various organ systems, such as those affecting lung, breast,
thyroid, lymphoid, gastrointestinal, and the genito-urinary tract.
The terms "cancer" or "neoplasms" also includes adenocarcinomas
that include malignancies such as prostate cancer and/or testicular
tumors, and non-small cell carcinoma of the lung.
[0385] The term "carcinoma" is art recognized and refers to
malignancies of epithelial or endocrine tissues including
respiratory system carcinomas, gastrointestinal system carcinomas,
genitourinary system carcinomas, testicular carcinomas, breast
carcinomas, prostatic carcinomas, endocrine system carcinomas, and
melanomas. Exemplary carcinomas include those forming from tissue
of the prostate, and liver. The term also includes carcinosarcomas,
e.g., malignant tumors composed of carcinomatous and sarcomatous
tissues. The term "sarcoma" is art recognized and refers to
malignant tumors of mesenchymal derivation.
[0386] An alteration in a 23436 nucleic acid or polypeptide can be
associated with susceptibility for prostate cancer, e.g.,
early-onset prostate cancer, and/or brain cancer. As used herein,
"a prostate disorder" refers to an abnormal condition occurring in
the male pelvic region characterized by, e.g., male sexual
dysfunction and/or urinary symptoms. This disorder may be
manifested in the form of genitourinary inflammation (e.g.,
inflammation of smooth muscle cells) as in several common diseases
of the prostate including prostatitis, benign prostatic hyperplasia
and cancer, e.g., adenocarcinoma or carcinoma, of the prostate.
[0387] As used herein, the term "brain cancer" includes a
hyperproliferative or neoplastic state of tissue in the brain,
including tumors such as gliomas, including astrocytoma, including
fibrillary (diffuse) astrocytoma and glioblastoma multiforme,
pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and brain
stem glioma, oligodendroglioma, and ependymoma and related
paraventricular mass lesions, neuronal tumors, poorly
differentiated neoplasms, including medulloblastoma, other
parenchymal tumors, including primary brain lymphoma, germ cell
tumors, and pineal parenchymal tumors, meningiomas, metastatic
tumors, paraneoplastic syndromes, peripheral nerve sheath tumors,
including schwannoma, neurofibroma, and malignant peripheral nerve
sheath tumor (malignant schwannoma), and neurocutaneous syndromes
(phakomatoses), including neurofibromotosis, including Type 1
neurofibromatosis (NF1) and TYPE 2 neurofibromatosis (NF2),
tuberous sclerosis, and Von Hippel-Lindau disease.
[0388] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein, fragments thereof, and derivatives and other variants of
the sequence in SEQ ID NO:2, 8, 15, 20, 25, 34, or 41 thereof are
collectively referred to as "polypeptides or proteins of the
invention" or "53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptides or proteins." Nucleic acid molecules encoding such
polypeptides or proteins are collectively referred to as "nucleic
acids of the invention" or "53070, 15985, 26583, 21953, m32404,
14089, or 23436 nucleic acids." 53070, 15985, 26583, 21953, m32404,
14089, or 23436 molecules refer to 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acids, polypeptides, and
antibodies.
[0389] As used herein, the term "nucleic acid molecule" includes
DNA molecules (e.g., a cDNA or genomic DNA), RNA molecules (e.g.,
an mRNA) and analogs of the DNA or RNA. A DNA or RNA analog can be
synthesized from nucleotide analogs. The nucleic acid molecule can
be single-stranded or double-stranded, but preferably is
double-stranded DNA.
[0390] The term "isolated nucleic acid molecule" or "purified
nucleic acid molecule" includes nucleic acid molecules that are
separated from other nucleic acid molecules present in the natural
source of the nucleic acid. For example, with regards to genomic
DNA, the term "isolated" includes nucleic acid molecules which are
separated from the chromosome with which the genomic DNA is
naturally associated. Preferably, an "isolated" nucleic acid is
free of sequences which naturally flank the nucleic acid (i.e.,
sequences located at the 5' and/or 3' ends of the nucleic acid) in
the genomic DNA of the organism from which the nucleic acid is
derived. For example, in various embodiments, the isolated nucleic
acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1
kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which
naturally flank the nucleic acid molecule in genomic DNA of the
cell from which the nucleic acid is derived. Moreover, an
"isolated" nucleic acid molecule, such as a cDNA molecule, can be
substantially free of other cellular material, or culture medium
when produced by recombinant techniques, or substantially free of
chemical precursors or other chemicals when chemically
synthesized.
[0391] As used herein, the term "hybridizes under low stringency,
medium stringency, high stringency, or very high stringency
conditions" describes conditions for hybridization and washing.
Guidance for performing hybridization reactions can be found in
Current Protocols in Molecular Biology, John Wiley & Sons, N.Y.
(1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous
and nonaqueous methods are described in that reference and either
can be used. Specific hybridization conditions referred to herein
are as follows: 1) low stringency hybridization conditions in
6.times. sodium chloride/sodium citrate (SSC) at about 45.degree.
C., followed by two washes in 0.2.times.SSC, 0.1% SDS at least at
50.degree. C. (the temperature of the washes can be increased to
55.degree. C. for low stringency conditions); 2) medium stringency
hybridization conditions in 6.times.SSC at about 45.degree. C.,
followed by one or more washes in 0.2.times.SSC, 0.1% SDS at
60.degree. C.; 3) high stringency hybridization conditions in
6.times.SSC at about 45.degree. C., followed by one or more washes
in 0.2.times.SSC, 0.1% SDS at 65.degree. C.; and preferably 4) very
high stringency hybridization conditions are 0.5M sodium phosphate,
7% SDS at 65.degree. C., followed by one or more washes at
0.2.times.SSC, 1% SDS at 65.degree. C. Very high stringency
conditions (4) are the preferred conditions and the ones that
should be used unless otherwise specified.
[0392] Preferably, an isolated nucleic acid molecule of the
invention that hybridizes under a stringency condition described
herein to the sequence of SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24,
26, 33, 35, 40, or 42, corresponds to a naturally-occurring nucleic
acid molecule.
[0393] As used herein, a "naturally-occurring" nucleic acid
molecule refers to an RNA or DNA molecule having a nucleotide
sequence that occurs in nature. For example a naturally occurring
nucleic acid molecule can encode a natural protein.
[0394] As used herein, the terms "gene" and "recombinant gene"
refer to nucleic acid molecules which include at least an open
reading frame encoding a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 protein. The gene can optionally further include
non-coding sequences, e.g., regulatory sequences and introns.
Preferably, a gene encodes a mammalian 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein or derivative thereof.
[0395] An "isolated" or "purified" polypeptide or protein is
substantially free of cellular material or other contaminating
proteins from the cell or tissue source from which the protein is
derived, or substantially free from chemical precursors or other
chemicals when chemically synthesized. "Substantially free" means
that a preparation of 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein is at least 10% pure. In a preferred embodiment, the
preparation of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein has less than about 30%, 20%, 10% and more preferably 5%
(by dry weight), of non-53070, 15985, 26583, 21953, m32404, 14089,
or 23436 protein (also referred to herein as a "contaminating
protein"), or of chemical precursors or non-53070, -15985, -26583,
-21953, -m32404, -14089, or -23436 chemicals. When the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein or
biologically active portion thereof is recombinantly produced, it
is also preferably substantially free of culture medium, i.e.,
culture medium represents less than about 20%, more preferably less
than about 10%, and most preferably less than about 5% of the
volume of the protein preparation. The invention includes isolated
or purified preparations of at least 0.01, 0.1, 1.0, and 10
milligrams in dry weight.
[0396] A "non-essential" amino acid residue is a residue that can
be altered from the wild-type sequence of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 without abolishing or substantially
altering a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
activity. Preferably the alteration does not substantially alter
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436 activity,
e.g., the activity is at least 20%, 40%, 60%, 70% or 80% of
wild-type. An "essential" amino acid residue is a residue that,
when altered from the wild-type sequence of 53070, 15985, 26583,
21953, m32404, 14089, or 23436, results in abolishing a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 activity such that
less than 20% of the wild-type activity is present. For example,
conserved amino acid residues in 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 are predicted to be particularly unamenable
to alteration.
[0397] A "conservative amino acid substitution" is one in which the
amino acid residue is replaced with an amino acid residue having a
similar side chain. Families of amino acid residues having similar
side chains have been defined in the art. These families include
amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g., glycine, asparagine,
glutamine, serine, threonine, tyrosine, cysteine), nonpolar side
chains (e.g., alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan), beta-branched side chains
(e.g., threonine, valine, isoleucine) and aromatic side chains
(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a
predicted nonessential amino acid residue in a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein is preferably replaced with
another amino acid residue from the same side chain family.
Alternatively, in another embodiment, mutations can be introduced
randomly along all or part of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 coding sequence, such as by saturation mutagenesis,
and the resultant mutants can be screened for 53070, 15985, 26583,
21953, m32404, 14089, or 23436 biological activity to identify
mutants that retain activity. Following mutagenesis of SEQ ID NO:
1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42, the encoded
protein can be expressed recombinantly and the activity of the
protein can be determined.
[0398] As used herein, a "biologically active portion" of a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein includes a
fragment of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein which participates in an interaction, e.g., an
intramolecular or an inter-molecular interaction. An
inter-molecular interaction can be a specific binding interaction
or an enzymatic interaction (e.g., the interaction can be transient
and a covalent bond is formed or broken). An inter-molecular
interaction can be between a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 molecule and a non-53070, -15985, -26583, -21953,
-m32404, -14089, or -23436 molecule or between a first 53070,
15985, 26583, 21953, m32404, 14089, or 23436 molecule and a second
53070, 15985, 26583, 21953, m32404, 14089, or 23436 molecule (e.g.,
a dimerization interaction). Biologically active portions of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein include
peptides comprising amino acid sequences sufficiently homologous to
or derived from the amino acid sequence of the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein, e.g., the amino acid
sequence shown in SEQ ID NO: 2, 8, 15, 20, 25, 34, or 41, which
include less amino acids than the full length 53070, 15985, 26583,
21953, m32404, 14089, or 23436 proteins, and exhibit at least one
activity of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein. Typically, biologically active portions comprise a domain
or motif with at least one activity of the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein, e.g., the ability to
phosphorylate a substrate, to bind microtubules and/or
phosphorylate proteins, to remove the phosphate from a serine or
threonine residue of a phosphorylated protein, to bind and/or
cleave polypeptide substrates, to bind peptide sequences and
exhibit proteolytic activity, to bind proteolytic substrates, or to
de-ubiquitinate substrates, respectively.
[0399] A biologically active portion of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein can be a polypeptide which
is, for example, 10, 25, 50, 100, 200 or more amino acids in
length. Biologically active portions of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein can be used as targets for
developing agents which modulate a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 mediated activity, e.g., substrate
phosphorylation; protein kinase activity or microtubule binding;
prolyl oligopeptidase activity; protease activity; proteolytic
cleavage of a substrate; or de-ubiquitinating activity or ubiquitin
carboxy-terminal hydrolase activity.
[0400] Calculations of homology or sequence identity between
sequences (the terms are used interchangeably herein) are performed
as follows.
[0401] To determine the percent identity of two amino acid
sequences, or of two nucleic acid sequences, the sequences are
aligned for optimal comparison purposes (e.g., gaps can be
introduced in one or both of a first and a second amino acid or
nucleic acid sequence for optimal alignment and non-homologous
sequences can be disregarded for comparison purposes). In a
preferred embodiment, the length of a reference sequence aligned
for comparison purposes is at least 30%, preferably at least 40%,
more preferably at least 50%, 60%, and even more preferably at
least 70%, 80%, 90%, 100% of the length of the reference sequence.
The amino acid residues or nucleotides at corresponding amino acid
positions or nucleotide positions are then compared. When a
position in the first sequence is occupied by the same amino acid
residue or nucleotide as the corresponding position in the second
sequence, then the molecules are identical at that position (as
used herein amino acid or nucleic acid "identity" is equivalent to
amino acid or nucleic acid "homology").
[0402] The percent identity between the two sequences is a function
of the number of identical positions shared by the sequences,
taking into account the number of gaps, and the length of each gap,
which need to be introduced for optimal alignment of the two
sequences.
[0403] The comparison of sequences and determination of percent
identity between two sequences can be accomplished using a
mathematical algorithm. In a preferred embodiment, the percent
identity between two amino acid sequences is determined using the
Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm
which has been incorporated into the GAP program in the GCG
software package, using either a Blossum 62 matrix or a PAM250
matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length
weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment,
the percent identity between two nucleotide sequences is determined
using the GAP program in the GCG software package using a
NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and
a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred
set of parameters (and the one that should be used unless otherwise
specified) are a Blossum 62 scoring matrix with a gap penalty of
12, a gap extend penalty of 4, and a frameshift gap penalty of
5.
[0404] The percent identity between two amino acid or nucleotide
sequences can be determined using the algorithm of E. Meyers and W.
Miller ((1989) CABIOS, 4:11-17) which has been incorporated into
the ALIGN program (version 2.0), using a PAM120 weight residue
table, a gap length penalty of 12 and a gap penalty of 4.
[0405] The nucleic acid and protein sequences described herein can
be used as a "query sequence" to perform a search against public
databases to, for example, identify other family members or related
sequences. Such searches can be performed using the NBLAST and
XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol.
Biol. 215:403-10. BLAST nucleotide searches can be performed with
the NBLAST program, score=100, wordlength=12 to obtain nucleotide
sequences homologous to 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 nucleic acid molecules of the invention. BLAST protein
searches can be performed with the XBLAST program, score=50,
wordlength=3 to obtain amino acid sequences homologous to 53070
protein molecules of the invention. To obtain gapped alignments for
comparison purposes, Gapped BLAST can be utilized as described in
Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When
utilizing BLAST and Gapped BLAST programs, the default parameters
of the respective programs (e.g., XBLAST and NBLAST) can be
used.
[0406] Particularly preferred 53070, 15985, 26583, 21953, m32404,
14089, or 23436 polypeptides of the present invention have an amino
acid sequence substantially identical to the amino acid sequence of
SEQ ID NO:2, 8, 15, 20, 25, 34, or 41, respectively. In the context
of an amino acid sequence, the term "substantially identical" is
used herein to refer to a first amino acid that contains a
sufficient or minimum number of amino acid residues that are i)
identical to, or ii) conservative substitutions of aligned amino
acid residues in a second amino acid sequence such that the first
and second amino acid sequences can have a common structural domain
and/or common functional activity. For example, amino acid
sequences that contain a common structural domain having at least
about 60%, or 65% identity, likely 75% identity, 80%, or 85%
identity, likely 90% identity, more likely 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% identity to SEQ ID NO:2, 8, 15, 20, 25, 34, or
41 are termed substantially identical.
[0407] In the context of nucleotide sequence, the term
"substantially identical" is used herein to refer to a first
nucleic acid sequence that contains a sufficient or minimum number
of nucleotides that are identical to aligned nucleotides in a
second nucleic acid sequence such that the first and second
nucleotide sequences encode a polypeptide having common functional
activity, or encode a common structural polypeptide domain or a
common functional polypeptide activity. For example, nucleotide
sequences having at least about 60%, or 65%, 70%, or 75% identity,
likely 80% identity, more likely 85%, 90%. 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98% or 99% identity to SEQ ID NO:1, 3, 7, 9, 14, 16, 19,
21, 24, 26, 33, 35, 40, or 42 are termed substantially
identical.
[0408] "Misexpression or aberrant expression", as used herein,
refers to a non-wildtype pattern of gene expression at the RNA or
protein level. It includes: expression at non-wild type levels,
i.e., over- or under-expression; a pattern of expression that
differs from wild type in terms of the time or stage at which the
gene is expressed, e.g., increased or decreased expression (as
compared with wild type) at a predetermined developmental period or
stage; a pattern of expression that differs from wild type in terms
of altered, e.g., increased or decreased, expression (as compared
with wild type) in a predetermined cell type or tissue type; a
pattern of expression that differs from wild type in terms of the
splicing size, translated amino acid sequence, post-transitional
modification, or biological activity of the expressed polypeptide;
a pattern of expression that differs from wild type in terms of the
effect of an environmental stimulus or extracellular stimulus on
expression of the gene, e.g., a pattern of increased or decreased
expression (as compared with wild type) in the presence of an
increase or decrease in the strength of the stimulus.
[0409] "Subject," as used herein, refers to human and non-human
animals. The term "non-human animals" of the invention includes all
vertebrates, e.g., mammals, such as non-human primates
(particularly higher primates), sheep, dog, rodent (e.g., mouse or
rat), guinea pig, goat, pig, cat, rabbits, cow, and non-mammals,
such as chickens, amphibians, reptiles, etc. In a preferred
embodiment, the subject is a human. In another embodiment, the
subject is an experimental animal or animal suitable as a disease
model.
[0410] A "purified preparation of cells", as used herein, refers to
an in vitro preparation of cells. In the case cells from
multicellular organisms (e.g., plants and animals), a purified
preparation of cells is a subset of cells obtained from the
organism, not the entire intact organism. In the case of
unicellular microorganisms (e.g., cultured cells and microbial
cells), it consists of a preparation of at least 10% and more
preferably 50% of the subject cells.
[0411] Various aspects of the invention are described in further
detail below.
Isolated Nucleic Acid Molecules
[0412] In one aspect, the invention provides, isolated or purified,
nucleic acid molecules that encode 53070, 15985, 26583, 21953,
m32404, 14089, and 23436 polypeptides described herein, e.g.,
full-length 53070, 15985, 26583, 21953, m32404, 14089, or 23436
proteins or fragments thereof, e.g., a biologically active portion
of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein.
Also included is a nucleic acid fragment suitable for use as a
hybridization probe, which can be used, e.g., to identify a nucleic
acid molecule encoding a polypeptide of the invention, 53070,
15985, 26583, 21953, m32404, 14089, or 23436 mRNA, and fragments
suitable for use as primers, e.g., PCR primers for the
amplification or mutation of nucleic acid molecules.
[0413] In one embodiment, an isolated nucleic acid molecule of the
invention includes the nucleotide sequences shown in SEQ ID NO:1,
7, 14, 19, 24, 33, and 40, or a portion of any of these nucleotide
sequences. In one embodiment, the nucleic acid molecule includes
sequences encoding the human 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein (i.e., "the coding region" of SEQ ID NO:1,
7, 14, 19, 24, 33, or 40, as shown in SEQ ID NO: 3, 9, 16, 21, 26,
35, or 42), as well as 5' untranslated sequences. Alternatively,
the nucleic acid molecule can include only the coding region of SEQ
ID NO:1, 7, 14, 19, 24, 33, or 40 (e.g., SEQ ID NO3, 9, 16, 21, 26,
35, or 42) and, e.g., no flanking sequences which normally
accompany the subject sequence. In another embodiment, the nucleic
acid molecule encodes a sequence corresponding to a fragment of the
15985 protein from about amino acid 394 to 651 of SEQ ID NO:8; a
fragment from about amino acid 67 to 158 of SEQ ID NO:8; or a
fragment from about amino acid 192 to 280 of SEQ ID NO:8. In
another embodiment, the nucleic acid molecule encodes a sequence
corresponding to the mature 26583 protein from about amino acid 1
to amino acid 537 of SEQ ID NO:15. In another embodiment, the
nucleic acid molecule encodes a sequence corresponding to a
fragment of the 21953 protein that includes amino acid 672 to 744,
88 to 663, or 88 to 744 of SEQ ID NO:20. In another embodiment, the
nucleic acid molecule encodes a sequence corresponding to a
fragment of the m32404 protein from about amino acid 45 to 268 of
SEQ ID NO:25. In another embodiment, the nucleic acid molecule
encodes a sequence corresponding to a fragment of the m32404
protein from about amino acid 300 to 520 of SEQ ID NO:25. In
another embodiment, the nucleic acid molecule encodes a sequence
corresponding to a fragment of the 14089 protein from about amino
acids 41 to 234 or 24 to 234 of SEQ ID NO:34 or the mature 14089
protein (about amino acids 19 to 241 of SEQ ID NO:34). In another
embodiment, the nucleic acid molecule encodes a sequence
corresponding to a fragment of the 23436 protein from about amino
acid 89 to 420 of SEQ ID NO:41.
[0414] In another embodiment, an isolated nucleic acid molecule of
the invention includes a nucleic acid molecule which is a
complement of the nucleotide sequence shown in SEQ ID NO: 1, 3, 7,
9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42, or a portion of any
of these nucleotide sequences. In other embodiments, the nucleic
acid molecule of the invention is sufficiently complementary to the
nucleotide sequence shown in SEQ ID NO: 1, 3, 7, 9, 14, 16, 19, 21,
24, 26, 33, 35, 40, or 42, such that it can hybridize (e.g., under
a stringency condition described herein) to the nucleotide sequence
shown in SEQ ID NO: 1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40,
or 42, thereby forming a stable duplex.
[0415] In one embodiment, an isolated nucleic acid molecule of the
present invention includes a nucleotide sequence which is at least
about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, or more homologous to the entire length of the
nucleotide sequence shown in SEQ ID NO: 1, 3, 7, 9, 14, 16, 19, 21,
24, 26, 33, 35, 40, or 42, or a portion, preferably of at least
260, 300, 350, 400, 450, 500, 520, 550, 590, 600, 650, 700, 750
800, 850, 900, 950, or 1000 nucleotides, of any of these nucleotide
sequences.
Nucleic Acid Fragments
[0416] A nucleic acid molecule of the invention can include only a
portion of the nucleic acid sequence of SEQ ID NO:1, 3, 7, 9, 14,
16, 19, 21, 24, 26, 33, 35, 40, or 42. For example, such a nucleic
acid molecule can include a fragment which can be used as a probe
or primer or a fragment encoding a portion of a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein, e.g., an immunogenic
or biologically active portion of a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein. A fragment can comprise: those
nucleotides of SEQ ID NO:1 which encode a protein kinase domain of
human 53070, e.g., about nucleotides 171 to 953 of SEQ ID NO:1;
those nucleotides of SEQ ID NO:7, which encode a protein kinase
domain or a doublecortin repeat of human 15985; those nucleotides
encoding amino acids 172 to 461 or 99 to 523 of SEQ ID NO:15, which
encode a phosphatase catalytic domain of human 26583; those
nucleotides of SEQ ID NO:19 which encode a prolyl oligopeptidase
domain of human 21953; those nucleotides of SEQ ID NO:24 which
encode a trypsin domain of human m32404; those nucleotides of SEQ
ID NO:33, which encode a trypsin domain of human 14809; or those
nucleotides of SEQ ID NO:40, which encode a ubiquitin
carboxy-terminal hydrolase domain of human 23436; The nucleotide
sequence determined from the cloning of the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 gene allows for the generation of
probes and primers designed for use in identifying and/or cloning
other 53070, 15985, 26583, 21953, m32404, 14089, or 23436 family
members, or fragments thereof, as well as 53070, 15985, 26583,
21953, m32404, 14089, or 23436 homologues, or fragments thereof,
from other species.
[0417] In another embodiment, a nucleic acid includes a nucleotide
sequence that includes part, or all, of the coding region and
extends into either (or both) the 5' or 3' noncoding region. Other
embodiments include a fragment which includes a nucleotide sequence
encoding an amino acid fragment described herein. Nucleic acid
fragments can encode a specific domain or site described herein or
fragments thereof, particularly fragments thereof which are at
least 50, 95, 100, 150, 200, 300, 360, 400, 600, 650, or 700 amino
acids in length. Fragments also include nucleic acid sequences
corresponding to specific amino acid sequences described above or
fragments thereof. Nucleic acid fragments should not be construed
as encompassing those fragments that may have been disclosed prior
to the invention.
[0418] A nucleic acid fragment can include a sequence corresponding
to a domain, region, or functional site described herein. A nucleic
acid fragment can also include one or more domains, regions, or
functional sites described herein. Thus, for example, a 53070
nucleic acid fragment can include a sequence corresponding to a
protein kinase domain or a C-terminal non-kinase domain; a 15985
nucleic acid fragment can include a sequence corresponding to
protein kinase domain or a doublecortin repeat; a 26583 nucleic
acid fragment can include a serine/threonine phosphatase catalytic
domain, a protein kinase C phosphorylation site, an N-glycosylation
site, a casein kinase II phosphorylation site, an N-myristoylation
sit, an amidation site, a protein phosphatase 2C signature domain,
or any combination thereof; a 21953 nucleic acid fragment can
include a sequence corresponding to a prolyl oligopeptidase domain;
an m32404 nucleic acid fragment can include a sequence
corresponding to a trypsin domain; a 14089 nucleic acid fragment
can include a sequence corresponding to a trypsin domain; and a
23436 nucleic acid fragment can include a sequence corresponding to
a ubiquitin carboxy-terminal hydrolase domain.
[0419] In one embodiment, a nucleic acid fragment can include
nucleotides 1 to 250, 50 to 300, 100 to 350, 150 to 400, 200 to
450, 250 to 500, 300 to 650, 350 to 700, 400 to 700, 450 to 750,
500 to 800, 550 to 850, 600 to 900, 650 to 950, 700 to 1000, 800 to
1200, 900 to 1300, 1000 to 1400, 1100 to 1500, 1200 to 1600, 1300
to 1700, 1400 to 1800, 1500 to 1900, 1600 to 2000, 1700 to 2100,
1253 to 1307, 1253 to 1337, 1241 to 1379, 1382 to 1505, 1241 to
1505, 773 to 1514, 953 to 1118, 953 to 1226, 1121 to 1226, 1253 to
1367, 773 to 1514, 500 to 560, or 512 to 605 of SEQ ID NO:40, or
any combination thereof.
[0420] In a preferred embodiment, the fragment is at least 300,
500, 520, 590, 600, 650, 700, 750, 800, 850, 900, 950, or 1000
nucleotides in length.
[0421] 53070, 15985, 26583, 21953, m32404, 14089, or 23436 probes
and primers are provided. Typically a probe/primer is an isolated
or purified oligonucleotide. The oligonucleotide typically includes
a region of nucleotide sequence that hybridizes under a stringency
condition described herein to at least about 7, 12 or 15,
preferably about 20 or 25, more preferably about 30, 35, 40, 45,
50, 55, 60, 65, or 75 consecutive nucleotides of a sense or
antisense sequence of SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24, 26,
33, 35, 40, or 42, or of a naturally occurring allelic variant or
mutant of SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40,
or 42.
[0422] In a preferred embodiment the nucleic acid is a probe which
is at least 5, 10, 12, 15, 18, or 20 and less than 500, 300, or
200, more preferably less than 100, or less than 50, base pairs in
length. It should be identical, or differ by 1, or less than in 5
or 10 bases, from a sequence disclosed herein. If alignment is
needed for this comparison the sequences should be aligned for
maximum homology. "Looped" out sequences from deletions or
insertions, or mismatches, are considered differences.
[0423] A probe or primer can be derived from the sense or
anti-sense strand of a nucleic acid which encodes: a kinase domain
of 53070, e.g., about nucleotides 171 to 953 of SEQ ID NO:1 or a
portion thereof, or a C-terminal non-kinase domain of 53070, e.g.,
about nucleotides 954 to 1241 of SEQ ID NO:1 or a portion thereof;
a protein kinase domain of 15985 from about amino acid 394 to 651
of SEQ ID NO:8; and/or doublecortin repeats from about amino acids
67 to 158 amino acids and from 192 to 280 of SEQ ID NO:8; a
serine/threonine phosphatase catalytic domain of 26583: amino acids
172 to 461 or 99 to 523 of SEQ ID NO:15; a fragment of the 21953
protein that includes amino acid 672 to 744, 88 to 663, or 88 to
744 of SEQ ID NO:20; a trypsin domain of the 14089 polypeptide
(about amino acid 24 to 234 or 41 to 234 of SEQ ID NO:34; or amino
acids about 89 to 420, 89 to 120, 332 to 378, 379 to 420, 332 to
420, 236 to 291, 292 to 327, 336 to 374, 176 to 423 and 85 to 105
of SEQ ID NO:41.
[0424] In another embodiment a set of primers is provided, e.g.,
primers suitable for use in a PCR, which can be used to amplify a
selected region of a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 sequence, e.g., a domain, region, site or other sequence
described herein. The primers should be at least 5, 10, or 50 base
pairs in length and less than 100, or less than 200, base pairs in
length. The primers should be identical, or differs by one base
from a sequence disclosed herein or from a naturally occurring
variant. For example, primers suitable for amplifying all or a
portion of any of the following regions are provided: a molecule
that encodes a protein kinase domain, from about nucleotides 171 to
593 of SEQ ID NO:1; a molecule that encodes a C-terminal non-kinase
domain, from about nucleotides 954 to 1241 of SEQ ID NO:1, a
protein kinase domain from about amino acid 394 to 651 of SEQ ID
NO:8; a doublecortin repeat from about amino acids 67 to 158 of SEQ
ID NO:8, or a doublecortin repeat from 192 to 280 of SEQ ID NO:8;
the serine/threonine phosphatase catalytic domain (amino acid
residues 172 to 461 or 99 to 523 of SEQ ID NO:15); a prolyl
oligopeptidase domain from about amino acid 672 to 744, 88 to 663,
or 88 to 744 of SEQ ID NO:20; a trypsin domain from about amino
acid 45 to 268 of SEQ ID NO:25; a trypsin domain from about amino
acid 311 to 520 of SEQ ID NO:25; a histidine active site located at
about amino acid 73 to 78 of SEQ ID NO:25; a histidine active site
located at about amino acid 337 to 342 of SEQ ID NO:25; and a
serine active site located at about amino acid 222 to 226 of SEQ ID
NO:25; a trypsin domain from about amino acid 24 to 234 or 41 to
234 of SEQ ID NO:34; a conserved histidine residue present at about
amino acid 56 of SEQ ID NO:34; a serine active site located at
amino acid 195 of SEQ ID NO:34; and a ubiquitin carboxy-terminal
hydrolase domain from about amino acid 89 to 420 of SEQ ID
NO:41.
[0425] A nucleic acid fragment can encode an epitope bearing region
of a polypeptide described herein.
[0426] A nucleic acid fragment encoding a "biologically active
portion of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide" can be prepared by isolating a portion of the
nucleotide sequence of SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24,
26, 33, 35, 40, or 42, which encodes a polypeptide having a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 biological activity
(e.g., the biological activities of the 53070, 15985, 26583, 21953,
m32404, 14089, and 23436 proteins are described herein), expressing
the encoded portion of the 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein (e.g., by recombinant expression in vitro)
and assessing the activity of the encoded portion of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein. For example,
a nucleic acid fragment encoding a biologically active portion of
53070 includes a protein kinase domain, e.g., about nucleotides 171
to 953 of SEQ ID NO:1. A nucleic acid fragment encoding a
biologically active portion of 15985 includes a protein kinase
domain, e.g., amino acid residues about 394 to 651 of SEQ ID NO:8,
a doublecortin repeat from about amino acid 67 to 158 of SEQ ID
NO:8, or a doublecortin repeat from about amino acid 192 to 280 of
SEQ ID NO:8. A nucleic acid fragment encoding a biologically active
portion of 26583 includes a serine/threonine phosphatase catalytic
domain, e.g., amino acid residues 99 to 523 of SEQ ID NO:15. A
nucleic acid fragment encoding a biologically active portion of
21953 includes a prolyl oligopeptidase domain e.g., amino acid
residues about 672 to 744, 88 to 663, or 88 to 744 of SEQ ID NO:20.
A nucleic acid fragment encoding a biologically active portion of
m32404 includes a trypsin domain, e.g., amino acid residues about
45 to 268 or 311 to 520 of SEQ ID NO:25. A nucleic acid fragment
encoding a biologically active portion of 14089 includes a trypsin
domain, e.g., amino acid residues about 24 to 234 or 41 to 234 of
SEQ ID NO:34. A nucleic acid fragment encoding a biologically
active portion of 23436 includes a ubiquitin carboxy-terminal
hydrolase domain, e.g. amino acid residues about 89 to 420 of SEQ
ID NO:41. A nucleic acid fragment encoding a biologically active
portion of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide, may comprise a nucleotide sequence which is greater
than 280, 300, 361, 400, 470, 800, 1000, 1600, or more nucleotides
in length.
[0427] In preferred embodiments, the nucleic acid fragment includes
a nucleotide sequence that is other than, e.g., differs by at least
one, two, three of more nucleotides from, the sequence of AA498169
or AI480580. E.g., a nucleic acid fragment can: include one or more
nucleotides from SEQ ID NO:24 or SEQ ID NO:26 outside the region of
nucleotides 1699-2033 or 1711-2034 of SEQ ID NO:24; not include all
of the nucleotides of AA498169 or AI480580, e.g., can be one or
more nucleotides shorter (at one or both ends) than the sequence of
AA498169 or AI480580; or can differ by one or more nucleotides in
the region of overlap.
[0428] In preferred embodiments, the fragment comprises the coding
region of 46508, e.g., the nucleotide sequence of SEQ ID NO:26. In
other embodiments, the fragment comprises nucleotides 1-1698 or
2034-2219 of SEQ ID NO:24, or a fragment thereof (e.g., nucleotides
1-500, 500-1000, 1000-1698, 2034-2100, 2100-2200, or 2200-2219 of
SEQ ID NO:24).
[0429] In preferred embodiments, a nucleic acid includes a
nucleotide sequence which is about 300, 340, 400, 500, 590, 600,
650, 700, 750, 800, 850, 900, 1000, 1100, 1200, 1300, 1400, 1500,
1600, 1700, 1800, 1900, 2100, 2200, 2300, 2400, 2500, 2600, 2700,
2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3550, or more
nucleotides in length and hybridizes under a stringency condition
described herein to a nucleic acid molecule of SEQ ID NO:1, 3, 7,
9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42. In a preferred
embodiment, a nucleic acid includes at least one contiguous
nucleotide from the region about nucleotides 1-200, 138-301,
171-401, 302-569, 402-692, 531-812, 660-932, 773-953, 873-1112,
954-1160, 1053-1241, 1161-1400, 1242-1550, 1350-1600, 1550-1704 of
SEQ ID NO:1 or SEQ ID NO:3. In a preferred embodiment, the nucleic
acid includes a contiguous sequence that includes approximately
nucleotide 1640, or 1642 of SEQ ID NO:19, e.g., the region from
nucleotide 1635 to 1645 of SEQ ID NO:19. In other embodiment the
nucleic acid includes a contiguous sequence that includes about
nucleotides 1 to 25, 1 to 66, 100 to 300, 300 to 700, 500 to 800,
800 to 1200, 1000 to 1400, or 1200 to 1600 of SEQ ID NO:19.
[0430] In a preferred embodiment, a nucleic acid fragment differs
by at least 1, 2, 3, 10, 20, or more nucleotides from, the sequence
of Genbank accession number U66059, e.g., from nucleotides 315-571
of SEQ ID NO:33; the sequence of SEQ ID NO:247 of WO 01/40466; the
sequence of SEQ ID NO:5 or 6 of WO 01/72961; the sequence of SEQ ID
NO:22 of WO 01/71004. Differences can include differing in length
or sequence identity. For example, a nucleic acid fragment can:
include one or more nucleotides from SEQ ID NO:33 or SEQ ID NO:35
located outside the region of nucleotides 315 to 571, 94 to 938,
136 to 861, 173 to 861, 1-570, 572 to 947 of SEQ ID NO:33, e.g.,
can be one or more nucleotides shorter (at one or both ends) than
the sequence of Genbank accession number U66059, e.g., from
nucleotides 315-571 of SEQ ID NO:33; the sequence of SEQ ID NO:247
of WO 01/40466; the sequence of SEQ ID NO:5 or 6 of WO 01/72961;
the sequence of SEQ ID NO:22 of WO 01/71004; or can differ by one
or more nucleotides in the region of overlap.
Nucleic Acid Variants
[0431] The invention further encompasses nucleic acid molecules
that differ from the nucleotide sequence shown in SEQ ID NO: 1, 3,
7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42. Such differences
can be due to degeneracy of the genetic code (and result in a
nucleic acid which encodes the same 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 proteins as those encoded by the nucleotide
sequence disclosed herein. In another embodiment, an isolated
nucleic acid molecule of the invention has a nucleotide sequence
encoding a protein having an amino acid sequence which differs, by
at least 1, but less than 5, 10, 20, 50, or 100 amino acid residues
that shown in SEQ ID NO: 2, 8, 15, 20, 25, 34, or 41. If alignment
is needed for this comparison the sequences should be aligned for
maximum homology. "Looped" out sequences from deletions or
insertions, or mismatches, are considered differences.
[0432] Nucleic acids of the invention can be chosen for having
codons, which are preferred, or non-preferred, for a particular
expression system. E.g., the nucleic acid can be one in which at
least one codon, at preferably at least 10%, or 20% of the codons
has been altered such that the sequence is optimized for expression
in E. coli, yeast, human, insect, or CHO cells.
[0433] Nucleic acid variants can be naturally occurring, such as
allelic variants (same locus), homologs (different locus), and
orthologs (different organism) or can be non naturally occurring.
Non-naturally occurring variants can be made by mutagenesis
techniques, including those applied to polynucleotides, cells, or
organisms. The variants can contain nucleotide substitutions,
deletions, inversions and insertions. Variation can occur in either
or both the coding and non-coding regions. The variations can
produce both conservative and non-conservative amino acid
substitutions (as compared in the encoded product).
[0434] In a preferred embodiment, the nucleic acid differs from
that of SEQ ID NO: 1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40,
or 42, e.g., as follows: by at least one but less than 10, 20, 30,
or 40 nucleotides; at least one but less than 1%, 5%, 10% or 20% of
the nucleotides in the subject nucleic acid. If necessary for this
analysis the sequences should be aligned for maximum homology.
"Looped" out sequences from deletions or insertions, or mismatches,
are considered differences.
[0435] Orthologs, homologs, and allelic variants can be identified
using methods known in the art. These variants comprise a
nucleotide sequence encoding a polypeptide that is 50%, at least
about 55%, typically at least about 70-75%, more typically at least
about 80-85%, and most typically at least about 90-95% or more
identical to the sequence shown in SEQ ID NO:2, 8, 15, 20, 25, 34,
or 41 or a fragment of this sequence. Such nucleic acid molecules
can readily be identified as being able to hybridize under a
stringency condition described herein, to the nucleotide sequence
shown in SEQ ID NO: 1, 7, 14, 19, 24, 33, or 40 or a fragment of
the sequence. Nucleic acid molecules corresponding to orthologs,
homologs, and allelic variants of the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 cDNAs of the invention can further be
isolated by mapping to the same chromosome or locus as the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 gene.
[0436] Preferred 53070 variants include those that are correlated
with protein kinase activity, particularly serine/threonine protein
kinase activity. Preferred 15985 variants include those that are
correlated with protein kinase and/or microtubule binding activity.
Preferred 26583 variants include those that are correlated with
phosphatase activity, e.g., serine/threonine phosphatase activity.
Preferred 21953 variants include those that are correlated with
dipeptidyl peptidase or prolyl endopeptidases activity. Preferred
m32404 variants include those that are correlated with modulating
(stimulating and/or enhancing or inhibiting) cellular
proliferation, differentiation, or tumorigenesis; modulating an
immune response (i.e. modulating the complementation system);
modulating hormone production; modulating the blood clotting
cascade; or modulating proteolysis of protein substrates. Preferred
14089 variants include those that are correlated with proteolytic
cleave of substrates. Preferred 23436 variants include those that
are correlated with de-ubiquitinating activity.
[0437] Allelic variants of 53070, 15985, 26583, 21953, m32404,
14089, or 23436, e.g., human 53070, 15985, 26583, 21953, m32404,
14089, or 23436, include both functional and non-functional
proteins. Functional allelic variants are naturally occurring amino
acid sequence variants of the 53070 protein within a population
that maintain the ability to bind ATP and phosphorylate substrates.
Functional allelic variants of the 15985 protein maintain the
ability to bind microtubules and/or phosphorylate proteins.
Functional allelic variants of the 26583 protein maintain the
ability to remove the phosphate from a serine or threonine residue
of a phosphorylated protein. Functional allelic variants of the
21953 protein maintain the ability to bind and/or cleave
polypeptide substrates, e.g., a polypeptide having a proline
residue. Functional allelic variants of the m32404 protein maintain
the ability to bind peptide sequences and exhibit proteolytic
activity. Functional allelic variants of the 14089 protein maintain
the ability to bind proteolytic substrates. Functional allelic
variants of the 23436 protein maintain the ability to
de-ubiquitinate substrates. Functional allelic variants will
typically contain only conservative substitution of one or more
amino acids of SEQ ID NO:2, 8, 15, 20, 25, 34, or 41, or
substitution, deletion or insertion of non-critical residues in
non-critical regions of the protein. Non-functional allelic
variants are naturally-occurring amino acid sequence variants of
the 53070, e.g., human 53070, protein within a population that do
not have the ability to bind ATP or phosphorylate some or all
substrates. Non-functional allelic variants of the 15985 protein
not have the ability to bind to cytoskeletal proteins, e.g.,
microtubules, or phosphorylate proteins. Non-functional allelic
variants of the 26583 protein not have the ability to remove the
phosphate from a serine or threonine residue of a phosphorylated
protein. Non-functional allelic variants of the 21953 protein not
have the ability to bind and/or cleave polypeptide substrates,
e.g., a polypeptide having a proline residue. Non-functional
allelic variants of the m32404 protein not have the ability to
peptide sequences and exhibit proteolytic activity. Non-functional
allelic variants of the 14089 protein not have the ability to
cleave a substrate. Non-functional allelic variants of the 23436
protein not have the ability to de-ubiquitinate substrates.
Non-functional allelic variants will typically contain a
non-conservative substitution, a deletion, or insertion, or
premature truncation of the amino acid sequence of SEQ ID NO:2, 8,
15, 20, 25, 34, or 41, or a substitution, insertion, or deletion in
critical residues or critical regions of the protein.
[0438] Moreover, nucleic acid molecules encoding other 53070,
15985, 26583, 21953, m32404, 14089, or 23436 family members and,
thus, which have a nucleotide sequence which differs from the
53070, 15985, 26583, 21953, m32404, 14089, or 23436 sequences of
SEQ ID NO:1, 3, 7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42 are
intended to be within the scope of the invention.
Antisense Nucleic Acid Molecules, Ribozymes and Modified Nucleic
Acid Molecules
[0439] In still another embodiment, a ribozyme. A ribozyme having
specificity for a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-,
or 23436-encoding nucleic acid can include one or more sequences
complementary to the nucleotide sequence of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 cDNA disclosed herein (i.e., 1, 3,
7, 9, 14, 16, 19, 21, 24, 26, 33, 35, 40, or 42), and a sequence
having known catalytic sequence responsible for mRNA cleavage (see
U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach (1988) Nature
334:585-591). For example, a derivative of a Tetrahymena L-19 IVS
RNA can be constructed in which the nucleotide sequence of the
active site is complementary to the nucleotide sequence to be
cleaved in a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No.
4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively,
53070, 15985, 26583, 21953, m32404, 14089, or 23436 mRNA can be
used to select a catalytic RNA having a specific ribonuclease
activity from a pool of RNA molecules. See, e.g., Bartel, D. and
Szostak, J. W. (1993) Science 261:1411-1418.
[0440] 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene
expression can be inhibited by targeting nucleotide sequences
complementary to the regulatory region of the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 (e.g., the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 promoter and/or enhancers) to form
triple helical structures that prevent transcription of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 gene in target cells.
See generally, Helene, C. (1991) Anticancer Drug Des. 6:569-84;
Helene, C. i (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher, L.
J. (1992) Bioassays 14:807-15. The potential sequences that can be
targeted for triple helix formation can be increased by creating a
so-called "switchback" nucleic acid molecule. Switchback molecules
are synthesized in an alternating 5'-3',3'-5' manner, such that
they base pair with first one strand of a duplex and then the
other, eliminating the necessity for a sizeable stretch of either
purines or pyrimidines to be present on one strand of a duplex.
[0441] The invention also provides detectably labeled
oligonucleotide primer and probe molecules. Typically, such labels
are chemiluminescent, fluorescent, radioactive, or
colorimetric.
[0442] A 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid molecule can be modified at the base moiety, sugar
moiety or phosphate backbone to improve, e.g., the stability,
hybridization, or solubility of the molecule. For non-limiting
examples of synthetic oligonucleotides with modifications see
Toulme (2001) Nature Biotech. 19:17 and Faria et al. (2001) Nature
Biotech. 19:40-44. Such phosphoramidite oligonucleotides can be
effective antisense agents.
[0443] For example, the deoxyribose phosphate backbone of the
nucleic acid molecules can be modified to generate peptide nucleic
acids (see Hyrup B. et al. (1996) Bioorganic & Medicinal
Chemistry 4: 5-23). As used herein, the terms "peptide nucleic
acid" or "PNA" refers to a nucleic acid mimic, e.g., a DNA mimic,
in which the deoxyribose phosphate backbone is replaced by a
pseudopeptide backbone and only the four natural nucleobases are
retained. The neutral backbone of a PNA can allow for specific
hybridization to DNA and RNA under conditions of low ionic
strength. The synthesis of PNA oligomers can be performed using
standard solid phase peptide synthesis protocols as described in
Hyrup B. et al. (1996) supra and Perry-O'Keefe et al. Proc. Natl.
Acad. Sci. 93: 14670-675.
[0444] PNAs of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid molecules can be used in therapeutic and diagnostic
applications. For example, PNAs can be used as antisense or
antigene agents for sequence-specific modulation of gene expression
by, for example, inducing transcription or translation arrest or
inhibiting replication. PNAs of 53070, 15985, 26583, 21953, m32404,
14089, or 23436 nucleic acid molecules can also be used in the
analysis of single base pair mutations in a gene, (e.g., by
PNA-directed PCR clamping); as `artificial restriction enzymes`
when used in combination with other enzymes, (e.g., S1 nucleases
(Hyrup B. et al. (1996) supra)); or as probes or primers for DNA
sequencing or hybridization (Hyrup B. et al. (1996) supra;
Perry-O'Keefe supra).
[0445] In other embodiments, the oligonucleotide may include other
appended groups such as peptides (e.g., for targeting host cell
receptors in vivo), or agents facilitating transport across the
cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad.
Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad.
Sci. USA 84:648-652; PCT Publication No. WO88/09810) or the
blood-brain barrier (see, e.g., PCT Publication No. WO89/10134). In
addition, oligonucleotides can be modified with
hybridization-triggered cleavage agents (see, e.g., Krol et al.
(1988) Bio-Techniques 6:958-976) or intercalating agents. (see,
e.g., Zon (1988) Pharm. Res. 5:539-549). To this end, the
oligonucleotide may be conjugated to another molecule, (e.g., a
peptide, hybridization triggered cross-linking agent, transport
agent, or hybridization-triggered cleavage agent).
[0446] The invention also includes molecular beacon oligonucleotide
primer and probe molecules having at least one region which is
complementary to a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 nucleic acid of the invention, two complementary regions one
having a fluorophore and one a quencher such that the molecular
beacon is useful for quantitating the presence of the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 nucleic acid of the invention
in a sample. Molecular beacon nucleic acids are described, for
example, in Lizardi et al., U.S. Pat. No. 5,854,033; Nazarenko et
al., U.S. Pat. No. 5,866,336, and Livak et al., U.S. Pat. No.
5,876,930.
Isolated Polypeptides of the Invention
[0447] In another aspect, the invention features, an isolated
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein, or
fragment, e.g., a biologically active portion, for use as
immunogens or antigens to raise or test (or more generally to bind)
anti-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
antibodies. 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein can be isolated from cells or tissue sources using standard
protein purification techniques. 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein or fragments thereof can be
produced by recombinant DNA techniques or synthesized
chemically.
[0448] Polypeptides of the invention include those which arise as a
result of the existence of multiple genes, alternative
transcription events, alternative RNA splicing events, and
alternative translational and post-translational events. The
polypeptide can be expressed in systems, e.g., cultured cells,
which result in substantially the same post-translational
modifications present when the polypeptide is expressed in a native
cell, or in systems which result in the alteration or omission of
post-translational modifications, e.g., glycosylation or cleavage,
present when expressed in a native cell.
[0449] In a preferred embodiment, a 53070 polypeptide has one or
more of the following characteristics:
[0450] it has the ability to bind a nucleoside tri-phosphate, e.g.,
ATP;
[0451] it has the ability to phosphorylate a substrate protein,
e.g., another protein or itself;
[0452] it has a molecular weight, e.g., a deduced molecular weight,
preferably ignoring any contribution of post translational
modifications, amino acid composition or other physical
characteristic of a 53070 polypeptide, e.g., a polypeptide of SEQ
ID NO:2;
[0453] it has an overall sequence similarity of at least 60%, 70%,
preferably at least 75%, more preferably at least 80%, 90%, or 95%,
with a polypeptide of SEQ ID NO:2;
[0454] it has a protein kinase domain which is preferably about
80%, 90%, 95%, or more homologous with amino acid residues about 12
to 272 of SEQ ID NO:2;
[0455] it has a serine/threonine protein kinase active-site
signature motif (PS00108);
[0456] it has at least one, preferably two, three, four, five, six,
seven, eight, nine, ten, eleven, twelve, or more preferably
thirteen of the invariant amino acid residues present in protein
kinase family members, and described above;
[0457] it has at least one, two, three, four, preferably five
predicted Protein kinase C phosphorylation sites (PS00005);
[0458] it has at least one, two, preferably three predicted Casein
kinase II phosphorylation sites (PS00006); and
[0459] it has at least one predicted N-myristoylation site
(PS00008).
[0460] In a preferred embodiment, a 15985 polypeptide has one or
more of the following characteristics:
[0461] it has the ability to phosphorylate a protein substrate,
e.g., a serine and/or threonine side chains of a protein
substrate;
[0462] it has the ability to bind to cytoskeletal proteins, e.g.,
microtubules;
[0463] it has the ability to modulate cell morphology and/or
migration;
[0464] it has a molecular weight, e.g., a deduced molecular weight,
preferably ignoring any contribution of post translational
modifications, amino acid composition or other physical
characteristic of a 15985 polypeptide, e.g., a polypeptide of SEQ
ID NO:8;
[0465] it has an overall sequence similarity of at least 60%, more
preferably at least 70, 80, 90, or 95%, with a polypeptide of SEQ
ID NO:8;
[0466] it can be found in a tumor cell (e.g., an ovarian, lung, or
breast tumor cell), neuronal cells;
[0467] it has a protein kinase domain which is preferably about
70%, 80%, 90% or 95% identical with amino acid residues about 394
to 651 of SEQ ID NO:8; it can colocalize with microtubules; or
[0468] it has at least one, and preferably two doublecortin repeats
which are preferably about 70%, 80%, 90% or 95% identical with
amino acid residues from about amino acids 67 to 158 and/or 192 to
280 of SEQ ID NO:8.
[0469] In a preferred embodiment, a 26583 polypeptide has one or
more of the following characteristics:
[0470] it has the ability to promote removal of phosphate from
phosphorylated serine or threonine residues of protein;
[0471] it has a molecular weight (e.g., a deduced molecular
weight), amino acid composition or other physical characteristic of
a 26583 protein, e.g., a 26583 protein of SEQ ID NO:15;
[0472] it has an overall sequence similarity of at least 60%, more
preferably at least 70, 80, 90, 95%, most preferably at least 99%,
with a polypeptide encoded by SEQ ID NO:16;
[0473] it has a phosphatase catalytic domain which is preferably
about 70%, 80%, 90%, 95%, most preferably at least 99%, identical
to amino acid residues 99-523 of SEQ ID NO:15;
[0474] it has a phosphatase catalytic domain which is preferably
about 70%, 80%, 90%, 95%, most preferably at least 99%, identical
to with amino acid residues 172 to 461 of SEQ ID NO:15; or
[0475] it has at least 70%, preferably at least 80%, and most
preferably at least 95% of the cysteines found in the amino acid
sequence of the native protein.
[0476] In a preferred embodiment, a 21953 polypeptide has one or
more of the following characteristics:
[0477] it has the ability to promote the degradation of
proline-containing peptides by cleaving the peptide bond at the
carboxyl side of proline residues;
[0478] it has a molecular weight, (e.g., about 97 KDa), amino acid
composition, or other physical characteristic, of a 21953
polypeptide, e.g., a polypeptide of SEQ ID NO:20;
[0479] it has an overall sequence similarity of at least 60%, more
preferably at least 70, 80, 90, or 95%, with a polypeptide of SEQ
ID NO:20;
[0480] it has a prolyl oligopeptidase domain which has preferably
about 70%, 80%, 90% or 95% sequence similarity with amino acid
residues 672-744 of SEQ ID NO:20; or
[0481] it has at least 70%, preferably 80%, and most preferably 90%
of the cysteines found in the amino acid sequence of the native
protein (SEQ ID NO:20).
[0482] In a preferred embodiment, an m32404 polypeptide has one or
more of the following characteristics:
[0483] it exhibits proteolytic activity;
[0484] it has a molecular weight, or an amino acid composition of
an m32404 polypeptide, e.g., a polypeptide of SEQ ID NO:25.
[0485] it has an overall sequence similarity of at least 60%, more
preferably at least 70, 80, 90, or 95%, with a polypeptide of SEQ
ID NO:25;
[0486] it can be found in human tissue;
[0487] it has a trypsin domain with a sequence which is preferably
about 70%, 80%, 90% or 95% similar with amino acid residues about
45 to 268 or 311 to 520 of SEQ ID NO:25; or
[0488] it has at least 10, preferably at least 12, and most
preferably at least 16 of the 22 cysteines found in the amino acid
sequence of the native protein.
[0489] In a preferred embodiment, a 14089 polypeptide has one or
more of the following characteristics:
[0490] it has protease activity;
[0491] it has a molecular weight, e.g., a deduced molecular weight,
preferably ignoring any contribution of post-translational
modifications, amino acid composition or other physical
characteristic of a 14089 polypeptide, e.g., a polypeptide of SEQ
ID NO:34;
[0492] it has an overall sequence similarity of at least 60%, more
preferably at least 70, 80, 90, or 95%, with a polypeptide of SEQ
ID NO:34;
[0493] it has a trypsin domain which is preferably about 70%, 80%,
90% or 95% with amino acid residues about 24 to 234 or 41 to 234 of
SEQ ID NO:34; or
[0494] it has at least 5, preferably 7, and most preferably 8 of
the 9 cysteines found in the amino acid sequence of the native
protein.
[0495] In a preferred embodiment, a 23436 polypeptide has one or
more of the following characteristics:
[0496] it has the ability to de-ubiquitinate substrates, e.g., by
means of a ubiquitin carboxy-terminal hydrolase activity;
[0497] it has a molecular weight, e.g., a deduced molecular weight,
preferably ignoring any contribution of post translational
modifications, amino acid composition or other physical
characteristic of SEQ ID NO:41;
[0498] it has an overall sequence similarity of at least 60%, more
preferably at least 70, 80, 90, 95%, 97%, 98% or 99%, with a
polypeptide a of SEQ ID NO:41;
[0499] it can be found in erythroid cells, erythroid precursors,
liver, prostate, and hypothalamus;
[0500] it has a ubiquitin carboxy-terminal hydrolase (family 2)
domain which is preferably about 70%, 80%, 90%, 95%, 98%, or 99%
homologous with amino acid residues about 89 to 420 of SEQ ID
NO:41; and/or
[0501] it has a conserved cysteine at about amino acid 98 of SEQ ID
NO:41 and two conserved histidines at about amino acids 344 and 353
of SEQ ID NO:41.
[0502] In a preferred embodiment the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein, or fragment thereof, differs from
the corresponding sequence in SEQ ID: 2, 8, 15, 20, 25, 34, or 41.
In one embodiment it differs by at least one but by less than 15,
10 or 5 amino acid residues. In another it differs from the
corresponding sequence in SEQ ID NO: 2, 8, 15, 20, 25, 34, or 41 by
at least one residue but less than 20%, 15%, 10% or 5% of the
residues in it differ from the corresponding sequence in SEQ ID NO:
2, 8, 15, 20, 25, 34, or 41. (If this comparison requires alignment
the sequences should be aligned for maximum homology. "Looped" out
sequences from deletions or insertions, or mismatches, are
considered differences.) The differences are, preferably,
differences or changes at a non essential residue or a conservative
substitution. In a preferred embodiment the differences are not in
the 53070 protein kinase domain, e.g., about amino acid residues 12
to 272 of SEQ ID NO:2. In another preferred embodiment one or more
differences are in the 53070 protein kinase domain, e.g., about
amino acid residues 12 to 272 of SEQ ID NO:2. In a preferred
embodiment the differences are not in the 15985 protein kinase
domain nor in the 15985 doublecortin repeats. In another preferred
embodiment one or more differences are in the 15985 protein kinase
domain and/or the 15985 doublecortin repeats. In a preferred
embodiment, the differences are not in the 26583 serine/threonine
phosphatase catalytic domain. In another preferred embodiment one
or more differences are at 26583 non-active site residues, e.g.,
amino acids 1-98, or 524 to 537 of SEQ ID NO:15. In a preferred
embodiment the differences are not in the 21953 prolyl
oligopeptidase domain and/or the DPP IV N-terminal domain. In
another preferred embodiment one or more differences are in the
21953 prolyl oligopeptidase domain and/or the DPP IV N-terminal
domain. In a preferred embodiment the differences are not in the
m32404 trypsin domain, i.e., from about amino acid 45 to 268 or 311
to 520 of SEQ ID NO:25. In another preferred embodiment one or more
differences are in the m32404 trypsin domain, i.e., from about
amino acid 45 to 268 or 311 to 520 of SEQ ID NO:25. In a preferred
embodiment the differences are not in the 14089 trypsin domain. In
another preferred embodiment one or more differences are in the
14089 trypsin domain. In a preferred embodiment the differences are
not in the 23436 ubiquitin carboxy-terminal hydrolase domain, e.g.,
the region from about amino acid 89 to 120 and 332 to 420 of SEQ ID
NO:41. In another preferred embodiment one or more differences are
in the 23436 ubiquitin carboxy-terminal hydrolase domain, e.g., the
region from about amino acid 89 to 120 and 332 to 420 of SEQ ID
NO:41.
[0503] Other embodiments include a protein that contain one or more
changes in amino acid sequence, e.g., a change in an amino acid
residue which is not essential for activity. Such 53070, 15985,
26583, 21953, m32404, 14089, or 23436 proteins differ in amino acid
sequence from SEQ ID NO: 2, 8, 15, 20, 25, 34, or 41, yet retain
biological activity.
[0504] In one embodiment, the protein includes an amino acid
sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,
98%, 99% or more homologous to SEQ ID NO: 2, 8, 15, 20, 25, 34, or
41.
[0505] The present invention also pertains to fragments of the
53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptides.
For examples, fragments of the 53070 polypeptides which include
amino acid residues about 103 to 119, about 226 to 247, or about
301 to 329 of SEQ ID NO:2, which correspond to hydrophilic regions
of the 53070 protein. Similarly, fragments of 53070 which include
residues about 63 to 73, about 86 to 102, or about 199 to 216 of
SEQ ID NO:2 correspond to hydrophobic regions of the 53070 protein.
Fragments of 53070 which include residues about 12 to 45, about 125
to 150, or about 150 to 175 of SEQ ID NO:2 correspond to protein
kinase domain of the 53070 protein; and fragments of 53070 which
include amino acid residues about 1 to 11 and 273 to 367 of SEQ ID
NO:2 correspond to non-kinase domain region of the 53070
protein.
[0506] A 53070 protein or fragment is provided which varies from
the sequence of SEQ ID NO:2 in regions defined by amino acids about
273 to 367 by at least one but by less than 15, or 5 amino acid
residues in the protein or fragment but which does not differ from
SEQ ID NO:2 in regions defined by amino acids about 1 to 272.
Additionally, a 53070 protein is provided which varies from the
sequence of SEQ ID NO:2 in regions defined by amino acids about 1
to 90 or, alternatively, 91 to 272 by at least one but by less than
15, 10, or 5 amino acid residues in the protein or fragment, but
which does not differ from SEQ ID NO:2 in regions defined by amino
acids 91 to 367 or 1 to 90 and 273 to 367, respectively. (If these
comparisons require alignment, the sequences should be aligned for
maximum homology. "Looped" out sequences from deletions or
insertions, or mismatches, are considered differences.) In some
embodiments the difference is at a non-essential residue or is a
conservative substitution, while in others the difference is at an
essential residue or is a non-conservative substitution.
[0507] A 15985 protein or fragment is provided which varies from
the sequence of SEQ ID NO:8 in regions defined by amino acids about
67 to 158, 192 to 280, and 394 to 651 by at least one but by less
than 15, 10 or 5 amino acid residues in the protein or fragment but
which does not differ from SEQ ID NO:8 in regions defined by amino
acids about 67 to 158, 192 to 280, and 394 to 651. (If this
comparison requires alignment the sequences should be aligned for
maximum homology. "Looped" out sequences from deletions or
insertions, or mismatches, are considered differences.) In some
embodiments the difference is at a non-essential residue or is a
conservative substitution, while in others the difference is at an
essential residue or is a non-conservative substitution.
[0508] In one embodiment, a biologically active portion of a 15985
protein includes a protein kinase domain and/or doublecortin
repeats. Moreover, other biologically active portions, in which
other regions of the protein are deleted, can be prepared by
recombinant techniques and evaluated for one or more of the
functional activities of a native 15985 protein.
[0509] In another embodiment, the protein includes an amino acid
sequence at least 213 amino acids in length, and about 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 98%, homologous to SEQ ID NO:15.
[0510] In another embodiment, a 26583 protein or fragment has an
amino acid sequence which differs from the sequence of AAA30697 by
at least one, two, three, five or more amino acids. The variations
may include the addition, replacement, and/or deletion of amino
acid residues.
[0511] A 26583 protein or fragment is provided which varies from
the sequence of SEQ ID NO:15 in non-active site residues by at
least one but by less than 15, 10 or 5 amino acid residues in the
protein or fragment, but which does not differ from SEQ ID NO:15 in
regions having phosphatase catalytic activity. (If this comparison
requires alignment the sequences should be aligned for maximum
homology. "Looped" out sequences from deletions, insertions, or
mismatches, are considered differences.) In some embodiments, the
difference is at a non-essential residue or is a conservative
substitution, while in others, the difference is at an essential
residue or is a non conservative substitution.
[0512] A 21953 protein or fragment is provided which varies from
the sequence of SEQ ID NO:20 in regions defined by amino acids
about 672 to 744 by at least one but by less than 15, 10 or 5 amino
acid residues in the protein or fragment but which does not differ
from SEQ ID NO:20 in regions defined by amino acids about 672 to
744. In some embodiments, the 21953 protein includes at least one
contiguous amino acid from the region of about amino acid 1 to 200,
100 to 300, 200 to 400, 300 to 500, 400 to 600, 500 to 700, or 600
to 800 of SEQ ID NO:20.
[0513] In another preferred embodiment, the 21953 protein has a
K.sub.m for the substrate H-Gly-Pro-p-nitroanilide (NA)/HCl (Sigma
Corp, MO, USA) (H-Gly-Pro-pNA) of less than about 10 mM, 5 mM, 1
mM, 0.5 mM, 0.2 mM, or 0.1 mM, and/or a V.sub.max for H-Gly-Pro-pNA
of about at least 100, 500, 1000, 3000, 5000, or 10000 absorbance
units-min.sup.-1. Such parameters can be determined using a prolyl
oligopeptidase assay described herein, e.g., as described in
"Screening Assays," below.
[0514] An m32404 protein or fragment is provided which varies from
the sequence of SEQ ID NO:25 in regions defined by amino acids
about 1 to 46 and 269 to 520 by at least one but by less than 15,
10 or 5 amino acid residues in the protein or fragment but which
does not differ from SEQ ID NO:25 in regions defined by amino acids
about 45 to 268. An m32404 protein or fragment is also provided
which varies from the sequence of SEQ ID NO:25 in regions defined
by amino acids about 1 to 310, and 521 to 552, of SEQ ID NO:25 by
at least one but by less than 15, 10 or 5 amino acid residues in
the protein or fragment but which does not differ from SEQ ID NO:25
in regions defined by amino acids about 311 to 520 of SEQ ID
NO:25.
[0515] A 14089 protein or fragment is provided which varies from
the sequence of SEQ ID NO:34 in regions defined by amino acids
about 41 to 234 by at least one but by less than 15, or 5 amino
acid residues in the protein or fragment but which does not differ
from SEQ ID NO:34 in regions defined by amino acids about 41 to
234.
[0516] In a preferred embodiment, a 14089 fragment differs by at
least 1, 2, 3, 10, 20, or more amino acid residues encoded by a
sequence present in Genbank accession number U66059, e.g., from
nucleotides 315-571 of SEQ ID NO:33; the sequence of SEQ ID NO:247
of WO 01/40466; the sequence of SEQ ID NO:5 or 6 of WO 01/72961;
the sequence of SEQ ID NO:22 of WO 01/71004. Differences can
include differing in length or sequence identity. For example, a
fragment can: include one or more amino acid residues from SEQ ID
NO:34 outside the region encoded by nucleotides 315 to 571, 94 to
938, 136 to 861, 173 to 861, 1-570, 572 to 947 of SEQ ID NO:33; not
include all of the amino acid residues encoded by a nucleotide
sequence in Genbank accession number U66059, e.g., from nucleotides
315-571 of SEQ ID NO:33; the sequence of SEQ ID NO:247 of WO
01/40466; the sequence of SEQ ID NO:5 or 6 of WO 01/72961; the
sequence of SEQ ID NO:22 of WO 01/71004, e.g., can be one or more
amino acid residues shorter (at one or both ends) than a sequence
encoded by the nucleotide sequence in Genbank accession number
U66059, e.g., from nucleotides 315-571 of SEQ ID NO:33; the
sequence of SEQ ID NO:247 of WO 01/40466; the sequence of SEQ ID
NO:5 or 6 of WO 01/72961; the sequence of SEQ ID NO:22 of WO
01/71004; or can differ by one or more amino acid residues in the
region of overlap.
[0517] A 23436 protein or fragment is provided which varies from
the sequence of SEQ ID NO:41 in regions defined by amino acids
about 1 to 88, 121 to 331, and 421 to 485 by at least one but by
less than 15, 10 or 5 amino acid residues in the protein or
fragment but which does not differ from SEQ ID NO:41 in regions
defined by amino acids about 89 to 120, and 332 to 420. Such
polypeptide fragments of 23436 containing functional domains,
signatures, and/or modification sites, and nucleic acids encoding
same can be useful, e.g., as immunogens or as competitive
inhibitors. For example, to inhibit 23436 mediated
de-ubiquitination, a ubiquitinated protein can be contacted with a
substrate binding subsequence of 23436 which lacks
de-ubiquitination activity thereby inhibiting or blocking
de-ubiquitination by 23436 having the activity. A variant of 23436
lacking de-ubiquitination activity can be generated by mutating the
conserved cysteine at about amino acid 98 of SEQ ID NO:41, e.g., to
alanine, or the conserved histidines at about amino acids 344 and
353 of SEQ ID NO:41, e.g., to alanine. To inhibit phosphorylation
of a particular site of 23436 polypeptide in a cell, a 23436
polypeptide having a mutation at the site, e.g., to alanine, can be
introduced or expressed in cells. To alter the activity of a 23436
polypeptide in a cell, a 23436 polypeptide having an activating
mutation, e.g., a mutation to aspartic or glutamic acid, of a
phosphorylation site, e.g., a predicted phosphorylation site
described herein, can be introduced or expressed in cells.
[0518] In one embodiment, a biologically active portion of a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein includes a
protein kinase domain, a protein kinase domain and/or doublecortin
repeats, a serine/threonine phosphatase catalytic domain, a prolyl
oligopeptidase domain and/or a DPP IV N-terminal domain, a trypsin
domain, a trypsin domain, or a ubiquitin carboxy-terminal hydrolase
domain, respectively. Moreover, other biologically active portions,
in which other regions of the protein are deleted, can be prepared
by recombinant techniques and evaluated for one or more of the
functional activities of a native 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein.
[0519] In a preferred embodiment, the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein has an amino acid sequence shown in
SEQ ID NO:2, 8, 15, 20, 25, 34, or 41, respectively. In other
embodiments, the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein is substantially identical to SEQ ID NO:2, 8, 15, 20,
25, 34, or 41, respectively. In yet another embodiment, the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein is
substantially identical to SEQ ID NO:2, 8, 15, 20, 25, 34, or 41
and retains the functional activity of the protein of SEQ ID NO:2,
8, 15, 20, 25, 34, or 41, as described in detail in the subsections
above.
Chimeric or Fusion Proteins
[0520] In another aspect, the invention provides 53070, 15985,
26583, 21953, m32404, 14089, or 23436 chimeric or fusion proteins.
As used herein, a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 "chimeric protein" or "fusion protein" includes a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 polypeptide linked to
a non-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
polypeptide. A "non-53070, -15985, -26583, -21953, -m32404, -14089,
or -23436 polypeptide" refers to a polypeptide having an amino acid
sequence corresponding to a protein which is not substantially
homologous to the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein, e.g., a protein which is different from the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein and which is
derived from the same or a different organism. The 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptide of the fusion
protein can correspond to all or a portion e.g., a fragment
described herein of a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 amino acid sequence. In a preferred embodiment, a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 fusion protein
includes at least one (or two) biologically active portion of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein. The
non-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
polypeptide can be fused to the N-terminus or C-terminus of the
53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide.
[0521] The fusion protein can include a moiety which has a high
affinity for a ligand. For example, the fusion protein can be a
GST-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
fusion protein in which the 53070, 15985, 26583, 21953, m32404,
14089, or 23436 sequences are fused to the C-terminus of the GST
sequences. Such fusion proteins can facilitate the purification of
recombinant 53070, 15985, 26583, 21953, m32404, 14089, or 23436.
Alternatively, the fusion protein can be a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein containing a heterologous
signal sequence at its N-terminus. In certain host cells (e.g.,
mammalian host cells), expression and/or secretion of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 can be increased through use
of a heterologous signal sequence.
[0522] Fusion proteins can include all or a part of a serum
protein, e.g., an IgG constant region, or human serum albumin.
[0523] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
fusion proteins of the invention can be incorporated into
pharmaceutical compositions and administered to a subject in vivo.
The 53070, 15985, 26583, 21953, m32404, 14089, or 23436 fusion
proteins can be used to affect the bioavailability of a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 substrate. 53070,
15985, 26583, 21953, m32404, 14089, or 23436 fusion proteins may be
useful therapeutically for the treatment of disorders caused by,
for example, (i) aberrant modification or mutation of a gene
encoding a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein; (ii) mis-regulation of the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 gene; and (iii) aberrant post-translational
modification of a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein.
[0524] Moreover, the 53070-, 15985-, 26583-, 21953-, m32404-,
14089-, or 23436-fusion proteins of the invention can be used as
immunogens to produce anti-53070, -15985, -26583, -21953, -m32404,
-14089, or -23436 antibodies in a subject, to purify 53070, 15985,
26583, 21953, m32404, 14089, or 23436 ligands and in screening
assays to identify molecules which inhibit the interaction of
53070, 15985, 26583, 21953, m32404, 14089, or 23436 with a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 substrate.
[0525] Expression vectors are commercially available that already
encode a fusion moiety (e.g., a GST polypeptide). A 53070-, 15985-,
26583-, 21953-, m32404-, 14089-, or 23436-encoding nucleic acid can
be cloned into such an expression vector such that the fusion
moiety is linked in-frame to the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein.
Variants of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
Proteins
[0526] In another aspect, the invention also features a variant of
a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptide,
e.g., which functions as an agonist (mimetics) or as an antagonist.
Variants of the 53070, 15985, 26583, 21953, m32404, 14089, or 23436
proteins can be generated by mutagenesis, e.g., discrete point
mutation, the insertion or deletion of sequences or the truncation
of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein.
An agonist of the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 proteins can retain substantially the same, or a subset, of
the biological activities of the naturally occurring form of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein. An
antagonist of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein can inhibit one or more of the activities of the naturally
occurring form of the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein by, for example, competitively modulating a 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-mediated activity
of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein.
Thus, specific biological effects can be elicited by treatment with
a variant of limited function. Preferably, treatment of a subject
with a variant having a subset of the biological activities of the
naturally occurring form of the protein has fewer side effects in a
subject relative to treatment with the naturally occurring form of
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein.
[0527] Variants of a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein can be identified by screening combinatorial
libraries of mutants, e.g., truncation mutants, of a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein for agonist or
antagonist activity.
[0528] Libraries of fragments e.g., N terminal, C terminal, or
internal fragments, of a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 protein coding sequence can be used to generate a
variegated population of fragments for screening and subsequent
selection of variants of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein. Variants in which a cysteine residues is
added or deleted or in which a residue which is glycosylated is
added or deleted are particularly preferred.
[0529] Methods for screening gene products of combinatorial
libraries made by point mutations or truncation, and for screening
cDNA libraries for gene products having a selected property are
known in the art. Such methods are adaptable for rapid screening of
the gene libraries generated by combinatorial mutagenesis of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 proteins. Recursive
ensemble mutagenesis (REM), a new technique which enhances the
frequency of functional mutants in the libraries, can be used in
combination with the screening assays to identify 53070, 15985,
26583, 21953, m32404, 14089, or 23436 variants (Arkin and Yourvan
(1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al.
(1993) Protein Engineering 6:327-331).
[0530] Cell-based assays can be exploited to analyze a variegated
53070, 15985, 26583, 21953, m32404, 14089, or 23436 library. For
example, a library of expression vectors can be transfected into a
cell line, e.g., a cell line, which ordinarily responds to 53070,
15985, 26583, 21953, m32404, 14089, or 23436 in a
substrate-dependent manner. The transfected cells are then
contacted with 53070, 15985, 26583, 21953, m32404, 14089, or 23436
and the effect of the expression of the mutant on signaling by the
53070, 15985, 26583, 21953, m32404, 14089, or 23436 substrate can
be detected, e.g., by measuring the phosphorylation of a substrate,
by measuring protein kinase activity and/or microtubule binding, by
measuring phosphorylation of serine or threonine residues, by
measuring prolyl oligopeptidase as described below, by measuring
m32404 protease activity, by measuring 14089 protease activity, or
by measuring de-ubiquitinating activity, respectively. Plasmid DNA
can then be recovered from the cells which score for inhibition, or
alternatively, potentiation of signaling by the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 substrate, and the individual
clones further characterized.
[0531] In another aspect, the invention features a method of making
a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptide,
e.g., a peptide having a non-wild type activity, e.g., an
antagonist, agonist, or super agonist of a naturally occurring
53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptide,
e.g., a naturally occurring 53070, 15985, 26583, 21953, m32404,
14089, or 23436 polypeptide. The method includes: altering the
sequence of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide, e.g., altering the sequence, e.g., by substitution or
deletion of one or more residues of a non-conserved region, a
domain or residue disclosed herein, and testing the altered
polypeptide for the desired activity.
[0532] In another aspect, the invention features a method of making
a fragment or analog of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 polypeptide a biological activity of a naturally
occurring 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide. The method includes: altering the sequence, e.g., by
substitution or deletion of one or more residues, of a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 polypeptide, e.g.,
altering the sequence of a non-conserved region, or a domain or
residue described herein, and testing the altered polypeptide for
the desired activity.
Anti-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
Antibodies
[0533] In another aspect, the invention provides an anti-53070,
-15985, -26583, -21953, -m32404, -14089, or -23436 antibody, or a
fragment thereof (e.g., an antigen-binding fragment thereof). The
term "antibody" as used herein refers to an immunoglobulin molecule
or immunologically active portion thereof, i.e., an antigen-binding
portion. As used herein, the term "antibody" refers to a protein
comprising at least one, and preferably two, heavy (H) chain
variable regions (abbreviated herein as VH), and at least one and
preferably two light (L) chain variable regions (abbreviated herein
as VL). The VH and VL regions can be further subdivided into
regions of hypervariability, termed "complementarity determining
regions" ("CDR"), interspersed with regions that are more
conserved, termed "framework regions" (FR). The extent of the
framework region and CDR's has been precisely defined (see, Kabat,
E. A., et al. (1991) Sequences of Proteins of Immunological
Interest, Fifth Edition, U.S. Department of Health and Human
Services, NIH Publication No. 91-3242, and Chothia, C. et al.
(1987) J. Mol. Biol. 196:901-917, which are incorporated herein by
reference). Each VH and VL is composed of three CDR's and four FRs,
arranged from amino-terminus to carboxy-terminus in the following
order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0534] The anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibody can further include a heavy and light chain
constant region, to thereby form a heavy and light immunoglobulin
chain, respectively. In one embodiment, the antibody is a tetramer
of two heavy immunoglobulin chains and two light immunoglobulin
chains, wherein the heavy and light immunoglobulin chains are
inter-connected by, e.g., disulfide bonds. The heavy chain constant
region is comprised of three domains, CH1, CH2 and CH3. The light
chain constant region is comprised of one domain, CL. The variable
region of the heavy and light chains contains a binding domain that
interacts with an antigen. The constant regions of the antibodies
typically mediate the binding of the antibody to host tissues or
factors, including various cells of the immune system (e.g.,
effector cells) and the first component (C1q) of the classical
complement system.
[0535] As used herein, the term "immunoglobulin" refers to a
protein consisting of one or more polypeptides substantially
encoded by immunoglobulin genes. The recognized human
immunoglobulin genes include the kappa, lambda, alpha (IgA1 and
IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu
constant region genes, as well as the myriad immunoglobulin
variable region genes. Full-length immunoglobulin "light chains"
(about 25 KDa or 214 amino acids) are encoded by a variable region
gene at the NH2-terminus (about 110 amino acids) and a kappa or
lambda constant region gene at the COOH-terminus. Full-length
immunoglobulin "heavy chains" (about 50 KDa or 446 amino acids),
are similarly encoded by a variable region gene (about 116 amino
acids) and one of the other aforementioned constant region genes,
e.g., gamma (encoding about 330 amino acids).
[0536] The term "antigen-binding fragment" of an antibody (or
simply "antibody portion," or "fragment"), as used herein, refers
to one or more fragments of a full-length antibody that retain the
ability to specifically bind to the antigen, e.g., 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptide or fragment
thereof. Examples of antigen-binding fragments of the anti-53070,
-15985, -26583, -21953, -m32404, -14089, or -23436 antibody
include, but are not limited to: (i) a Fab fragment, a monovalent
fragment consisting of the VL, VH, CL and CH1 domains; (ii) a
F(ab').sub.2 fragment, a bivalent fragment comprising two Fab
fragments linked by a disulfide bridge at the hinge region; (iii) a
Fd fragment consisting of the VH and CH1 domains; (iv) a Fv
fragment consisting of the VL and VH domains of a single arm of an
antibody, (v) a dAb fragment (Ward et al., (1989) Nature
341:544-546), which consists of a VH domain; and (vi) an isolated
complementarity determining region (CDR). Furthermore, although the
two domains of the Fv fragment, VL and VH, are coded for by
separate genes, they can be joined, using recombinant methods, by a
synthetic linker that enables them to be made as a single protein
chain in which the VL and VH regions pair to form monovalent
molecules (known as single chain Fv (scFv); see e.g., Bird et al.
(1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl.
Acad. Sci. USA 85:5879-5883). Such single chain antibodies are also
encompassed within the term "antigen-binding fragment" of an
antibody. These antibody fragments are obtained using conventional
techniques known to those with skill in the art, and the fragments
are screened for utility in the same manner as are intact
antibodies.
[0537] The anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibody can be a polyclonal or a monoclonal antibody. In
other embodiments, the antibody can be recombinantly produced,
e.g., produced by phage display or by combinatorial methods.
[0538] Phage display and combinatorial methods for generating
anti-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
antibodies are known in the art (as described in, e.g., Ladner et
al. U.S. Pat. No. 5,223,409; Kang et al. International Publication
No. WO 92/18619; Dower et al. International Publication No. WO
91/17271; Winter et al. International Publication WO 92/20791;
Markland et al. International Publication No. WO 92/15679;
Breitling et al. International Publication WO 93/01288; McCafferty
et al. International Publication No. WO 92/01047; Garrard et al.
International Publication No. WO 92/09690; Ladner et al.
International Publication No. WO 90/02809; Fuchs et al. (1991)
Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Antibod
Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281;
Griffths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J
Mol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628;
Gram et al. (1992) PNAS 89:3576-3580; Garrad et al. (1991)
Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res
19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982, the
contents of all of which are incorporated by reference herein).
[0539] In one embodiment, the anti-53070, -15985, -26583, -21953,
-m32404, -14089, or -23436 antibody is a fully human antibody
(e.g., an antibody made in a mouse which has been genetically
engineered to produce an antibody from a human immunoglobulin
sequence), or a non-human antibody, e.g., a rodent (mouse or rat),
goat, primate (e.g., monkey), camel antibody. Preferably, the
non-human antibody is a rodent (mouse or rat antibody). Method of
producing rodent antibodies are known in the art.
[0540] Human monoclonal antibodies can be generated using
transgenic mice carrying the human immunoglobulin genes rather than
the mouse system. Splenocytes from these transgenic mice immunized
with the antigen of interest are used to produce hybridomas that
secrete human mAbs with specific affinities for epitopes from a
human protein (see, e.g., Wood et al. International Application WO
91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg
et al. International Application WO 92/03918; Kay et al.
International Application 92/03917; Lonberg, N. et al. 1994 Nature
368:856-859; Green, L. L. et al. 1994 Nature Genet. 7:13-21;
Morrison, S. L. et al. 1994 Proc. Natl. Acad. Sci. USA
81:6851-6855; Bruggeman et al. 1993 Year Immunol 7:33-40; Tuaillon
et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur J Immunol
21:1323-1326).
[0541] An anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibody can be one in which the variable region, or a
portion thereof, e.g., the CDR's, are generated in a non-human
organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and
humanized antibodies are within the invention. Antibodies generated
in a non-human organism, e.g., a rat or mouse, and then modified,
e.g., in the variable framework or constant region, to decrease
antigenicity in a human are within the invention.
[0542] Chimeric antibodies can be produced by recombinant DNA
techniques known in the art. For example, a gene encoding the Fc
constant region of a murine (or other species) monoclonal antibody
molecule is digested with restriction enzymes to remove the region
encoding the murine Fc, and the equivalent portion of a gene
encoding a human Fc constant region is substituted (see Robinson et
al., International Patent Publication PCT/US86/02269; Akira, et
al., European Patent Application 184,187; Taniguchi, M., European
Patent Application 171,496; Morrison et al., European Patent
Application 173,494; Neuberger et al., International Application WO
86/01533; Cabilly et al. U.S. Pat. No. 4,816,567; Cabilly et al.,
European Patent Application 125,023; Better et al. (1988 Science
240:1041-1043); Liu et al. (1987) PNAS 84:3439-3443; Liu et al.,
1987, J. Immunol. 139:3521-3526; Sun et al. (1987) PNAS 84:214-218;
Nishimura et al., 1987, Canc. Res. 47:999-1005; Wood et al. (1985)
Nature 314:446-449; and Shaw et al., 1988, J. Natl Cancer Inst.
80:1553-1559).
[0543] A humanized or CDR-grafted antibody will have at least one
or two but generally all three recipient CDR's (of heavy and or
light immuoglobulin chains) replaced with a donor CDR. The antibody
may be replaced with at least a portion of a non-human CDR or only
some of the CDR's may be replaced with non-human CDR's. It is only
necessary to replace the number of CDR's required for binding of
the humanized antibody to a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 or a fragment thereof. Preferably, the donor will
be a rodent antibody, e.g., a rat or mouse antibody, and the
recipient will be a human framework or a human consensus framework.
Typically, the immunoglobulin providing the CDR's is called the
"donor" and the immunoglobulin providing the framework is called
the "acceptor." In one embodiment, the donor immunoglobulin is a
non-human (e.g., rodent). The acceptor framework is a
naturally-occurring (e.g., a human) framework or a consensus
framework, or a sequence about 85% or higher, preferably 90%, 95%,
99% or higher identical thereto.
[0544] As used herein, the term "consensus sequence" refers to the
sequence formed from the most frequently occurring amino acids (or
nucleotides) in a family of related sequences (See e.g., Winnaker,
From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987).
In a family of proteins, each position in the consensus sequence is
occupied by the amino acid occurring most frequently at that
position in the family. If two amino acids occur equally
frequently, either can be included in the consensus sequence. A
"consensus framework" refers to the framework region in the
consensus immunoglobulin sequence.
[0545] An antibody can be humanized by methods known in the art.
Humanized antibodies can be generated by replacing sequences of the
Fv variable region which are not directly involved in antigen
binding with equivalent sequences from human Fv variable regions.
General methods for generating humanized antibodies are provided by
Morrison, S. L., 1985, Science 229:1202-1207, by Oi et al., 1986,
BioTechniques 4:214, and by Queen et al. U.S. Pat. No. 5,585,089,
U.S. Pat. No. 5,693,761 and U.S. Pat. No. 5,693,762, the contents
of all of which are hereby incorporated by reference. Those methods
include isolating, manipulating, and expressing the nucleic acid
sequences that encode all or part of immunoglobulin Fv variable
regions from at least one of a heavy or light chain. Sources of
such nucleic acid are well known to those skilled in the art and,
for example, may be obtained from a hybridoma producing an antibody
against a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide or fragment thereof. The recombinant DNA encoding the
humanized antibody, or fragment thereof, can then be cloned into an
appropriate expression vector.
[0546] Humanized or CDR-grafted antibodies can be produced by
CDR-grafting or CDR substitution, wherein one, two, or all CDR's of
an immunoglobulin chain can be replaced. See e.g., U.S. Pat. No.
5,225,539; Jones et al. 1986 Nature 321:552-525; Verhoeyan et al.
1988 Science 239:1534; Beidler et al. 1988 J. Immunol.
141:4053-4060; Winter U.S. Pat. No. 5,225,539, the contents of all
of which are hereby expressly incorporated by reference. Winter
describes a CDR-grafting method which may be used to prepare the
humanized antibodies of the present invention (UK Patent
Application GB 2188638A, filed on Mar. 26, 1987; Winter U.S. Pat.
No. 5,225,539), the contents of which is expressly incorporated by
reference.
[0547] Also within the scope of the invention are humanized
antibodies in which specific amino acids have been substituted,
deleted or added. Preferred humanized antibodies have amino acid
substitutions in the framework region, such as to improve binding
to the antigen. For example, a humanized antibody will have
framework residues identical to the donor framework residue or to
another amino acid other than the recipient framework residue. To
generate such antibodies, a selected, small number of acceptor
framework residues of the humanized immunoglobulin chain can be
replaced by the corresponding donor amino acids. Preferred
locations of the substitutions include amino acid residues adjacent
to the CDR, or which are capable of interacting with a CDR (see
e.g., U.S. Pat. No. 5,585,089). Criteria for selecting amino acids
from the donor are described in U.S. Pat. No. 5,585,089, e.g.,
columns 12-16 of U.S. Pat. No. 5,585,089, the e.g., columns 12-16
of U.S. Pat. No. 5,585,089, the contents of which are hereby
incorporated by reference. Other techniques for humanizing
antibodies are described in Padlan et al. EP 519596 A1, published
on Dec. 23, 1992.
[0548] In preferred embodiments an antibody can be made by
immunizing with purified 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 antigen, or a fragment thereof, e.g., a fragment described
herein, membrane associated antigen, tissue, e.g., crude tissue
preparations, whole cells, preferably living cells, lysed cells, or
cell fractions, e.g., cytosolic fractions.
[0549] A full-length 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein or, antigenic peptide fragment of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 can be used as an immunogen
or can be used to identify anti-53070, -15985, -26583, -21953,
-m32404, -14089, or -23436 antibodies made with other immunogens,
e.g., cells, membrane preparations, and the like. The antigenic
peptide of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
should include at least 8 amino acid residues of the amino acid
sequence shown in SEQ ID NO: 2, 8, 15, 20, 25, 34, or 41 and
encompass an epitope of 53070, 15985, 26583, 21953, m32404, 14089,
or 23436. Preferably, the antigenic peptide includes at least 10
amino acid residues, more preferably at least 15 amino acid
residues, even more preferably at least 20 amino acid residues, and
most preferably at least 30 amino acid residues.
[0550] Fragments of 53070, 15985, 26583, 21953, m32404, 14089, or
23436 can be used as immunogens or to characterize the specificity
of an antibody.
[0551] Fragments of 53070 which include amino acid residues about
103 to 119, about 226 to 247, or about 301 to 329 of SEQ ID NO:2,
for example, can be used to make antibodies against hydrophilic
regions of the 53070 protein. Similarly, fragments of 53070 which
include residues about 63 to 73, about 86 to 102, or about 199 to
216 of SEQ ID NO:2 can be used to make an antibody against a
hydrophobic region of the 53070 protein; fragments of 53070 which
include residues about 12 to 45, about 125 to 150, or about 150 to
175 of SEQ ID NO:2 can be used to make an antibody against the
protein kinase domain of the 53070 protein; and fragments of 53070
which include amino acid residues about 1 to 11 and 273 to 367 of
SEQ ID NO:2 can be used to make antibodies against a non-kinase
domain region of the 53070 protein.
[0552] Fragments of 15985 which include residues 8 to 20, from
about 592 to 600, or from about 652 to 672 can be used to make,
e.g., used as immunogens or used to characterize the specificity of
an antibody, antibodies against hydrophilic regions of the 15985
protein. Similarly, fragments of 15985 which include residues 83 to
91, from about 465 to 472, or from about 568 to 585 of SEQ ID NO:8
can be used to make an antibody against a hydrophobic region of the
15985 protein; a fragment of 15985 which include residues 394 to
651 can be used to make an antibody against the protein kinase
region of the 15985 protein; and a fragment of 15985 which includes
residues 67 to 158 or residues 192 to 280 can be used to make an
antibody against a doublecortin repeat of the 15985 protein.
[0553] Fragments of 26583 which include residues about 60-70 can be
used to make, e.g., used as immunogens or used to characterize the
specificity of an antibody, antibodies against hydrophilic regions
of the 26583 protein. Similarly, fragments of 26583 which include
residues 262-279 can be used to make an antibody against a
hydrophobic region of the 26583 protein; a fragment of 26583 which
includes residues about 172 to 461 or 99 to 523 can be used to make
an antibody against the phosphatase region of the 26583
protein.
[0554] Hydrophilic fragments of 21953, e.g., those which include
residues 20 to 40, 65 to 80, or 780 to 790, can be used to make,
e.g., used as immunogens or used to characterize the specificity of
an antibody, antibodies against hydrophilic regions of the 21953
protein. Similarly, a hydrophobic fragment of 21953, e.g. which
include residues 250 to 270, 370 to 390, or 681 to 695, can be used
to make an antibody against a hydrophobic region of the 21953
protein; a fragment of 21953 which include residues about 672 to
744, 672 to 690, 690 to 710, or 710 to 744 can be used to make an
antibody against the prolyl oligopeptidase domain of the 21953
protein.
[0555] Fragments of m32404 which include residues about 30 to 60 of
SEQ ID NO:25 can be used to make, e.g., can be used as immunogens
or used to characterize the specificity of an antibody, antibodies
against hydrophilic regions of the m32404 protein. Similarly, a
fragment of m32404 which includes residues about 320 to 340, or
about 450 to 470 of SEQ ID NO:25 can be used to make an antibody
against a hydrophobic region of the m32404 protein; a fragment of
m32404 which include residues about 45 to 268, or about 311 to 520
of SEQ ID NO:25 (or a fragment thereof, e.g., residues 45 to 100,
73 to 78, 100 to 150, 150 to 200, 200 to 250, 218 to 229, 250 to
268, 311 to 360, 337 to 342, 360 to 400, 400 to 450, 450 to 500,
500 to 520 of SEQ ID NO:25) can be used to make an antibody against
the trypsin region of the m32404 protein.
[0556] Fragments of 14089 that include residues about 71 to 79,
about 161 to 171, or about 185 to 192 of SEQ ID NO:34 can be used
to make, e.g., used as immunogens or used to characterize the
specificity of an antibody, antibodies against hydrophilic regions
of the 14089 protein. Similarly, fragments of 14089 that include
residues about 35 to 55, 58 to 70, or 175 to 184 of SEQ ID NO:34
can be used to make an antibody against a hydrophobic region of the
14089 protein; a fragment of 14089 that includes residues about
41-234 of SEQ ID NO:34, or small fragments, e.g., 24 to 44, 74 to
94, or 170 to 190 of SEQ ID NO:34 can be used to make an antibody
against the trypsin region of the 14089 protein. In a preferred
embodiment, the antibody can bind to the extracellular portion of
the 14089 protein, e.g., it can bind to a whole cell which
expresses the 14089 protein.
[0557] Fragments of 23436 which include residues about 76 to 87,
from about 138 to 143, and from about 458 to 478 of SEQ ID NO:41
can be used to make, e.g., used as immunogens or used to
characterize the specificity of an antibody, antibodies against
hydrophilic regions of the 23436 protein. Similarly, fragments of
23436 which include residues about 103 to 114, from about 285 to
297, and from about 413 to 420 of SEQ ID NO:41 can be used to make
an antibody against a hydrophobic region of the 23436 protein;
fragments of 23436 which include residues about 89 to 120, 332 to
420, or 89 to 420 of SEQ ID NO:41 can be used to make an antibody
against the ubiquitin carboxy-terminal hydrolase region of the
23436 protein.
[0558] Antibodies reactive with, or specific for, any of these
regions, or other regions or domains described herein are
provided.
[0559] Antibodies which bind only native 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein, only denatured or otherwise
non-native 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein, or which bind both, are with in the invention. Antibodies
with linear or conformational epitopes are within the invention.
Conformational epitopes can sometimes be identified by identifying
antibodies which bind to native but not denatured 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein.
[0560] Preferred epitopes encompassed by the antigenic peptide are
regions of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 are
located on the surface of the protein, e.g., hydrophilic regions,
as well as regions with high antigenicity. For example, an Emini
surface probability analysis of the human 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein sequence can be used to
indicate the regions that have a particularly high probability of
being localized to the surface of the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein and are thus likely to constitute
surface residues useful for targeting antibody production.
[0561] In preferred embodiments antibodies can bind one or more of
purified antigen, membrane associated antigen, tissue, e.g., tissue
sections, whole cells, preferably living cells, lysed cells, cell
fractions, e.g., cytosolic fractions.
[0562] The anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibody can be a single chain antibody. A single-chain
antibody (scFV) may be engineered (see, for example, Colcher, D. et
al. (1999) Ann NY Acad Sci 880:263-80; and Reiter, Y. (1996) Clin
Cancer Res 2:245-52). The single chain antibody can be dimerized or
multimerized to generate multivalent antibodies having
specificities for different epitopes of the same target 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein.
[0563] In a preferred embodiment, the antibody has effector
function, and/or can fix complement. In other embodiments, the
antibody does not, recruit effector cells, or fix complement.
[0564] In a preferred embodiment, the antibody has reduced or no
ability to bind an Fc receptor. For example, it is a isotype or
subtype, fragment or other mutant, which does not support binding
to an Fc receptor, e.g., it has a mutagenized or deleted Fc
receptor binding region.
[0565] In a preferred embodiment, an anti-53070 antibody alters
(e.g., increases or decreases) the kinase activity of a 53070
polypeptide. For example, the antibody can bind at or in proximity
to the active site, e.g., to an epitope that includes a residue
located from about 120 to 180 of SEQ ID NO:2.
[0566] In a preferred embodiment, an anti-15985 antibody alters
(e.g., increases or decreases) an activity of a 15985 polypeptide,
e.g. phosphorylation of a protein substrate.
[0567] In a preferred embodiment, an anti-21953 antibody alters
(e.g., increases or decreases) the prolyl oligopeptidase activity
of a 21953 polypeptide. For example, the antibody can specifically
bind a residue of the active site of 21953 polypeptide, e.g., a
residue located between about 730 to 750, 805 to 830, 835 to 860 of
SEQ ID NO:20. The antibody can block the binding of substrate to
the 21953 polypeptide. In another preferred embodiment, the
antibody specifically binds a residue in the 21953 prolyl
oligopeptidase domain, e.g., from about amino acid 672 to 744, or
610 to 883 of SEQ ID NO:20, or in the DPP IV N-terminal residue,
e.g., a residue between about amino acids 88 to 663 of SEQ ID
NO:20.
[0568] In a preferred embodiment, an anti-m32404 antibody alters
(e.g., increases or decreases) the proteolytic activity of an
m32404 polypeptide. For example, the antibody can bind at or in
proximity to the active site, e.g., to an epitope that includes a
residue located from about 73 to 78, 337 to 342, or 218 to 229 of
SEQ ID NO:25.
[0569] In a preferred embodiment, the antibody alters (e.g.,
increases or decreases) the de-ubiquitinating activity of a 23436
polypeptide.
[0570] The antibody can be coupled to a toxin, e.g., a polypeptide
toxin, e,g, ricin or diphtheria toxin or active fragment hereof, or
a radioactive nucleus, or imaging agent, e.g. a radioactive,
enzymatic, or other, e.g., imaging agent, e.g., a NMR contrast
agent. Labels which produce detectable radioactive emissions or
fluorescence are preferred.
[0571] An anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibody (e.g., monoclonal antibody) can be used to isolate
53070, 15985, 26583, 21953, m32404, 14089, or 23436 by standard
techniques, such as affinity chromatography or immunoprecipitation.
Moreover, an anti-53070, -15985, -26583, -21953, -m32404, -14089,
or -23436 antibody can be used to detect 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein (e.g., in a cellular lysate
or cell supernatant) in order to evaluate the abundance and pattern
of expression of the protein. Anti-53070, -15985, -26583, -21953,
-m32404, -14089, or -23436 antibodies can be used diagnostically to
monitor protein levels in tissue as part of a clinical testing
procedure, e.g., to determine the efficacy of a given treatment
regimen. Detection can be facilitated by coupling (i.e., physically
linking) the antibody to a detectable substance (i.e., antibody
labelling). Examples of detectable substances include various
enzymes, prosthetic groups, fluorescent materials, luminescent
materials, bioluminescent materials, and radioactive materials.
Examples of suitable enzymes include horseradish peroxidase,
alkaline phosphatase, .beta.-galactosidase, or
acetylcholinesterase; examples of suitable prosthetic group
complexes include streptavidin/biotin and avidin/biotin; examples
of suitable fluorescent materials include umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine,
dichlorotriazinylamine fluorescein, dansyl chloride or
phycoerythrin; an example of a luminescent material includes
luminol; examples of bioluminescent materials include luciferase,
luciferin, and aequorin, and examples of suitable radioactive
material include .sup.125I, .sup.131I, .sup.35S or .sup.3H.
[0572] The invention also includes a nucleic acid which encodes an
anti-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
antibody, e.g., an anti-53070, -15985, -26583, -21953, -m32404,
-14089, or -23436 antibody described herein. Also included are
vectors which include the nucleic acid and cells transformed with
the nucleic acid, particularly cells which are useful for producing
an antibody, e.g., mammalian cells, e.g. CHO or lymphatic
cells.
[0573] The invention also includes cell lines, e.g., hybridomas,
which make an anti-53070, -15985, -26583, -21953, -m32404, -14089,
or -23436 antibody, e.g., and antibody described herein, and method
of using said cells to make a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 antibody.
Recombinant Expression Vectors, Host Cells and Genetically
Engineered Cells
[0574] In another aspect, the invention includes, vectors,
preferably expression vectors, containing a nucleic acid encoding a
polypeptide described herein. As used herein, the term "vector"
refers to a nucleic acid molecule capable of transporting another
nucleic acid to which it has been linked and can include a plasmid,
cosmid or viral vector. The vector can be capable of autonomous
replication or it can integrate into a host DNA. Viral vectors
include, e.g., replication defective retroviruses, adenoviruses and
adeno-associated viruses.
[0575] A vector can include a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 nucleic acid in a form suitable for expression of
the nucleic acid in a host cell. Preferably the recombinant
expression vector includes one or more regulatory sequences
operatively linked to the nucleic acid sequence to be expressed.
The term "regulatory sequence" includes promoters, enhancers and
other expression control elements (e.g., polyadenylation signals).
Regulatory sequences include those which direct constitutive
expression of a nucleotide sequence, as well as tissue-specific
regulatory and/or inducible sequences. The design of the expression
vector can depend on such factors as the choice of the host cell to
be transformed, the level of expression of protein desired, and the
like. The expression vectors of the invention can be introduced
into host cells to thereby produce proteins or polypeptides,
including fusion proteins or polypeptides, encoded by nucleic acids
as described herein (e.g., 53070, 15985, 26583, 21953, m32404,
14089, or 23436 proteins, mutant forms of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 proteins, fusion proteins, and the
like).
[0576] The recombinant expression vectors of the invention can be
designed for expression of 53070, 15985, 26583, 21953, m32404,
14089, or 23436 proteins in prokaryotic or eukaryotic cells. For
example, polypeptides of the invention can be expressed in E. coli,
insect cells (e.g., using baculovirus expression vectors), yeast
cells or mammalian cells. Suitable host cells are discussed further
in Goeddel, (1990) Gene Expression Technology: Methods in
Enzymology 185, Academic Press, San Diego, Calif. Alternatively,
the recombinant expression vector can be transcribed and translated
in vitro, for example using T7 promoter regulatory sequences and T7
polymerase.
[0577] Expression of proteins in prokaryotes is most often carried
out in E. coli with vectors containing constitutive or inducible
promoters directing the expression of either fusion or non-fusion
proteins. Fusion vectors add a number of amino acids to a protein
encoded therein, usually to the amino terminus of the recombinant
protein. Such fusion vectors typically serve three purposes: 1) to
increase expression of recombinant protein; 2) to increase the
solubility of the recombinant protein; and 3) to aid in the
purification of the recombinant protein by acting as a ligand in
affinity purification. Often, a proteolytic cleavage site is
introduced at the junction of the fusion moiety and the recombinant
protein to enable separation of the recombinant protein from the
fusion moiety subsequent to purification of the fusion protein.
Such enzymes, and their cognate recognition sequences, include
Factor Xa, thrombin and enterokinase. Typical fusion expression
vectors include pGEX (Pharmacia Biotech Inc; Smith, D. B. and
Johnson, K. S. (1988) Gene 67:31-40), pMAL (New England Biolabs,
Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse
glutathione S-transferase (GST), maltose E binding protein, or
protein A, respectively, to the target recombinant protein.
[0578] Purified fusion proteins can be used in 53070, 15985, 26583,
21953, m32404, 14089, or 23436 activity assays, (e.g., direct
assays or competitive assays described in detail below), or to
generate antibodies specific for 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 proteins. In a preferred embodiment, a
fusion protein expressed in a retroviral expression vector of the
present invention can be used to infect bone marrow cells which are
subsequently transplanted into irradiated recipients. The pathology
of the subject recipient is then examined after sufficient time has
passed (e.g., six weeks).
[0579] To maximize recombinant protein expression in E. coli is to
express the protein in a host bacteria with an impaired capacity to
proteolytically cleave the recombinant protein (Gottesman, S.,
(1990) Gene Expression Technology: Methods in Enzymology 185,
Academic Press, San Diego, Calif. 119-128). Another strategy is to
alter the nucleic acid sequence of the nucleic acid to be inserted
into an expression vector so that the individual codons for each
amino acid are those preferentially utilized in E. coli (Wada et
al., (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of
nucleic acid sequences of the invention can be carried out by
standard DNA synthesis techniques.
[0580] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
expression vector can be a yeast expression vector, a vector for
expression in insect cells, e.g., a baculovirus expression vector
or a vector suitable for expression in mammalian cells.
[0581] When used in mammalian cells, the expression vector's
control functions can be provided by viral regulatory elements. For
example, commonly used promoters are derived from polyoma,
Adenovirus 2, cytomegalovirus and Simian Virus 40.
[0582] In another embodiment, the promoter is an inducible
promoter, e.g., a promoter regulated by a steroid hormone, by a
polypeptide hormone (e.g., by means of a signal transduction
pathway), or by a heterologous polypeptide (e.g., the
tetracycline-inducible systems, "Tet-On" and "Tet-Off"; see, e.g.,
Clontech Inc., CA, Gossen and Bujard (1992) Proc. Natl. Acad. Sci.
USA 89:5547, and Paillard (1989) Human Gene Therapy 9:983).
[0583] In another embodiment, the recombinant mammalian expression
vector is capable of directing expression of the nucleic acid
preferentially in a particular cell type (e.g., tissue-specific
regulatory elements are used to express the nucleic acid).
Non-limiting examples of suitable tissue-specific promoters include
the albumin promoter (liver-specific; Pinkert et al. (1987) Genes
Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton
(1988) Adv. Immunol. 43:235-275), in particular promoters of T cell
receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and
immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and
Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g.,
the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl.
Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund
et al. (1985) Science 230:912-916), and mammary gland-specific
promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and
European Application Publication No. 264,166).
Developmentally-regulated promoters are also encompassed, for
example, the murine hox promoters (Kessel and Gruss (1990) Science
249:374-379) and the .alpha.-fetoprotein promoter (Campes and
Tilghman (1989) Genes Dev. 3:537-546).
[0584] The invention further provides a recombinant expression
vector comprising a DNA molecule of the invention cloned into the
expression vector in an antisense orientation. Regulatory sequences
(e.g., viral promoters and/or enhancers) operatively linked to a
nucleic acid cloned in the antisense orientation can be chosen
which direct the constitutive, tissue specific or cell type
specific expression of antisense RNA in a variety of cell types.
The antisense expression vector can be in the form of a recombinant
plasmid, phagemid or attenuated virus.
[0585] Another aspect the invention provides a host cell which
includes a nucleic acid molecule described herein, e.g., a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecule
within a recombinant expression vector or a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 nucleic acid molecule containing
sequences which allow it to homologously recombine into a specific
site of the host cell's genome. The terms "host cell" and
"recombinant host cell" are used interchangeably herein. Such terms
refer not only to the particular subject cell but to the progeny or
potential progeny of such a cell. Because certain modifications may
occur in succeeding generations due to either mutation or
environmental influences, such progeny may not, in fact, be
identical to the parent cell, but are still included within the
scope of the term as used herein.
[0586] A host cell can be any prokaryotic or eukaryotic cell. For
example, a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein can be expressed in bacterial cells (such as E. coli),
insect cells, yeast or mammalian cells (such as Chinese hamster
ovary cells (CHO) or COS cells (African green monkey kidney cells
CV-1 origin SV40 cells; Gluzman (1981) Cell I23:175-182)). Other
suitable host cells are known to those skilled in the art.
[0587] Vector DNA can be introduced into host cells via
conventional transformation or transfection techniques. As used
herein, the terms "transformation" and "transfection" are intended
to refer to a variety of art-recognized techniques for introducing
foreign nucleic acid (e.g., DNA) into a host cell, including
calcium phosphate or calcium chloride co-precipitation,
DEAE-dextran-mediated transfection, lipofection, or
electroporation.
[0588] A host cell of the invention can be used to produce (i.e.,
express) a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein. Accordingly, the invention further provides methods for
producing a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein using the host cells of the invention. In one embodiment,
the method includes culturing the host cell of the invention (into
which a recombinant expression vector encoding a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein has been introduced)
in a suitable medium such that a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein is produced. In another embodiment,
the method further includes isolating a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein from the medium or the host
cell.
[0589] In another aspect, the invention features, a cell or
purified preparation of cells which include a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 transgene, or which otherwise
misexpress 53070, 15985, 26583, 21953, m32404, 14089, or 23436. The
cell preparation can consist of human or non-human cells, e.g.,
rodent cells, e.g., mouse or rat cells, rabbit cells, or pig cells.
In preferred embodiments, the cell or cells include a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 transgene, e.g., a
heterologous form of a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436, e.g., a gene derived from humans (in the case of a
non-human cell). The 53070, 15985, 26583, 21953, m32404, 14089, or
23436 transgene can be misexpressed, e.g., overexpressed or
underexpressed. In other preferred embodiments, the cell or cells
include a gene that mis-expresses an endogenous 53070, 15985,
26583, 21953, m32404, 14089, or 23436, e.g., a gene the expression
of which is disrupted, e.g., a knockout. Such cells can serve as a
model for studying disorders that are related to mutated or
mis-expressed 53070, 15985, 26583, 21953, m32404, 14089, or 23436
alleles or for use in drug screening.
[0590] In another aspect, the invention features, a human cell,
e.g., a hematopoietic stem cell, transformed with nucleic acid
which encodes a subject 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 polypeptide.
[0591] Also provided are cells, preferably human cells, e.g., human
hematopoietic or fibroblast cells, in which an endogenous 53070,
15985, 26583, 21953, m32404, 14089, or 23436 is under the control
of a regulatory sequence that does not normally control the
expression of the endogenous 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene. The expression characteristics of an
endogenous gene within a cell, e.g., a cell line or microorganism,
can be modified by inserting a heterologous DNA regulatory element
into the genome of the cell such that the inserted regulatory
element is operably linked to the endogenous 53070, 15985, 26583,
21953, m32404, 14089, or 23436 gene. For example, an endogenous
53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene which is
"transcriptionally silent," e.g., not normally expressed, or
expressed only at very low levels, may be activated by inserting a
regulatory element which is capable of promoting the expression of
a normally expressed gene product in that cell. Techniques such as
targeted homologous recombinations, can be used to insert the
heterologous DNA as described in, e.g., Chappel, U.S. Pat. No.
5,272,071; WO 91/06667, published in May 16, 1991.
[0592] In a preferred embodiment, recombinant cells described
herein can be used for replacement therapy in a subject. For
example, a nucleic acid encoding a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 polypeptide operably linked to an inducible
promoter (e.g., a steroid hormone receptor-regulated promoter) is
introduced into a human or nonhuman, e.g., mammalian, e.g., porcine
recombinant cell. The cell is cultivated and encapsulated in a
biocompatible material, such as poly-lysine alginate, and
subsequently implanted into the subject. See, e.g., Lanza (1996)
Nat. Biotechnol. 14:1107; Joki et al. (2001) Nat. Biotechnol.
19:35; and U.S. Pat. No. 5,876,742. Production of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptide can be regulated
in the subject by administering an agent (e.g., a steroid hormone)
to the subject. In another preferred embodiment, the implanted
recombinant cells express and secrete an antibody specific for a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptide.
The antibody can be any antibody or any antibody derivative
described herein.
53070, 15985, 26583, 21953, m32404, 14089, or 23436 Transgenic
Animals
[0593] The invention provides non-human transgenic animals. Such
animals are useful for studying the function and/or activity of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein and for
identifying and/or evaluating modulators of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 activity. As used herein, a
"transgenic animal" is a non-human animal, preferably a mammal,
more preferably a rodent such as a rat or mouse, in which one or
more of the cells of the animal includes a transgene. Other
examples of transgenic animals include non-human primates, sheep,
dogs, cows, goats, chickens, amphibians, and the like. A transgene
is exogenous DNA or a rearrangement, e.g., a deletion of endogenous
chromosomal DNA, which preferably is integrated into or occurs in
the genome of the cells of a transgenic animal. A transgene can
direct the expression of an encoded gene product in one or more
cell types or tissues of the transgenic animal, other transgenes,
e.g., a knockout, reduce expression. Thus, a transgenic animal can
be one in which an endogenous 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene has been altered by, e.g., by homologous
recombination between the endogenous gene and an exogenous DNA
molecule introduced into a cell of the animal, e.g., an embryonic
cell of the animal, prior to development of the animal.
[0594] Intronic sequences and polyadenylation signals can also be
included in the transgene to increase the efficiency of expression
of the transgene. A tissue-specific regulatory sequence(s) can be
operably linked to a transgene of the invention to direct
expression of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein to particular cells. A transgenic founder animal can be
identified based upon the presence of a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 transgene in its genome and/or expression
of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 mRNA in
tissues or cells of the animals. A transgenic founder animal can
then be used to breed additional animals carrying the transgene.
Moreover, transgenic animals carrying a transgene encoding a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein can further be
bred to other transgenic animals carrying other transgenes.
[0595] 53070, 15985, 26583, 21953, m32404, 14089, or 23436 proteins
or polypeptides can be expressed in transgenic animals or plants,
e.g., a nucleic acid encoding the protein or polypeptide can be
introduced into the genome of an animal. In preferred embodiments
the nucleic acid is placed under the control of a tissue specific
promoter, e.g., a milk or egg specific promoter, and recovered from
the milk or eggs produced by the animal. Suitable animals are mice,
pigs, cows, goats, and sheep.
[0596] The invention also includes a population of cells from a
transgenic animal, as discussed, e.g., below.
Uses of 53070, 15985, 26583, 21953, m32404, 14089, and 23436
[0597] The nucleic acid molecules, proteins, protein homologues,
and antibodies described herein can be used in one or more of the
following methods: a) screening assays; b) predictive medicine
(e.g., diagnostic assays, prognostic assays, monitoring clinical
trials, and pharmacogenetics); and c) methods of treatment (e.g.,
therapeutic and prophylactic).
[0598] The isolated nucleic acid molecules of the invention can be
used, for example, to express a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein (e.g., via a recombinant expression vector
in a host cell in gene therapy applications), to detect a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 mRNA (e.g., in a
biological sample) or a genetic alteration in a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 gene, and to modulate 53070,
15985, 26583, 21953, m32404, 14089, or 23436 activity, as described
further below. The 53070, 15985, 26583, 21953, m32404, 14089, or
23436 proteins can be used to treat disorders characterized by
insufficient or excessive production of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 substrate or production of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 inhibitors. In
addition, the 53070, 15985, 26583, 21953, m32404, 14089, or 23436
proteins can be used to screen for naturally occurring 53070,
15985, 26583, 21953, m32404, 14089, or 23436 substrates, to screen
for drugs or compounds which modulate 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 activity, as well as to treat disorders
characterized by insufficient or excessive production of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein or production
of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
forms which have decreased, aberrant or unwanted activity compared
to 53070, 15985, 26583, 21953, m32404, 14089, or 23436 wild type
protein (e.g., a cellular proliferative and/or differentiative
disorder; imbalance of protein serine/threonine kinase and protein
serine/threonine phosphorylase activities, leading to an increase
or decrease in lipid biosynthesis, such as cholesterol or cell
cycle progression and neoplastic transformation; a cancer, e.g., a
cancer of the lung, prostate, breast, ovary, or colon; or an
erythroid cell disorder or a proliferative disorder of erythroid,
liver, prostate, or brain cells). Moreover, the anti-53070, -15985,
-26583, -21953, -m32404, -14089, or -23436 antibodies of the
invention can be used to detect and isolate 53070, 15985, 26583,
21953, m32404, 14089, or 23436 proteins, regulate the
bioavailability of 53070, 15985, 26583, 21953, m32404, 14089, or
23436 proteins, and modulate 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity.
[0599] A method of evaluating a compound for the ability to
interact with, e.g., bind, a subject 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 polypeptide is provided. The method
includes: contacting the compound with the subject 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptide; and evaluating
ability of the compound to interact with, e.g., to bind or form a
complex with the subject 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 polypeptide. This method can be performed in vitro, e.g.,
in a cell free system, or in vivo, e.g., in a two-hybrid
interaction trap assay. This method can be used to identify
naturally occurring molecules that interact with subject 53070,
15985, 26583, 21953, m32404, 14089, or 23436 polypeptide. It can
also be used to find natural or synthetic inhibitors of subject
53070, 15985, 26583, 21953, m32404, 14089, or 23436 polypeptide.
Screening methods are discussed in more detail below.
[0600] The 21953 polypeptide is also an enzyme useful for
processing polypeptide hormone precursors. For example, the 21953
polypeptide can be used in a method that includes a) providing a
polypeptide hormone precursor; b) combining the polypeptide hormone
polypeptide with a 21953 polypeptide or active fragment thereof
(e.g., in an effective amount) to provide a reaction mixture; and
c) maintaining the mixture under conditions such that the
polypeptide hormone precursor is modified to yield the processed
polypeptide hormone, e.g., an active form thereof. The method can
further include d) separating the processed polypeptide hormone
from the 21953 polypeptide. The polypeptide hormone precursor can
be obtained from a synthetic process or from a producing cell. The
method can be used in the preparation of a pharmaceutical
composition that includes the processed hormone.
53070, 15985, 26583, 21953, m32404, 14089, and 23436 Screening
Assays
[0601] The invention provides methods (also referred to herein as
"screening assays") for identifying modulators, i.e., candidate or
test compounds or agents (e.g., proteins, peptides,
peptidomimetics, peptoids, small molecules or other drugs) which
bind to 53070, 15985, 26583, 21953, m32404, 14089, or 23436
proteins, have a stimulatory or inhibitory effect on, for example,
53070, 15985, 26583, 21953, m32404, 14089, or 23436 expression or
53070, 15985, 26583, 21953, m32404, 14089, or 23436 activity, or
have a stimulatory or inhibitory effect on, for example, the
expression or activity of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 substrate. Compounds thus identified can be used to
modulate the activity of target gene products (e.g., 53070, 15985,
26583, 21953, m32404, 14089, or 23436 genes) in a therapeutic
protocol, to elaborate the biological function of the target gene
product, or to identify compounds that disrupt normal target gene
interactions.
[0602] In any screening assay, a 26583 polypeptide that may have,
e.g., a serine/threonine phosphatase domain, can be used.
[0603] In one embodiment, the invention provides assays for
screening candidate or test compounds which are substrates of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein or
polypeptide or a biologically active portion thereof. In another
embodiment, the invention provides assays for screening candidate
or test compounds that bind to or modulate an activity of a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein or polypeptide
or a biologically active portion thereof.
[0604] In one embodiment, an activity of a 53070 protein can be
assayed directly in vitro by: expressing an affinity tagged 53070
protein in either bacteria or an appropriate mammalian cell line;
purifying the 53070 protein, e.g., by immunoprecipitation or in an
affinity column; mixing the 53070 protein with radioactively
labeled ATP, e.g., K.sup.32P-ATP; and determining the amount of
radioactive phosphate that is transferred to proteins in the
presence and absence of a suitable substrate. Alternatively, an
activity of a 53070 protein can be assayed indirectly by
overexpressing the protein in an appropriate mammalian cell line
and then assaying for an increase in phosphorylation of a 53070
substrate that is present in the cells, or by assaying for a
cellular response, e.g., altered cell morphology, the adoption of a
transformed phenotype, increased cell migration, or increased cell
growth or cell death. Assays like these are well known in the art
and could easily be adapted to allow for the analysis of 53070
proteins.
[0605] In one embodiment, the activity of a 15985 protein can be
assayed in a manner acceptable for detecting kinase activity. For
example, kinase activity can be assayed in kinase reaction buffer
containing 20 mM MgAcetate, 20 mM ATP, 100 mM NaCl, 100 mM Tris-HCl
pH 6.8, 1 mM ZnCl 2 and 2.5 mCi .quadrature.g32P]ATP and 1 mg
myelin basic protein. The kinase reaction can be allowed to proceed
for 30 minutes before termination by addition of sample buffer with
10 mM EDTA. Following separation by SDS-PAGE, gels can be stained
with Coomassie Blue and subjected to autoradiography. Burgess et
al. (2001) J. Biol. Chem. published Jul. 25, 2001 as
10.1074/jbc.M105153200.
[0606] The prolyl oligopeptidase activity of a 21953 polypeptide
can be assayed in vitro using an enzymatic assay such as described
in Abbott et al. (199) FEBS Lett. 458:278-284 and Abbott et al.
(2000) Eur. J. Biochem 267:6140-4150. A sample to be assayed is
combined with substrate in phosphate buffer pH 7.4. Substrates
include H-Gly-Pro-p-nitroanilide (NA)/HCl (Sigma Corp, MO, USA),
and Gly-Pro-7-amino-4-trifluoromethylcoumarin (Calbiochem, San
Diego, Calif., USA) and other peptidyl substrates. The reaction is
incubated for 30 minutes at 37.degree. C. For example, hydrolysis
of H-Gly-Pro-pNA is monitored spectroscopically at 405 nm. The
sample to be assayed can be a purified 21953 polypeptide, e.g., a
21953 polypeptide or a 21953 fusion protein purified by a method
described herein. Routine Michaelis-Menten analysis of kinetic
parameters can be used to quantify the enzymatic activity.
Alternatively, the reaction can be quenched and total substrate
hydrolyzed can be measured as indication of the activity.
[0607] De-ubiquitination assays useful for detecting a ubiquitin
carboxy-terminal hydrolase activity are described, for example, in
Zhu et al. (1997) Journal of Biological Chemistry 272:51-57, Mitch
et al. (1999) American Journal of Physiology 276:C1132-C1138, Liu
et al. (1999) Molecular and Cell Biology 19:3029-3038, and such as
those cited in various reviews, for example, Ciechanover et al.
(1994) The FASEB Journal 8:182-192, Chiechanover (1994) Biol. Chem.
Hoppe-Seyler 375:565-581, Hershko et al. (1998) Annual Review of
Biochemistry 67:425-479, Swartz (1999) Annual Review of Medicine
50:57-74, Ciechanover (1998) EMBO Journal 17:7151-7160, and
D'Andrea et al. (1998) Critical Reviews in Biochemistry and
Molecular Biology 33:337-352. These assays include, but are not
limited to, the disappearance of substrate, including a decrease in
the amount of polyubiquitin or ubiquitinated substrate protein or
protein remnant, appearance of intermediate and end products, such
as appearance of free ubiquitin monomers, general protein turnover,
specific protein turnover, ubiquitin binding, binding to
ubiquitinated substrate protein, subunit interaction, interaction
with ATP, interaction with cellular components such as trans-acting
regulatory factors, stabilization of specific proteins, and the
like.
[0608] For example, in order to identify a polypeptide having
ubiquitin carboxy-terminal hydrolase activity in vitro, a reporter
protein (e.g., green fluorescent protein or galactosidase) is
engineered as a translation fusion with an amino-terminal ubiquitin
moiety. The substrate is incubated in solution with a polypeptide
such as 23436 or a fragment thereof suspected of having ubiquitin
specific protease activity. The production of free ubiquitin or the
de-ubiquitinated reporter protein can be determined, e.g., by PAGE
electrophoresis and comparison to a control incubation lacking the
23436 polypeptide (Zhu et al. (1997) Journal of Biological
Chemistry 272:51-57). A similar assay can be performed using a
reporter polypeptide having a lysine side chain to which a
ubiquitin moiety is conjugated.
[0609] The test compounds of the present invention can be obtained
using any of the numerous approaches in combinatorial library
methods known in the art, including: biological libraries; peptoid
libraries (libraries of molecules having the functionalities of
peptides, but with a novel, non-peptide backbone which are
resistant to enzymatic degradation but which nevertheless remain
bioactive; see, e.g., Zuckermann, R. N. et al. (1994) J. Med. Chem.
37:2678-85); spatially addressable parallel solid phase or solution
phase libraries; synthetic library methods requiring deconvolution;
the `one-bead one-compound` library method; and synthetic library
methods using affinity chromatography selection. The biological
library and peptoid library approaches are limited to peptide
libraries, while the other four approaches are applicable to
peptide, non-peptide oligomer or small molecule libraries of
compounds (Lam (1997) Anticancer Drug Des. 12:145).
[0610] Examples of methods for the synthesis of molecular libraries
can be found in the art, for example in: DeWitt et al. (1993) Proc.
Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl.
Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem.
37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994)
Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew.
Chem. Int. Ed. Engl. 33:2061; and Gallop et al. (1994) J. Med.
Chem. 37:1233.
[0611] Libraries of compounds may be presented in solution (e.g.,
Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991)
Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556),
bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner U.S.
Pat. No. 5,223,409), plasmids (Cull et al. (1992) Proc Natl Acad
Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science
249:386-390; Devlin (1990) Science 249:404-406; Cwirla et al.
(1990) Proc. Natl. Acad. Sci. 87:6378-6382; Felici (1991) J. Mol.
Biol. 222:301-310; Ladner supra.).
[0612] In one embodiment, an assay is a cell-based assay in which a
cell which expresses a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 protein or biologically active portion thereof is
contacted with a test compound, and the ability of the test
compound to modulate 53070, 15985, 26583, 21953, m32404, 14089, or
23436 activity is determined. Determining the ability of the test
compound to modulate 53070 activity can be accomplished by
monitoring, for example, substrate phosphorylation. Determining the
ability of the test compound to modulate 15985 activity can be
accomplished by monitoring, for example, protein kinase activity
and/or microtubule binding. Determining the ability of the test
compound to modulate 26583 activity can be accomplished by
monitoring, for example, serine/threonine phosphatase activity.
Determining the ability of the test compound to modulate 21953
activity can be accomplished by monitoring, for example, prolyl
oligopeptidase activity. Determining the ability of the test
compound to modulate m32404 activity can be accomplished by
monitoring, for example, trypsin protease activity. Determining the
ability of the test compound to modulate 14089 activity can be
accomplished by monitoring, for example, protease activity.
Determining the ability of the test compound to modulate 23436
activity can be accomplished by monitoring, for example,
de-ubiquitinating activity.
[0613] The cell, for example, can be of mammalian origin, e.g.,
human.
[0614] The ability of the test compound to modulate 53070, 15985,
26583, 21953, m32404, 14089, or 23436 binding to a compound, e.g.,
a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 substrate, or
to bind to 53070, 15985, 26583, 21953, m32404, 14089, or 23436 can
also be evaluated. This can be accomplished, for example, by
coupling the compound, e.g., the substrate, with a radioisotope or
enzymatic label such that binding of the compound, e.g., the
substrate, to 53070, 15985, 26583, 21953, m32404, 14089, or 23436
can be determined by detecting the labeled compound, e.g.,
substrate, in a complex. Alternatively, 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 could be coupled with a radioisotope or
enzymatic label to monitor the ability of a test compound to
modulate 53070, 15985, 26583, 21953, m32404, 14089, or 23436
binding to a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
substrate in a complex. For example, compounds (e.g., 53070, 15985,
26583, 21953, m32404, 14089, or 23436 substrates) can be labeled
with .sup.125I, .sup.35S, .sup.14C, or .sup.3H, either directly or
indirectly, and the radioisotope detected by direct counting of
radioemmission or by scintillation counting. Alternatively,
compounds can be enzymatically labeled with, for example,
horseradish peroxidase, alkaline phosphatase, or luciferase, and
the enzymatic label detected by determination of conversion of an
appropriate substrate to product.
[0615] The ability of a compound (e.g., a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 substrate) to interact with 53070,
15985, 26583, 21953, m32404, 14089, or 23436 with or without the
labeling of any of the interactants can be evaluated. For example,
a microphysiometer can be used to detect the interaction of a
compound with 53070, 15985, 26583, 21953, m32404, 14089, or 23436
without the labeling of either the compound or the 53070, 15985,
26583, 21953, m32404, 14089, or 23436. McConnell, H. M. et al.
(1992) Science 257:1906-1912. As used herein, a "microphysiometer"
(e.g., Cytosensor) is an analytical instrument that measures the
rate at which a cell acidifies its environment using a
light-addressable potentiometric sensor (LAPS). Changes in this
acidification rate can be used as an indicator of the interaction
between a compound and 53070, 15985, 26583, 21953, m32404, 14089,
or 23436.
[0616] In yet another embodiment, a cell-free assay is provided in
which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
or biologically active portion thereof is contacted with a test
compound and the ability of the test compound to bind to the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein or
biologically active portion thereof is evaluated. Preferred
biologically active portions of the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 proteins to be used in assays of the
present invention include fragments which participate in
interactions with non-53070, 15985, 26583, 21953, m32404, 14089, or
23436 molecules, e.g., fragments with high surface probability
scores.
[0617] Soluble and/or membrane-bound forms of isolated proteins
(e.g., 53070, 15985, 26583, 21953, m32404, 14089, or 23436 proteins
or biologically active portions thereof) can be used in the
cell-free assays of the invention. When membrane-bound forms of the
protein are used, it may be desirable to utilize a solubilizing
agent. Examples of such solubilizing agents include non-ionic
detergents such as n-octylglucoside, n-dodecylglucoside,
n-dodecylmaltoside, octanoyl-N-methylglucamide,
decanoyl-N-methylglucamide, Triton.RTM. X-100, Triton.RTM. X-114,
Thesit.RTM., Isotridecypoly(ethylene glycol ether).sub.n,
3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS),
3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane
sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane
sulfonate.
[0618] Cell-free assays involve preparing a reaction mixture of the
target gene protein and the test compound under conditions and for
a time sufficient to allow the two components to interact and bind,
thus forming a complex that can be removed and/or detected.
[0619] The interaction between two molecules can also be detected,
e.g., using fluorescence energy transfer (FET) (see, for example,
Lakowicz et al., U.S. Pat. No. 5,631,169; Stavrianopoulos, et al.,
U.S. Pat. No. 4,868,103). A fluorophore label on the first, `donor`
molecule is selected such that its emitted fluorescent energy will
be absorbed by a fluorescent label on a second, `acceptor`
molecule, which in turn is able to fluoresce due to the absorbed
energy. Alternately, the `donor` protein molecule may simply
utilize the natural fluorescent energy of tryptophan residues.
Labels are chosen that emit different wavelengths of light, such
that the `acceptor` molecule label may be differentiated from that
of the `donor`. Since the efficiency of energy transfer between the
labels is related to the distance separating the molecules, the
spatial relationship between the molecules can be assessed. In a
situation in which binding occurs between the molecules, the
fluorescent emission of the `acceptor` molecule label in the assay
should be maximal. An FET binding event can be conveniently
measured through standard fluorometric detection means well known
in the art (e.g., using a fluorimeter).
[0620] In another embodiment, determining the ability of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein to bind to a
target molecule can be accomplished using real-time Biomolecular
Interaction Analysis (BIA) (see, e.g., Sjolander, S. and
Urbaniczky, C. (1991) Anal. Chem. 63:2338-2345 and Szabo et al.
(1995) Curr. Opin. Struct. Biol. 5:699-705). "Surface plasmon
resonance" or "BIA" detects biospecific interactions in real time,
without labeling any of the interactants (e.g., BIAcore). Changes
in the mass at the binding surface (indicative of a binding event)
result in alterations of the refractive index of light near the
surface (the optical phenomenon of surface plasmon resonance
(SPR)), resulting in a detectable signal which can be used as an
indication of real-time reactions between biological molecules.
[0621] In one embodiment, the target gene product or the test
substance is anchored onto a solid phase. The target gene
product/test compound complexes anchored on the solid phase can be
detected at the end of the reaction. Preferably, the target gene
product can be anchored onto a solid surface, and the test
compound, (which is not anchored), can be labeled, either directly
or indirectly, with detectable labels discussed herein.
[0622] It may be desirable to immobilize either 53070, 15985,
26583, 21953, m32404, 14089, or 23436, an anti-53070, -15985,
-26583, -21953, -m32404, -14089, or -23436 antibody or its target
molecule to facilitate separation of complexed from uncomplexed
forms of one or both of the proteins, as well as to accommodate
automation of the assay. Binding of a test compound to a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein, or
interaction of a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein with a target molecule in the presence and absence of
a candidate compound, can be accomplished in any vessel suitable
for containing the reactants. Examples of such vessels include
microtiter plates, test tubes, and micro-centrifuge tubes. In one
embodiment, a fusion protein can be provided which adds a domain
that allows one or both of the proteins to be bound to a matrix.
For example, glutathione-S-transferase/53070, 15985, 26583, 21953,
m32404, 14089, or 23436 fusion proteins or
glutathione-S-transferase/target fusion proteins can be adsorbed
onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.)
or glutathione derivatized microtiter plates, which are then
combined with the test compound or the test compound and either the
non-adsorbed target protein or 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein, and the mixture incubated under conditions
conducive to complex formation (e.g., at physiological conditions
for salt and pH). Following incubation, the beads or microtiter
plate wells are washed to remove any unbound components, the matrix
immobilized in the case of beads, complex determined either
directly or indirectly, for example, as described above.
Alternatively, the complexes can be dissociated from the matrix,
and the level of 53070, 15985, 26583, 21953, m32404, 14089, or
23436 binding or activity determined using standard techniques.
[0623] Other techniques for immobilizing either a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein or a target molecule
on matrices include using conjugation of biotin and streptavidin.
Biotinylated 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein or target molecules can be prepared from biotin-NHS
(N-hydroxy-succinimide) using techniques known in the art (e.g.,
biotinylation kit, Pierce Chemicals, Rockford, Ill.), and
immobilized in the wells of streptavidin-coated 96 well plates
(Pierce Chemical).
[0624] In order to conduct the assay, the non-immobilized component
is added to the coated surface containing the anchored component.
After the reaction is complete, unreacted components are removed
(e.g., by washing) under conditions such that any complexes formed
will remain immobilized on the solid surface. The detection of
complexes anchored on the solid surface can be accomplished in a
number of ways. Where the previously non-immobilized component is
pre-labeled, the detection of label immobilized on the surface
indicates that complexes were formed. Where the previously
non-immobilized component is not pre-labeled, an indirect label can
be used to detect complexes anchored on the surface; e.g., using a
labeled antibody specific for the immobilized component (the
antibody, in turn, can be directly labeled or indirectly labeled
with, e.g., a labeled anti-Ig antibody).
[0625] In one embodiment, this assay is performed utilizing
antibodies reactive with 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 protein or target molecules but which do not interfere
with binding of the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein to its target molecule. Such antibodies can be
derivatized to the wells of the plate, and unbound target or 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein trapped in the
wells by antibody conjugation. Methods for detecting such
complexes, in addition to those described above for the
GST-immobilized complexes, include immunodetection of complexes
using antibodies reactive with the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein or target molecule, as well as
enzyme-linked assays which rely on detecting an enzymatic activity
associated with the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 protein or target molecule.
[0626] Alternatively, cell free assays can be conducted in a liquid
phase. In such an assay, the reaction products are separated from
unreacted components, by any of a number of standard techniques,
including but not limited to: differential centrifugation (see, for
example, Rivas, G., and Minton, A. P., (1993) Trends Biochem Sci
18:284-7); chromatography (gel filtration chromatography,
ion-exchange chromatography); electrophoresis (see, e.g., Ausubel,
F. et al., eds. Current Protocols in Molecular Biology 1999, J.
Wiley: New York.); and immunoprecipitation (see, for example,
Ausubel, F. et al., eds. (1999) Current Protocols in Molecular
Biology, J. Wiley: New York). Such resins and chromatographic
techniques are known to one skilled in the art (see, e.g.,
Heegaard, N. H., (1998) J Mol Recognit 11:141-8; Hage, D. S., and
Tweed, S. A. (1997) J Chromatogr B Biomed Sci Appl. 699:499-525).
Further, fluorescence energy transfer may also be conveniently
utilized, as described herein, to detect binding without further
purification of the complex from solution.
[0627] In a preferred embodiment, the assay includes contacting the
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein or
biologically active portion thereof with a known compound which
binds 53070, 15985, 26583, 21953, m32404, 14089, or 23436 to form
an assay mixture, contacting the assay mixture with a test
compound, and determining the ability of the test compound to
interact with a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein, wherein determining the ability of the test compound to
interact with a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein includes determining the ability of the test compound to
preferentially bind to 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 or biologically active portion thereof, or to modulate the
activity of a target molecule, as compared to the known
compound.
[0628] The target gene products of the invention can, in vivo,
interact with one or more cellular or extracellular macromolecules,
such as proteins. For the purposes of this discussion, such
cellular and extracellular macromolecules are referred to herein as
"binding partners." Compounds that disrupt such interactions can be
useful in regulating the activity of the target gene product. Such
compounds can include, but are not limited to molecules such as
antibodies, peptides, and small molecules. The preferred target
genes/products for use in this embodiment are the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 genes herein identified. In
an alternative embodiment, the invention provides methods for
determining the ability of the test compound to modulate the
activity of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein through modulation of the activity of a downstream effector
of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 target
molecule. For example, the activity of the effector molecule on an
appropriate target can be determined, or the binding of the
effector to an appropriate target can be determined, as previously
described.
[0629] To identify compounds that interfere with the interaction
between the target gene product and its cellular or extracellular
binding partner(s), a reaction mixture containing the target gene
product and the binding partner is prepared, under conditions and
for a time sufficient, to allow the two products to form complex.
In order to test an inhibitory agent, the reaction mixture is
provided in the presence and absence of the test compound. The test
compound can be initially included in the reaction mixture, or can
be added at a time subsequent to the addition of the target gene
and its cellular or extracellular binding partner. Control reaction
mixtures are incubated without the test compound or with a placebo.
The formation of any complexes between the target gene product and
the cellular or extracellular binding partner is then detected. The
formation of a complex in the control reaction, but not in the
reaction mixture containing the test compound, indicates that the
compound interferes with the interaction of the target gene product
and the interactive binding partner. Additionally, complex
formation within reaction mixtures containing the test compound and
normal target gene product can also be compared to complex
formation within reaction mixtures containing the test compound and
mutant target gene product. This comparison can be important in
those cases wherein it is desirable to identify compounds that
disrupt interactions of mutant but not normal target gene
products.
[0630] These assays can be conducted in a heterogeneous or
homogeneous format. Heterogeneous assays involve anchoring either
the target gene product or the binding partner onto a solid phase,
and detecting complexes anchored on the solid phase at the end of
the reaction. In homogeneous assays, the entire reaction is carried
out in a liquid phase. In either approach, the order of addition of
reactants can be varied to obtain different information about the
compounds being tested. For example, test compounds that interfere
with the interaction between the target gene products and the
binding partners, e.g., by competition, can be identified by
conducting the reaction in the presence of the test substance.
Alternatively, test compounds that disrupt preformed complexes,
e.g., compounds with higher binding constants that displace one of
the components from the complex, can be tested by adding the test
compound to the reaction mixture after complexes have been formed.
The various formats are briefly described below.
[0631] In a heterogeneous assay system, either the target gene
product or the interactive cellular or extracellular binding
partner, is anchored onto a solid surface (e.g., a microtiter
plate), while the non-anchored species is labeled, either directly
or indirectly. The anchored species can be immobilized by
non-covalent or covalent attachments. Alternatively, an immobilized
antibody specific for the species to be anchored can be used to
anchor the species to the solid surface.
[0632] In order to conduct the assay, the partner of the
immobilized species is exposed to the coated surface with or
without the test compound. After the reaction is complete,
unreacted components are removed (e.g., by washing) and any
complexes formed will remain immobilized on the solid surface.
Where the non-immobilized species is pre-labeled, the detection of
label immobilized on the surface indicates that complexes were
formed. Where the non-immobilized species is not pre-labeled, an
indirect label can be used to detect complexes anchored on the
surface; e.g., using a labeled antibody specific for the initially
non-immobilized species (the antibody, in turn, can be directly
labeled or indirectly labeled with, e.g., a labeled anti-Ig
antibody). Depending upon the order of addition of reaction
components, test compounds that inhibit complex formation or that
disrupt preformed complexes can be detected.
[0633] Alternatively, the reaction can be conducted in a liquid
phase in the presence or absence of the test compound, the reaction
products separated from unreacted components, and complexes
detected; e.g., using an immobilized antibody specific for one of
the binding components to anchor any complexes formed in solution,
and a labeled antibody specific for the other partner to detect
anchored complexes. Again, depending upon the order of addition of
reactants to the liquid phase, test compounds that inhibit complex
or that disrupt preformed complexes can be identified.
[0634] In an alternate embodiment of the invention, a homogeneous
assay can be used. For example, a preformed complex of the target
gene product and the interactive cellular or extracellular binding
partner product is prepared in that either the target gene products
or their binding partners are labeled, but the signal generated by
the label is quenched due to complex formation (see, e.g., U.S.
Pat. No. 4,109,496 that utilizes this approach for immunoassays).
The addition of a test substance that competes with and displaces
one of the species from the preformed complex will result in the
generation of a signal above background. In this way, test
substances that disrupt target gene product-binding partner
interaction can be identified.
[0635] In yet another aspect, the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 proteins can be used as "bait proteins" in
a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No.
5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al.
(1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993)
Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene
8:1693-1696; and Brent WO94/10300), to identify other proteins,
which bind to or interact with 53070, 15985, 26583, 21953, m32404,
14089, or 23436 ("53070-, 15985-, 26583-, 21953-, m32404-, 14089-,
or 23436-binding proteins" or "53070-, 15985-, 26583-, 21953-,
m32404-, 14089-, or 23436-bp") and are involved in 53070, 15985,
26583, 21953, m32404, 14089, or 23436 activity. Such 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-bps can be
activators or inhibitors of signals by the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 proteins or 53070, 15985, 26583,
21953, m32404, 14089, or 23436 targets as, for example, downstream
elements of a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-mediated signaling pathway.
[0636] The two-hybrid system is based on the modular nature of most
transcription factors, which consist of separable DNA-binding and
activation domains. Briefly, the assay utilizes two different DNA
constructs. In one construct, the gene that codes for a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein is fused to a
gene encoding the DNA binding domain of a known transcription
factor (e.g., GAL-4). In the other construct, a DNA sequence, from
a library of DNA sequences, that encodes an unidentified protein
("prey" or "sample") is fused to a gene that codes for the
activation domain of the known transcription factor. (Alternatively
the: 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
can be the fused to the activator domain.) If the "bait" and the
"prey" proteins are able to interact, in vivo, forming a 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-dependent
complex, the DNA-binding and activation domains of the
transcription factor are brought into close proximity. This
proximity allows transcription of a reporter gene (e.g., lacZ)
which is operably linked to a transcriptional regulatory site
responsive to the transcription factor. Expression of the reporter
gene can be detected and cell colonies containing the functional
transcription factor can be isolated and used to obtain the cloned
gene which encodes the protein which interacts with the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein.
[0637] In another embodiment, modulators of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 expression are identified. For
example, a cell or cell free mixture is contacted with a candidate
compound and the expression of 53070, 15985, 26583, 21953, m32404,
14089, or 23436 mRNA or protein evaluated relative to the level of
expression of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
mRNA or protein in the absence of the candidate compound. When
expression of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
mRNA or protein is greater in the presence of the candidate
compound than in its absence, the candidate compound is identified
as a stimulator of 53070, 15985, 26583, 21953, m32404, 14089, or
23436 mRNA or protein expression. Alternatively, when expression of
53070, 15985, 26583, 21953, m32404, 14089, or 23436 mRNA or protein
is less (statistically significantly less) in the presence of the
candidate compound than in its absence, the candidate compound is
identified as an inhibitor of 53070, 15985, 26583, 21953, m32404,
14089, or 23436 mRNA or protein expression. The level of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 mRNA or protein
expression can be determined by methods described herein for
detecting 53070, 15985, 26583, 21953, m32404, 14089, or 23436 mRNA
or protein.
[0638] In another aspect, the invention pertains to a combination
of two or more of the assays described herein. For example, a
modulating agent can be identified using a cell-based or a cell
free assay, and the ability of the agent to modulate the activity
of a 53070 protein can be confirmed in vivo, e.g., in an animal
such as an animal model for cellular proliferative and/or
differentiative disorder. For example, a modulating agent can be
identified using a cell-based or a cell free assay, and the ability
of the agent to modulate the activity of a 15985 protein can be
confirmed in vivo, e.g., in an animal such as an animal model for
neural migration defects, immune cell migration defects, or
metastasis. For example, a modulating agent can be identified using
a cell-based or a cell free assay, and the ability of the agent to
modulate the activity of a 26583 protein can be confirmed in vivo,
e.g., in an animal such as an animal model overexpressing a gene
encoding a protein serine/threonine kinase. For example, a
modulating agent can be identified using a cell-based or a cell
free assay, and the ability of the agent to modulate the activity
of a 21953 protein can be confirmed in vivo, e.g., in an animal
such as an animal model for a cell proliferative or cell
differentiative disorder, e.g., a cancer, e.g., a cancer of the
lung, prostate, breast, or colon; an animal model for an
immunological disorder; or an animal model for a neurological
disorder. For example, a modulating agent can be identified using a
cell-based or a cell free assay, and the ability of the agent to
modulate the activity of an m32404 protein can be confirmed in
vivo, e.g., in an animal such as an animal model for cancer. For
example, a modulating agent can be identified using a cell-based or
a cell free assay, and the ability of the agent to modulate the
activity of a 14089 protein can be confirmed in vivo, e.g., in an
animal such as an animal model for cancer. For example, a
modulating agent can be identified using a cell-based or a cell
free assay, and the ability of the agent to modulate the activity
of a 23436 protein can be confirmed in vivo, e.g., in an animal
such as an animal model for an erythroid cell disorder or a
proliferative disorder of erythroid, liver, prostate, or brain
cells.
[0639] This invention further pertains to novel agents identified
by the above-described screening assays. Accordingly, it is within
the scope of this invention to further use an agent identified as
described herein (e.g., a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 modulating agent, an antisense 53070, 15985, 26583,
21953, m32404, 14089, or 23436 nucleic acid molecule, a 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-specific
antibody, or a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-binding partner) in an appropriate animal model to determine
the efficacy, toxicity, side effects, or mechanism of action, of
treatment with such an agent. Furthermore, novel agents identified
by the above-described screening assays can be used for treatments
as described herein.
53070, 15985, 26583, 21953, m32404, 14089, and 23436 Detection
Assays
[0640] Portions or fragments of the nucleic acid sequences
identified herein can be used as polynucleotide reagents. For
example, these sequences can be used to: (i) map their respective
genes on a chromosome e.g., to locate gene regions associated with
genetic disease or to associate 53070, 15985, 26583, 21953, m32404,
14089, or 23436 with a disease; (ii) identify an individual from a
minute biological sample (tissue typing); and (iii) aid in forensic
identification of a biological sample. These applications are
described in the subsections below.
53070, 15985, 26583, 21953, m32404, 14089, and 23436 Chromosome
Mapping
[0641] The 53070, 15985, 26583, 21953, m32404, 14089, and 23436
nucleotide sequences or portions thereof can be used to map the
location of the 53070, 15985, 26583, 21953, m32404, 14089, and
23436 genes on a chromosome. This process is called chromosome
mapping. Chromosome mapping is useful in correlating the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 sequences with genes
associated with disease.
[0642] The 23436 nucleotide sequences or portions thereof can be
used to map the location of the 23436 genes on a chromosome,
particularly chromosome 1, e.g., chromosomal cytogenetic region
1p36. This process is called chromosome mapping. Chromosome mapping
is useful in correlating the 23436 sequences with genes associated
with disease such prostate cancer and/or brain cancer (see, e.g.,
Gibbs et al. (1999) Am. J. Hum. Genet. 64:776).
[0643] Briefly, 53070, 15985, 26583, 21953, m32404, 14089, or 23436
genes can be mapped to chromosomes by preparing PCR primers
(preferably 15-25 bp in length) from the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 nucleotide sequences. These primers
can then be used for PCR screening of somatic cell hybrids
containing individual human chromosomes. Only those hybrids
containing the human gene corresponding to the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 sequences will yield an amplified
fragment.
[0644] A panel of somatic cell hybrids in which each cell line
contains either a single human chromosome or a small number of
human chromosomes, and a full set of mouse chromosomes, can allow
easy mapping of individual genes to specific human chromosomes.
(D'Eustachio P. et al. (1983) Science 220:919-924).
[0645] Other mapping strategies e.g., in situ hybridization
(described in Fan, Y. et al. (1990) Proc. Natl. Acad. Sci. USA,
87:6223-27), pre-screening with labeled flow-sorted chromosomes,
and pre-selection by hybridization to chromosome specific cDNA
libraries can be used to map 53070, 15985, 26583, 21953, m32404,
14089, or 23436 to a chromosomal location.
[0646] Fluorescence in situ hybridization (FISH) of a DNA sequence
to a metaphase chromosomal spread can further be used to provide a
precise chromosomal location in one step. The FISH technique can be
used with a DNA sequence as short as 500 or 600 bases. However,
clones larger than 1,000 bases have a higher likelihood of binding
to a unique chromosomal location with sufficient signal intensity
for simple detection. Preferably 1,000 bases, and more preferably
2,000 bases will suffice to get good results at a reasonable amount
of time. For a review of this technique, see Verma et al., Human
Chromosomes: A Manual of Basic Techniques ((1988) Pergamon Press,
New York).
[0647] Reagents for chromosome mapping can be used individually to
mark a single chromosome or a single site on that chromosome, or
panels of reagents can be used for marking multiple sites and/or
multiple chromosomes. Reagents corresponding to noncoding regions
of the genes actually are preferred for mapping purposes. Coding
sequences are more likely to be conserved within gene families,
thus increasing the chance of cross hybridizations during
chromosomal mapping.
[0648] Once a sequence has been mapped to a precise chromosomal
location, the physical position of the sequence on the chromosome
can be correlated with genetic map data. (Such data are found, for
example, in V. McKusick, Mendelian Inheritance in Man, available
on-line through Johns Hopkins University Welch Medical Library).
The relationship between a gene and a disease, mapped to the same
chromosomal region, can then be identified through linkage analysis
(co-inheritance of physically adjacent genes), described in, for
example, Egeland, J. et al. (1987) Nature, 325:783-787.
[0649] Moreover, differences in the DNA sequences between
individuals affected and unaffected with a disease associated with
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene, can
be determined. If a mutation is observed in some or all of the
affected individuals but not in any unaffected individuals, then
the mutation is likely to be the causative agent of the particular
disease. Comparison of affected and unaffected individuals
generally involves first looking for structural alterations in the
chromosomes, such as deletions or translocations that are visible
from chromosome spreads or detectable using PCR based on that DNA
sequence. Ultimately, complete sequencing of genes from several
individuals can be performed to confirm the presence of a mutation
and to distinguish mutations from polymorphisms.
53070, 15985, 26583, 21953, m32404, 14089, and 23436 Tissue
Typing
[0650] 53070, 15985, 26583, 21953, m32404, 14089, or 23436
sequences can be used to identify individuals from biological
samples using, e.g., restriction fragment length polymorphism
(RFLP). In this technique, an individual's genomic DNA is digested
with one or more restriction enzymes, the fragments separated,
e.g., in a Southern blot, and probed to yield bands for
identification. The sequences of the present invention are useful
as additional DNA markers for RFLP (described in U.S. Pat. No.
5,272,057).
[0651] Furthermore, the sequences of the present invention can also
be used to determine the actual base-by-base DNA sequence of
selected portions of an individual's genome. Thus, the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 nucleotide sequences
described herein can be used to prepare two PCR primers from the 5'
and 3' ends of the sequences. These primers can then be used to
amplify an individual's DNA and subsequently sequence it. Panels of
corresponding DNA sequences from individuals, prepared in this
manner, can provide unique individual identifications, as each
individual will have a unique set of such DNA sequences due to
allelic differences.
[0652] Allelic variation occurs to some degree in the coding
regions of these sequences, and to a greater degree in the
noncoding regions. Each of the sequences described herein can, to
some degree, be used as a standard against which DNA from an
individual can be compared for identification purposes. Because
greater numbers of polymorphisms occur in the noncoding regions,
fewer sequences are necessary to differentiate individuals. The
noncoding sequences of SEQ ID NO:1, 7, 14, 19, 24, 33, or 40 can
provide positive individual identification with a panel of perhaps
10 to 1,000 primers which each yield a noncoding amplified sequence
of 100 bases. If predicted coding sequences, such as those in SEQ
ID NO:3, 9, 16, 21, 26, 35, or 42 are used, a more appropriate
number of primers for positive individual identification would be
500-2,000.
[0653] If a panel of reagents from 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleotide sequences described herein is
used to generate a unique identification database for an
individual, those same reagents can later be used to identify
tissue from that individual. Using the unique identification
database, positive identification of the individual, living or
dead, can be made from extremely small tissue samples.
Use of Partial 53070, 15985, 26583, 21953, m32404, 14089, or 23436
Sequences in Forensic Biology
[0654] DNA-based identification techniques can also be used in
forensic biology. To make such an identification, PCR technology
can be used to amplify DNA sequences taken from very small
biological samples such as tissues, e.g., hair or skin, or body
fluids, e.g., blood, saliva, or semen found at a crime scene. The
amplified sequence can then be compared to a standard, thereby
allowing identification of the origin of the biological sample.
[0655] The sequences of the present invention can be used to
provide polynucleotide reagents, e.g., PCR primers, targeted to
specific loci in the human genome, which can enhance the
reliability of DNA-based forensic identifications by, for example,
providing another "identification marker" (i.e. another DNA
sequence that is unique to a particular individual). As mentioned
above, actual base sequence information can be used for
identification as an accurate alternative to patterns formed by
restriction enzyme generated fragments. Sequences targeted to
noncoding regions of SEQ ID NO:1, 7, 14, 19, 24, 33, or 40 (e.g.,
fragments derived from the noncoding regions of SEQ ID NO:1, 7, 14,
19, 24, 33, or 40 having a length of at least 20 bases, preferably
at least 30 bases) are particularly appropriate for this use.
[0656] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleotide sequences described herein can further be used to
provide polynucleotide reagents, e.g., labeled or labelable probes
which can be used in, for example, an in situ hybridization
technique, to identify a specific tissue. This can be very useful
in cases where a forensic pathologist is presented with a tissue of
unknown origin. Panels of such 53070, 15985, 26583, 21953, m32404,
14089, or 23436 probes can be used to identify tissue by species
and/or by organ type.
[0657] The 26583 nucleotide sequences described herein can further
be used to provide polynucleotide reagents, e.g., labeled or
labelable probes which can be used in, for example, an in situ
hybridization technique, to identify a specific tissue, e.g., a
tissue containing 26583 serine/threonine phosphatase activity.
[0658] In a similar fashion, these reagents, e.g., 53070, 15985,
26583, 21953, m32404, 14089, or 23436 primers or probes can be used
to screen tissue culture for contamination (i.e. screen for the
presence of a mixture of different types of cells in a
culture).
Predictive Medicine of 53070, 15985, 26583, 21953, m32404, 14089,
or 23436
[0659] The present invention also pertains to the field of
predictive medicine in which diagnostic assays, prognostic assays,
and monitoring clinical trials are used for prognostic (predictive)
purposes to thereby treat an individual.
[0660] Generally, the invention provides, a method of determining
if a subject is at risk for a disorder related to a lesion in or
the misexpression of a gene which encodes 53070, 15985, 26583,
21953, m32404, 14089, or 23436.
[0661] Such disorders include, e.g., a disorder associated with the
misexpression of 53070 gene, such as a cellular proliferative
and/or differentiative disorder; a disorder associated with the
misexpression of 15985 gene, e.g., a cancer, a neurological or a
cardiovascular (e.g., blood vessel) disorder; a disorder associated
with the misexpression of 21953 gene, a disorder of cell
proliferation (such as lung, breast, colon, prostate, or ovarian
cancer) or of the nervous system; a disorder associated with the
misexpression of the m32404 gene, a disorder of cell
differentiation or proliferation, or of the immune system or blood
clotting system; a disorder associated with the misexpression of
14089 gene, a disorder of the complement system; and a disorder
associated with the misexpression of 23436 gene, a disorder of the
hematopoietic system, e.g., of erythroid cells or erythroid cell
precursors.
[0662] The method includes one or more of the following:
[0663] detecting, in a tissue of the subject, the presence or
absence of a mutation which affects the expression of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 gene, or detecting the
presence or absence of a mutation in a region which controls the
expression of the gene, e.g., a mutation in the 5' control
region;
[0664] detecting, in a tissue of the subject, the presence or
absence of a mutation which alters the structure of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 gene;
[0665] detecting, in a tissue of the subject, the misexpression of
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene, at
the mRNA level, e.g., detecting a non-wild type level of a
mRNA;
[0666] detecting, in a tissue of the subject, the misexpression of
the gene, at the protein level, e.g., detecting a non-wild type
level of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
polypeptide.
[0667] In preferred embodiments the method includes: ascertaining
the existence of at least one of: a deletion of one or more
nucleotides from the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 gene; an insertion of one or more nucleotides into the gene,
a point mutation, e.g., a substitution of one or more nucleotides
of the gene, a gross chromosomal rearrangement of the gene, e.g., a
translocation, inversion, or deletion.
[0668] For example, detecting the genetic lesion can include: (i)
providing a probe/primer including an oligonucleotide containing a
region of nucleotide sequence which hybridizes to a sense or
antisense sequence from SEQ ID NO:1, 7, 14, 19, 24, 33, or 40, or
naturally occurring mutants thereof or 5' or 3' flanking sequences
naturally associated with the 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene; (ii) exposing the probe/primer to nucleic
acid of the tissue; and detecting, by hybridization, e.g., in situ
hybridization, of the probe/primer to the nucleic acid, the
presence or absence of the genetic lesion.
[0669] In preferred embodiments detecting the misexpression
includes ascertaining the existence of at least one of: an
alteration in the level of a messenger RNA transcript of the 53070,
15985, 26583, 21953, m32404, 14089, or 23436 gene; the presence of
a non-wild type splicing pattern of a messenger RNA transcript of
the gene; or a non-wild type level of 53070, 15985, 26583, 21953,
m32404, 14089, or 23436.
[0670] Methods of the invention can be used prenatally or to
determine if a subject's offspring will be at risk for a
disorder.
[0671] In preferred embodiments the method includes determining the
structure of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
gene, an abnormal structure being indicative of risk for the
disorder.
[0672] In preferred embodiments the method includes contacting a
sample from the subject with an antibody to the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein or a nucleic acid,
which hybridizes specifically with the gene. These and other
embodiments are discussed below.
Diagnostic and Prognostic Assays of 53070, 15985, 26583, 21953,
m32404, 14089, or 23436
[0673] Diagnostic and prognostic assays of the invention include
method for assessing the expression level of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 molecules and for identifying
variations and mutations in the sequence of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 molecules.
[0674] Expression Monitoring and Profiling:
[0675] The presence, level, or absence of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein or nucleic acid in a
biological sample can be evaluated by obtaining a biological sample
from a test subject and contacting the biological sample with a
compound or an agent capable of detecting 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein or nucleic acid (e.g., mRNA,
genomic DNA) that encodes 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein such that the presence of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein or nucleic acid is
detected in the biological sample. The term "biological sample"
includes tissues, cells and biological fluids isolated from a
subject, as well as tissues, cells and fluids present within a
subject. A preferred biological sample is serum. The level of
expression of the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 gene can be measured in a number of ways, including, but not
limited to: measuring the mRNA encoded by the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 genes; measuring the amount of
protein encoded by the 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 genes; or measuring the activity of the protein encoded by
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436 genes.
[0676] The level of mRNA corresponding to the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 gene in a cell can be determined
both by in situ and by in vitro formats.
[0677] The isolated mRNA can be used in hybridization or
amplification assays that include, but are not limited to, Southern
or Northern analyses, polymerase chain reaction analyses and probe
arrays. One preferred diagnostic method for the detection of mRNA
levels involves contacting the isolated mRNA with a nucleic acid
molecule (probe) that can hybridize to the mRNA encoded by the gene
being detected. The nucleic acid probe can be, for example, a
full-length 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid, such as the nucleic acid of SEQ ID NO:1, 7, 14, 19,
24, 33, or 40, respectively, or a portion thereof, such as an
oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500
nucleotides in length and sufficient to specifically hybridize
under stringent conditions to 53070, 15985, 26583, 21953, m32404,
14089, or 23436 mRNA or genomic DNA. The probe can be disposed on
an address of an array, e.g., an array described below. Other
suitable probes for use in the diagnostic assays are described
herein.
[0678] In one format, mRNA (or cDNA) is immobilized on a surface
and contacted with the probes, for example by running the isolated
mRNA on an agarose gel and transferring the mRNA from the gel to a
membrane, such as nitrocellulose. In an alternative format, the
probes are immobilized on a surface and the mRNA (or cDNA) is
contacted with the probes, for example, in a two-dimensional gene
chip array described below. A skilled artisan can adapt known mRNA
detection methods for use in detecting the level of mRNA encoded by
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436 genes.
[0679] The level of mRNA in a sample that is encoded by one of
53070, 15985, 26583, 21953, m32404, 14089, or 23436 can be
evaluated with nucleic acid amplification, e.g., by rtPCR (Mullis
(1987) U.S. Pat. No. 4,683,202), ligase chain reaction (Barany
(1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained
sequence replication (Guatelli et al., (1990) Proc. Natl. Acad.
Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh
et al., (1989), Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta
Replicase (Lizardi et al., (1988) Bio/Technology 6:1197), rolling
circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any
other nucleic acid amplification method, followed by the detection
of the amplified molecules using techniques known in the art. As
used herein, amplification primers are defined as being a pair of
nucleic acid molecules that can anneal to 5' or 3' regions of a
gene (plus and minus strands, respectively, or vice-versa) and
contain a short region in between. In general, amplification
primers are from about 10 to 30 nucleotides in length and flank a
region from about 50 to 200 nucleotides in length. Under
appropriate conditions and with appropriate reagents, such primers
permit the amplification of a nucleic acid molecule comprising the
nucleotide sequence flanked by the primers.
[0680] For in situ methods, a cell or tissue sample can be
prepared/processed and immobilized on a support, typically a glass
slide, and then contacted with a probe that can hybridize to mRNA
that encodes the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 gene being analyzed.
[0681] In another embodiment, the methods further contacting a
control sample with a compound or agent capable of detecting 53070,
15985, 26583, 21953, m32404, 14089, or 23436 mRNA, or genomic DNA,
and comparing the presence of 53070, 15985, 26583, 21953, m32404,
14089, or 23436 mRNA or genomic DNA in the control sample with the
presence of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
mRNA or genomic DNA in the test sample. In still another
embodiment, serial analysis of gene expression, as described in
U.S. Pat. No. 5,695,937, is used to detect 53070, 15985, 26583,
21953, m32404, 14089, or 23436 transcript levels.
[0682] A variety of methods can be used to determine the level of
protein encoded by 53070, 15985, 26583, 21953, m32404, 14089, or
23436. In general, these methods include contacting an agent that
selectively binds to the protein, such as an antibody with a
sample, to evaluate the level of protein in the sample. In a
preferred embodiment, the antibody bears a detectable label.
Antibodies can be polyclonal, or more preferably, monoclonal. An
intact antibody, or a fragment thereof (e.g., Fab or F(ab').sub.2)
can be used. The term "labeled", with regard to the probe or
antibody, is intended to encompass direct labeling of the probe or
antibody by coupling (i.e., physically linking) a detectable
substance to the probe or antibody, as well as indirect labeling of
the probe or antibody by reactivity with a detectable substance.
Examples of detectable substances are provided herein.
[0683] The detection methods can be used to detect 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein in a biological
sample in vitro as well as in vivo. In vitro techniques for
detection of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein include enzyme linked immunosorbent assays (ELISAs),
immunoprecipitations, immunofluorescence, enzyme immunoassay (EIA),
radioimmunoassay (RIA), and Western blot analysis. In vivo
techniques for detection of 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein include introducing into a subject a
labeled anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibody. For example, the antibody can be labeled with a
radioactive marker whose presence and location in a subject can be
detected by standard imaging techniques. In another embodiment, the
sample is labeled, e.g., biotinylated and then contacted to the
antibody, e.g., an anti-53070, -15985, -26583, -21953, -m32404,
-14089, or -23436 antibody positioned on an antibody array (as
described below). The sample can be detected, e.g., with avidin
coupled to a fluorescent label.
[0684] In another embodiment, the methods further include
contacting the control sample with a compound or agent capable of
detecting 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein, and comparing the presence of 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 protein in the control sample with the
presence of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein in the test sample.
[0685] The invention also includes, kits for detecting the presence
of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 in a
biological sample. For example, the kit can include a compound or
agent capable of detecting 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein or mRNA in a biological sample; and a
standard. The compound or agent can be packaged in a suitable
container. The kit can further comprise instructions for using the
kit to detect 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein or nucleic acid.
[0686] For antibody-based kits, the kit can include: (1) a first
antibody (e.g., attached to a solid support) which binds to a
polypeptide corresponding to a marker of the invention; and,
optionally, (2) a second, different antibody which binds to either
the polypeptide or the first antibody and is conjugated to a
detectable agent.
[0687] For oligonucleotide-based kits, the kit can include: (1) an
oligonucleotide, e.g., a detectably labeled oligonucleotide, which
hybridizes to a nucleic acid sequence encoding a polypeptide
corresponding to a marker of the invention or (2) a pair of primers
useful for amplifying a nucleic acid molecule corresponding to a
marker of the invention. The kit can also includes a buffering
agent, a preservative, or a protein stabilizing agent. The kit can
also includes components necessary for detecting the detectable
agent (e.g., an enzyme or a substrate). The kit can also contain a
control sample or a series of control samples which can be assayed
and compared to the test sample contained. Each component of the
kit can be enclosed within an individual container and all of the
various containers can be within a single package, along with
instructions for interpreting the results of the assays performed
using the kit.
[0688] The diagnostic methods described herein can identify
subjects having, or at risk of developing, a disease or disorder
associated with misexpressed or aberrant or unwanted 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression or activity. As
used herein, the term "unwanted" includes an unwanted phenomenon
involved in a biological response such as deregulated cell
proliferation; pain; a cell proliferative or cell differentiative
disorder, e.g., a cancer, e.g., a cancer of the lung, prostate,
breast, or colon or deregulated cell proliferation; or cell
proliferation, cell differentiation, coagulation, or cell
signaling.
[0689] In one embodiment, a disease or disorder associated with
aberrant or unwanted 53070, 15985, 26583, 21953, m32404, 14089, or
23436 expression or activity is identified. A test sample is
obtained from a subject and 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein or nucleic acid (e.g., mRNA or genomic DNA)
is evaluated, wherein the level, e.g., the presence or absence, of
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein or
nucleic acid is diagnostic for a subject having or at risk of
developing a disease or disorder associated with aberrant or
unwanted 53070, 15985, 26583, 21953, m32404, 14089, or 23436
expression or activity. As used herein, a "test sample" refers to a
biological sample obtained from a subject of interest, including a
biological fluid (e.g., serum), cell sample, or tissue.
[0690] The prognostic assays described herein can be used to
determine whether a subject can be administered an agent (e.g., an
agonist, antagonist, peptidomimetic, protein, peptide, nucleic
acid, small molecule, or other drug candidate) to treat a disease
or disorder associated with aberrant or unwanted 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression or activity. For
example, such methods can be used to determine whether a subject
can be effectively treated with an agent for a cellular
proliferative and/or differentiative disorder; a cell motility
disorder; a metabolic disorder, e.g., a mitochondrial related
disorder or a cholesterol biosynthesis related disorder, or a cell
proliferation or differentiation disorder, e.g., a tumor; a cell
proliferative or cell differentiative disorder, e.g., a cancer,
e.g., a cancer of the lung, prostate, breast, or colon disorder;
cell proliferation, cell differentiation, coagulation, or cell
signaling; or an erythroid cell disorder or a proliferative
disorder of erythroid, liver, prostate, or brain cells.
[0691] In another aspect, the invention features a computer medium
having a plurality of digitally encoded data records. Each data
record includes a value representing the level of expression of
53070, 15985, 26583, 21953, m32404, 14089, or 23436 in a sample,
and a descriptor of the sample. The descriptor of the sample can be
an identifier of the sample, a subject from which the sample was
derived (e.g., a patient), a diagnosis, or a treatment (e.g., a
preferred treatment). In a preferred embodiment, the data record
further includes values representing the level of expression of
genes other than 53070, 15985, 26583, 21953, m32404, 14089, or
23436 (e.g., other genes associated with a 53070-, 15985-, 26583-,
21953-, m32404-, 14089-, or 23436-disorder, or other genes on an
array). The data record can be structured as a table, e.g., a table
that is part of a database such as a relational database (e.g., a
SQL database of the Oracle or Sybase database environments).
[0692] Also featured is a method of evaluating a sample. The method
includes providing a sample, e.g., from the subject, and
determining a gene expression profile of the sample, wherein the
profile includes a value representing the level of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression. The method can
further include comparing the value or the profile (i.e., multiple
values) to a reference value or reference profile. The gene
expression profile of the sample can be obtained by any of the
methods described herein (e.g., by providing a nucleic acid from
the sample and contacting the nucleic acid to an array). The method
can be used to diagnose a disorder, e.g., a cellular proliferative
and/or differentiative disorder; a metabolic disorder, e.g., a
mitochondrial related disorder or a cholesterol biosynthesis
related disorder, or a cell proliferation or differentiation
disorder, e.g., a tumor; a cell proliferative or cell
differentiative disorder, e.g., a cancer, e.g., a cancer of the
lung; or an erythroid cell disorder or a proliferative disorder of
erythroid, liver, prostate, or brain cells, in a subject wherein
either an increase or a decrease in 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 expression may be an indication that the
subject has or is disposed to having a the disorder. The method can
be used to monitor a treatment for a disorder in a subject. For
example, the gene expression profile can be determined for a sample
from a subject undergoing treatment. The profile can be compared to
a reference profile or to a profile obtained from the subject prior
to treatment or prior to onset of the disorder (see, e.g., Golub et
al. (1999) Science 286:531).
[0693] In yet another aspect, the invention features a method of
evaluating a test compound (see also, "Screening Assays", above).
The method includes providing a cell and a test compound;
contacting the test compound to the cell; obtaining a subject
expression profile for the contacted cell; and comparing the
subject expression profile to one or more reference profiles. The
profiles include a value representing the level of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression. In a preferred
embodiment, the subject expression profile is compared to a target
profile, e.g., a profile for a normal cell or for desired condition
of a cell. The test compound is evaluated favorably if the subject
expression profile is more similar to the target profile than an
expression profile obtained from an uncontacted cell.
[0694] In another aspect, the invention features, a method of
evaluating a subject. The method includes: a) obtaining a sample
from a subject, e.g., from a caregiver, e.g., a caregiver who
obtains the sample from the subject; b) determining a subject
expression profile for the sample. Optionally, the method further
includes either or both of steps: c) comparing the subject
expression profile to one or more reference expression profiles;
and d) selecting the reference profile most similar to the subject
reference profile. The subject expression profile and the reference
profiles include a value representing the level of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression. A variety of
routine statistical measures can be used to compare two reference
profiles. One possible metric is the length of the distance vector
that is the difference between the two profiles. Each of the
subject and reference profile is represented as a multi-dimensional
vector, wherein each dimension is a value in the profile.
[0695] The method can further include transmitting a result to a
caregiver. The result can be the subject expression profile, a
result of a comparison of the subject expression profile with
another profile, a most similar reference profile, or a descriptor
of any of the aforementioned. The result can be transmitted across
a computer network, e.g., the result can be in the form of a
computer transmission, e.g., a computer data signal embedded in a
carrier wave.
[0696] Also featured is a computer medium having executable code
for effecting the following steps: receive a subject expression
profile; access a database of reference expression profiles; and
either i) select a matching reference profile most similar to the
subject expression profile or ii) determine at least one comparison
score for the similarity of the subject expression profile to at
least one reference profile. The subject expression profile, and
the reference expression profiles each include a value representing
the level of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
expression.
53070, 15985, 26583, 21953, m32404, 14089, or 23436 Arrays and Uses
Thereof
[0697] In another aspect, the invention features an array that
includes a substrate having a plurality of addresses. At least one
address of the plurality includes a capture probe that binds
specifically to a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 molecule (e.g., a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 nucleic acid or a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 polypeptide). The array can have a density of at
least than 10, 50, 100, 200, 500, 1,000, 2,000, or 10,000 or more
addresses/cm.sup.2, and ranges between. In a preferred embodiment,
the plurality of addresses includes at least 10, 100, 500, 1,000,
5,000, 10,000, 50,000 addresses. In a preferred embodiment, the
plurality of addresses includes equal to or less than 10, 100, 500,
1,000, 5,000, 10,000, or 50,000 addresses. The substrate can be a
two-dimensional substrate such as a glass slide, a wafer (e.g.,
silica or plastic), a mass spectroscopy plate, or a
three-dimensional substrate such as a gel pad. Addresses in
addition to address of the plurality can be disposed on the
array.
[0698] In a preferred embodiment, at least one address of the
plurality includes a nucleic acid capture probe that hybridizes
specifically to a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 nucleic acid, e.g., the sense or anti-sense strand. In one
preferred embodiment, a subset of addresses of the plurality of
addresses has a nucleic acid capture probe for 53070, 15985, 26583,
21953, m32404, 14089, or 23436. Each address of the subset can
include a capture probe that hybridizes to a different region of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid.
In another preferred embodiment, addresses of the subset include a
capture probe for a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 nucleic acid. Each address of the subset is unique,
overlapping, and complementary to a different variant of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 (e.g., an allelic
variant, or all possible hypothetical variants). The array can be
used to sequence 53070, 15985, 26583, 21953, m32404, 14089, or
23436 by hybridization (see, e.g., U.S. Pat. No. 5,695,940).
[0699] An array can be generated by various methods, e.g., by
photolithographic methods (see, e.g., U.S. Pat. Nos. 5,143,854;
5,510,270; and 5,527,681), mechanical methods (e.g., directed-flow
methods as described in U.S. Pat. No. 5,384,261), pin-based methods
(e.g., as described in U.S. Pat. No. 5,288,514), and bead-based
techniques (e.g., as described in PCT US/93/04145).
[0700] In another preferred embodiment, at least one address of the
plurality includes a polypeptide capture probe that binds
specifically to a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 polypeptide or fragment thereof. The polypeptide can be a
naturally-occurring interaction partner of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 polypeptide. Preferably, the
polypeptide is an antibody, e.g., an antibody described herein (see
"Anti-53070, -15985, -26583, -21953, -m32404, -14089, or -23436
Antibodies," above), such as a monoclonal antibody or a
single-chain antibody.
[0701] In another aspect, the invention features a method of
analyzing the expression of 53070, 15985, 26583, 21953, m32404,
14089, or 23436. The method includes providing an array as
described above; contacting the array with a sample and detecting
binding of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecule (e.g., nucleic acid or polypeptide) to the array. In a
preferred embodiment, the array is a nucleic acid array. Optionally
the method further includes amplifying nucleic acid from the sample
prior or during contact with the array.
[0702] In another embodiment, the array can be used to assay gene
expression in a tissue to ascertain tissue specificity of genes in
the array, particularly the expression of 53070, 15985, 26583,
21953, m32404, 14089, or 23436. If a sufficient number of diverse
samples is analyzed, clustering (e.g., hierarchical clustering,
k-means clustering, Bayesian clustering and the like) can be used
to identify other genes which are co-regulated with 53070, 15985,
26583, 21953, m32404, 14089, or 23436. For example, the array can
be used for the quantitation of the expression of multiple genes.
Thus, not only tissue specificity, but also the level of expression
of a battery of genes in the tissue is ascertained. Quantitative
data can be used to group (e.g., cluster) genes on the basis of
their tissue expression per se and level of expression in that
tissue.
[0703] For example, array analysis of gene expression can be used
to assess the effect of cell-cell interactions on 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression. A first tissue
can be perturbed and nucleic acid from a second tissue that
interacts with the first tissue can be analyzed. In this context,
the effect of one cell type on another cell type in response to a
biological stimulus can be determined, e.g., to monitor the effect
of cell-cell interaction at the level of gene expression.
[0704] In another embodiment, cells are contacted with a
therapeutic agent. The expression profile of the cells is
determined using the array, and the expression profile is compared
to the profile of like cells not contacted with the agent. For
example, the assay can be used to determine or analyze the
molecular basis of an undesirable effect of the therapeutic agent.
If an agent is administered therapeutically to treat one cell type
but has an undesirable effect on another cell type, the invention
provides an assay to determine the molecular basis of the
undesirable effect and thus provides the opportunity to
co-administer a counteracting agent or otherwise treat the
undesired effect. Similarly, even within a single cell type,
undesirable biological effects can be determined at the molecular
level. Thus, the effects of an agent on expression of other than
the target gene can be ascertained and counteracted.
[0705] In another embodiment, the array can be used to monitor
expression of one or more genes in the array with respect to time.
For example, samples obtained from different time points can be
probed with the array. Such analysis can identify and/or
characterize the development of a 53070-, 15985-, 26583-, 21953-,
m32404-, 14089-, or 23436-associated disease or disorder; and
processes, such as a cellular transformation associated with a
53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-associated disease or disorder. The method can also evaluate
the treatment and/or progression of a 53070-, 15985-, 26583-,
21953-, m32404-, 14089-, or 23436-associated disease or
disorder.
[0706] The array is also useful for ascertaining differential
expression patterns of one or more genes in normal and abnormal
cells. This provides a battery of genes (e.g., including 53070,
15985, 26583, 21953, m32404, 14089, or 23436) that could serve as a
molecular target for diagnosis or therapeutic intervention.
[0707] In another aspect, the invention features an array having a
plurality of addresses. Each address of the plurality includes a
unique polypeptide. At least one address of the plurality has
disposed thereon a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 polypeptide or fragment thereof. Methods of producing
polypeptide arrays are described in the art, e.g., in De Wildt et
al. (2000). Nature Biotech. 18, 989-994; Lueking et al. (1999).
Anal. Biochem. 270, 103-111; Ge, H. (2000). Nucleic Acids Res. 28,
e3, I-VII; MacBeath, G., and Schreiber, S. L. (2000). Science 289,
1760-1763; and WO 99/51773A1. In a preferred embodiment, each
addresses of the plurality has disposed thereon a polypeptide at
least 60, 70, 80, 85, 90, 95 or 99% identical to a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 polypeptide or fragment
thereof. For example, multiple variants of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 polypeptide (e.g., encoded by
allelic variants, site-directed mutants, random mutants, or
combinatorial mutants) can be disposed at individual addresses of
the plurality. Addresses in addition to the address of the
plurality can be disposed on the array.
[0708] The polypeptide array can be used to detect a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 binding compound, e.g., an
antibody in a sample from a subject with specificity for a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 polypeptide or the
presence of a 53070-, 15985-, 26583-, 21953-, m32404-, 14089-, or
23436-binding protein or ligand.
[0709] The array is also useful for ascertaining the effect of the
expression of a gene on the expression of other genes in the same
cell or in different cells (e.g., ascertaining the effect of 53070,
15985, 26583, 21953, m32404, 14089, or 23436 expression on the
expression of other genes). This provides, for example, for a
selection of alternate molecular targets for therapeutic
intervention if the ultimate or downstream target cannot be
regulated.
[0710] In another aspect, the invention features a method of
analyzing a plurality of probes. The method is useful, e.g., for
analyzing gene expression. The method includes: providing a two
dimensional array having a plurality of addresses, each address of
the plurality being positionally distinguishable from each other
address of the plurality having a unique capture probe, e.g.,
wherein the capture probes are from a cell or subject which express
53070, 15985, 26583, 21953, m32404, 14089, or 23436 or from a cell
or subject in which a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 mediated response has been elicited, e.g., by contact of the
cell with 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid or protein, or administration to the cell or subject
53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid or
protein; providing a two dimensional array having a plurality of
addresses, each address of the plurality being positionally
distinguishable from each other address of the plurality, and each
address of the plurality having a unique capture probe, e.g.,
wherein the capture probes are from a cell or subject which does
not express 53070, 15985, 26583, 21953, m32404, 14089, or 23436 (or
does not express as highly as in the case of the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 positive plurality of capture
probes) or from a cell or subject which in which a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 mediated response has not
been elicited (or has been elicited to a lesser extent than in the
first sample); contacting the array with one or more inquiry probes
(which is preferably other than a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acid, polypeptide, or antibody),
and thereby evaluating the plurality of capture probes. Binding,
e.g., in the case of a nucleic acid, hybridization with a capture
probe at an address of the plurality, is detected, e.g., by signal
generated from a label attached to the nucleic acid, polypeptide,
or antibody.
[0711] In another aspect, the invention features a method of
analyzing a plurality of probes or a sample. The method is useful,
e.g., for analyzing gene expression. The method includes: providing
a two dimensional array having a plurality of addresses, each
address of the plurality being positionally distinguishable from
each other address of the plurality having a unique capture probe,
contacting the array with a first sample from a cell or subject
which express or mis-express 53070, 15985, 26583, 21953, m32404,
14089, or 23436 or from a cell or subject in which a 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-mediated response
has been elicited, e.g., by contact of the cell with 53070, 15985,
26583, 21953, m32404, 14089, or 23436 nucleic acid or protein, or
administration to the cell or subject 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acid or protein; providing a two
dimensional array having a plurality of addresses, each address of
the plurality being positionally distinguishable from each other
address of the plurality, and each address of the plurality having
a unique capture probe, and contacting the array with a second
sample from a cell or subject which does not express 53070, 15985,
26583, 21953, m32404, 14089, or 23436 (or does not express as
highly as in the case of the 53070, 15985, 26583, 21953, m32404,
14089, or 23436 positive plurality of capture probes) or from a
cell or subject which in which a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 mediated response has not been elicited (or
has been elicited to a lesser extent than in the first sample); and
comparing the binding of the first sample with the binding of the
second sample. Binding, e.g., in the case of a nucleic acid,
hybridization with a capture probe at an address of the plurality,
is detected, e.g., by signal generated from a label attached to the
nucleic acid, polypeptide, or antibody. The same array can be used
for both samples or different arrays can be used. If different
arrays are used the plurality of addresses with capture probes
should be present on both arrays.
[0712] In another aspect, the invention features a method of
analyzing 53070, 15985, 26583, 21953, m32404, 14089, or 23436,
e.g., analyzing structure, function, or relatedness to other
nucleic acid or amino acid sequences. The method includes:
providing a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid or amino acid sequence; comparing the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 sequence with one or more
preferably a plurality of sequences from a collection of sequences,
e.g., a nucleic acid or protein sequence database; to thereby
analyze 53070, 15985, 26583, 21953, m32404, 14089, or 23436.
Detection of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
Variations or Mutations
[0713] The methods of the invention can also be used to detect
genetic alterations in a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 gene, thereby determining if a subject with the altered
gene is at risk for a disorder characterized by misregulation in
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
activity or nucleic acid expression, such as a cellular
proliferative and/or differentiative disorder; a cancer or a
neurological disorder; a metabolic disorder, e.g., a mitochondrial
related disorder or a cholesterol biosynthesis related disorder, or
a cell proliferation or differentiation disorder, e.g., a tumor;
coagulation, or cell signaling disorders; or an erythroid cell
disorder or a proliferative disorder of erythroid, liver, prostate,
or brain cells disorder. In preferred embodiments, the methods
include detecting, in a sample from the subject, the presence or
absence of a genetic alteration characterized by at least one of an
alteration affecting the integrity of a gene encoding a 53070,
15985, 26583, 21953, m32404, 14089, or 23436-protein, or the
mis-expression of the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 gene. For example, such genetic alterations can be detected
by ascertaining the existence of at least one of 1) a deletion of
one or more nucleotides from a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene; 2) an addition of one or more nucleotides to
a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene; 3) a
substitution of one or more nucleotides of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 gene, 4) a chromosomal rearrangement
of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene; 5)
an alteration in the level of a messenger RNA transcript of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene, 6)
aberrant modification of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene, such as of the methylation pattern of the
genomic DNA, 7) the presence of a non-wild type splicing pattern of
a messenger RNA transcript of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene, 8) a non-wild type level of a 53070, 15985,
26583, 21953, m32404, 14089, or 23436-protein, 9) allelic loss of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene, and 10)
inappropriate post-translational modification of a 53070, 15985,
26583, 21953, m32404, 14089, or 23436-protein.
[0714] An alteration can be detected without a probe/primer in a
polymerase chain reaction, such as anchor PCR or RACE PCR, or,
alternatively, in a ligation chain reaction (LCR), the latter of
which can be particularly useful for detecting point mutations in
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436-gene. This
method can include the steps of collecting a sample of cells from a
subject, isolating nucleic acid (e.g., genomic, mRNA or both) from
the sample, contacting the nucleic acid sample with one or more
primers which specifically hybridize to a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 gene under conditions such that
hybridization and amplification of the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436-gene (if present) occurs, and detecting the
presence or absence of an amplification product, or detecting the
size of the amplification product and comparing the length to a
control sample. It is anticipated that PCR and/or LCR may be
desirable to use as a preliminary amplification step in conjunction
with any of the techniques used for detecting mutations described
herein. Alternatively, other amplification methods described herein
or known in the art can be used.
[0715] In another embodiment, mutations in a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 gene from a sample cell can be
identified by detecting alterations in restriction enzyme cleavage
patterns. For example, sample and control DNA is isolated,
amplified (optionally), digested with one or more restriction
endonucleases, and fragment length sizes are determined, e.g., by
gel electrophoresis and compared. Differences in fragment length
sizes between sample and control DNA indicates mutations in the
sample DNA. Moreover, the use of sequence specific ribozymes (see,
for example, U.S. Pat. No. 5,498,531) can be used to score for the
presence of specific mutations by development or loss of a ribozyme
cleavage site.
[0716] In other embodiments, genetic mutations in 53070, 15985,
26583, 21953, m32404, 14089, or 23436 can be identified by
hybridizing a sample and control nucleic acids, e.g., DNA or RNA,
two-dimensional arrays, e.g., chip based arrays. Such arrays
include a plurality of addresses, each of which is positionally
distinguishable from the other. A different probe is located at
each address of the plurality. A probe can be complementary to a
region of a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
nucleic acid or a putative variant (e.g., allelic variant) thereof.
A probe can have one or more mismatches to a region of a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid (e.g., a
destabilizing mismatch). The arrays can have a high density of
addresses, e.g., can contain hundreds or thousands of
oligonucleotides probes (Cronin, M. T. et al. (1996) Human Mutation
7: 244-255; Kozal, M. J. et al. (1996) Nature Medicine 2: 753-759).
For example, genetic mutations in 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 can be identified in two-dimensional arrays
containing light-generated DNA probes as described in Cronin, M. T.
et al. supra. Briefly, a first hybridization array of probes can be
used to scan through long stretches of DNA in a sample and control
to identify base changes between the sequences by making linear
arrays of sequential overlapping probes. This step allows the
identification of point mutations. This step is followed by a
second hybridization array that allows the characterization of
specific mutations by using smaller, specialized probe arrays
complementary to all variants or mutations detected. Each mutation
array is composed of parallel probe sets, one complementary to the
wild-type gene and the other complementary to the mutant gene.
[0717] In yet another embodiment, any of a variety of sequencing
reactions known in the art can be used to directly sequence the
53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene and detect
mutations by comparing the sequence of the sample 53070, 15985,
26583, 21953, m32404, 14089, or 23436 with the corresponding
wild-type (control) sequence. Automated sequencing procedures can
be utilized when performing the diagnostic assays ((1995)
Biotechniques 19:448), including sequencing by mass
spectrometry.
[0718] Other methods for detecting mutations in the 53070, 15985,
26583, 21953, m32404, 14089, or 23436 gene include methods in which
protection from cleavage agents is used to detect mismatched bases
in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science
230:1242; Cotton et al. (1988) Proc. Natl. Acad Sci USA 85:4397;
Saleeba et al. (1992) Methods Enzymol. 217:286-295).
[0719] In still another embodiment, the mismatch cleavage reaction
employs one or more proteins that recognize mismatched base pairs
in double-stranded DNA (so called "DNA mismatch repair" enzymes) in
defined systems for detecting and mapping point mutations in 53070,
15985, 26583, 21953, m32404, 14089, or 23436 cDNAs obtained from
samples of cells. For example, the mutY enzyme of E. coli cleaves A
at G/A mismatches and the thymidine DNA glycosylase from HeLa cells
cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis
15:1657-1662; U.S. Pat. No. 5,459,039).
[0720] In other embodiments, alterations in electrophoretic
mobility will be used to identify mutations in 53070, 15985, 26583,
21953, m32404, 14089, or 23436 genes. For example, single strand
conformation polymorphism (SSCP) may be used to detect differences
in electrophoretic mobility between mutant and wild type nucleic
acids (Orita et al. (1989) Proc Natl. Acad. Sci USA: 86:2766, see
also Cotton (1993) Mutat. Res. 285:125-144; and Hayashi (1992)
Genet. Anal. Tech. Appl. 9:73-79). Single-stranded DNA fragments of
sample and control 53070, 15985, 26583, 21953, m32404, 14089, or
23436 nucleic acids will be denatured and allowed to renature. The
secondary structure of single-stranded nucleic acids varies
according to sequence, the resulting alteration in electrophoretic
mobility enables the detection of even a single base change. The
DNA fragments may be labeled or detected with labeled probes. The
sensitivity of the assay may be enhanced by using RNA (rather than
DNA), in which the secondary structure is more sensitive to a
change in sequence. In a preferred embodiment, the subject method
utilizes heteroduplex analysis to separate double stranded
heteroduplex molecules on the basis of changes in electrophoretic
mobility (Keen et al. (1991) Trends Genet 7:5).
[0721] In yet another embodiment, the movement of mutant or
wild-type fragments in polyacrylamide gels containing a gradient of
denaturant is assayed using denaturing gradient gel electrophoresis
(DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as
the method of analysis, DNA will be modified to insure that it does
not completely denature, for example by adding a GC clamp of
approximately 40 bp of high-melting GC-rich DNA by PCR. In a
further embodiment, a temperature gradient is used in place of a
denaturing gradient to identify differences in the mobility of
control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem
265:12753).
[0722] Examples of other techniques for detecting point mutations
include, but are not limited to, selective oligonucleotide
hybridization, selective amplification, or selective primer
extension (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989)
Proc. Natl. Acad. Sci USA 86:6230). A further method of detecting
point mutations is the chemical ligation of oligonucleotides as
described in Xu et al. ((2001) Nature Biotechnol. 19:148). Adjacent
oligonucleotides, one of which selectively anneals to the query
site, are ligated together if the nucleotide at the query site of
the sample nucleic acid is complementary to the query
oligonucleotide; ligation can be monitored, e.g., by fluorescent
dyes coupled to the oligonucleotides.
[0723] Alternatively, allele specific amplification technology that
depends on selective PCR amplification may be used in conjunction
with the instant invention. Oligonucleotides used as primers for
specific amplification may carry the mutation of interest in the
center of the molecule (so that amplification depends on
differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res.
17:2437-2448) or at the extreme 3' end of one primer where, under
appropriate conditions, mismatch can prevent, or reduce polymerase
extension (Prossner (1993) Tibtech 11:238). In addition it may be
desirable to introduce a novel restriction site in the region of
the mutation to create cleavage-based detection (Gasparini et al.
(-1992) Mol. Cell Probes 6:1). It is anticipated that in certain
embodiments amplification may also be performed using Taq ligase
for amplification (Barany (1991) Proc. Natl. Acad. Sci USA 88:189).
In such cases, ligation will occur only if there is a perfect match
at the 3' end of the 5' sequence making it possible to detect the
presence of a known mutation at a specific site by looking for the
presence or absence of amplification.
[0724] In another aspect, the invention features a set of
oligonucleotides. The set includes a plurality of oligonucleotides,
each of which is at least partially complementary (e.g., at least
50%, 60%, 70%, 80%, 90%, 92%, 95%, 97%, 98%, or 99% complementary)
to a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic
acid.
[0725] In a preferred embodiment the set includes a first and a
second oligonucleotide. The first and second oligonucleotide can
hybridize to the same or to different locations of SEQ ID NO:1, 7,
14, 19, 24, 33, or 40 or the complement of SEQ ID NO: 1, 7, 14, 19,
24, 33, or 40. Different locations can be different but
overlapping, or non-overlapping on the same strand. The first and
second oligonucleotide can hybridize to sites on the same or on
different strands.
[0726] The set can be useful, e.g., for identifying SNP's, or
identifying specific alleles of 53070, 15985, 26583, 21953, m32404,
14089, or 23436. In a preferred embodiment, each oligonucleotide of
the set has a different nucleotide at an interrogation position. In
one embodiment, the set includes two oligonucleotides, each
complementary to a different allele at a locus, e.g., a biallelic
or polymorphic locus.
[0727] In another embodiment, the set includes four
oligonucleotides, each having a different nucleotide (e.g.,
adenine, guanine, cytosine, or thymidine) at the interrogation
position. The interrogation position can be a SNP or the site of a
mutation. In another preferred embodiment, the oligonucleotides of
the plurality are identical in sequence to one another (except for
differences in length). The oligonucleotides can be provided with
differential labels, such that an oligonucleotide that hybridizes
to one allele provides a signal that is distinguishable from an
oligonucleotide that hybridizes to a second allele. In still
another embodiment, at least one of the oligonucleotides of the set
has a nucleotide change at a position in addition to a query
position, e.g., a destabilizing mutation to decrease the T.sub.m of
the oligonucleotide. In another embodiment, at least one
oligonucleotide of the set has a non-natural nucleotide, e.g.,
inosine. In a preferred embodiment, the oligonucleotides are
attached to a solid support, e.g., to different addresses of an
array or to different beads or nanoparticles.
[0728] In a preferred embodiment the set of oligo nucleotides can
be used to specifically amplify, e.g., by PCR, or detect, a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid.
[0729] The methods described herein may be performed, for example,
by utilizing pre-packaged diagnostic kits comprising at least one
probe nucleic acid or antibody reagent described herein, which may
be conveniently used, e.g., in clinical settings to diagnose
patients exhibiting symptoms or family history of a disease or
illness involving a 53070, 15985, 26583, 21953, m32404, 14089, or
23436 gene.
Use of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
Molecules as Surrogate Markers
[0730] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecules of the invention are also useful as markers of disorders
or disease states, as markers for precursors of disease states, as
markers for predisposition of disease states, as markers of drug
activity, or as markers of the pharmacogenomic profile of a
subject. Using the methods described herein, the presence, absence
and/or quantity of the 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 molecules of the invention may be detected, and may be
correlated with one or more biological states in vivo. For example,
the 53070, 15985, 26583, 21953, m32404, 14089, or 23436 molecules
of the invention may serve as surrogate markers for one or more
disorders or disease states or for conditions leading up to disease
states. As used herein, a "surrogate marker" is an objective
biochemical marker which correlates with the absence or presence of
a disease or disorder, or with the progression of a disease or
disorder (e.g., with the presence or absence of a tumor). The
presence or quantity of such markers is independent of the disease.
Therefore, these markers may serve to indicate whether a particular
course of treatment is effective in lessening a disease state or
disorder. Surrogate markers are of particular use when the presence
or extent of a disease state or disorder is difficult to assess
through standard methodologies (e.g., early stage tumors), or when
an assessment of disease progression is desired before a
potentially dangerous clinical endpoint is reached (e.g., an
assessment of cardiovascular disease may be made using cholesterol
levels as a surrogate marker, and an analysis of HIV infection may
be made using HIV RNA levels as a surrogate marker, well in advance
of the undesirable clinical outcomes of myocardial infarction or
fully-developed AIDS). Examples of the use of surrogate markers in
the art include: Koomen et al. (2000) J. Mass. Spectrom. 35:
258-264; and James (1994) AIDS Treatment News Archive 209.
[0731] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecules of the invention are also useful as pharmacodynamic
markers. As used herein, a "pharmacodynamic marker" is an objective
biochemical marker which correlates specifically with drug effects.
The presence or quantity of a pharmacodynamic marker is not related
to the disease state or disorder for which the drug is being
administered; therefore, the presence or quantity of the marker is
indicative of the presence or activity of the drug in a subject.
For example, a pharmacodynamic marker may be indicative of the
concentration of the drug in a biological tissue, in that the
marker is either expressed or transcribed or not expressed or
transcribed in that tissue in relationship to the level of the
drug. In this fashion, the distribution or uptake of the drug may
be monitored by the pharmacodynamic marker. Similarly, the presence
or quantity of the pharmacodynamic marker may be related to the
presence or quantity of the metabolic product of a drug, such that
the presence or quantity of the marker is indicative of the
relative breakdown rate of the drug in vivo. Pharmacodynamic
markers are of particular use in increasing the sensitivity of
detection of drug effects, particularly when the drug is
administered in low doses. Since even a small amount of a drug may
be sufficient to activate multiple rounds of marker (e.g., a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 marker) transcription
or expression, the amplified marker may be in a quantity which is
more readily detectable than the drug itself. Also, the marker may
be more easily detected due to the nature of the marker itself; for
example, using the methods described herein, anti-53070, -15985,
-26583, -21953, -m32404, -14089, or -23436 antibodies may be
employed in an immune-based detection system for a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein marker, or 53070-,
15985-, 26583-, 21953-, m32404-, 14089-, or 23436-specific
radiolabeled probes may be used to detect a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 mRNA marker. Furthermore, the use of
a pharmacodynamic marker may offer mechanism-based prediction of
risk due to drug treatment beyond the range of possible direct
observations. Examples of the use of pharmacodynamic markers in the
art include: Matsuda et al. U.S. Pat. No. 6,033,862; Hattis et al.
(1991) Env. Health Perspect. 90: 229-238; Schentag (1999) Am. J.
Health-Syst. Pharm. 56 Suppl. 3: S21-S24; and Nicolau (1999) Am, J.
Health-Syst. Pharm. 56 Suppl. 3: S16-S20.
[0732] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecules of the invention are also useful as pharmacogenomic
markers. As used herein, a "pharmacogenomic marker" is an objective
biochemical marker which correlates with a specific clinical drug
response or susceptibility in a subject (see, e.g., McLeod et al.
(1999) Eur. J. Cancer 35:1650-1652). The presence or quantity of
the pharmacogenomic marker is related to the predicted response of
the subject to a specific drug or class of drugs prior to
administration of the drug. By assessing the presence or quantity
of one or more pharmacogenomic markers in a subject, a drug therapy
which is most appropriate for the subject, or which is predicted to
have a greater degree of success, may be selected. For example,
based on the presence or quantity of RNA, or protein (e.g., 53070,
15985, 26583, 21953, m32404, 14089, or 23436 protein or RNA) for
specific tumor markers in a subject, a drug or course of treatment
may be selected that is optimized for the treatment of the specific
tumor likely to be present in the subject. Similarly, the presence
or absence of a specific sequence mutation in 53070, 15985, 26583,
21953, m32404, 14089, or 23436 DNA may correlate 53070, 15985,
26583, 21953, m32404, 14089, or 23436 drug response. The use of
pharmacogenomic markers therefore permits the application of the
most appropriate treatment for each subject without having to
administer the therapy.
Pharmaceutical Compositions of 53070, 15985, 26583, 21953, m32404,
14089, or 23436
[0733] The nucleic acid and polypeptides, fragments thereof, as
well as anti-53070, -15985, -26583, -21953, -m32404, -14089, or
-23436 antibodies (also referred to herein as "active compounds")
of the invention can be incorporated into pharmaceutical
compositions. Such compositions typically include the nucleic acid
molecule, protein, or antibody and a pharmaceutically acceptable
carrier. As used herein the language "pharmaceutically acceptable
carrier" includes solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents, and the like, compatible with pharmaceutical
administration. Supplementary active compounds can also be
incorporated into the compositions.
[0734] A pharmaceutical composition is formulated to be compatible
with its intended route of administration. Examples of routes of
administration include parenteral, e.g., intravenous, intradermal,
subcutaneous, oral (e.g., inhalation), transdermal (topical),
transmucosal, and rectal administration. Solutions or suspensions
used for parenteral, intradermal, or subcutaneous application can
include the following components: a sterile diluent such as water
for injection, saline solution, fixed oils, polyethylene glycols,
glycerine, propylene glycol or other synthetic solvents;
antibacterial agents such as benzyl alcohol or methyl parabens;
antioxidants such as ascorbic acid or sodium bisulfite; chelating
agents such as ethylenediaminetetraacetic acid; buffers such as
acetates, citrates or phosphates and agents for the adjustment of
tonicity such as sodium chloride or dextrose. pH can be adjusted
with acids or bases, such as hydrochloric acid or sodium hydroxide.
The parenteral preparation can be enclosed in ampoules, disposable
syringes or multiple dose vials made of glass or plastic.
[0735] Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersion. For intravenous
administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor EL.TM. (BASF, Parsippany, N.J.) or
phosphate buffered saline (PBS). In all cases, the composition must
be sterile and should be fluid to the extent that easy
syringability exists. It should be stable under the conditions of
manufacture and storage and must be preserved against the
contaminating action of microorganisms such as bacteria and fungi.
The carrier can be a solvent or dispersion medium containing, for
example, water, ethanol, polyol (for example, glycerol, propylene
glycol, and liquid polyetheylene glycol, and the like), and
suitable mixtures thereof. The proper fluidity can be maintained,
for example, by the use of a coating such as lecithin, by the
maintenance of the required particle size in the case of dispersion
and by the use of surfactants. Prevention of the action of
microorganisms can be achieved by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol, phenol,
ascorbic acid, thimerosal, and the like. In many cases, it will be
preferable to include isotonic agents, for example, sugars,
polyalcohols such as manitol, sorbitol, sodium chloride in the
composition. Prolonged absorption of the injectable compositions
can be brought about by including in the composition an agent which
delays absorption, for example, aluminum monostearate and
gelatin.
[0736] Sterile injectable solutions can be prepared by
incorporating the active compound in the required amount in an
appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the active
compound into a sterile vehicle which contains a basic dispersion
medium and the required other ingredients from those enumerated
above. In the case of sterile powders for the preparation of
sterile injectable solutions, the preferred methods of preparation
are vacuum drying and freeze-drying which yields a powder of the
active ingredient plus any additional desired ingredient from a
previously sterile-filtered solution thereof.
[0737] Oral compositions generally include an inert diluent or an
edible carrier. For the purpose of oral therapeutic administration,
the active compound can be incorporated with excipients and used in
the form of tablets, troches, or capsules, e.g., gelatin capsules.
Oral compositions can also be prepared using a fluid carrier for
use as a mouthwash. Pharmaceutically compatible binding agents,
and/or adjuvant materials can be included as part of the
composition. The tablets, pills, capsules, troches and the like can
contain any of the following ingredients, or compounds of a similar
nature: a binder such as microcrystalline cellulose, gum tragacanth
or gelatin; an excipient such as starch or lactose, a
disintegrating agent such as alginic acid, Primogel, or corn
starch; a lubricant such as magnesium stearate or Sterotes; a
glidant such as colloidal silicon dioxide; a sweetening agent such
as sucrose or saccharin; or a flavoring agent such as peppermint,
methyl salicylate, or orange flavoring.
[0738] For administration by inhalation, the compounds are
delivered in the form of an aerosol spray from pressured container
or dispenser which contains a suitable propellant, e.g., a gas such
as carbon dioxide, or a nebulizer.
[0739] Systemic administration can also be by transmucosal or
transdermal means. For transmucosal or transdermal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the art,
and include, for example, for transmucosal administration,
detergents, bile salts, and fusidic acid derivatives. Transmucosal
administration can be accomplished through the use of nasal sprays
or suppositories. For transdermal administration, the active
compounds are formulated into ointments, salves, gels, or creams as
generally known in the art.
[0740] The compounds can also be prepared in the form of
suppositories (e.g., with conventional suppository bases such as
cocoa butter and other glycerides) or retention enemas for rectal
delivery.
[0741] In one embodiment, the active compounds are prepared with
carriers that will protect the compound against rapid elimination
from the body, such as a controlled release formulation, including
implants and microencapsulated delivery systems. Biodegradable,
biocompatible polymers can be used, such as ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and
polylactic acid. Methods for preparation of such formulations will
be apparent to those skilled in the art. The materials can also be
obtained commercially from Alza Corporation and Nova
Pharmaceuticals, Inc. Liposomal suspensions (including liposomes
targeted to infected cells with monoclonal antibodies to viral
antigens) can also be used as pharmaceutically acceptable carriers.
These can be prepared according to methods known to those skilled
in the art, for example, as described in U.S. Pat. No.
4,522,811.
[0742] It is advantageous to formulate oral or parenteral
compositions in dosage unit form for ease of administration and
uniformity of dosage. Dosage unit form as used herein refers to
physically discrete units suited as unitary dosages for the subject
to be treated; each unit containing a predetermined quantity of
active compound calculated to produce the desired therapeutic
effect in association with the required pharmaceutical carrier.
[0743] Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the LD50 (the dose
lethal to 50% of the population) and the ED50 (the dose
therapeutically effective in 50% of the population). The dose ratio
between toxic and therapeutic effects is the therapeutic index and
it can be expressed as the ratio LD50/ED50. Compounds which exhibit
high therapeutic indices are preferred. While compounds that
exhibit toxic side effects may be used, care should be taken to
design a delivery system that targets such compounds to the site of
affected tissue in order to minimize potential damage to uninfected
cells and, thereby, reduce side effects.
[0744] The data obtained from the cell culture assays and animal
studies can be used in formulating a range of dosage for use in
humans. The dosage of such compounds lies preferably within a range
of circulating concentrations that include the ED50 with little or
no toxicity. The dosage may vary within this range depending upon
the dosage form employed and the route of administration utilized.
For any compound used in the method of the invention, the
therapeutically effective dose can be estimated initially from cell
culture assays. A dose may be formulated in animal models to
achieve a circulating plasma concentration range that includes the
IC50 (i.e., the concentration of the test compound which achieves a
half-maximal inhibition of symptoms) as determined in cell culture.
Such information can be used to more accurately determine useful
doses in humans. Levels in plasma may be measured, for example, by
high performance liquid chromatography.
[0745] As defined herein, a therapeutically effective amount of
protein or polypeptide (i.e., an effective dosage) ranges from
about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25
mg/kg body weight, more preferably about 0.1 to 20 mg/kg body
weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg,
3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The
protein or polypeptide can be administered one time per week for
between about 1 to 10 weeks, preferably between 2 to 8 weeks, more
preferably between about 3 to 7 weeks, and even more preferably for
about 4, 5, or 6 weeks. The skilled artisan will appreciate that
certain factors may influence the dosage and timing required to
effectively treat a subject, including but not limited to the
severity of the disease or disorder, previous treatments, the
general health and/or age of the subject, and other diseases
present. Moreover, treatment of a subject with a therapeutically
effective amount of a protein, polypeptide, or antibody can include
a single treatment or, preferably, can include a series of
treatments.
[0746] For antibodies, the preferred dosage is 0.1 mg/kg of body
weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act
in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually
appropriate. Generally, partially human antibodies and fully human
antibodies have a longer half-life within the human body than other
antibodies. Accordingly, lower dosages and less frequent
administration is often possible. Modifications such as lipidation
can be used to stabilize antibodies and to enhance uptake and
tissue penetration (e.g., into the brain). A method for lipidation
of antibodies is described by Cruikshank et al. ((1997) J. Acquired
Immune Deficiency Syndromes and Human Retrovirology 14:193).
[0747] The present invention encompasses agents which modulate
expression or activity. An agent may, for example, be a small
molecule. For example, such small molecules include, but are not
limited to, peptides, peptidomimetics (e.g., peptoids), amino
acids, amino acid analogs, polynucleotides, polynucleotide analogs,
nucleotides, nucleotide analogs, organic or inorganic compounds
(i.e., including heteroorganic and organometallic compounds) having
a molecular weight less than about 10,000 grams per mole, organic
or inorganic compounds having a molecular weight less than about
5,000 grams per mole, organic or inorganic compounds having a
molecular weight less than about 1,000 grams per mole, organic or
inorganic compounds having a molecular weight less than about 500
grams per mole, and salts, esters, and other pharmaceutically
acceptable forms of such compounds.
[0748] Exemplary doses include milligram or microgram amounts of
the small molecule per kilogram of subject or sample weight (e.g.,
about 1 microgram per kilogram to about 500 milligrams per
kilogram, about 100 micrograms per kilogram to about 5 milligrams
per kilogram, or about 1 microgram per kilogram to about 50
micrograms per kilogram. It is furthermore understood that
appropriate doses of a small molecule depend upon the potency of
the small molecule with respect to the expression or activity to be
modulated. When one or more of these small molecules is to be
administered to an animal (e.g., a human) in order to modulate
expression or activity of a polypeptide or nucleic acid of the
invention, a physician, veterinarian, or researcher may, for
example, prescribe a relatively low dose at first, subsequently
increasing the dose until an appropriate response is obtained. In
addition, it is understood that the specific dose level for any
particular animal subject will depend upon a variety of factors
including the activity of the specific compound employed, the age,
body weight, general health, gender, and diet of the subject, the
time of administration, the route of administration, the rate of
excretion, any drug combination, and the degree of expression or
activity to be modulated.
[0749] An antibody (or fragment thereof) may be conjugated to a
therapeutic moiety such as a cytotoxin, a therapeutic agent or a
radioactive ion. A cytotoxin or cytotoxic agent includes any agent
that is detrimental to cells. Examples include taxol, cytochalasin
B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide,
tenoposide, vincristine, vinblastine, colchicin, doxorubicin,
daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin,
actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine,
tetracaine, lidocaine, propranolol, puromycin, maytansinoids, e.g.,
maytansinol (see U.S. Pat. No. 5,208,020), CC-1065 (see U.S. Pat.
Nos. 5,475,092, 5,585,499, 5,846,545) and analogs or homologs
thereof. Therapeutic agents include, but are not limited to,
antimetabolites (e.g., methotrexate, 6-mercaptopurine,
6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating
agents (e.g., mechlorethamine, thioepa chlorambucil, CC-1065,
melphalan, carmustine (BSNU) and lomustine (CCNU),
cyclothosphamide, busulfan, dibromomannitol, streptozotocin,
mitomycin C, and cis-dichlorodiamine platinum (II) (DDP)
cisplatin), anthracyclines (e.g., daunorubicin (formerly
daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin
(formerly actinomycin), bleomycin, mithramycin, and anthramycin
(AMC)), and anti-mitotic agents (e.g., vincristine, vinblastine,
taxol and maytansinoids). Radioactive ions include, but are not
limited to iodine, yttrium and praseodymium.
[0750] The conjugates of the invention can be used for modifying a
given biological response, the drug moiety is not to be construed
as limited to classical chemical therapeutic agents. For example,
the drug moiety may be a protein or polypeptide possessing a
desired biological activity. Such proteins may include, for
example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or
diphtheria toxin; a protein such as tumor necrosis factor,
.alpha.-interferon, .beta.-interferon, nerve growth factor,
platelet derived growth factor, tissue plasminogen activator; or,
biological response modifiers such as, for example, lymphokines,
interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6
("IL-6"), granulocyte macrophase colony stimulating factor
("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or
other growth factors.
[0751] Alternatively, an antibody can be conjugated to a second
antibody to form an antibody heteroconjugate as described by Segal
in U.S. Pat. No. 4,676,980.
[0752] The nucleic acid molecules of the invention can be inserted
into vectors and used as gene therapy vectors. Gene therapy vectors
can be delivered to a subject by, for example, intravenous
injection, local administration (see U.S. Pat. No. 5,328,470) or by
stereotactic injection (see e.g., Chen et al. (1994) Proc. Natl.
Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the
gene therapy vector can include the gene therapy vector in an
acceptable diluent, or can comprise a slow release matrix in which
the gene delivery vehicle is imbedded. Alternatively, where the
complete gene delivery vector can be produced intact from
recombinant cells, e.g., retroviral vectors, the pharmaceutical
preparation can include one or more cells which produce the gene
delivery system.
[0753] The pharmaceutical compositions can be included in a
container, pack, or dispenser together with instructions for
administration.
Methods of Treatment for 53070, 15985, 26583, 21953, m32404, 14089,
or 23436
[0754] The present invention provides for both prophylactic and
therapeutic methods of treating a subject at risk of (or
susceptible to) a disorder or having a disorder associated with
aberrant or unwanted 53070, 15985, 26583, 21953, m32404, 14089, or
23436 expression or activity. As used herein, the term "treatment"
is defined as the application or administration of a therapeutic
agent to a patient, or application or administration of a
therapeutic agent to an isolated tissue or cell line from a
patient, who has a disease, a symptom of disease or a
predisposition toward a disease, with the purpose to cure, heal,
alleviate, relieve, alter, remedy, ameliorate, improve or affect
the disease, the symptoms of disease or the predisposition toward
disease. A therapeutic agent includes, but is not limited to, small
molecules, peptides, antibodies, ribozymes and antisense
oligonucleotides.
[0755] With regards to both prophylactic and therapeutic methods of
treatment, such treatments may be specifically tailored or
modified, based on knowledge obtained from the field of
pharmacogenomics. "Pharmacogenomics", as used herein, refers to the
application of genomics technologies such as gene sequencing,
statistical genetics, and gene expression analysis to drugs in
clinical development and on the market. More specifically, the term
refers the study of how a patient's genes determine his or her
response to a drug (e.g., a patient's "drug response phenotype", or
"drug response genotype".) Thus, another aspect of the invention
provides methods for tailoring an individual's prophylactic or
therapeutic treatment with either the 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 molecules of the present invention or
53070, 15985, 26583, 21953, m32404, 14089, or 23436 modulators
according to that individual's drug response genotype.
Pharmacogenomics allows a clinician or physician to target
prophylactic or therapeutic treatments to patients who will most
benefit from the treatment and to avoid treatment of patients who
will experience toxic drug-related side effects.
[0756] In one aspect, the invention provides a method for
preventing in a subject, a disease or condition associated with an
aberrant or unwanted 53070, 15985, 26583, 21953, m32404, 14089, or
23436 expression or activity, by administering to the subject a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 or an agent
which modulates 53070, 15985, 26583, 21953, m32404, 14089, or 23436
expression or at least one 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity. Subjects at risk for a disease which is
caused or contributed to by aberrant or unwanted 53070, 15985,
26583, 21953, m32404, 14089, or 23436 expression or activity can be
identified by, for example, any or a combination of diagnostic or
prognostic assays as described herein. Administration of a
prophylactic agent can occur prior to the manifestation of symptoms
characteristic of the 53070, 15985, 26583, 21953, m32404, 14089, or
23436 aberrance, such that a disease or disorder is prevented or,
alternatively, delayed in its progression. Depending on the type of
53070, 15985, 26583, 21953, m32404, 14089, or 23436 aberrance, for
example, a 53070, 15985, 26583, 21953, m32404, 14089, or 23436,
53070, 15985, 26583, 21953, m32404, 14089, or 23436 agonist or
53070, 15985, 26583, 21953, m32404, 14089, or 23436 antagonist
agent can be used for treating the subject. The appropriate agent
can be determined based on screening assays described herein.
[0757] It is possible that some 53070, 15985, 26583, 21953, m32404,
14089, or 23436 disorders can be caused, at least in part, by an
abnormal level of gene product, or by the presence of a gene
product exhibiting abnormal activity. As such, the reduction in the
level and/or activity of such gene products would bring about the
amelioration of disorder symptoms.
[0758] The 53070 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders, disorders
associated with bone metabolism, immune disorders, cardiovascular
disorders, liver disorders, viral diseases, pain or metabolic
disorders.
[0759] The 15985 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders, immune disorders,
cardiovascular disorders, as described above, as well as liver
disorders, lung disorders, ovarian disorders, viral diseases, pain
or metabolic disorders.
[0760] The 21953 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders, disorders
associated with bone metabolism, immune disorders, cardiovascular
disorders, liver disorders, viral diseases, pain or metabolic
disorders.
[0761] The m32404 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders, disorders
associated with bone metabolism, immune disorders, hematopoietic
disorders, cardiovascular disorders, liver disorders, viral
diseases, pain or metabolic disorders
[0762] The 14089 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders as described above,
disorders associated with bone metabolism, immune disorders,
hematopoietic disorders, cardiovascular disorders, liver disorders,
viral diseases, pain or metabolic disorders.
[0763] The 23436 molecules can act as novel diagnostic targets and
therapeutic agents for controlling one or more of cellular
proliferative and/or differentiative disorders (e.g., lymphomas,
leukemias, prostate, liver, and brain cancers), and disorders
associated with erythroid cell differentiation and erythroid cell
function, e.g., a disorder described herein.
[0764] Examples of such disorders are discussed above and
below.
[0765] Aberrant expression and/or activity of 53070, 21953, m32404,
or 14089 molecules may mediate disorders associated with bone
metabolism. "Bone metabolism" refers to direct or indirect effects
in the formation or degeneration of bone structures, e.g., bone
formation, bone resorption, etc., which may ultimately affect the
concentrations in serum of calcium and phosphate. This term also
includes activities mediated by 53070, 21953, m32404, or 14089
molecules effects in bone cells, e.g. osteoclasts and osteoblasts,
that may in turn result in bone formation and degeneration. For
example, 53070, 21953, m32404, or 14089 molecules may support
different activities of bone resorbing osteoclasts such as the
stimulation of differentiation of monocytes and mononuclear
phagocytes into osteoclasts. Accordingly, 53070, 21953, m32404, or
14089 molecules that modulate the production of bone cells can
influence bone formation and degeneration, and thus may be used to
treat bone disorders. Examples of such disorders include, but are
not limited to, osteoporosis, osteodystrophy, osteomalacia,
rickets, osteitis fibrosa cystica, renal osteodystrophy,
osteosclerosis, anti-convulsant treatment, osteopenia,
fibrogenesis-imperfecta ossium, secondary hyperparathyrodism,
hypoparathyroidism, hyperparathyroidism, cirrhosis, obstructive
jaundice, drug induced metabolism, medullary carcinoma, chronic
renal disease, rickets, sarcoidosis, glucocorticoid antagonism,
malabsorption syndrome, steatorrhea, tropical sprue, idiopathic
hypercalcemia and milk fever.
[0766] Disorders associated with the liver include, but are not
limited to, those arising from an accumulation in the liver of
fibrous tissue, such as that resulting from an imbalance between
production and degradation of the extracellular matrix accompanied
by the collapse and condensation of preexisting fibers;
hepatocellular necrosis or injury induced by a wide variety of
agents including processes which disturb homeostasis, such as an
inflammatory process, tissue damage resulting from toxic injury or
altered hepatic blood flow, and infections (e.g., bacterial, viral
and parasitic); and portal hypertension or hepatic fibrosis, e.g.,
fibrosis resulting from a storage disorder such as Gaucher's
disease (lipid abnormalities) or a glycogen storage disease,
A1-antitrypsin deficiency; a disorder mediating the accumulation
(e.g., storage) of an exogenous substance, for example,
hemochromatosis (iron-overload syndrome) and copper storage
diseases (Wilson's disease), disorders resulting in the
accumulation of a toxic metabolite (e.g., tyrosinemia, fructosemia
and galactosemia) and peroxisomal disorders (e.g., Zellweger
syndrome). Additionally, liver disorders can include injury
associated with the administration of various chemicals or drugs,
such as for example, methotrexate, isonizaid, oxyphenisatin,
methyldopa, chlorpromazine, tolbutamide or alcohol, or a hepatic
manifestation of a vascular disorder such as obstruction of either
the intrahepatic or extrahepatic bile flow or an alteration in
hepatic circulation resulting, for example, from chronic heart
failure, veno-occlusive disease, portal vein thrombosis or
Budd-Chiari syndrome.
[0767] Examples of disorders of the lung include, but are not
limited to, congenital anomalies; atelectasis; diseases of vascular
origin, such as pulmonary congestion and edema, including
hemodynamic pulmonary edema and edema caused by microvascular
injury, adult respiratory distress syndrome (diffuse alveolar
damage), pulmonary embolism, hemorrhage, and infarction, and
pulmonary hypertension and vascular sclerosis; chronic obstructive
pulmonary disease, such as emphysema, chronic bronchitis, bronchial
asthma, and bronchiectasis; diffuse interstitial (infiltrative,
restrictive) diseases, such as pneumoconioses, sarcoidosis,
idiopathic pulmonary fibrosis, desquamative interstitial
pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia
(pulmonary infiltration with eosinophilia), Bronchiolitis
obliterans-organizing pneumonia, diffuse pulmonary hemorrhage
syndromes, including Goodpasture syndrome, idiopathic pulmonary
hemosiderosis and other hemorrhagic syndromes, pulmonary
involvement in collagen vascular disorders, and pulmonary alveolar
proteinosis; complications of therapies, such as drug-induced lung
disease, radiation-induced lung disease, and lung transplantation;
tumors, such as bronchogenic carcinoma, including paraneoplastic
syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors,
such as bronchial carcinoid, miscellaneous tumors, and metastatic
tumors; pathologies of the pleura, including inflammatory pleural
effusions, noninflammatory pleural effusions, pneumothorax, and
pleural tumors, including solitary fibrous tumors (pleural fibroma)
and malignant mesothelioma.
[0768] Disorders involving the ovary include, for example,
polycystic ovarian disease, Stein-leventhal syndrome, Pseudomyxoma
peritonei and stromal hyperthecosis; ovarian tumors such as, tumors
of coelomic epithelium, serous tumors, mucinous tumors,
endometeriod tumors, clear cell adenocarcinoma, cystadenofibroma,
brenner tumor, surface epithelial tumors; germ cell tumors such as
mature (benign) teratomas, monodermal teratomas, immature malignant
teratomas, dysgerminoma, endodermal sinus tumor, choriocarcinoma;
sex cord-stomal tumors such as, granulosa-theca cell tumors,
thecoma-fibromas, androblastomas, hill cell tumors, and
gonadoblastoma; and metastatic tumors such as Krukenberg
tumors.
[0769] Examples of cellular proliferative and/or differentiative
disorders include cancers and proliferative disorders mentioned
above. Further examples of cancers or neoplastic conditions, in
addition to the ones described above include, but are not limited
to, a fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma,
osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma,
gastric cancer, esophageal cancer, rectal cancer, pancreatic
cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of
the head and neck, skin cancer, brain cancer, squamous cell
carcinoma, sebaceous gland carcinoma, papillary carcinoma,
papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma,
bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's
tumor, cervical cancer, testicular cancer, small cell lung
carcinoma, non-small cell lung carcinoma, bladder carcinoma,
epithelial carcinoma, glioma, astrocytoma, medulloblastoma,
craniopharyngioma, ependymoma, pinealoma, hemangioblastoma,
acoustic neuroma, oligodendroglioma, meningioma, melanoma,
neuroblastoma, retinoblastoma, leukemia, lymphoma, or Kaposi
sarcoma.
[0770] Disorders involving T-cells include, but are not limited to,
cell-mediated hypersensitivity, such as delayed type
hypersensitivity and T-cell-mediated cytotoxicity, and transplant
rejection; autoimmune diseases, such as systemic lupus
erythematosus, Sjogren syndrome, systemic sclerosis, inflammatory
myopathies, mixed connective tissue disease, and polyarteritis
nodosa and other vasculitides; immunologic deficiency syndromes,
including but not limited to, primary immunodeficiencies, such as
thymic hypoplasia, severe combined immunodeficiency diseases, and
AIDS; leukopenia; reactive (inflammatory) proliferations of white
cells, including but not limited to, leukocytosis, acute
nonspecific lymphadenitis, and chronic nonspecific lymphadenitis;
neoplastic proliferations of white cells, including but not limited
to lymphoid neoplasms, such as precursor T-cell neoplasms, such as
acute lymphoblastic leukemia/lymphoma, peripheral T-cell and
natural killer cell neoplasms that include peripheral T-cell
lymphoma, unspecified, adult T-cell leukemia/lymphoma, mycosis
fungoides and Sezary syndrome, and Hodgkin disease.
[0771] Examples of disorders involving the heart or "cardiovascular
disorder" include, but are not limited to, a disease, disorder, or
state involving the cardiovascular system, e.g., the heart, the
blood vessels, and/or the blood. A cardiovascular disorder can be
caused by an imbalance in arterial pressure, a malfunction of the
heart, or an occlusion of a blood vessel, e.g., by a thrombus.
Examples of such disorders include hypertension, atherosclerosis,
coronary artery spasm, congestive heart failure. coronary artery
disease, valvular disease, arrhythmias, and cardiomyopathies. Other
disorders involving blood vessels include, but are not limited to,
responses of vascular cell walls to injury, such as endothelial
dysfunction and endothelial activation and intimal thickening;
vascular diseases including, but not limited to, congenital
anomalies, such as arteriovenous fistula, artherosclerosis, and
hypertensive vascular disease; inflammatory disease--the
vasculitides, such as giant cell (temporal) arteritis, Takayasu
arterisis, polyarterisis nodosa (classic), Kawasaki syndrome
(mucocutaneous lymph node syndrome), microscopic polyanglitis
(microscopic polyarteritis, hypersensitivity or leukocytoclastic
anglitis), Wegener granulomatosis, thromboanglitis obliterans
(Buerger disease), vasculitis associated with other disorders, and
infectious arteritis; Raynaud disease; aneurysms and dissection,
such as abdominal aortic aneurysms, syphilitic (luetic) aneurysms,
and aortic dissection (dissecting hematoma); disorders of veins and
lymphatics, such as varicose veins, thrombophlebitis and
phlebothrombosis, obstruction of superior vena cava (superior vena
cava syndrome), obstruction of inferior vena cava (inferior vena
cava syndrome), and lymphangitis and lymphedema; tumors, including
benign tumors and tumor-like conditions, such as hemangioma,
lymphangioma, glomus tumor (glomangioma), vascular ectasias, and
bacillary angiomatosis, and intermediate grade (borderline
low-grade malignant) tumors, such as Kaposi sarcoma and
hemangloendothelioma, and malignant tumors, such as angiosarcoma
and hemangiopericytoma; and pathology of therapeutic interventions
in vascular disease, such as balloon angioplasty and related
techniques and vascular replacement, such as coronary artery bypass
graft surgery.
[0772] Disorders of the blood coagulation systems include, but are
not limited to, hemorrhagic diatheses, nonthrombocytopenic
purpuras, thrombocytopenia, idiopathic thrombocytopenic purpura
(ITP), HIV-associated thrombocytopenia, thrombotic
microangiopathies, hemorrhagic diatheses, and disseminated
intravascular coagulation (DIC).
[0773] m32404 may also be involved in disorders involving the
thymus, including the developmental disorders, such as DiGeorge
syndrome with thymic hypoplasia or aplasia; thymic cysts; thymic
hypoplasia, which involves the appearance of lymphoid follicles
within the thymus, creating thymic follicular hyperplasia; and
thymomas, including germ cell tumors, lymphomas, Hodgkin disease,
and carcinoids. Thymomas can include benign or encapsulated
thymoma, and malignant thymoma Type I (invasive thymoma) or Type
II, designated thymic carcinoma.
[0774] Examples of hematopoieitic disorders or diseases include,
but are not limited to, autoimmune diseases (including, for
example, diabetes mellitus, arthritis (including rheumatoid
arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic
arthritis), multiple sclerosis, encephalomyelitis, myasthenia
gravis, systemic lupus erythematosis, autoimmune thyroiditis,
dermatitis (including atopic dermatitis and eczematous dermatitis),
psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer,
iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis,
asthma, allergic asthma, cutaneous lupus erythematosus,
scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal
reactions, erythema nodosum leprosum, autoimmune uveitis, allergic
encephalomyelitis, acute necrotizing hemorrhagic encephalopathy,
idiopathic bilateral progressive sensorineural hearing loss,
aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia,
polychondritis, Wegener's granulomatosis, chronic active hepatitis,
Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves'
disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior,
and interstitial lung fibrosis), graft-versus-host disease, cases
of transplantation, and allergy such as, atopic allergy.
[0775] Additionally, 53070, 15985, 21953, m32404, or 14089
molecules may play an important role in the etiology of certain
viral diseases, including but not limited to Hepatitis B, Hepatitis
C and Herpes Simplex Virus (HSV). Modulators of 53070, 15985,
21953, m32404, or 14089 activity could be used to control viral
diseases. The modulators can be used in the treatment and/or
diagnosis of viral infected tissue or virus-associated tissue
fibrosis, especially liver and liver fibrosis. Also, 53070, 15985,
21953, m32404, or 14089 modulators can be used in the treatment
and/or diagnosis of virus-associated carcinoma, especially
hepatocellular cancer.
[0776] Additionally, 53070, 15985, 21953, m32404, or 14089 may play
an important role in the regulation of metabolism or pain
disorders, e.g. by 21953 processing neuropeptides and metabolic
peptide hormones. Diseases of metabolic imbalance include, but are
not limited to, obesity, anorexia nervosa, cachexia, lipid
disorders, and diabetes. Examples of pain disorders include, but
are not limited to, pain response elicited during various forms of
tissue injury, e.g., inflammation, infection, and ischemia, usually
referred to as hyperalgesia (described in, for example, Fields, H.
L. (1987) Pain, New York:McGraw-Hill); pain associated with
musculoskeletal disorders, e.g., joint pain; tooth pain; headaches;
pain associated with surgery; pain related to irritable bowel
syndrome; or chest pain.
[0777] Modulators of 15985 activity could be used to control viral
diseases. The modulators can be used in the treatment and/or
diagnosis of viral infected tissue or virus-associated tissue
fibrosis, especially liver and liver fibrosis. Also, 15985
modulators can be used in the treatment and/or diagnosis of
virus-associated carcinoma, especially hepatocellular cancer.
[0778] As discussed, successful treatment of 53070, 15985, 26583,
21953, m32404, 14089, or 23436 disorders can be brought about by
techniques that serve to inhibit the expression or activity of
target gene products. For example, compounds, e.g., an agent
identified using an assays described above, that proves to exhibit
negative modulatory activity, can be used in accordance with the
invention to prevent and/or ameliorate symptoms of 53070, 15985,
26583, 21953, m32404, 14089, or 23436 disorders. Such molecules can
include, but are not limited to peptides, phosphopeptides, small
organic or inorganic molecules, or antibodies (including, for
example, polyclonal, monoclonal, humanized, anti-idiotypic,
chimeric or single chain antibodies, and Fab, F(ab').sub.2 and Fab
expression library fragments, scFV molecules, and epitope-binding
fragments thereof).
[0779] Further, antisense and ribozyme molecules that inhibit
expression of the target gene can also be used in accordance with
the invention to reduce the level of target gene expression, thus
effectively reducing the level of target gene activity. Still
further, triple helix molecules can be utilized in reducing the
level of target gene activity. Antisense, ribozyme and triple helix
molecules are discussed above.
[0780] It is possible that the use of antisense, ribozyme, and/or
triple helix molecules to reduce or inhibit mutant gene expression
can also reduce or inhibit the transcription (triple helix) and/or
translation (antisense, ribozyme) of mRNA produced by normal target
gene alleles, such that the concentration of normal target gene
product present can be lower than is necessary for a normal
phenotype. In such cases, nucleic acid molecules that encode and
express target gene polypeptides exhibiting normal target gene
activity can be introduced into cells via gene therapy method.
Alternatively, in instances in that the target gene encodes an
extracellular protein, it can be preferable to co-administer normal
target gene protein into the cell or tissue in order to maintain
the requisite level of cellular or tissue target gene activity.
[0781] Another method by which nucleic acid molecules may be
utilized in treating or preventing a disease characterized by
53070, 15985, 26583, 21953, m32404, 14089, or 23436 expression is
through the use of aptamer molecules specific for 53070, 15985,
26583, 21953, m32404, 14089, or 23436 protein. Aptamers are nucleic
acid molecules having a tertiary structure which permits them to
specifically bind to protein ligands (see, e.g., Osborne, et al.
(1997) Curr. Opin. Chem Biol. 1: 5-9; and Patel, D. J. (1997) Curr
Opin Chem Biol 1:32-46). Since nucleic acid molecules may in many
cases be more conveniently introduced into target cells than
therapeutic protein molecules may be, aptamers offer a method by
which 53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
activity may be specifically decreased without the introduction of
drugs or other molecules which may have pluripotent effects.
[0782] Antibodies can be generated that are both specific for
target gene product and that reduce target gene product activity.
Such antibodies may, therefore, by administered in instances
whereby negative modulatory techniques are appropriate for the
treatment of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
disorders. For a description of antibodies, see the Antibody
section above.
[0783] In circumstances wherein injection of an animal or a human
subject with a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein or epitope for stimulating antibody production is harmful
to the subject, it is possible to generate an immune response
against 53070, 15985, 26583, 21953, m32404, 14089, or 23436 through
the use of anti-idiotypic antibodies (see, for example, Herlyn, D.
(1999) Ann Med 31:66-78; and Bhattacharya-Chatterjee, M., and Foon,
K. A. (1998) Cancer Treat Res. 94:51-68). If an anti-idiotypic
antibody is introduced into a mammal or human subject, it should
stimulate the production of anti-anti-idiotypic antibodies, which
should be specific to the 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein. Vaccines directed to a disease
characterized by 53070, 15985, 26583, 21953, m32404, 14089, or
23436 expression may also be generated in this fashion.
[0784] In instances where the target antigen is intracellular and
whole antibodies are used, internalizing antibodies may be
preferred. Lipofectin or liposomes can be used to deliver the
antibody or a fragment of the Fab region that binds to the target
antigen into cells. Where fragments of the antibody are used, the
smallest inhibitory fragment that binds to the target antigen is
preferred. For example, peptides having an amino acid sequence
corresponding to the Fv region of the antibody can be used.
Alternatively, single chain neutralizing antibodies that bind to
intracellular target antigens can also be administered. Such single
chain antibodies can be administered, for example, by expressing
nucleotide sequences encoding single-chain antibodies within the
target cell population (see e.g., Marasco et al. (1993) Proc. Natl.
Acad. Sci. USA 90:7889-7893).
[0785] The identified compounds that inhibit target gene
expression, synthesis and/or activity can be administered to a
patient at therapeutically effective doses to prevent, treat or
ameliorate 53070, 15985, 26583, 21953, m32404, 14089, or 23436
disorders. A therapeutically effective dose refers to that amount
of the compound sufficient to result in amelioration of symptoms of
the disorders. Toxicity and therapeutic efficacy of such compounds
can be determined by standard pharmaceutical procedures as
described above.
[0786] The data obtained from the cell culture assays and animal
studies can be used in formulating a range of dosage for use in
humans. The dosage of such compounds lies preferably within a range
of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage can vary within this range
depending upon the dosage form employed and the route of
administration utilized. For any compound used in the method of the
invention, the therapeutically effective dose can be estimated
initially from cell culture assays. A dose can be formulated in
animal models to achieve a circulating plasma concentration range
that includes the IC.sub.50 (i.e., the concentration of the test
compound that achieves a half-maximal inhibition of symptoms) as
determined in cell culture. Such information can be used to more
accurately determine useful doses in humans. Levels in plasma can
be measured, for example, by high performance liquid
chromatography.
[0787] Another example of determination of effective dose for an
individual is the ability to directly assay levels of "free" and
"bound" compound in the serum of the test subject. Such assays may
utilize antibody mimics and/or "biosensors" that have been created
through molecular imprinting techniques. The compound which is able
to modulate 53070, 15985, 26583, 21953, m32404, 14089, or 23436
activity is used as a template, or "imprinting molecule", to
spatially organize polymerizable monomers prior to their
polymerization with catalytic reagents. The subsequent removal of
the imprinted molecule leaves a polymer matrix which contains a
repeated "negative image" of the compound and is able to
selectively rebind the molecule under biological assay conditions.
A detailed review of this technique can be seen in Ansell, R. J. et
al (1996) Current Opinion in Biotechnology 7:89-94 and in Shea, K.
J. (1994) Trends in Polymer Science 2:166-173. Such "imprinted"
affinity matrixes are amenable to ligand-binding assays, whereby
the immobilized monoclonal antibody component is replaced by an
appropriately imprinted matrix. An example of the use of such
matrixes in this way can be seen in Vlatakis, G. et al (1993)
Nature 361:645-647. Through the use of isotope-labeling, the "free"
concentration of compound which modulates the expression or
activity of 53070, 15985, 26583, 21953, m32404, 14089, or 23436 can
be readily monitored and used in calculations of IC.sub.50.
[0788] Such "imprinted" affinity matrixes can also be designed to
include fluorescent groups whose photon-emitting properties
measurably change upon local and selective binding of target
compound. These changes can be readily assayed in real time using
appropriate fiberoptic devices, in turn allowing the dose in a test
subject to be quickly optimized based on its individual IC.sub.50.
A rudimentary example of such a "biosensor" is discussed in Kriz,
D. et al (1995) Analytical Chemistry 67:2142-2144.
[0789] Another aspect of the invention pertains to methods of
modulating 53070, 15985, 26583, 21953, m32404, 14089, or 23436
expression or activity for therapeutic purposes. Accordingly, in an
exemplary embodiment, the modulatory method of the invention
involves contacting a cell with a 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 or agent that modulates one or more of the
activities of 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein activity associated with the cell. An agent that modulates
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein
activity can be an agent as described herein, such as a nucleic
acid or a protein, a naturally-occurring target molecule of a
53070, 15985, 26583, 21953, m32404, 14089, or 23436 protein (e.g.,
a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 substrate or
receptor), a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
antibody, a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
agonist or antagonist, a peptidomimetic of a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 agonist or antagonist, or other
small molecule.
[0790] In one embodiment, the agent stimulates one or more 53070,
15985, 26583, 21953, m32404, 14089, or 23436 activities. Examples
of such stimulatory agents include activated 53070, 15985, 26583,
21953, m32404, 14089, or 23436 protein and a nucleic acid molecule
encoding 53070, 15985, 26583, 21953, m32404, 14089, or 23436. In
another embodiment, the agent inhibits one or more 53070, 15985,
26583, 21953, m32404, 14089, or 23436 activities. Examples of such
inhibitory agents include antisense 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 nucleic acid molecules, anti-53070, -15985,
-26583, -21953, -m32404, -14089, or -23436 antibodies, and 53070,
15985, 26583, 21953, m32404, 14089, or 23436 inhibitors. These
modulatory methods can be performed in vitro (e.g., by culturing
the cell with the agent) or, alternatively, in vivo (e.g., by
administering the agent to a subject). As such, the present
invention provides methods of treating an individual afflicted with
a disease or disorder characterized by aberrant or unwanted
expression or activity of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein or nucleic acid molecule. In one
embodiment, the method involves administering an agent (e.g., an
agent identified by a screening assay described herein), or
combination of agents that modulates (e.g., up regulates or down
regulates) 53070, 15985, 26583, 21953, m32404, 14089, or 23436
expression or activity. In another embodiment, the method involves
administering a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
protein or nucleic acid molecule as therapy to compensate for
reduced, aberrant, or unwanted 53070, 15985, 26583, 21953, m32404,
14089, or 23436 expression or activity.
[0791] Stimulation of 53070, 15985, 26583, 21953, m32404, 14089, or
23436 activity is desirable in situations in which 53070, 15985,
26583, 21953, m32404, 14089, or 23436 is abnormally downregulated
and/or in which increased 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity is likely to have a beneficial effect. For
example, stimulation of 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 activity is desirable in situations in which a 53070,
15985, 26583, 21953, m32404, 14089, or 23436 is downregulated
and/or in which increased 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity is likely to have a beneficial effect.
Likewise, inhibition of 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 activity is desirable in situations in which 53070, 15985,
26583, 21953, m32404, 14089, or 23436 is abnormally upregulated
and/or in which decreased 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity is likely to have a beneficial effect.
53070, 15985, 26583, 21953, m32404, 14089, or 23436
Pharmacogenomics
[0792] The 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecules of the present invention, as well as agents, or
modulators which have a stimulatory or inhibitory effect on 53070,
15985, 26583, 21953, m32404, 14089, or 23436 activity (e.g., 53070,
15985, 26583, 21953, m32404, 14089, or 23436 gene expression) as
identified by a screening assay described herein can be
administered to individuals to treat (prophylactically or
therapeutically) 53070, 15985, 26583, 21953, m32404, 14089, or
23436 associated disorders (e.g., cellular proliferative and/or
differentiative disorders; neuronal migration; hyperproliferative
disorders; a cancer, e.g., a cancer of the lung, prostate, breast,
or colon in the case of 21953; coagulative disorders, organogenetic
disorders, complement activation disorders, hormone production
disorders; or an erythroid cell disorder or a proliferative
disorder of erythroid, liver, prostate, or brain cells) associated
with aberrant or unwanted 53070, 15985, 26583, 21953, m32404,
14089, or 23436 activity. In conjunction with such treatment,
pharmacogenomics (i.e., the study of the relationship between an
individual's genotype and that individual's response to a foreign
compound or drug) may be considered. Differences in metabolism of
therapeutics can lead to severe toxicity or therapeutic failure by
altering the relation between dose and blood concentration of the
pharmacologically active drug. Thus, a physician or clinician may
consider applying knowledge obtained in relevant pharmacogenomics
studies in determining whether to administer a 53070, 15985, 26583,
21953, m32404, 14089, or 23436 molecule or 53070, 15985, 26583,
21953, m32404, 14089, or 23436 modulator as well as tailoring the
dosage and/or therapeutic regimen of treatment with a 53070, 15985,
26583, 21953, m32404, 14089, or 23436 molecule or 53070, 15985,
26583, 21953, m32404, 14089, or 23436 modulator.
[0793] Pharmacogenomics deals with clinically significant
hereditary variations in the response to drugs due to altered drug
disposition and abnormal action in affected persons. See, for
example, Eichelbaum, M. et al. (1996) Clin. Exp. Pharmacol.
Physiol. 23:983-985 and Linder, M. W. et al. (1997) Clin. Chem.
43:254-266. In general, two types of pharmacogenetic conditions can
be differentiated. Genetic conditions transmitted as a single
factor altering the way drugs act on the body (altered drug action)
or genetic conditions transmitted as single factors altering the
way the body acts on drugs (altered drug metabolism). These
pharmacogenetic conditions can occur either as rare genetic defects
or as naturally-occurring polymorphisms. For example,
glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common
inherited enzymopathy in which the main clinical complication is
haemolysis after ingestion of oxidant drugs (anti-malarials,
sulfonamides, analgesics, nitrofurans) and consumption of fava
beans.
[0794] One pharmacogenomics approach to identifying genes that
predict drug response, known as "a genome-wide association", relies
primarily on a high-resolution map of the human genome consisting
of already known gene-related markers (e.g., a "bi-allelic" gene
marker map which consists of 60,000-100,000 polymorphic or variable
sites on the human genome, each of which has two variants.) Such a
high-resolution genetic map can be compared to a map of the genome
of each of a statistically significant number of patients taking
part in a Phase II/III drug trial to identify markers associated
with a particular observed drug response or side effect.
Alternatively, such a high resolution map can be generated from a
combination of some ten-million known single nucleotide
polymorphisms (SNPs) in the human genome. As used herein, a "SNP"
is a common alteration that occurs in a single nucleotide base in a
stretch of DNA. For example, a SNP may occur once per every 1000
bases of DNA. A SNP may be involved in a disease process, however,
the vast majority may not be disease-associated. Given a genetic
map based on the occurrence of such SNPs, individuals can be
grouped into genetic categories depending on a particular pattern
of SNPs in their individual genome. In such a manner, treatment
regimens can be tailored to groups of genetically similar
individuals, taking into account traits that may be common among
such genetically similar individuals.
[0795] Alternatively, a method termed the "candidate gene
approach," can be utilized to identify genes that predict drug
response. According to this method, if a gene that encodes a drug's
target is known (e.g., a 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 protein of the present invention), all common variants of
that gene can be fairly easily identified in the population and it
can be determined if having one version of the gene versus another
is associated with a particular drug response.
[0796] Alternatively, a method termed the "gene expression
profiling," can be utilized to identify genes that predict drug
response. For example, the gene expression of an animal dosed with
a drug (e.g., a 53070, 15985, 26583, 21953, m32404, 14089, or 23436
molecule or 53070, 15985, 26583, 21953, m32404, 14089, or 23436
modulator of the present invention) can give an indication whether
gene pathways related to toxicity have been turned on.
[0797] Information generated from more than one of the above
pharmacogenomics approaches can be used to determine appropriate
dosage and treatment regimens for prophylactic or therapeutic
treatment of an individual. This knowledge, when applied to dosing
or drug selection, can avoid adverse reactions or therapeutic
failure and thus enhance therapeutic or prophylactic efficiency
when treating a subject with a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 molecule or 53070, 15985, 26583, 21953, m32404,
14089, or 23436 modulator, such as a modulator identified by one of
the exemplary screening assays described herein.
[0798] The present invention further provides methods for
identifying new agents, or combinations, that are based on
identifying agents that modulate the activity of one or more of the
gene products encoded by one or more of the 53070, 15985, 26583,
21953, m32404, 14089, or 23436 genes of the present invention,
wherein these products may be associated with resistance of the
cells to a therapeutic agent. Specifically, the activity of the
proteins encoded by the 53070, 15985, 26583, 21953, m32404, 14089,
or 23436 genes of the present invention can be used as a basis for
identifying agents for overcoming agent resistance. By blocking the
activity of one or more of the resistance proteins, target cells,
e.g., human cells, will become sensitive to treatment with an agent
that the unmodified target cells were resistant to.
[0799] Monitoring the influence of agents (e.g., drugs) on the
expression or activity of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 protein can be applied in clinical trials. For
example, the effectiveness of an agent determined by a screening
assay as described herein to increase 53070, 15985, 26583, 21953,
m32404, 14089, or 23436 gene expression, protein levels, or
upregulate 53070, 15985, 26583, 21953, m32404, 14089, or 23436
activity, can be monitored in clinical trials of subjects
exhibiting decreased 53070, 15985, 26583, 21953, m32404, 14089, or
23436 gene expression, protein levels, or downregulated 53070,
15985, 26583, 21953, m32404, 14089, or 23436 activity.
Alternatively, the effectiveness of an agent determined by a
screening assay to decrease 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene expression, protein levels, or downregulate
53070, 15985, 26583, 21953, m32404, 14089, or 23436 activity, can
be monitored in clinical trials of subjects exhibiting increased
53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene
expression, protein levels, or upregulated 53070, 15985, 26583,
21953, m32404, 14089, or 23436 activity. In such clinical trials,
the expression or activity of a 53070, 15985, 26583, 21953, m32404,
14089, or 23436 gene, and preferably, other genes that have been
implicated in, for example, a 53070, 15985, 26583, 21953, m32404,
14089, or 23436-associated disorder can be used as a "read out" or
markers of the phenotype of a particular cell.
[0800] This invention is further illustrated by the following
examples that should not be construed as limiting. The contents of
all references, patents and published patent applications cited
throughout this application are incorporated herein by
reference.
EXAMPLES
Examples for 53070
Example 1
Identification and Characterization of Human 53070 cDNA
[0801] The human 53070 sequence (FIG. 1; SEQ ID NO:1), which is
approximately 1704 nucleotides long. The nucleic acid sequence
includes an initiation codon (ATG) and a termination codon (TGA).
The region between and inclusive of the initiation codon and the
termination codon is a methionine-initiated coding sequence of
about 1104 nucleotides, including the termination codon
(nucleotides indicated as "coding" of SEQ ID NO:1; SEQ ID NO:3).
The coding sequence encodes a 367 amino acid protein (SEQ ID
NO:2).
Example 2
Tissue Distribution of 53070 mRNA by TaqMan Analysis
[0802] Endogenous human 53070 gene expression can be determined
using the Perkin-Elmer/ABI 7700 Sequence Detection System which
employs TaqMan technology. Briefly, TaqMan technology relies on
standard RT-PCR with the addition of a third gene-specific
oligonucleotide (referred to as a probe) which has a fluorescent
dye coupled to its 5' end (typically 6-FAM) and a quenching dye at
the 3' end (typically TAMRA). When the fluorescently tagged
oligonucleotide is intact, the fluorescent signal from the 5' dye
is quenched. As PCR proceeds, the 5' to 3' nucleolytic activity of
Taq polymerase digests the labeled primer, producing a free
nucleotide labeled with 6-FAM, which is now detected as a
fluorescent signal. The PCR cycle where fluorescence is first
released and detected is directly proportional to the starting
amount of the gene of interest in the test sample, thus providing a
quantitative measure of the initial template concentration. Samples
can be internally controlled by the addition of a second set of
primers/probe specific for a housekeeping gene such as GAPDH which
has been labeled with a different fluorophore on the 5' end
(typically VIC).
[0803] To determine the level of 53070 in various human tissues a
primer/probe set can be designed. Total RNA can be prepared from a
series of human tissues using an RNeasy kit from Qiagen. First
strand cDNA can be prepared from 1 .mu.g total RNA using an
oligo-dT primer and Superscript II reverse transcriptase
(Gibco/BRL). cDNA obtained from approximately 50 ng total RNA is
used per TaqMan reaction. Tissues tested can include human tissues,
e.g., colon, liver, lung, breast, heart, brain, blood, or testes,
as well as cell lines of human origin, e.g., cell lines obtains
from tumors.
Example 3
Tissue Distribution of 53070 mRNA by Northern Analysis
[0804] Northern blot hybridizations with various RNA samples can be
performed under standard conditions and washed under stringent
conditions, i.e., 0.2.times.SSC at 65.degree. C. A DNA probe
corresponding to all or a portion of the 53070 cDNA (SEQ ID NO:1)
can be used. The DNA was radioactively labeled with .sup.32P-dCTP
using the Prime-It Kit (Stratagene, La Jolla, Calif.) according to
the instructions of the supplier. Filters containing mRNA from
mouse hematopoietic and endocrine tissues, and cancer cell lines
(Clontech, Palo Alto, Calif.) can be probed in ExpressHyb
hybridization solution (Clontech) and washed at high stringency
according to manufacturer's recommendations.
Example 4
Recombinant Expression of 53070 in Bacterial Cells
[0805] In this example, 53070 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
53070 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-53070 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 5
Expression of Recombinant 53070 Protein in COS Cells
[0806] To express the 53070 gene in COS cells (e.g., COS-7 cells,
CV-1 origin SV40 cells; Gluzman (1981) Cell I23:175-182), the
pcDNA/Amp vector by Invitrogen Corporation (San Diego, Calif.) is
used. This vector contains an SV40 origin of replication, an
ampicillin resistance gene, an E. coli replication origin, a CMV
promoter followed by a polylinker region, and an SV40 intron and
polyadenylation site. A DNA fragment encoding the entire 53070
protein and an HA tag (Wilson et al. (1984) Cell 37:767) or a FLAG
tag fused in-frame to its 3' end of the fragment is cloned into the
polylinker region of the vector, thereby placing the expression of
the recombinant protein under the control of the CMV promoter.
[0807] To construct the plasmid, the 53070 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the 53070 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the 53070 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the 53070_gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5.alpha., SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0808] COS cells are subsequently transfected with the
53070-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. The
expression of the 53070 polypeptide is detected by radiolabelling
(.sup.35S-methionine or .sup.35S-cysteine available from NEN,
Boston, Mass., can be used) and immunoprecipitation (Harlow, E. and
Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.) using an HA specific
monoclonal antibody. Briefly, the cells are labeled for 8 hours
with .sup.35S-methionine (or .sup.35S-cysteine). The culture media
are then collected and the cells are lysed using detergents (RIPA
buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH
7.5). Both the cell lysate and the culture media are precipitated
with an HA specific monoclonal antibody. Precipitated polypeptides
are then analyzed by SDS-PAGE.
[0809] Alternatively, DNA containing the 53070 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the 53070 polypeptide is detected by radiolabelling
and immunoprecipitation using a 53070 specific monoclonal
antibody.
Examples for 15985
Example 6
Identification and Characterization of Human 15985 cDNA
[0810] The human 15985 sequence (FIG. 4; SEQ ID NO:7), which is
approximately 3552 nucleotides long. The nucleic acid sequence
includes an initiation codon (ATG) and a termination codon (TGA).
The region between and inclusive of the initiation codon and the
termination codon is a methionine-initiated coding sequence of
about 2301 nucleotides, including the termination codon
(nucleotides indicated as "coding" of SEQ ID NO:7; SEQ ID NO:9).
The coding sequence encodes a 766 amino acid protein (SEQ ID
NO:8).
Example 7
Tissue Distribution of 15985 mRNA by TaqMan Analysis
[0811] Endogenous human 15985 gene expression was determined using
the Perkin-Elmer/ABI 7700 Sequence Detection System which employs
TaqMan technology. Briefly, TaqMan technology relies on standard
RT-PCR with the addition of a third gene-specific oligonucleotide
(referred to as a probe) which has a fluorescent dye coupled to its
5' end (typically 6-FAM) and a quenching dye at the 3' end
(typically TAMRA). When the fluorescently tagged oligonucleotide is
intact, the fluorescent signal from the 5' dye is quenched. As PCR
proceeds, the 5' to 3' nucleolytic activity of Taq polymerase
digests the labeled primer, producing a free nucleotide labeled
with 6-FAM, which is now detected as a fluorescent signal. The PCR
cycle where fluorescence is first released and detected is directly
proportional to the starting amount of the gene of interest in the
test sample, thus providing a quantitative measure of the initial
template concentration. Samples can be internally controlled by the
addition of a second set of primers/probe specific for a
housekeeping gene such as GAPDH which has been labeled with a
different fluorophore on the 5' end (typically VIC).
[0812] To determine the level of 15985 in various human tissues a
primer/probe set was designed. Total RNA was prepared from a series
of human tissues using an RNeasy kit from Qiagen. First strand cDNA
was prepared from 1 .mu.g total RNA using an oligo-dT primer and
Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained
from approximately 50 ng total RNA was used per TaqMan reaction.
Tissues tested include the human tissues and several cell lines
shown in Tables 1, 2, and 3.
[0813] Table 1 below depicts the expression of 15985 mRNA in a
panel of normal and tumor human tissues using TaqMan analysis.
Elevated expression of 15985 mRNA was found in the following
tissues: normal vein, hemangionoma, heart (Congestive Heart
Failure), normal adipose, normal brain cortex, ovary and ovary
tumor, normal prostate, normal colon, and normal lung.
TABLE-US-00001 Tissue Type Expression Artery normal 0.0132 Aorta
diseased 0.0252 Vein normal 2.5329 Coronary SMC 0.0116 HUVEC 0.0922
Hemangioma 0.3513 Heart normal 0.0321 Heart CHF 0.2163 Kidney 0.017
Skeletal Muscle 0.0386 Adipose normal 0.2672 Pancreas 0.0301
primary osteoblasts 0.0087 Osteoclasts (diff) 0.0015 Skin normal
0.0687 Spinal cord normal 0.0519 Brain Cortex normal 0.3335 Brain
Hypothalamus normal 0.9017 Nerve 0.0074 DRG (Dorsal Root Ganglion)
0.2644 Breast normal 0.0258 Breast tumor 0.026 Ovary normal 0.1373
Ovary Tumor 0.5143 Prostate Normal 0.2493 Prostate Tumor 0.0182
Salivary glands 0.0049 Colon normal 0.2718 Colon Tumor 0.0223 Lung
normal 0.2785 Lung tumor 0.0585 Lung COPD 0.1005 Liver normal 0.017
Liver fibrosis 0.0494 Spleen normal 0.0491 Tonsil normal 0.0432
Lymph node normal 0.0211 Small intestine normal 0.0922
Skin-Decubitus 0.0321 Synovium 0.0275 BM-MNC 0.0041 Activated PBMC
0.0043 Neutrophils 0.0003 Megakaryocytes 0.0108 Erythroid 0.0009
Lung COPD 0.0998
[0814] Table 2 below depicts the expression of 15985 mRNA in a
panel of normal and tumor breast tissues using TaqMan analysis.
Increased expression of 15985 mRNA can be observed in SkBr3 and
Hs578Bst cells.
TABLE-US-00002 Tissue Type Expression MCF10MS 0.00 MCF10A 0.00
MCF10AT.cl1 0.05 MCF10AT.cl3 0.09 MCF10AT1 0.00 MCF10AT3B 0.08
MCF10CA1a.cl1 0.00 MCF10CA1a.cl1 Agar 0.00 MCF10A.m25 Plastic 0.00
MCF10CA Agar 0.00 MCF10CA Plastic 0.00 MCF3B Agar 0.00 MCF3B
Plastic 0.00 MCF10A EGF 0 hr 0.02 MCF10A EGF 0.5 hr 0.01 MCF10A EGF
1 hr 0.02 MCF10A EGF 2 hr 0.00 MCF10A EGF 4 hr 0.00 MCF10A EGF 8 hr
0.00 MCF10A IGF1A 0 hr 0.00 MCF10A IGF1A 0.5 hr 0.00 MCF10A IGF1A 1
hr 0.00 MCF10A IGF1A 3 hr 0.00 MCF10A IGF1A 24 hr 0.00
MCF10AT3B.cl5 Plastic 0.33 MCF10AT3B.cl6 Plastic 0.00 MCF10AT3B.cl3
Plastic 0.00 MCF10AT3B.cl1 Plastic 0.35 MCF10AT3B.cl4 Plastic 0.19
MCF10AT3B.cl2 Plastic 0.23 MCF10AT3B.cl5 Agar 0.00 MCF10AT3B.cl6
Agar 0.00 MCF-7 0.00 ZR-75 0.00 T47D 0.00 MDA-231 0.12 MDA-435 0.00
SkBr3 1.93 Hs578Bst 1.46 Hs578T 0.12 MCF10AT3B Agar 0.31
[0815] Table 3 below also depicts the expression of 15985 mRNA in a
panel of normal and tumor human tissue. Increased expression can be
observed in ovary tumor and lung tumor samples.
TABLE-US-00003 Tissue Type Expression PIT 400 Breast N 0.36 PIT 372
Breast N 0.35 CHT 1228 Breast Normal 0.09 MDA 304 Breast T: MD-IDC
0.05 CHT 2002 Breast T: IDC 0.25 MDA 236-Breast T: PD-IDC(ILC?)
0.00 CHT 562 Breast T: IDC 0.04 NDR 138 Breast T ILC (LG) 0.10 CHT
1841 Lymph node (Breast met) 0.00 PIT 58 Lung (Breast met) 0.00 CHT
620 Ovary N 1.32 PIT 208 Ovary N 2.15 CLN 012 Ovary T 26.46 CLN 07
Ovary T 2.87 CLN 17 Ovary T 4.52 MDA 25 Ovary T 0.00 CLN 08 Ovary T
0.87 PIT 298 Lung N 0.03 MDA 185 Lung N 0.07 CLN 930 Lung N 0.29
MPI 215 Lung T-SmC 2.95 MDA 259 Lung T-PDNSCCL 12.78 CHT 832 Lung
T-PDNSCCL 0.07 MDA 262 Lung T-SCC 2.27 CHT 793 Lung T-ACA 0.03 CHT
331 Lung T-ACA 0.91 CHT 405 Colon N 0.03 CHT 523 Colon N 0.25 CHT
371 Colon N 0.01 CHT 382 Colon T: MD 0.00 CHT 528 Colon T: MD 0.03
CLN 609 Colon T 1.74 NDR 210 Colon T: MD-PD 0.46 CHT 340
Colon-Liver Met 0.00 CHT 1637Colon-Liver Met 0.00 PIT 260 Liver N
(female) 0.00 CHT 1653 Cervix Squamous CC 0.23 CHT 569 Cervix
Squamous CC 0.00 A24 HMVEC-Arr 0.08 C48 HMVEC-Prol 0.04 Pooled
Hemangiomas 0.12 HCT116N22 Normoxic 2.08 HCT116H22 Hypoxic 0.00
Example 8
Tissue Distribution of 15985 mRNA by Northern Analysis
[0816] Northern blot hybridizations with various RNA samples can be
performed under standard conditions and washed under stringent
conditions, i.e., 0.2.times.SSC at 65.degree. C. A DNA probe
corresponding to all or a portion of the 15985 cDNA (SEQ ID NO:7)
can be used. The DNA was radioactively labeled with .sup.32P-dCTP
using the Prime-It Kit (Stratagene, La Jolla, Calif.) according to
the instructions of the supplier. Filters containing mRNA from
mouse hematopoietic and endocrine tissues, and cancer cell lines
(Clontech, Palo Alto, Calif.) can be probed in ExpressHyb
hybridization solution (Clontech) and washed at high stringency
according to manufacturer's recommendations.
Example 9
Recombinant Expression of 15985 in Bacterial Cells
[0817] In this example, 15985 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
15985 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-15985 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 10
Expression of Recombinant 15985 Protein in COS Cells
[0818] To express the 15985 gene in COS cells (e.g., COS-7 cells,
CV-1 origin SV40 cells; Gluzman (1981) Cell I23:175-182), the
pcDNA/Amp vector by Invitrogen Corporation (San Diego, Calif.) is
used. This vector contains an SV40 origin of replication, an
ampicillin resistance gene, an E. coli replication origin, a CMV
promoter followed by a polylinker region, and an SV40 intron and
polyadenylation site. A DNA fragment encoding the entire 15985
protein and an HA tag (Wilson et al. (1984) Cell 37:767) or a FLAG
tag fused in-frame to its 3' end of the fragment is cloned into the
polylinker region of the vector, thereby placing the expression of
the recombinant protein under the control of the CMV promoter.
[0819] To construct the plasmid, the 15985 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the 15985 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the 15985 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the 15985_gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5.alpha.c, SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0820] COS cells are subsequently transfected with the
15985-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. The
expression of the 15985 polypeptide is detected by radiolabelling
(.sup.35S-methionine or .sup.35S-cysteine available from NEN,
Boston, Mass., can be used) and immunoprecipitation (Harlow, E. and
Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.) using an HA specific
monoclonal antibody. Briefly, the cells are labeled for 8 hours
with .sup.35S-methionine (or .sup.35S-cysteine). The culture media
are then collected and the cells are lysed using detergents (RIPA
buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH
7.5). Both the cell lysate and the culture media are precipitated
with an HA specific monoclonal antibody. Precipitated polypeptides
are then analyzed by SDS-PAGE.
[0821] Alternatively, DNA containing the 15985 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the 15985 polypeptide is detected by radiolabelling
and immunoprecipitation using a 15985 specific monoclonal
antibody.
Examples for 26583
Example 11
Identification and Characterization of Human 26583 cDNA
[0822] The human 26583 sequence (SEQ ID NO:14), which is
approximately 2838 nucleotides long including untranslated regions,
contains a predicted methionine-initiated coding sequence of about
1613 nucleotides (nucleotides 462 to 2075 of SEQ ID NO:14; SEQ ID
NO:16). The coding sequence encodes a 537 amino acid protein (SEQ
ID NO:15).
Example 12
Tissue Distribution of 26583 mRNA
[0823] Endogenous human 26583 gene expression was determined using
the Perkin-Elmer/ABI 7700 Sequence Detection System which employs
TaqMan technology. Briefly, TaqMan technology relies on standard
RT-PCR with the addition of a third gene-specific oligonucleotide
(referred to as a probe) which has a fluorescent dye coupled to its
5' end (typically 6-FAM) and a quenching dye at the 3' end
(typically TAMRA). When the fluorescently tagged oligonucleotide is
intact, the fluorescent signal from the 5' dye is quenched. As PCR
proceeds, the 5' to 3' nucleolytic activity of Taq polymerase
digests the labeled primer, producing a free nucleotide labeled
with 6-FAM, which is now detected as a fluorescent signal. The PCR
cycle where fluorescence is first released and detected is directly
proportional to the starting amount of the gene of interest in the
test sample, thus providing a way of quantitating the initial
template concentration. Samples can be internally controlled by the
addition of a second set of primers/probe specific for a
housekeeping gene such as GAPDH which has been labeled with a
different fluorophore on the 5' end (typically VIC).
[0824] To determine the level of 26583 in various human tissues a
primer/probe set was designed using Primer Express (Perkin-Elmer)
software and primary cDNA sequence information. Total RNA was
prepared from a series of human tissues using an RNeasy kit from
Qiagen. First strand cDNA was prepared from 1 .mu.g total RNA using
an oligo-dT primer and Superscript II reverse transcriptase
(Gibco/BRL). cDNA obtained from approximately 50 ng total RNA was
used per TaqMan reaction.
[0825] 26583 mRNA was analyzed in a variety of normal and tumor
clinical tissue samples. 26853 expression was found in human
breast, lung, colon, liver, and brain. FIG. 11 shows relative 26583
mRNA expression on mRNA derived from the following tissue samples:
columns 1-3, normal breast; columns 4-10, breast tumor; columns
11-13, normal lung; columns 14-20, lung tumor; columns 21-23,
normal colon; columns 24-31, colon tumor; columns 32-35, colon
metastases; columns 36-37, normal liver; columns 38-39, normal
brain; columns 40-42, brain tumor. On average, 26583 expression was
increased in lung tumor tissue as compared to normal lung tissue.
26583 expression levels were substantially lower in brain tumor
tissue compared to normal brain.
[0826] Northern blot hybridizations with various RNA samples can be
performed under standard conditions and washed under stringent
conditions, i.e., 0.2.times.SSC at 65.degree. C. A DNA probe
corresponding to all or a portion of the 26583 cDNA (SEQ ID NO:14)
can be used. The DNA can be radioactively labeled with
.sup.32P-dCTP using the Prime-It Kit (Stratagene, La Jolla, Calif.)
according to the instructions of the supplier. Filters containing
mRNA from mouse hematopoietic and endocrine tissues, and cancer
cell lines (Clontech, Palo Alto, Calif.) can be probed in
ExpressHyb hybridization solution (Clontech) and washed at high
stringency according to manufacturer's recommendations.
Example 13
Recombinant Expression of 26583 in Bacterial Cells
[0827] In this example, 26583 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
26583 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-26583 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 14
Expression of Recombinant 26583 Protein in COS Cells
[0828] To express the 26583 gene in COS cells, the pcDNA/Amp vector
by Invitrogen Corporation (San Diego, Calif.) is used. This vector
contains an SV40 origin of replication, an ampicillin resistance
gene, an E. coli replication origin, a CMV promoter followed by a
polylinker region, and an SV40 intron and polyadenylation site. A
DNA fragment encoding the entire 26583 protein and an HA tag
(Wilson et al. (1984) Cell 37:767) or a FLAG tag fused in-frame to
its 3' end of the fragment is cloned into the polylinker region of
the vector, thereby placing the expression of the recombinant
protein under the control of the CMV promoter.
[0829] To construct the plasmid, the 26583 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the 26583 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the 26583 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the 26583 gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5.alpha., SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0830] COS cells are subsequently transfected with the
26583-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory
Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1989. The expression of
the 26583 polypeptide is detected by radiolabeling
(.sup.35S-methionine or .sup.35S-cysteine available from NEN,
Boston, Mass., can be used) and immunoprecipitation (Harlow, E. and
Lane, D. Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1988) using an HA
specific monoclonal antibody. Briefly, the cells are labeled for 8
hours with .sup.35S-methionine (or .sup.35S-cysteine). The culture
media are then collected and the cells are lysed using detergents
(RIPA buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM
Tris, pH 7.5). Both the cell lysate and the culture media are
precipitated with an HA specific monoclonal antibody. Precipitated
polypeptides are then analyzed by SDS-PAGE.
[0831] Alternatively, DNA containing the 26583 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the 26583 polypeptide is detected by radiolabelling
and immunoprecipitation using a 26583 specific monoclonal
antibody.
Examples for 21953
Example 15
Identification and Characterization of Human 21953 cDNA
[0832] The human 21953 nucleic acid sequence (SEQ ID NO:19) is
approximately 3143 nucleotides long. The nucleic acid sequence
includes an initiation codon (ATG) and a termination codon (TAA).
The region between and inclusive of the initiation codon and the
termination codon is a methionine-initiated coding sequence of
about 2646 nucleotides (nucleotides 229-2874 of SEQ ID NO:19,
designated as SEQ ID NO:21). The coding sequence encodes an 882
amino acid protein.
Example 16
21953 mRNA Expression
[0833] Endogenous human 21953 gene expression was determined using
the Perkin-Elmer/ABI 7700 Sequence Detection System which employs
TaqMan technology. Briefly, TaqMan technology relies on standard
RT-PCR with the addition of a third gene-specific oligonucleotide
(referred to as a probe) which has a fluorescent dye coupled to its
5' end (typically 6-FAM) and a quenching dye at the 3' end
(typically TAMRA). When the fluorescently tagged oligonucleotide is
intact, the fluorescent signal from the 5' dye is quenched. As PCR
proceeds, the 5' to 3' nucleolytic activity of Taq polymerase
digests the labeled primer, producing a free nucleotide labeled
with 6-FAM, which is now detected as a fluorescent signal. The PCR
cycle where fluorescence is first released and detected is directly
proportional to the starting amount of the gene of interest in the
test sample, thus providing a quantitative measure of the initial
template concentration. Samples were internally controlled by the
addition of a second set of primers/probe specific for a reference
gene such as .beta.2-macroglobulin, GAPDH which has been labeled
with a different fluorophore on the 5' end (typically VIC).
[0834] To determine the level of 21953 in various human tissues a
primer/probe set was designed. Total RNA was prepared from a series
of human tissues using an RNeasy kit from Qiagen. First strand cDNA
was prepared from 1 .mu.g total RNA using an oligo-dT primer and
Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained
from approximately 50 ng total RNA was used per TaqMan reaction.
Tissues tested include the human tissues and several cell lines
shown in the left column of the tables below.
[0835] 21953 mRNA expression was elevated in 85% of clinical lung
tumor samples tested, and is similarly elevated in a number of
breast tumor and colon tumor samples (see, e.g., Table 4
below).
TABLE-US-00004 TABLE 4 Sample Relative Expression Breast Normal
0.02 Breast Normal 0.07 Breast Tumor 0.08 Breast Tumor 0.07 Breast
Tumor 0.19 Breast Tumor 0.21 Breast Tumor 0.07 Breast Tumor 0.30
Ovary Normal 0.37 Ovary Normal 0.26 Ovary Normal 0.33 Ovary Tumor
0.16 Ovary Tumor 0.13 Ovary Tumor 0.17 Ovary Tumor 0.10 Ovary Tumor
0.12 Ovary Tumor 0.08 Ovary Tumor 0.52 Ovary Tumor 0.06 Lung Normal
0.02 Lung Normal 0.01 Lung Normal 0.10 Lung Normal 0.01 Lung Tumor
0.59 Lung Tumor 0.18 Lung Tumor 0.24 Lung Tumor 0.04 Lung Tumor
0.78 Lung Tumor 0.37 Lung Tumor 0.16
[0836] Many tested lung tumor samples in Table 4 (6 of 7) expressed
21953 mRNA at higher levels than did normal lung tumor samples.
Similarly, a number of breast tumor samples expressed 21953 mRNA to
a greater extent that did normal breast tumor samples.
TABLE-US-00005 TABLE 5 Sample Relative Expression Colon Normal 0.00
Colon Normal 0.02 Colon Normal 0.05 Colon Normal 0.01 Colon Tumor
0.03 Colon Tumor 0.24 Colon Tumor 0.07 Colon Tumor 0.03 Colon Tumor
0.03 Colon Tumor 0.04 Liver Metastatic 0.07 Liver Metastatic 0.16
Liver Metastatic 0.23 Liver Normal 0.05 Liver Normal 0.19 Brain
Normal 1.50 Brain Normal 0.98 Astrocyte 0.37 Brain Tumor 0.04 Brain
Tumor 0.10 Brain Tumor 0.04 Brain Tumor 0.13 HMVEC-Arr 0.22
HMVEC-Prol 0.26 Placenta 0.11 Fetal Adrenal 0.15 Fetal Adrenal 0.18
Fetal Liver 0.71 Fetal Liver 0.18
[0837] The mRNA expression data for 21953 mRNA tabulated in Table 5
indicated that (1) 21953 mRNA can be overexpressed in some colon
tumor samples relative to normal colon tissue samples; (2) 21953
mRNA is well expressed in metastatic liver samples; (3) 21953 mRNA
is highly expressed in normal brain tissue (e.g., increased
expression relative to brain tumors), astrocytes, and fetal liver;
and (4) 21953 mRNA is also expressed in HMVEC (human microvascular
endothelial cells), and fetal adrenal cells.
TABLE-US-00006 TABLE 6 Sample Relative Expression Aorta/normal 0.00
Fetal heart/normal 2.42 Heart normal 0.66 Heart/CHF 0.72
Vein/Normal 0.13 SMC (Aortic) 0.89 Spinal cord/Normal 0.66 Brain
cortex/Normal 5.94 Brain hypothalamus/Normal 4.13 Glial cells
(Astrocytes) 1.35 Brain/Glioblastoma 1.12 Breast/Normal 0.18 Breast
tumor/IDC 0.38 Ovary/Normal 0.39 Ovary/Tumor 0.16 Pancreas 0.25
Prostate/Normal 0.18 Prostate/Tumor 0.15 Colon/normal 0.07
Colon/tumor 0.56 Colon/IBD 0.10 Kidney/normal 0.71 Liver/normal
0.10 Liver fibrosis 0.22 Fetal Liver/normal 2.21 Lung/normal 0.16
Lung/tumor 0.39 Lung/COPD 0.22 Spleen/normal 0.14 Tonsil/normal
0.11 Lymph node/normal 0.27 Thymus/normal 1.16 Epithelial Cells
(prostate) 2.04 Endothelial Cells (aortic) 0.27 Skeletal
Muscle/Normal 1.22 Fibroblasts (Dermal) 0.18 Skin/normal 0.35
Adipose/Normal 0.06 Osteoblasts (primary) 0.44 Osteoblasts (Undiff)
0.32 Osteoblasts(Diff) 0.29 Osteoclasts 0.08 Aortic SMC Early 1.27
Aortic SMC Late 2.61 shear HUVEC 3.39 static HUVEC 2.14
[0838] The mRNA expression data for 21953 mRNA tabulated in Table 6
indicated that 21953 mRNA is highly expressed, for example, in
fetal heart, brain cortex, brain hypothalamus, fetal liver,
epithelial cells from prostate, aortic smooth muscle cells, and
human umbilical vein endothelial cells under both shear and static
conditions.
TABLE-US-00007 TABLE 7 Sample Relative Expression MCF-7 Breast
Tumor 15.15 ZR75 Breast Tumor 6.11 T47D Breast Tumor 1.50 MDA 231
Breast Tumor 0.01 MDA 435 Breast Tumor 0.00 DLD 1 ColonT (stageC)
22.33 SW480 ColonT (stageB) 0.06 SW620 ColonT (stageC) 5.23 HCT116
0.63 HT29 0.01 Colo 205 0.00 NCIH125 0.75 NCIH69 23.28 NCIH322
20.91 NCIH460 1.25 A549 7.11 NHBE 0.83 SKOV-3 ovary 0.22 OVCAR-3
ovary 17.28 293 ovary 44.97 293T ovary 59.75 A549 t6 0.83 A549 t9
1.27 A549 t18 14.63 A549 t24 1.99
[0839] Tumor cell lines were xenografted into nude mice. Expression
of human 21953 mRNA in tumors harvested from the mice was analyzed
using TaqMan. Results are tabulated in Table 7 (excepting the final
four rows, see below). The results indicated that, for example,
21953 mRNA is highly expressed in some xenografted colon tumor
samples (colonT), some xenografted breast tumor samples, and
xenografted ovarian cell lines.
[0840] The final four rows of Table 7 tabulate relative 21953 mRNA
expression in samples of A549 human lung cancer cells at various
hourly time points (time in hours being indicated with the prefix
t) after release from aphidocolin treatment. 21953 mRNA expression
peaked at the G1 to S phase transition.
TABLE-US-00008 TABLE 8 Relative Sample Expression PIT 337 Colon
Normal 0.28 CHT 410 Colon Normal 0.03 CHT 425 Colon Normal 0.13 CHT
371 Colon Normal 0.03 CHT 414 Colonic ACA-B 0.16 CHT 841 Colonic
ACA-B 0.07 CHT 807 Colonic ACA-B 0.21 CHT 382 Colonic ACA-B 0.32
CHT 596 Colonic ACA-C 0.00 CHT 907 Colonic ACA-C 0.13 CHT 372
Colonic ACA-C 0.49 NDR 210 Colonic ACA-C 0.13 CHT 1365 Colonic
ACA-C 0.03 CLN 741 Liver Normal 0.00 NDR 165 Liver Normal 0.00 NDR
150 Liver Normal 0.06 PIT 236 Liver Normal 0.00 CHT 077 Col Liver
Metastatis 0.06 CHT 119 Col Liver Metastatis 4.79 CHT 131 Col Liver
Metastatis 0.76 CHT 218 Col Liver Metastatis 1.12 CHT 739 Col Liver
Metastatis 0.18 CHT 215 Col Abdominal Metastatis 0.01
[0841] 21953 mRNA is cell cycle regulated in the lung carcinoma
cell line A549. A549 cells were synchronized with aphidocholin, and
then released. mRNA was prepared from the cells at regular
intervals after release. 21953 expression peaked during the G1 to S
phase transition.
[0842] In situ hybridization experiments which provided additional
confirmatory results are tabulated in Table 9. 21953 mRNA was
observed by in situ hybridization in lung small cell carcinoma and
differentiated tumors, but not in normal lung tissue. Similarly, by
this analysis, 21953 mRNA expression was elevated in colon tumor
samples (2 of 2), metastatic colon tumor samples (2 of 2), and in a
differentiated papillary ovarian tumor sample. 21953 mRNA was also
detected in normal breast tissue (1 of 1), normal ovarian tissue (1
of 1), and ovarian tumors (2 of 2).
TABLE-US-00009 TABLE 9 Tissue Diagnosis Results Breast Normal +
Breast Intraductal Carcinoma - Colon Normal - Colon Normal - Colon
Tumor + Colon Tumor + Colon Metastasis + Colon Metastasis ++ Liver
Normal - Lung Normal - Lung Small Cell Carcinoma ++ Lung
Differentiated ++ Lung Differentiated +/- Lung Differentiated ++
Ovary Normal + Ovary Tumor (well differentiated carcinoma) + Ovary
Tumor (moderately differentiated papillary) ++
Example 17
Recombinant Expression of 21953 in Bacterial Cells
[0843] In this example, 21953 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
21953 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-21953 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 18
Expression of Recombinant 21953 Protein in COS Cells
[0844] To express the 21953 gene in COS cells, the pcDNA/Amp vector
by Invitrogen Corporation (San Diego, Calif.) is used. This vector
contains an SV40 origin of replication, an ampicillin resistance
gene, an E. coli replication origin, a CMV promoter followed by a
polylinker region, and an SV40 intron and polyadenylation site. A
DNA fragment encoding the entire 21953 protein and an HA tag
(Wilson et al. (1984) Cell 37:767) or a FLAG tag fused in-frame to
its 3' end of the fragment is cloned into the polylinker region of
the vector, thereby placing the expression of the recombinant
protein under the control of the CMV promoter.
[0845] To construct the plasmid, the 21953 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the 21953 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the 21953 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the 21953_gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5.alpha., SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0846] COS cells are subsequently transfected with the
21953-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. The
expression of the 21953 polypeptide is detected by radiolabelling
(.sup.35S-methionine or .sup.35S-cysteine available from NEN,
Boston, Mass., can be used) and immunoprecipitation (Harlow, E. and
Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.) using an HA specific
monoclonal antibody. Briefly, the cells are labeled for 8 hours
with .sup.35S-methionine (or .sup.35S-cysteine). The culture media
are then collected and the cells are lysed using detergents (RIPA
buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH
7.5). Both the cell lysate and the culture media are precipitated
with an HA specific monoclonal antibody. Precipitated polypeptides
are then analyzed by SDS-PAGE.
[0847] Alternatively, DNA containing the 21953 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the 21953 polypeptide is detected by radiolabelling
and immunoprecipitation using a 21953 specific monoclonal
antibody.
Examples for m32404
Example 19
Identification and Characterization of Human m32404 cDNA
[0848] The human m32404 sequence (SEQ ID NO:24), which is
approximately 2219 nucleotides long. The nucleic acid sequence
includes an initiation codon (ATG) and a termination codon (TGA).
The region between and inclusive of the initiation codon and the
termination codon is a methionine-initiated coding sequence of
about 1659 nucleotides, including the termination codon
(nucleotides indicated as "coding" of SEQ ID NO:24; SEQ ID NO:26).
The coding sequence encodes a 552 amino acid protein (SEQ ID
NO:25).
Example 20
Tissue Distribution of m32404 mRNA by TaqMan Analysis
[0849] Endogenous human m32404 gene expression was determined using
the Perkin-Elmer/ABI 7700 Sequence Detection System which employs
TaqMan technology. Briefly, TaqMan technology relies on standard
RT-PCR with the addition of a third gene-specific oligonucleotide
(referred to as a probe) which has a fluorescent dye coupled to its
5' end (typically 6-FAM) and a quenching dye at the 3' end
(typically TAMRA). When the fluorescently tagged oligonucleotide is
intact, the fluorescent signal from the 5' dye is quenched. As PCR
proceeds, the 5' to 3' nucleolytic activity of Taq polymerase
digests the labeled primer, producing a free nucleotide labeled
with 6-FAM, which is now detected as a fluorescent signal. The PCR
cycle where fluorescence is first released and detected is directly
proportional to the starting amount of the gene of interest in the
test sample, thus providing a quantitative measure of the initial
template concentration. Samples can be internally controlled by the
addition of a second set of primers/probe specific for a
housekeeping gene such as GAPDH which has been labeled with a
different fluorophore on the 5' end (typically VIC).
[0850] To determine the level of m32404 in various human tissues a
primer/probe set was designed. Total RNA was prepared from a series
of human tissues using an RNeasy kit from Qiagen. First strand cDNA
was prepared from 1 .mu.g total RNA using an oligo-dT primer and
Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained
from approximately 50 ng total RNA was used per TaqMan
reaction.
Example 21
Tissue Distribution of m32404 mRNA by Northern Analysis
[0851] Northern blot hybridizations with various RNA samples can be
performed under standard conditions and washed under stringent
conditions, i.e., 0.2.times.SSC at 65.degree. C. A DNA probe
corresponding to all or a portion of the m32404 cDNA (SEQ ID NO:24)
can be used. The DNA was radioactively labeled with .sup.32P-dCTP
using the Prime-It Kit (Stratagene, La Jolla, Calif.) according to
the instructions of the supplier. Filters containing mRNA from
mouse hematopoietic and endocrine tissues, and cancer cell lines
(Clontech, Palo Alto, Calif.) can be probed in ExpressHyb
hybridization solution (Clontech) and washed at high stringency
according to manufacturer's recommendations.
Example 22
Recombinant Expression of m32404 in Bacterial Cells
[0852] In this example, m32404 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
m32404 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-m32404 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 23
Expression of Recombinant m32404 Protein in COS Cells
[0853] To express the m32404 gene in COS cells, the pcDNA/Amp
vector by Invitrogen Corporation (San Diego, Calif.) is used. This
vector contains an SV40 origin of replication, an ampicillin
resistance gene, an E. coli replication origin, a CMV promoter
followed by a polylinker region, and an SV40 intron and
polyadenylation site. A DNA fragment encoding the entire m32404
protein and an HA tag (Wilson et al. (1984) Cell 37:767) or a FLAG
tag fused in-frame to its 3' end of the fragment is cloned into the
polylinker region of the vector, thereby placing the expression of
the recombinant protein under the control of the CMV promoter.
[0854] To construct the plasmid, the m32404 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the m32404 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the m32404 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the m32404 gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5a, SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0855] COS cells are subsequently transfected with the
m32404-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory
Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1989. The expression of
the m32404 polypeptide is detected by radiolabelling
(35S-methionine or 35S-cysteine available from NEN, Boston, Mass.,
can be used) and immunoprecipitation (Harlow, E. and Lane, D.
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y., 1988) using an HA specific
monoclonal antibody. Briefly, the cells are labeled for 8 hours
with 35S-methionine (or 35S-cysteine). The culture media are then
collected and the cells are lysed using detergents (RIPA buffer,
150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5).
Both the cell lysate and the culture media are precipitated with an
HA specific monoclonal antibody. Precipitated polypeptides are then
analyzed by SDS-PAGE.
[0856] Alternatively, DNA containing the m32404 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the m32404 polypeptide is detected by radiolabelling
and immunoprecipitation using an m32404 specific monoclonal
antibody.
Examples for 14089
Example 24
Identification and Characterization of Human 14089 cDNA
[0857] The human 14089 sequence (SEQ ID NO:33) is approximately 957
nucleotides long. The nucleic acid sequence includes an initiation
codon (ATG) and a termination codon (TGA). The region between and
inclusive of the initiation codon and the termination codon is a
methionine-initiated coding sequence of about 726 nucleotides,
including the termination codon (nucleotides indicated as "coding"
of SEQ ID NO:33; SEQ ID NO:35). The coding sequence encodes a 241
amino acid protein (SEQ ID NO:34).
Example 25
Tissue Distribution of 14089 mRNA
[0858] Northern blot hybridizations with various RNA samples can be
performed under standard conditions and washed under stringent
conditions, i.e., 0.2.times.SSC at 65.degree. C. A DNA probe
corresponding to all or a portion of the 14089 cDNA (SEQ ID NO:33)
can be used. The DNA was radioactively labeled with .sup.32P-dCTP
using the Prime-It Kit (Stratagene, La Jolla, Calif.) according to
the instructions of the supplier. Filters containing mRNA from
mouse hematopoietic and endocrine tissues, and cancer cell lines
(Clontech, Palo Alto, Calif.) can be probed in ExpressHyb
hybridization solution (Clontech) and washed at high stringency
according to manufacturer's recommendations.
Example 26
Recombinant Expression of 14089 in Bacterial Cells
[0859] In this example, 14089 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
14089 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-14089 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 27
Expression of Recombinant 14089 Protein in COS Cells
[0860] To express the 14089 gene in COS cells, the pcDNA/Amp vector
by Invitrogen Corporation (San Diego, Calif.) is used. This vector
contains an SV40 origin of replication, an ampicillin resistance
gene, an E. coli replication origin, a CMV promoter followed by a
polylinker region, and an SV40 intron and polyadenylation site. A
DNA fragment encoding the entire 14089 protein and an HA tag
(Wilson et al. (1984) Cell 37:767) or a FLAG tag fused in-frame to
its 3' end of the fragment is cloned into the polylinker region of
the vector, thereby placing the expression of the recombinant
protein under the control of the CMV promoter.
[0861] To construct the plasmid, the 14089 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the 14089 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the 14089 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the 14089_gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5.alpha., SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0862] COS cells are subsequently transfected with the
14089-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. The
expression of the 14089 polypeptide is detected by radiolabelling
(.sup.35S-methionine or .sup.35S-cysteine available from NEN,
Boston, Mass., can be used) and immunoprecipitation (Harlow, E. and
Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.) using an HA specific
monoclonal antibody. Briefly, the cells are labeled for 8 hours
with .sup.35S-methionine (or .sup.35S-cysteine). The culture media
are then collected and the cells are lysed using detergents (RIPA
buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH
7.5). Both the cell lysate and the culture media are precipitated
with an HA specific monoclonal antibody. Precipitated polypeptides
are then analyzed by SDS-PAGE.
[0863] Alternatively, DNA containing the 14089 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the 14089 polypeptide is detected by radiolabelling
and immunoprecipitation using a 14089 specific monoclonal
antibody.
Examples for 23436
Example 28
Identification and Characterization of Human 23436 cDNA
[0864] The human 23436 sequence (SEQ ID NO:40), which is
approximately 2446 nucleotides long, including untranslated
regions, contains a predicted methionine-initiated coding sequence
of about 1458 nucleotides, including the termination codon
(nucleotides indicated as "coding" of SEQ ID NO:40; SEQ ID NO:42).
The coding sequence encodes a 485 amino acid protein (SEQ ID
NO:41).
Example 29
Tissue Distribution of 23436 mRNA
[0865] Endogenous human 23436 gene expression was determined using
the Perkin-Elmer/ABI 7700 Sequence Detection System which employs
TaqMan technology. Briefly, TaqMan technology relies on standard
RT-PCR with the addition of a third gene-specific oligonucleotide
(referred to as a probe) which has a fluorescent dye coupled to its
5' end (typically 6-FAM) and a quenching dye at the 3' end
(typically TAMRA). When the fluorescently tagged oligonucleotide is
intact, the fluorescent signal from the 5' dye is quenched. As PCR
proceeds, the 5' to 3' nucleolytic activity of Taq polymerase
digests the labeled primer, producing a free nucleotide labeled
with 6-FAM, which is now detected as a fluorescent signal. The PCR
cycle where fluorescence is first released and detected is directly
proportional to the starting amount of the gene of interest in the
test sample, thus providing a quantitative measure of the initial
template concentration. Samples can be internally controlled by the
addition of a second set of primers/probe specific for a
housekeeping gene such as GAPDH which has been labeled with a
different fluorophore on the 5' end (typically VIC).
[0866] To determine the level of 23436 in various human tissues a
primer/probe set was designed. Total RNA was prepared from a series
of human tissues using an RNeasy kit from Qiagen. First strand cDNA
was prepared from 1 .mu.g total RNA using an oligo-dT primer and
Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained
from approximately 50 ng total RNA was used per TaqMan reaction.
Tissues tested include the human tissues and several cell lines
shown in FIGS. 23 to 28. 23436 mRNA was detected in erythroid cells
(FIGS. 23-26). 23436 expression was also found in prostate,
hypothalamus and bone marrow (FIG. 27). The 23436 mRNA is also
expressed in HepG2 cells, a liver derived cell line (FIG. 28).
[0867] Northern blot hybridizations with various RNA samples can be
performed under standard conditions and washed under stringent
conditions, i.e., 0.2.times.SSC at 65.degree. C. A DNA probe
corresponding to all or a portion of the 23436 cDNA (SEQ ID NO:40)
can be used. The DNA was radioactively labeled with .sup.32P-dCTP
using the Prime-It Kit (Stratagene, La Jolla, Calif.) according to
the instructions of the supplier. Filters containing mRNA from
mouse hematopoietic and endocrine tissues, and cancer cell lines
(Clontech, Palo Alto, Calif.) can be probed in ExpressHyb
hybridization solution (Clontech) and washed at high stringency
according to manufacturer's recommendations.
Example 30
Recombinant Expression of 23436 in Bacterial Cells
[0868] In this example, 23436 is expressed as a recombinant
glutathione-S-transferase (GST) fusion polypeptide in E. coli and
the fusion polypeptide is isolated and characterized. Specifically,
23436 is fused to GST and this fusion polypeptide is expressed in
E. coli, e.g., strain PEB199. Expression of the GST-23436 fusion
protein in PEB199 is induced with IPTG. The recombinant fusion
polypeptide is purified from crude bacterial lysates of the induced
PEB199 strain by affinity chromatography on glutathione beads.
Using polyacrylamide gel electrophoretic analysis of the
polypeptide purified from the bacterial lysates, the molecular
weight of the resultant fusion polypeptide is determined.
Example 31
Expression of Recombinant 23436 Protein in COS Cells
[0869] To express the 23436 gene in COS cells, the pcDNA/Amp vector
by Invitrogen Corporation (San Diego, Calif.) is used. This vector
contains an SV40 origin of replication, an ampicillin resistance
gene, an E. coli replication origin, a CMV promoter followed by a
polylinker region, and an SV40 intron and polyadenylation site. A
DNA fragment encoding the entire 23436 protein and an HA tag
(Wilson et al. (1984) Cell 37:767) or a FLAG tag fused in-frame to
its 3' end of the fragment is cloned into the polylinker region of
the vector, thereby placing the expression of the recombinant
protein under the control of the CMV promoter.
[0870] To construct the plasmid, the 23436 DNA sequence is
amplified by PCR using two primers. The 5' primer contains the
restriction site of interest followed by approximately twenty
nucleotides of the 23436 coding sequence starting from the
initiation codon; the 3' end sequence contains complementary
sequences to the other restriction site of interest, a translation
stop codon, the HA tag or FLAG tag and the last 20 nucleotides of
the 23436 coding sequence. The PCR amplified fragment and the
pCDNA/Amp vector are digested with the appropriate restriction
enzymes and the vector is dephosphorylated using the CIAP enzyme
(New England Biolabs, Beverly, Mass.). Preferably the two
restriction sites chosen are different so that the 23436 gene is
inserted in the correct orientation. The ligation mixture is
transformed into E. coli cells (strains HB101, DH5.alpha., SURE,
available from Stratagene Cloning Systems, La Jolla, Calif., can be
used), the transformed culture is plated on ampicillin media
plates, and resistant colonies are selected. Plasmid DNA is
isolated from transformants and examined by restriction analysis
for the presence of the correct fragment.
[0871] COS cells are subsequently transfected with the
23436-pcDNA/Amp plasmid DNA using the calcium phosphate or calcium
chloride co-precipitation methods, DEAE-dextran-mediated
transfection, lipofection, or electroporation. Other suitable
methods for transfecting host cells can be found in Sambrook, J.,
Fritsh, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. The
expression of the 23436 polypeptide is detected by radiolabelling
(.sup.35S-methionine or .sup.35S-cysteine available from NEN,
Boston, Mass., can be used) and immunoprecipitation (Harlow, E. and
Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.) using an HA specific
monoclonal antibody. Briefly, the cells are labeled for 8 hours
with .sup.35S-methionine (or .sup.35S-cysteine). The culture media
are then collected and the cells are lysed using detergents (RIPA
buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH
7.5). Both the cell lysate and the culture media are precipitated
with an HA specific monoclonal antibody. Precipitated polypeptides
are then analyzed by SDS-PAGE.
[0872] Alternatively, DNA containing the 23436 coding sequence is
cloned directly into the polylinker of the pCDNA/Amp vector using
the appropriate restriction sites. The resulting plasmid is
transfected into COS cells in the manner described above, and the
expression of the 23436 polypeptide is detected by radiolabelling
and immunoprecipitation using a 23436 specific monoclonal
antibody.
EQUIVALENTS
[0873] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed by the
following claims.
Sequence CWU 1
1
6312297DNAHomo sapiensCDS(154)...(1656)misc_feature(1)...(2297)n =
A,T,C or G 1cacgcgtccg cgaagcggct gcatctggcg ccgcgtctgc cccgcgtgct
cggagcggat 60tctgcccgcc gtccccggag ccctcggcgc cccgctgagc ccgcgatcac
ttcctccctg 120tgaccaaccg gcgctgcagg ttagagcctg gca atg ccg ttt ggg
tgt gtg act 174 Met Pro Phe Gly Cys Val Thr 1 5ctg ggc gac aag aag
aac tat aac cag cca tcg gag gtg act gac aga 222Leu Gly Asp Lys Lys
Asn Tyr Asn Gln Pro Ser Glu Val Thr Asp Arg 10 15 20tat gat ttg gga
cag gtc atc aag act gag gag ttt tgt gaa atc ttc 270Tyr Asp Leu Gly
Gln Val Ile Lys Thr Glu Glu Phe Cys Glu Ile Phe 25 30 35cgg gcc aag
gac aag acg aca ggc aag ctg cac acc tgc aag aag ttc 318Arg Ala Lys
Asp Lys Thr Thr Gly Lys Leu His Thr Cys Lys Lys Phe 40 45 50 55cag
aag cgg gac ggc cgc aag gtg cgg aaa gct gcc aag aac gag ata 366Gln
Lys Arg Asp Gly Arg Lys Val Arg Lys Ala Ala Lys Asn Glu Ile 60 65
70ggc atc ctc aag atg gtg aag cat ccc aac atc cta cag ctg gtg gat
414Gly Ile Leu Lys Met Val Lys His Pro Asn Ile Leu Gln Leu Val Asp
75 80 85gtg ttt gtg acc cgc aag gag tac ttt atc ttc ctg gag ctg gcc
acg 462Val Phe Val Thr Arg Lys Glu Tyr Phe Ile Phe Leu Glu Leu Ala
Thr 90 95 100ggg agg gag gtg ttt gac tgg atc ctg gac cag ggc tac
tac tcg gag 510Gly Arg Glu Val Phe Asp Trp Ile Leu Asp Gln Gly Tyr
Tyr Ser Glu 105 110 115cga gac aca agc aac gtg gta cgg caa gtc ctg
gag gcc gtg gcc tat 558Arg Asp Thr Ser Asn Val Val Arg Gln Val Leu
Glu Ala Val Ala Tyr120 125 130 135ttg cac tca ctc aag atc gtg cac
agg aat ctc aag ctg gag aac ctg 606Leu His Ser Leu Lys Ile Val His
Arg Asn Leu Lys Leu Glu Asn Leu 140 145 150gtt tac tac aac cgg ctg
aag aac tcg aag att gtc atc agt gac ttc 654Val Tyr Tyr Asn Arg Leu
Lys Asn Ser Lys Ile Val Ile Ser Asp Phe 155 160 165cat ctg gct aag
cta gaa aat ggc ctc atc aag gag ccc tgt ggg acc 702His Leu Ala Lys
Leu Glu Asn Gly Leu Ile Lys Glu Pro Cys Gly Thr 170 175 180ccc gag
tat ctg gcc cca gag gtg gta ggc cgg cag cgg tat gga cgc 750Pro Glu
Tyr Leu Ala Pro Glu Val Val Gly Arg Gln Arg Tyr Gly Arg 185 190
195cct gtg gac tgc tgg gcc att gga gtc atc atg tac atc ctg ctt tca
798Pro Val Asp Cys Trp Ala Ile Gly Val Ile Met Tyr Ile Leu Leu
Ser200 205 210 215ggc aat cca cct ttc tat gag gag gtg gaa gaa gat
gat tat gag aac 846Gly Asn Pro Pro Phe Tyr Glu Glu Val Glu Glu Asp
Asp Tyr Glu Asn 220 225 230cat gat aag aat ctc ttc cgc aag atc ctg
gct ggt gac tat gag ttt 894His Asp Lys Asn Leu Phe Arg Lys Ile Leu
Ala Gly Asp Tyr Glu Phe 235 240 245gac tct cca tat tgg gat gat att
tcg cag gca gcc aaa gac ctg gtc 942Asp Ser Pro Tyr Trp Asp Asp Ile
Ser Gln Ala Ala Lys Asp Leu Val 250 255 260aca agg ctg atg gag gtg
gag caa gac cag cgg atc act gca gaa gag 990Thr Arg Leu Met Glu Val
Glu Gln Asp Gln Arg Ile Thr Ala Glu Glu 265 270 275gcc atc tcc cat
gag tgg att tct ggc aat gct gct tct gat aag aac 1038Ala Ile Ser His
Glu Trp Ile Ser Gly Asn Ala Ala Ser Asp Lys Asn280 285 290 295atc
aag gat ggt gtc tgt gcc cag att gaa aag aac ttt gcc agg gcc 1086Ile
Lys Asp Gly Val Cys Ala Gln Ile Glu Lys Asn Phe Ala Arg Ala 300 305
310aag tgg aag aag gct gtc cga gtg acc acc ctc atg aaa cgg ctc cgg
1134Lys Trp Lys Lys Ala Val Arg Val Thr Thr Leu Met Lys Arg Leu Arg
315 320 325gca cca gag cag tcc agc acg gct gca gcc cag tcg gcc tca
gcc aca 1182Ala Pro Glu Gln Ser Ser Thr Ala Ala Ala Gln Ser Ala Ser
Ala Thr 330 335 340gac act gcc acc ccc ggg gct gca ggt ggg gcc aca
gct gca gct gcg 1230Asp Thr Ala Thr Pro Gly Ala Ala Gly Gly Ala Thr
Ala Ala Ala Ala 345 350 355agt gga gct acc tca gcc cct gag ggt gat
gct gct cgt gct gca aag 1278Ser Gly Ala Thr Ser Ala Pro Glu Gly Asp
Ala Ala Arg Ala Ala Lys360 365 370 375agt gat aat gtg gcc ccc gca
gac cgt agt gcc acc cca gcc aca gat 1326Ser Asp Asn Val Ala Pro Ala
Asp Arg Ser Ala Thr Pro Ala Thr Asp 380 385 390gga agt gcc acc cca
gcc act gat ggc agt gtc acc cca gcc acc gat 1374Gly Ser Ala Thr Pro
Ala Thr Asp Gly Ser Val Thr Pro Ala Thr Asp 395 400 405gga agc atc
act cca gcc act gat ggg agt gtc acc cca gcc act gac 1422Gly Ser Ile
Thr Pro Ala Thr Asp Gly Ser Val Thr Pro Ala Thr Asp 410 415 420agg
agc gct act cca gcc act gat ggg aga gcc aca cca gcc aca gaa 1470Arg
Ser Ala Thr Pro Ala Thr Asp Gly Arg Ala Thr Pro Ala Thr Glu 425 430
435gag agc act gtg ccc acc acc caa agc agt gcc atg ctg gcc acc aag
1518Glu Ser Thr Val Pro Thr Thr Gln Ser Ser Ala Met Leu Ala Thr
Lys440 445 450 455gca gct gcc acc cct gag ccg gct atg gcc cag ccg
gac agc aca gcc 1566Ala Ala Ala Thr Pro Glu Pro Ala Met Ala Gln Pro
Asp Ser Thr Ala 460 465 470cca gag ggc gcc aca ggc cag gct cca ccc
tct agt aaa ggg gaa gag 1614Pro Glu Gly Ala Thr Gly Gln Ala Pro Pro
Ser Ser Lys Gly Glu Glu 475 480 485gct gct ggt tat gcc cag gag tct
caa agg gag gag gcc agc 1656Ala Ala Gly Tyr Ala Gln Glu Ser Gln Arg
Glu Glu Ala Ser 490 495 500tgagtaggca gcctggtgag ggggggcagg
ggatgggcag gagggtggga gagtggatga 1716ggggcttctc actgtacata
gagtcactgg catgatgccc tcgctccccc atgcccccac 1776atcccagtgg
ggcataacta ggggtcacgg gagagcagtc tcgtctcctg tgtgtatgtg
1836tgtgagtggt gggcaggcca gtggcagggc cggccccagc ccctgcatgg
attccttgtg 1896gcttttctgt cttttgctag cttcaccagt ttctgttcct
tgtgggatgc tgctctaggg 1956atactcaggg ggctcctgct ctccttcccc
ttcccttctt gcctcaccat tcccctaggc 2016aggccctgca ggtcccacac
tctcccaggc cctaaacttg ggcggccttg ccctgagagc 2076tggtcctcca
gcgaggccct gtcagcggtc ttaggctcct gcacatgaag gtgtgtgcct
2136gtggtgtgtg ggctgctcta ggagcagata caggctggta tagaggatgc
agaaaggtag 2196ggcagtatgt ttaagtccag acttggcaca tggctaggga
tactgctcac tagctgtgga 2256ggtcctcagg agtggagaga atgagtagga
nggcagaanc t 22972501PRTHomo sapiens 2Met Pro Phe Gly Cys Val Thr
Leu Gly Asp Lys Lys Asn Tyr Asn Gln 1 5 10 15Pro Ser Glu Val Thr
Asp Arg Tyr Asp Leu Gly Gln Val Ile Lys Thr 20 25 30Glu Glu Phe Cys
Glu Ile Phe Arg Ala Lys Asp Lys Thr Thr Gly Lys 35 40 45Leu His Thr
Cys Lys Lys Phe Gln Lys Arg Asp Gly Arg Lys Val Arg 50 55 60Lys Ala
Ala Lys Asn Glu Ile Gly Ile Leu Lys Met Val Lys His Pro65 70 75
80Asn Ile Leu Gln Leu Val Asp Val Phe Val Thr Arg Lys Glu Tyr Phe
85 90 95Ile Phe Leu Glu Leu Ala Thr Gly Arg Glu Val Phe Asp Trp Ile
Leu 100 105 110Asp Gln Gly Tyr Tyr Ser Glu Arg Asp Thr Ser Asn Val
Val Arg Gln 115 120 125Val Leu Glu Ala Val Ala Tyr Leu His Ser Leu
Lys Ile Val His Arg 130 135 140Asn Leu Lys Leu Glu Asn Leu Val Tyr
Tyr Asn Arg Leu Lys Asn Ser145 150 155 160Lys Ile Val Ile Ser Asp
Phe His Leu Ala Lys Leu Glu Asn Gly Leu 165 170 175Ile Lys Glu Pro
Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Val 180 185 190Gly Arg
Gln Arg Tyr Gly Arg Pro Val Asp Cys Trp Ala Ile Gly Val 195 200
205Ile Met Tyr Ile Leu Leu Ser Gly Asn Pro Pro Phe Tyr Glu Glu Val
210 215 220Glu Glu Asp Asp Tyr Glu Asn His Asp Lys Asn Leu Phe Arg
Lys Ile225 230 235 240Leu Ala Gly Asp Tyr Glu Phe Asp Ser Pro Tyr
Trp Asp Asp Ile Ser 245 250 255Gln Ala Ala Lys Asp Leu Val Thr Arg
Leu Met Glu Val Glu Gln Asp 260 265 270Gln Arg Ile Thr Ala Glu Glu
Ala Ile Ser His Glu Trp Ile Ser Gly 275 280 285Asn Ala Ala Ser Asp
Lys Asn Ile Lys Asp Gly Val Cys Ala Gln Ile 290 295 300Glu Lys Asn
Phe Ala Arg Ala Lys Trp Lys Lys Ala Val Arg Val Thr305 310 315
320Thr Leu Met Lys Arg Leu Arg Ala Pro Glu Gln Ser Ser Thr Ala Ala
325 330 335Ala Gln Ser Ala Ser Ala Thr Asp Thr Ala Thr Pro Gly Ala
Ala Gly 340 345 350Gly Ala Thr Ala Ala Ala Ala Ser Gly Ala Thr Ser
Ala Pro Glu Gly 355 360 365Asp Ala Ala Arg Ala Ala Lys Ser Asp Asn
Val Ala Pro Ala Asp Arg 370 375 380Ser Ala Thr Pro Ala Thr Asp Gly
Ser Ala Thr Pro Ala Thr Asp Gly385 390 395 400Ser Val Thr Pro Ala
Thr Asp Gly Ser Ile Thr Pro Ala Thr Asp Gly 405 410 415Ser Val Thr
Pro Ala Thr Asp Arg Ser Ala Thr Pro Ala Thr Asp Gly 420 425 430Arg
Ala Thr Pro Ala Thr Glu Glu Ser Thr Val Pro Thr Thr Gln Ser 435 440
445Ser Ala Met Leu Ala Thr Lys Ala Ala Ala Thr Pro Glu Pro Ala Met
450 455 460Ala Gln Pro Asp Ser Thr Ala Pro Glu Gly Ala Thr Gly Gln
Ala Pro465 470 475 480Pro Ser Ser Lys Gly Glu Glu Ala Ala Gly Tyr
Ala Gln Glu Ser Gln 485 490 495Arg Glu Glu Ala Ser 50031503DNAHomo
sapiens 3atgccgtttg ggtgtgtgac tctgggcgac aagaagaact ataaccagcc
atcggaggtg 60actgacagat atgatttggg acaggtcatc aagactgagg agttttgtga
aatcttccgg 120gccaaggaca agacgacagg caagctgcac acctgcaaga
agttccagaa gcgggacggc 180cgcaaggtgc ggaaagctgc caagaacgag
ataggcatcc tcaagatggt gaagcatccc 240aacatcctac agctggtgga
tgtgtttgtg acccgcaagg agtactttat cttcctggag 300ctggccacgg
ggagggaggt gtttgactgg atcctggacc agggctacta ctcggagcga
360gacacaagca acgtggtacg gcaagtcctg gaggccgtgg cctatttgca
ctcactcaag 420atcgtgcaca ggaatctcaa gctggagaac ctggtttact
acaaccggct gaagaactcg 480aagattgtca tcagtgactt ccatctggct
aagctagaaa atggcctcat caaggagccc 540tgtgggaccc ccgagtatct
ggccccagag gtggtaggcc ggcagcggta tggacgccct 600gtggactgct
gggccattgg agtcatcatg tacatcctgc tttcaggcaa tccacctttc
660tatgaggagg tggaagaaga tgattatgag aaccatgata agaatctctt
ccgcaagatc 720ctggctggtg actatgagtt tgactctcca tattgggatg
atatttcgca ggcagccaaa 780gacctggtca caaggctgat ggaggtggag
caagaccagc ggatcactgc agaagaggcc 840atctcccatg agtggatttc
tggcaatgct gcttctgata agaacatcaa ggatggtgtc 900tgtgcccaga
ttgaaaagaa ctttgccagg gccaagtgga agaaggctgt ccgagtgacc
960accctcatga aacggctccg ggcaccagag cagtccagca cggctgcagc
ccagtcggcc 1020tcagccacag acactgccac ccccggggct gcaggtgggg
ccacagctgc agctgcgagt 1080ggagctacct cagcccctga gggtgatgct
gctcgtgctg caaagagtga taatgtggcc 1140cccgcagacc gtagtgccac
cccagccaca gatggaagtg ccaccccagc cactgatggc 1200agtgtcaccc
cagccaccga tggaagcatc actccagcca ctgatgggag tgtcacccca
1260gccactgaca ggagcgctac tccagccact gatgggagag ccacaccagc
cacagaagag 1320agcactgtgc ccaccaccca aagcagtgcc atgctggcca
ccaaggcagc tgccacccct 1380gagccggcta tggcccagcc ggacagcaca
gccccagagg gcgccacagg ccaggctcca 1440ccctctagta aaggggaaga
ggctgctggt tatgcccagg agtctcaaag ggaggaggcc 1500agc
150344417DNAHomo sapiensCDS(337)...(1713) 4gggagcgccc cgcgtccggg
acaagccgca gacaaaaccc ctcagacacc aaagggcttt 60attcggccgg gagcatcagc
aaacttaggt ctcaaaaaac caagctctcc aagttacaag 120atgttcacct
aagattgaga cctagtgact acgtttccta cgggaacaaa taaatggttt
180ttcatctccc ggagatacat tacaaacaaa tatggtgcta aaagaactcc
ttacctttct 240ctgactacaa tttatttgga catacttttg tattgaagag
aggtatacat actgaagcta 300cttgctgtac tataggagac tctgtcctgt aggatc
atg gac cat cct agt agg 354 Met Asp His Pro Ser Arg 1 5gaa aag gat
gaa aga caa cgg aca act aaa ccc atg gca caa agg agt 402Glu Lys Asp
Glu Arg Gln Arg Thr Thr Lys Pro Met Ala Gln Arg Ser 10 15 20gca cac
tgc tct cga cca tct ggc tcc tca tcg tcc tct ggg gtt ctt 450Ala His
Cys Ser Arg Pro Ser Gly Ser Ser Ser Ser Ser Gly Val Leu 25 30 35atg
gtg gga ccc aac ttc agg gtt ggc aag aag ata gga tgt ggg aac 498Met
Val Gly Pro Asn Phe Arg Val Gly Lys Lys Ile Gly Cys Gly Asn 40 45
50ttc gga gag ctc aga tta ggt aaa aat ctc tac acc aat gaa tat gta
546Phe Gly Glu Leu Arg Leu Gly Lys Asn Leu Tyr Thr Asn Glu Tyr Val
55 60 65 70gca atc aaa ctg gaa cca ata aaa tca cgt gct cca cag ctt
cat tta 594Ala Ile Lys Leu Glu Pro Ile Lys Ser Arg Ala Pro Gln Leu
His Leu 75 80 85gag tac aga ttt tat aaa cag ctt ggc agt gca ggt gaa
ggt ctc cca 642Glu Tyr Arg Phe Tyr Lys Gln Leu Gly Ser Ala Gly Glu
Gly Leu Pro 90 95 100cag gtg tat tac ttt gga cca tgt ggg aaa tat
aat gcc atg gtg ctg 690Gln Val Tyr Tyr Phe Gly Pro Cys Gly Lys Tyr
Asn Ala Met Val Leu 105 110 115gag ctc ctt ggc cct agc ttg gag gac
ttg ttt gac ctc tgt gac cga 738Glu Leu Leu Gly Pro Ser Leu Glu Asp
Leu Phe Asp Leu Cys Asp Arg 120 125 130aca ttt act ttg aag acg gtg
tta atg ata gcc atc cag ctg ctt tct 786Thr Phe Thr Leu Lys Thr Val
Leu Met Ile Ala Ile Gln Leu Leu Ser135 140 145 150cga atg gaa tac
gtg cac tca aag aac ctc att tac cga gat gtc aag 834Arg Met Glu Tyr
Val His Ser Lys Asn Leu Ile Tyr Arg Asp Val Lys 155 160 165cca gag
aac ttc ctg att ggt cga caa ggc aat aag aaa gag cat gtt 882Pro Glu
Asn Phe Leu Ile Gly Arg Gln Gly Asn Lys Lys Glu His Val 170 175
180ata cac att ata gac ttt gga ctg gcc aag gaa tac att gac ccc gaa
930Ile His Ile Ile Asp Phe Gly Leu Ala Lys Glu Tyr Ile Asp Pro Glu
185 190 195acc aaa aaa cac ata cct tat agg gaa cac aaa agt tta act
gga act 978Thr Lys Lys His Ile Pro Tyr Arg Glu His Lys Ser Leu Thr
Gly Thr 200 205 210gcg aga tat atg tct atc aac acg cat ctt ggc aaa
gag caa agc cgg 1026Ala Arg Tyr Met Ser Ile Asn Thr His Leu Gly Lys
Glu Gln Ser Arg215 220 225 230aga gat gat ttg gaa gcc cta ggc cat
atg ttc atg tat ttc ctt cga 1074Arg Asp Asp Leu Glu Ala Leu Gly His
Met Phe Met Tyr Phe Leu Arg 235 240 245ggc agc ctc ccc tgg caa gga
ctc aag gct gac aca tta aaa gag aga 1122Gly Ser Leu Pro Trp Gln Gly
Leu Lys Ala Asp Thr Leu Lys Glu Arg 250 255 260tat caa aaa att ggt
gac acc aaa agg aat act ccc att gaa gct ctc 1170Tyr Gln Lys Ile Gly
Asp Thr Lys Arg Asn Thr Pro Ile Glu Ala Leu 265 270 275tgt gag aac
ttt cca gag gag atg gca acc tac ctt cga tat gtc agg 1218Cys Glu Asn
Phe Pro Glu Glu Met Ala Thr Tyr Leu Arg Tyr Val Arg 280 285 290cga
ctg gac ttc ttt gaa aaa cct gat tat gag tat tta cgg acc ctc 1266Arg
Leu Asp Phe Phe Glu Lys Pro Asp Tyr Glu Tyr Leu Arg Thr Leu295 300
305 310ttc aca gac ctc ttt gaa aag aaa ggc tac acc ttt gac tat gcc
tat 1314Phe Thr Asp Leu Phe Glu Lys Lys Gly Tyr Thr Phe Asp Tyr Ala
Tyr 315 320 325gat tgg gtt ggg aga cct att cct act cca gta ggg tca
gtt cac gta 1362Asp Trp Val Gly Arg Pro Ile Pro Thr Pro Val Gly Ser
Val His Val 330 335 340gat tct ggt gca tct gca ata act cga gaa agc
cac aca cat agg gat 1410Asp Ser Gly Ala Ser Ala Ile Thr Arg Glu Ser
His Thr His Arg Asp 345 350 355cgg cca tca caa cag cag cct ctt cga
aat cag aat gta tca tca gag 1458Arg Pro Ser Gln Gln Gln Pro Leu Arg
Asn Gln Asn Val Ser Ser Glu 360 365 370cgc cga gga gag tgg gaa att
cag ccc agc cgg cag acc aat acc tca 1506Arg Arg Gly Glu Trp Glu Ile
Gln Pro Ser Arg Gln Thr Asn Thr Ser375 380 385 390tac cta acg tct
cac ttg gct gca gac cgc cat ggg gga tca gtg cag 1554Tyr Leu Thr Ser
His Leu Ala Ala Asp Arg His Gly Gly Ser Val Gln 395 400 405gtg gtt
agc tca acc aat gga gag ctg aat gtt gat gat ccc acg gga 1602Val Val
Ser Ser Thr Asn Gly Glu Leu Asn Val Asp Asp Pro Thr Gly 410 415
420gcc cac tcc aat gca cca
atc aca gct cat gcc gag gtg gag gta gtg 1650Ala His Ser Asn Ala Pro
Ile Thr Ala His Ala Glu Val Glu Val Val 425 430 435gag gaa gct aag
tgc tgc tgt ttc ttt aag agg aaa agg aag aag act 1698Glu Glu Ala Lys
Cys Cys Cys Phe Phe Lys Arg Lys Arg Lys Lys Thr 440 445 450gct cag
cgc cac aag tgaccagtgc ctcccaggag tcctcaggcc ctggggactc 1753Ala Gln
Arg His Lys455tgactcaatt gtacctgcag ctcctgccat ttctcattgg
aagggactcc tctttggggg 1813agggtggata tccaaaccaa aaagaagaaa
acagatgccc ccagaagggg ccagtgcggg 1873cagccagggc ctagtgggtc
attggccatc tccgcctgcc taaggctctg agcaggtccc 1933agagctgctg
ttcctccact gcttgcccat agggctgcct ggttgactct ccttcccatt
1993gtttacagtg aaggtgtcat tcacaaaaac tcaaggactg ctattctcct
tcttcccctt 2053agtttactcc tggtttttac cccaccctca accctctcca
gcataaaacc tagtgagcta 2113aaggctttgt ctgcagaagg agatcaagag
gctgggggta aggccaagaa ggtaggagga 2173aaatggcaga cctgggctgg
agaagaacct tctccgtatc ccaggtgtgc ctggcagtat 2233ggtttcctct
tcctctgtgc ctgtgcagca ttcatcccag ctggccttgg ggttcaggtt
2293ccttcttccc tccctcctgt gaagttacac tgtaggacac aagctgtgag
caatctgcag 2353tctactgtcc ctgtgtgttg gcgttcttag cttttttgac
aaactctttt ctccaggtag 2413taggacaatg aaaattgttc taagcaaagg
aaagaaaact gactttgttg cacttttagt 2473ttttttaaaa aaaacaaaaa
caaaaacatg gcagatgcat attgtgtctg gttatattgg 2533gggttttact
tttacctgtt ttgaggggga tggggccggc caagccattc agagagaaca
2593tgggtccaga ggacattctc agtggaaaga gtttgatctg cagcacccag
aagagaagcc 2653aaactcggtg tcattctgag tgaacactca ggttggcaag
aaaacatact tgaattttca 2713ttcatcttct cagcagctga agaatgtccc
taccagagca tcttgaccta atcagcttac 2773agtttgaaaa cctagctctc
cagaacatga gatgagccag ccgagccaga ctgtgaccag 2833gaaacagctc
atcccagaga aggagatgct taacaaaaaa aaattgaaat tgtttcccat
2893gctgccaggg acttccaact agatagccat gtgacgtcct ggtgacttgg
gggaaaaatt 2953agtgatgaaa cagccaccac catattgcca ttagtggaaa
aaaagaggac agtgaacctg 3013ccttccacct gccagaggga cctcagggtg
tggcattata gggccaggaa aagaaaatcg 3073gtgtatccta tctgccccaa
tagctgagct gtagcatttg ggctggcctg ccttatcaga 3133aaccaagctt
atgaagatct tctcccagca ggtccatagc agtaggctta ggatgcagta
3193tatggggccg catttaaaag gagggaaaga ttgtttggtg ctggaacatt
ccagggaaaa 3253ggagactgga atgaaaggtc tgaaattatc ttctcaattg
gactccttcc agaaaggtgg 3313ccgtgcctct aagcatgttt ttcccagtat
gccctaggcc tccccccatg gtgttttcat 3373atgaggtact actgtgaagg
atctggttcc tcattcactg tttgacaagt ctttcatgtg 3433tggagttact
cttctcatgc ccaattttca tttgagttta gtggcttaac caaacaatga
3493ctcctcattc cagcggtgac agaagagaaa gggtcattta catcaggaaa
gaggtcttgt 3553atctgggagt agagagctaa ccatggagca cagtggctgg
tgggtgactt agtctgatgg 3613tttgtggacc atagaagtct tcacctctgg
tttgaggtgc agggctgtct tttgtactgg 3673agggtgtggg gatattttct
gatagttgcc atttcttgaa aaattccctt gatgtacctt 3733acacagagca
gaaataacat taacatggat cagaggtact gggcttcatc tgttccattg
3793gaccttggct agggaatatc atttcactgg catcaaacct gcttagctta
tgaaaagatg 3853gtaatatgtc atttctataa atgtttctat atatgaaaca
taaagtggca gggagataca 3913atatcacacc ccttccccac aaggactgtg
aatattggga tttatgtcct tgccattacc 3973tagtggttac agccctatca
ctaaaattta catcgtttct cagttgggat ttgggcattg 4033ctaacttact
gtatagaaag tttaactttt cctcacccct gtatagaaaa tgccttgcct
4093ctcaagagag ggcagagggg gggccaggtg cagtggctca cgcctgtaat
cccagcagtt 4153tgggaggcca aggcaagtgg atcatgtgag gtcaagagtt
cgagaccagc ctggccaaca 4213tggtgaaacc ccgtctctac aaaaaataca
aaaattagct gggcatggtg gcatgctccc 4273gtagtcccag ctactcggag
gctgaggcag gagaatcact tgagcctggg aggcagaagt 4333tgcagtgagc
cgagatcgca ccactgcact ccagcctggg caacagagtg agactctgtc
4393taaaaaaaaa aaaaaaaaag ggcg 44175459PRTHomo sapiens 5Met Asp His
Pro Ser Arg Glu Lys Asp Glu Arg Gln Arg Thr Thr Lys 1 5 10 15Pro
Met Ala Gln Arg Ser Ala His Cys Ser Arg Pro Ser Gly Ser Ser 20 25
30Ser Ser Ser Gly Val Leu Met Val Gly Pro Asn Phe Arg Val Gly Lys
35 40 45Lys Ile Gly Cys Gly Asn Phe Gly Glu Leu Arg Leu Gly Lys Asn
Leu 50 55 60Tyr Thr Asn Glu Tyr Val Ala Ile Lys Leu Glu Pro Ile Lys
Ser Arg65 70 75 80Ala Pro Gln Leu His Leu Glu Tyr Arg Phe Tyr Lys
Gln Leu Gly Ser 85 90 95Ala Gly Glu Gly Leu Pro Gln Val Tyr Tyr Phe
Gly Pro Cys Gly Lys 100 105 110Tyr Asn Ala Met Val Leu Glu Leu Leu
Gly Pro Ser Leu Glu Asp Leu 115 120 125Phe Asp Leu Cys Asp Arg Thr
Phe Thr Leu Lys Thr Val Leu Met Ile 130 135 140Ala Ile Gln Leu Leu
Ser Arg Met Glu Tyr Val His Ser Lys Asn Leu145 150 155 160Ile Tyr
Arg Asp Val Lys Pro Glu Asn Phe Leu Ile Gly Arg Gln Gly 165 170
175Asn Lys Lys Glu His Val Ile His Ile Ile Asp Phe Gly Leu Ala Lys
180 185 190Glu Tyr Ile Asp Pro Glu Thr Lys Lys His Ile Pro Tyr Arg
Glu His 195 200 205Lys Ser Leu Thr Gly Thr Ala Arg Tyr Met Ser Ile
Asn Thr His Leu 210 215 220Gly Lys Glu Gln Ser Arg Arg Asp Asp Leu
Glu Ala Leu Gly His Met225 230 235 240Phe Met Tyr Phe Leu Arg Gly
Ser Leu Pro Trp Gln Gly Leu Lys Ala 245 250 255Asp Thr Leu Lys Glu
Arg Tyr Gln Lys Ile Gly Asp Thr Lys Arg Asn 260 265 270Thr Pro Ile
Glu Ala Leu Cys Glu Asn Phe Pro Glu Glu Met Ala Thr 275 280 285Tyr
Leu Arg Tyr Val Arg Arg Leu Asp Phe Phe Glu Lys Pro Asp Tyr 290 295
300Glu Tyr Leu Arg Thr Leu Phe Thr Asp Leu Phe Glu Lys Lys Gly
Tyr305 310 315 320Thr Phe Asp Tyr Ala Tyr Asp Trp Val Gly Arg Pro
Ile Pro Thr Pro 325 330 335Val Gly Ser Val His Val Asp Ser Gly Ala
Ser Ala Ile Thr Arg Glu 340 345 350Ser His Thr His Arg Asp Arg Pro
Ser Gln Gln Gln Pro Leu Arg Asn 355 360 365Gln Asn Val Ser Ser Glu
Arg Arg Gly Glu Trp Glu Ile Gln Pro Ser 370 375 380Arg Gln Thr Asn
Thr Ser Tyr Leu Thr Ser His Leu Ala Ala Asp Arg385 390 395 400His
Gly Gly Ser Val Gln Val Val Ser Ser Thr Asn Gly Glu Leu Asn 405 410
415Val Asp Asp Pro Thr Gly Ala His Ser Asn Ala Pro Ile Thr Ala His
420 425 430Ala Glu Val Glu Val Val Glu Glu Ala Lys Cys Cys Cys Phe
Phe Lys 435 440 445Arg Lys Arg Lys Lys Thr Ala Gln Arg His Lys 450
45561377DNAHomo sapiens 6atggaccatc ctagtaggga aaaggatgaa
agacaacgga caactaaacc catggcacaa 60aggagtgcac actgctctcg accatctggc
tcctcatcgt cctctggggt tcttatggtg 120ggacccaact tcagggttgg
caagaagata ggatgtggga acttcggaga gctcagatta 180ggtaaaaatc
tctacaccaa tgaatatgta gcaatcaaac tggaaccaat aaaatcacgt
240gctccacagc ttcatttaga gtacagattt tataaacagc ttggcagtgc
aggtgaaggt 300ctcccacagg tgtattactt tggaccatgt gggaaatata
atgccatggt gctggagctc 360cttggcccta gcttggagga cttgtttgac
ctctgtgacc gaacatttac tttgaagacg 420gtgttaatga tagccatcca
gctgctttct cgaatggaat acgtgcactc aaagaacctc 480atttaccgag
atgtcaagcc agagaacttc ctgattggtc gacaaggcaa taagaaagag
540catgttatac acattataga ctttggactg gccaaggaat acattgaccc
cgaaaccaaa 600aaacacatac cttataggga acacaaaagt ttaactggaa
ctgcgagata tatgtctatc 660aacacgcatc ttggcaaaga gcaaagccgg
agagatgatt tggaagccct aggccatatg 720ttcatgtatt tccttcgagg
cagcctcccc tggcaaggac tcaaggctga cacattaaaa 780gagagatatc
aaaaaattgg tgacaccaaa aggaatactc ccattgaagc tctctgtgag
840aactttccag aggagatggc aacctacctt cgatatgtca ggcgactgga
cttctttgaa 900aaacctgatt atgagtattt acggaccctc ttcacagacc
tctttgaaaa gaaaggctac 960acctttgact atgcctatga ttgggttggg
agacctattc ctactccagt agggtcagtt 1020cacgtagatt ctggtgcatc
tgcaataact cgagaaagcc acacacatag ggatcggcca 1080tcacaacagc
agcctcttcg aaatcagaat gtatcatcag agcgccgagg agagtgggaa
1140attcagccca gccggcagac caatacctca tacctaacgt ctcacttggc
tgcagaccgc 1200catgggggat cagtgcaggt ggttagctca accaatggag
agctgaatgt tgatgatccc 1260acgggagccc actccaatgc accaatcaca
gctcatgccg aggtggaggt agtggaggaa 1320gctaagtgct gctgtttctt
taagaggaaa aggaagaaga ctgctcagcg ccacaag 137772046DNAHomo
sapiensCDS(119)...(1906)misc_feature(1)...(2046)n = A,T,C or G
7ccacgcgtcc gctgctcctg agcagccgct gggagacaga cggcaaccag gttgcccctc
60tttgctccag ctagaaagac ttgagttaga caagcagcag cacacgcctc cctacctc
118atg gcg aca gaa aat gga gca gtt gag ctg gga att cag aac cca tca
166Met Ala Thr Glu Asn Gly Ala Val Glu Leu Gly Ile Gln Asn Pro Ser
1 5 10 15aca gac aag gca cct aaa ggt ccc aca ggt gaa aga ccc ctg
gct gca 214Thr Asp Lys Ala Pro Lys Gly Pro Thr Gly Glu Arg Pro Leu
Ala Ala 20 25 30ggg aaa gac cct ggc ccc cca gac cca aag aaa gct ccg
gat cca ccc 262Gly Lys Asp Pro Gly Pro Pro Asp Pro Lys Lys Ala Pro
Asp Pro Pro 35 40 45acc ctg aag aaa gat gcc aaa gcc cct gcc tca gag
aaa ggg gat ggt 310Thr Leu Lys Lys Asp Ala Lys Ala Pro Ala Ser Glu
Lys Gly Asp Gly 50 55 60acc ctg gcc caa ccc tca act agc agc caa ggc
ccc aaa gga gag ggt 358Thr Leu Ala Gln Pro Ser Thr Ser Ser Gln Gly
Pro Lys Gly Glu Gly 65 70 75 80gac agg ggc ggg ggg ccc gcg gag ggc
agt gct ggg ccc ccg gca gcc 406Asp Arg Gly Gly Gly Pro Ala Glu Gly
Ser Ala Gly Pro Pro Ala Ala 85 90 95ctg ccc cag cag act gcg aca cct
gag acc agc gtc aag aag ccc aag 454Leu Pro Gln Gln Thr Ala Thr Pro
Glu Thr Ser Val Lys Lys Pro Lys 100 105 110gct gag cag gga gcc tca
ggc agc cag gat cct gga aag ccc agg gtg 502Ala Glu Gln Gly Ala Ser
Gly Ser Gln Asp Pro Gly Lys Pro Arg Val 115 120 125ggc aag aag gca
gca gag ggc caa gca gca gcc agg agg ggc tca cct 550Gly Lys Lys Ala
Ala Glu Gly Gln Ala Ala Ala Arg Arg Gly Ser Pro 130 135 140gcc ttt
ctg cat agc ccc agc tgt cct gcc atc atc tcc agt tct gag 598Ala Phe
Leu His Ser Pro Ser Cys Pro Ala Ile Ile Ser Ser Ser Glu145 150 155
160aag ctg ctg gcc aag aag ccc cca agc gag gca tca gag ctc acc ttt
646Lys Leu Leu Ala Lys Lys Pro Pro Ser Glu Ala Ser Glu Leu Thr Phe
165 170 175gaa ggg gtg ccc atg acc cac agc ccc acg gat ccc agg cca
gcc aag 694Glu Gly Val Pro Met Thr His Ser Pro Thr Asp Pro Arg Pro
Ala Lys 180 185 190gca gaa gaa gga aag aac atc ctg gca gag agc cag
aag gaa gtg gga 742Ala Glu Glu Gly Lys Asn Ile Leu Ala Glu Ser Gln
Lys Glu Val Gly 195 200 205gag aaa acc cca ggc cag gct ggc cag gct
aag atg caa ggg gac acc 790Glu Lys Thr Pro Gly Gln Ala Gly Gln Ala
Lys Met Gln Gly Asp Thr 210 215 220tcg agg ggg att gag ttc cag gct
gtt ccc tca gag aaa tcc gag gtg 838Ser Arg Gly Ile Glu Phe Gln Ala
Val Pro Ser Glu Lys Ser Glu Val225 230 235 240ggg cag gcc ctc tgt
ctc aca gcc agg gag gag gac tgc ttc cag att 886Gly Gln Ala Leu Cys
Leu Thr Ala Arg Glu Glu Asp Cys Phe Gln Ile 245 250 255ttg gat gat
tgc ccg cca cct ccg gcc ccc ttc cct cac cgc atg gtg 934Leu Asp Asp
Cys Pro Pro Pro Pro Ala Pro Phe Pro His Arg Met Val 260 265 270gag
ctg agg acc ggg aat gtc agc agt gaa ttc agt atg aac tcc aag 982Glu
Leu Arg Thr Gly Asn Val Ser Ser Glu Phe Ser Met Asn Ser Lys 275 280
285gag gcg ctc gga ggt ggc aag ttt ggg gca gtc tgt acc tgc atg gag
1030Glu Ala Leu Gly Gly Gly Lys Phe Gly Ala Val Cys Thr Cys Met Glu
290 295 300aaa gcc aca ggc ctc aag ctg gca gcc aag gtc atc aag aaa
cag act 1078Lys Ala Thr Gly Leu Lys Leu Ala Ala Lys Val Ile Lys Lys
Gln Thr305 310 315 320ccc aaa gac aag gaa atg gtg ttg ctg gag att
gag gtc atg aac cag 1126Pro Lys Asp Lys Glu Met Val Leu Leu Glu Ile
Glu Val Met Asn Gln 325 330 335ctg aac cac cgc aat ctg atc cag ctg
tat gca gcc atc gag act ccg 1174Leu Asn His Arg Asn Leu Ile Gln Leu
Tyr Ala Ala Ile Glu Thr Pro 340 345 350cat gag atc gtc ctg ttc atg
gag tac atc gag ggc gga gag ctc ttc 1222His Glu Ile Val Leu Phe Met
Glu Tyr Ile Glu Gly Gly Glu Leu Phe 355 360 365gag agg att gtg gat
gag gac tac cat ctg acc gag gtg gac acc atg 1270Glu Arg Ile Val Asp
Glu Asp Tyr His Leu Thr Glu Val Asp Thr Met 370 375 380gtg ttt gtc
agg cag atc tgt gac ggg atc ctc ttc atg cac aag atg 1318Val Phe Val
Arg Gln Ile Cys Asp Gly Ile Leu Phe Met His Lys Met385 390 395
400agg gtt ttg cac ctg gac ctc aag cca gag aac atc ctg tgt gtc aac
1366Arg Val Leu His Leu Asp Leu Lys Pro Glu Asn Ile Leu Cys Val Asn
405 410 415acc acc ggg cat ttg gtg aag atc att gac ttt ggc ctg gca
cgg agg 1414Thr Thr Gly His Leu Val Lys Ile Ile Asp Phe Gly Leu Ala
Arg Arg 420 425 430tat aac ccc aac gag aag ctg aag gtg aac ttt ggg
acc cca gag ttc 1462Tyr Asn Pro Asn Glu Lys Leu Lys Val Asn Phe Gly
Thr Pro Glu Phe 435 440 445ctg tca cct gag gtg gtg aat tat gac caa
atc tcc gat aag aca gac 1510Leu Ser Pro Glu Val Val Asn Tyr Asp Gln
Ile Ser Asp Lys Thr Asp 450 455 460atg tgg agt atg ggg gtg atc acc
tac atg ctg ctg agc ggc ctc tcc 1558Met Trp Ser Met Gly Val Ile Thr
Tyr Met Leu Leu Ser Gly Leu Ser465 470 475 480ccc ttc ctg gga gat
gat gac aca gag acc cta aac aac gtt cta tct 1606Pro Phe Leu Gly Asp
Asp Asp Thr Glu Thr Leu Asn Asn Val Leu Ser 485 490 495ggc aac tgg
tac ttt gat gaa gag acc ttt gag gcc gta tca gac gag 1654Gly Asn Trp
Tyr Phe Asp Glu Glu Thr Phe Glu Ala Val Ser Asp Glu 500 505 510gcc
aaa gac ttt gtc tcc aac ctc atc gtc aag gac cag agg gcc cgg 1702Ala
Lys Asp Phe Val Ser Asn Leu Ile Val Lys Asp Gln Arg Ala Arg 515 520
525atg aac gct gcc cag tgt ctc gcc cat ccc tgg ctc aac aac ctg gcg
1750Met Asn Ala Ala Gln Cys Leu Ala His Pro Trp Leu Asn Asn Leu Ala
530 535 540gag aaa gcc aaa cgc tgt aac cga cgc ctt aag tcc cag atc
ttg ctt 1798Glu Lys Ala Lys Arg Cys Asn Arg Arg Leu Lys Ser Gln Ile
Leu Leu545 550 555 560aag aaa tac ctc atg aag agg cgc tgg aag aaa
aac ttc att gct gtc 1846Lys Lys Tyr Leu Met Lys Arg Arg Trp Lys Lys
Asn Phe Ile Ala Val 565 570 575agc gct gcc aac cgc ttc aag aag atc
agc agc tcg ggg gca ctg atg 1894Ser Ala Ala Asn Arg Phe Lys Lys Ile
Ser Ser Ser Gly Ala Leu Met 580 585 590gct ctg ggg gtc tgagccctgg
gcgcantgga aagcctggac gcagccacac 1946Ala Leu Gly Val 595agtggcgggg
gcttgaagcc acacagccca gaaggccaga aaaggcagcc agatccccag
2006ggcagcctcg ttaggacaag gctgtgccaa gggctgggaa 20468596PRTHomo
sapiens 8Met Ala Thr Glu Asn Gly Ala Val Glu Leu Gly Ile Gln Asn
Pro Ser 1 5 10 15Thr Asp Lys Ala Pro Lys Gly Pro Thr Gly Glu Arg
Pro Leu Ala Ala 20 25 30Gly Lys Asp Pro Gly Pro Pro Asp Pro Lys Lys
Ala Pro Asp Pro Pro 35 40 45Thr Leu Lys Lys Asp Ala Lys Ala Pro Ala
Ser Glu Lys Gly Asp Gly 50 55 60Thr Leu Ala Gln Pro Ser Thr Ser Ser
Gln Gly Pro Lys Gly Glu Gly65 70 75 80Asp Arg Gly Gly Gly Pro Ala
Glu Gly Ser Ala Gly Pro Pro Ala Ala 85 90 95Leu Pro Gln Gln Thr Ala
Thr Pro Glu Thr Ser Val Lys Lys Pro Lys 100 105 110Ala Glu Gln Gly
Ala Ser Gly Ser Gln Asp Pro Gly Lys Pro Arg Val 115 120 125Gly Lys
Lys Ala Ala Glu Gly Gln Ala Ala Ala Arg Arg Gly Ser Pro 130 135
140Ala Phe Leu His Ser Pro Ser Cys Pro Ala Ile Ile Ser Ser Ser
Glu145 150 155 160Lys Leu Leu Ala Lys Lys Pro Pro Ser Glu Ala Ser
Glu Leu Thr Phe 165 170 175Glu Gly Val Pro Met Thr His Ser Pro Thr
Asp Pro Arg Pro Ala Lys 180 185 190Ala Glu Glu Gly Lys Asn Ile Leu
Ala Glu Ser Gln Lys Glu Val Gly 195 200 205Glu Lys Thr Pro Gly Gln
Ala Gly Gln Ala Lys Met Gln Gly Asp Thr 210 215 220Ser Arg Gly Ile
Glu Phe Gln Ala Val Pro Ser Glu Lys Ser Glu Val225 230 235 240Gly
Gln Ala Leu Cys Leu Thr Ala Arg Glu Glu Asp Cys Phe Gln Ile 245 250
255Leu Asp Asp
Cys Pro Pro Pro Pro Ala Pro Phe Pro His Arg Met Val 260 265 270Glu
Leu Arg Thr Gly Asn Val Ser Ser Glu Phe Ser Met Asn Ser Lys 275 280
285Glu Ala Leu Gly Gly Gly Lys Phe Gly Ala Val Cys Thr Cys Met Glu
290 295 300Lys Ala Thr Gly Leu Lys Leu Ala Ala Lys Val Ile Lys Lys
Gln Thr305 310 315 320Pro Lys Asp Lys Glu Met Val Leu Leu Glu Ile
Glu Val Met Asn Gln 325 330 335Leu Asn His Arg Asn Leu Ile Gln Leu
Tyr Ala Ala Ile Glu Thr Pro 340 345 350His Glu Ile Val Leu Phe Met
Glu Tyr Ile Glu Gly Gly Glu Leu Phe 355 360 365Glu Arg Ile Val Asp
Glu Asp Tyr His Leu Thr Glu Val Asp Thr Met 370 375 380Val Phe Val
Arg Gln Ile Cys Asp Gly Ile Leu Phe Met His Lys Met385 390 395
400Arg Val Leu His Leu Asp Leu Lys Pro Glu Asn Ile Leu Cys Val Asn
405 410 415Thr Thr Gly His Leu Val Lys Ile Ile Asp Phe Gly Leu Ala
Arg Arg 420 425 430Tyr Asn Pro Asn Glu Lys Leu Lys Val Asn Phe Gly
Thr Pro Glu Phe 435 440 445Leu Ser Pro Glu Val Val Asn Tyr Asp Gln
Ile Ser Asp Lys Thr Asp 450 455 460Met Trp Ser Met Gly Val Ile Thr
Tyr Met Leu Leu Ser Gly Leu Ser465 470 475 480Pro Phe Leu Gly Asp
Asp Asp Thr Glu Thr Leu Asn Asn Val Leu Ser 485 490 495Gly Asn Trp
Tyr Phe Asp Glu Glu Thr Phe Glu Ala Val Ser Asp Glu 500 505 510Ala
Lys Asp Phe Val Ser Asn Leu Ile Val Lys Asp Gln Arg Ala Arg 515 520
525Met Asn Ala Ala Gln Cys Leu Ala His Pro Trp Leu Asn Asn Leu Ala
530 535 540Glu Lys Ala Lys Arg Cys Asn Arg Arg Leu Lys Ser Gln Ile
Leu Leu545 550 555 560Lys Lys Tyr Leu Met Lys Arg Arg Trp Lys Lys
Asn Phe Ile Ala Val 565 570 575Ser Ala Ala Asn Arg Phe Lys Lys Ile
Ser Ser Ser Gly Ala Leu Met 580 585 590Ala Leu Gly Val
59591788DNAHomo sapiens 9atggcgacag aaaatggagc agttgagctg
ggaattcaga acccatcaac agacaaggca 60cctaaaggtc ccacaggtga aagacccctg
gctgcaggga aagaccctgg ccccccagac 120ccaaagaaag ctccggatcc
acccaccctg aagaaagatg ccaaagcccc tgcctcagag 180aaaggggatg
gtaccctggc ccaaccctca actagcagcc aaggccccaa aggagagggt
240gacaggggcg gggggcccgc ggagggcagt gctgggcccc cggcagccct
gccccagcag 300actgcgacac ctgagaccag cgtcaagaag cccaaggctg
agcagggagc ctcaggcagc 360caggatcctg gaaagcccag ggtgggcaag
aaggcagcag agggccaagc agcagccagg 420aggggctcac ctgcctttct
gcatagcccc agctgtcctg ccatcatctc cagttctgag 480aagctgctgg
ccaagaagcc cccaagcgag gcatcagagc tcacctttga aggggtgccc
540atgacccaca gccccacgga tcccaggcca gccaaggcag aagaaggaaa
gaacatcctg 600gcagagagcc agaaggaagt gggagagaaa accccaggcc
aggctggcca ggctaagatg 660caaggggaca cctcgagggg gattgagttc
caggctgttc cctcagagaa atccgaggtg 720gggcaggccc tctgtctcac
agccagggag gaggactgct tccagatttt ggatgattgc 780ccgccacctc
cggccccctt ccctcaccgc atggtggagc tgaggaccgg gaatgtcagc
840agtgaattca gtatgaactc caaggaggcg ctcggaggtg gcaagtttgg
ggcagtctgt 900acctgcatgg agaaagccac aggcctcaag ctggcagcca
aggtcatcaa gaaacagact 960cccaaagaca aggaaatggt gttgctggag
attgaggtca tgaaccagct gaaccaccgc 1020aatctgatcc agctgtatgc
agccatcgag actccgcatg agatcgtcct gttcatggag 1080tacatcgagg
gcggagagct cttcgagagg attgtggatg aggactacca tctgaccgag
1140gtggacacca tggtgtttgt caggcagatc tgtgacggga tcctcttcat
gcacaagatg 1200agggttttgc acctggacct caagccagag aacatcctgt
gtgtcaacac caccgggcat 1260ttggtgaaga tcattgactt tggcctggca
cggaggtata accccaacga gaagctgaag 1320gtgaactttg ggaccccaga
gttcctgtca cctgaggtgg tgaattatga ccaaatctcc 1380gataagacag
acatgtggag tatgggggtg atcacctaca tgctgctgag cggcctctcc
1440cccttcctgg gagatgatga cacagagacc ctaaacaacg ttctatctgg
caactggtac 1500tttgatgaag agacctttga ggccgtatca gacgaggcca
aagactttgt ctccaacctc 1560atcgtcaagg accagagggc ccggatgaac
gctgcccagt gtctcgccca tccctggctc 1620aacaacctgg cggagaaagc
caaacgctgt aaccgacgcc ttaagtccca gatcttgctt 1680aagaaatacc
tcatgaagag gcgctggaag aaaaacttca ttgctgtcag cgctgccaac
1740cgcttcaaga agatcagcag ctcgggggca ctgatggctc tgggggtc
178810265PRTArtificial Sequenceconsensus sequence 10Lys Val Tyr Lys
Ala Lys His Lys Thr Gly Lys Ile Val Ala Val Lys 1 5 10 15Ile Leu
Lys Lys Glu Ser Leu Ser Leu Arg Glu Ile Gln Ile Leu Lys 20 25 30Arg
Leu Ser His Pro Asn Ile Val Arg Leu Leu Gly Val Phe Glu Asp 35 40
45Thr Asp Asp His Leu Tyr Leu Val Met Glu Tyr Met Glu Gly Gly Asp
50 55 60Leu Phe Asp Tyr Leu Arg Arg Asn Gly Pro Leu Ser Glu Lys Glu
Ala65 70 75 80Lys Lys Ile Ala Leu Gln Ile Leu Arg Gly Leu Glu Tyr
Leu His Ser 85 90 95Asn Gly Ile Val His Arg Asp Leu Lys Pro Glu Asn
Ile Leu Leu Asp 100 105 110Glu Asn Gly Thr Val Lys Ile Ala Asp Phe
Gly Leu Ala Arg Leu Leu 115 120 125Glu Lys Leu Thr Thr Phe Val Gly
Thr Pro Trp Tyr Met Met Ala Pro 130 135 140Glu Val Ile Leu Glu Gly
Arg Gly Tyr Ser Ser Lys Val Asp Val Trp145 150 155 160Ser Leu Gly
Val Ile Leu Tyr Glu Leu Leu Thr Gly Gly Pro Leu Phe 165 170 175Pro
Gly Ala Asp Leu Pro Ala Phe Thr Gly Gly Asp Glu Val Asp Gln 180 185
190Leu Ile Ile Phe Val Leu Lys Leu Pro Phe Ser Asp Glu Leu Pro Lys
195 200 205Thr Arg Ile Asp Pro Leu Glu Glu Leu Phe Arg Ile Lys Lys
Arg Arg 210 215 220Leu Pro Leu Pro Ser Asn Cys Ser Glu Glu Leu Lys
Asp Leu Leu Lys225 230 235 240Lys Cys Leu Asn Lys Asp Pro Ser Lys
Arg Pro Gly Ser Ala Thr Ala 245 250 255Lys Glu Ile Leu Asn His Pro
Trp Phe 260 26511230PRTArtificial Sequenceconsensus sequence 11Tyr
Glu Leu Leu Lys Lys Leu Gly Lys Gly Ala Phe Gly Lys Val Tyr 1 5 10
15Leu Ala Arg Asp Lys Lys Thr Gly Arg Leu Val Ala Ile Lys Val Ile
20 25 30Lys Glu Arg Ile Leu Arg Glu Ile Lys Ile Leu Lys Lys Asp His
Pro 35 40 45Asn Ile Val Lys Leu Tyr Asp Val Phe Glu Asp Asp Lys Leu
Tyr Leu 50 55 60Val Met Glu Tyr Cys Glu Gly Asp Leu Gly Asp Leu Phe
Asp Leu Leu65 70 75 80Lys Lys Arg Gly Arg Arg Gly Leu Arg Lys Val
Leu Ser Glu Glu Ala 85 90 95Arg Phe Tyr Phe Arg Gln Ile Leu Ser Ala
Leu Glu Tyr Leu His Ser 100 105 110Gln Gly Ile Ile His Arg Asp Leu
Lys Pro Glu Asn Ile Leu Leu Asp 115 120 125Ser Val Lys Leu Ala Asp
Phe Gly Leu Ala Arg Gln Leu Thr Thr Phe 130 135 140Val Gly Thr Pro
Glu Tyr Met Ala Pro Glu Val Leu Gly Tyr Gly Lys145 150 155 160Pro
Ala Val Asp Ile Trp Ser Leu Gly Cys Ile Leu Tyr Glu Leu Leu 165 170
175Thr Gly Lys Pro Pro Phe Pro Gln Leu Asp Leu Ile Phe Lys Lys Ile
180 185 190Gly Ser Pro Glu Ala Lys Asp Leu Ile Lys Lys Leu Leu Val
Lys Asp 195 200 205Pro Glu Lys Arg Leu Thr Ala Glu Ala Leu Glu Asp
Glu Leu Asp Ile 210 215 220Lys Ala His Pro Phe Phe225
23012239PRTArtificial Sequenceconsensus sequence 12Tyr Glu Leu Leu
Glu Lys Leu Gly Glu Gly Ser Phe Gly Lys Val Tyr 1 5 10 15Lys Ala
Lys His Lys Thr Gly Lys Ile Val Ala Val Lys Ile Leu Lys 20 25 30Lys
Glu Ser Leu Ser Leu Arg Glu Ile Gln Ile Leu Lys Arg Leu Ser 35 40
45His Pro Asn Ile Val Arg Leu Leu Gly Val Phe Glu Asp Thr Asp Asp
50 55 60His Leu Tyr Leu Val Met Glu Tyr Met Glu Gly Gly Asp Leu Phe
Asp65 70 75 80Tyr Leu Arg Arg Asn Gly Pro Leu Ser Glu Lys Glu Ala
Lys Lys Ile 85 90 95Ala Leu Gln Ile Leu Arg Gly Leu Glu Tyr Leu His
Ser Asn Gly Ile 100 105 110Val His Arg Asp Leu Lys Pro Glu Asn Ile
Leu Leu Asp Glu Asn Gly 115 120 125Thr Val Lys Ile Ala Asp Phe Gly
Leu Ala Arg Leu Leu Glu Lys Leu 130 135 140Thr Thr Phe Val Gly Thr
Pro Trp Tyr Met Met Ala Pro Glu Val Ile145 150 155 160Leu Glu Gly
Arg Gly Tyr Ser Ser Lys Val Asp Val Trp Ser Leu Gly 165 170 175Val
Ile Leu Tyr Glu Leu Leu Thr Gly Gly Pro Leu Phe Pro Gly Ala 180 185
190Asp Leu Pro Ala Phe Thr Gly Gly Asp Glu Val Asp Gln Leu Ile Ile
195 200 205Phe Val Leu Lys Leu Pro Phe Ser Asp Glu Leu Pro Lys Thr
Arg Ile 210 215 220Asp Pro Leu Glu Glu Leu Phe Arg Ile Lys Lys Arg
Arg Leu Pro225 230 23513278PRTArtificial Sequenceconsensus sequence
13Tyr Glu Leu Leu Glu Lys Leu Gly Glu Gly Ser Phe Gly Lys Val Tyr 1
5 10 15Lys Ala Lys His Lys Thr Gly Lys Ile Val Ala Val Lys Ile Leu
Lys 20 25 30Lys Glu Ser Leu Ser Leu Arg Glu Ile Gln Ile Leu Lys Arg
Leu Ser 35 40 45His Pro Asn Ile Val Arg Leu Leu Gly Val Phe Glu Asp
Thr Asp Asp 50 55 60His Leu Tyr Leu Val Met Glu Tyr Met Glu Gly Gly
Asp Leu Phe Asp65 70 75 80Tyr Leu Arg Arg Asn Gly Pro Leu Ser Glu
Lys Glu Ala Lys Lys Ile 85 90 95Ala Leu Gln Ile Leu Arg Gly Leu Glu
Tyr Leu His Ser Asn Gly Ile 100 105 110Val His Arg Asp Leu Lys Pro
Glu Asn Ile Leu Leu Asp Glu Asn Gly 115 120 125Thr Val Lys Ile Ala
Asp Phe Gly Leu Ala Arg Leu Leu Glu Lys Leu 130 135 140Thr Thr Phe
Val Gly Thr Pro Trp Tyr Met Met Ala Pro Glu Val Ile145 150 155
160Leu Glu Gly Arg Gly Tyr Ser Ser Lys Val Asp Val Trp Ser Leu Gly
165 170 175Val Ile Leu Tyr Glu Leu Leu Thr Gly Gly Pro Leu Phe Pro
Gly Ala 180 185 190Asp Leu Pro Ala Phe Thr Gly Gly Asp Glu Val Asp
Gln Leu Ile Ile 195 200 205Phe Val Leu Lys Leu Pro Phe Ser Asp Glu
Leu Pro Lys Thr Arg Ile 210 215 220Asp Pro Leu Glu Glu Leu Phe Arg
Ile Lys Lys Arg Arg Leu Pro Leu225 230 235 240Pro Ser Asn Cys Ser
Glu Glu Leu Lys Asp Leu Leu Lys Lys Cys Leu 245 250 255Asn Lys Asp
Pro Ser Lys Arg Pro Gly Ser Ala Thr Ala Lys Glu Ile 260 265 270Leu
Asn His Pro Trp Phe 275141704DNAHomo sapiensCDS(138)...(1238)
14ggcctctagg aggcaggaac agcaggcctg gcctgcccaa aggactctct atccaggatg
60taaatgagca cactgctggc ccatgcgcct cggggctgta gagggcagcc tcagaggcac
120tgggcattcc tggcacc atg gat gac gct gct gtc ctc aag cga cga ggc
170 Met Asp Asp Ala Ala Val Leu Lys Arg Arg Gly 1 5 10tac ctc ctg
ggg ata aat tta gga gag ggc tcc tat gca aaa gta aaa 218Tyr Leu Leu
Gly Ile Asn Leu Gly Glu Gly Ser Tyr Ala Lys Val Lys 15 20 25tct gct
tac tct gag cgc ctg aag ttc aat gtg gcg atc aag atc atc 266Ser Ala
Tyr Ser Glu Arg Leu Lys Phe Asn Val Ala Ile Lys Ile Ile 30 35 40gac
cgc aag aag gcc ccc gca gac ttc ttg gag aaa ttc ctt ccc cgg 314Asp
Arg Lys Lys Ala Pro Ala Asp Phe Leu Glu Lys Phe Leu Pro Arg 45 50
55gaa att gag att ctg gcc atg tta aac cac tgc tcc atc att aag acc
362Glu Ile Glu Ile Leu Ala Met Leu Asn His Cys Ser Ile Ile Lys Thr
60 65 70 75tac gag atc ttt gag aca tca cat ggc aag gtc tac atc gtc
atg gag 410Tyr Glu Ile Phe Glu Thr Ser His Gly Lys Val Tyr Ile Val
Met Glu 80 85 90ctc gcg gtc cag ggc gac ctc ctc gag tta atc aaa acc
cgg gga gcc 458Leu Ala Val Gln Gly Asp Leu Leu Glu Leu Ile Lys Thr
Arg Gly Ala 95 100 105ctg cat gag gac gaa gct cgc aag aag ttc cac
cag ctt tcc ttg gcc 506Leu His Glu Asp Glu Ala Arg Lys Lys Phe His
Gln Leu Ser Leu Ala 110 115 120atc aag tac tgc cac gac ctg gac gtc
gtc cac cgg gac ctc aag tgt 554Ile Lys Tyr Cys His Asp Leu Asp Val
Val His Arg Asp Leu Lys Cys 125 130 135gac aac ctt ctc ctt gac aag
gac ttc aac atc aag ctg tcc gac ttc 602Asp Asn Leu Leu Leu Asp Lys
Asp Phe Asn Ile Lys Leu Ser Asp Phe140 145 150 155agc ttc tcc aag
cgc tgc ctg cgg gat gac agt ggt cga atg gca tta 650Ser Phe Ser Lys
Arg Cys Leu Arg Asp Asp Ser Gly Arg Met Ala Leu 160 165 170agc aag
acc ttc tgt ggg tca cca gcg tat gcg gcc cca gag gtg ctg 698Ser Lys
Thr Phe Cys Gly Ser Pro Ala Tyr Ala Ala Pro Glu Val Leu 175 180
185cag ggc att ccc tac cag ccc aag gtg tac gac atc tgg agc cta ggc
746Gln Gly Ile Pro Tyr Gln Pro Lys Val Tyr Asp Ile Trp Ser Leu Gly
190 195 200gtg atc ctc tac atc atg gtc tgc ggc tcc atg ccc tac gac
gac tcc 794Val Ile Leu Tyr Ile Met Val Cys Gly Ser Met Pro Tyr Asp
Asp Ser 205 210 215aac atc aag aag atg ctg cgt atc cag aag gag cac
cgc gtc aac ttc 842Asn Ile Lys Lys Met Leu Arg Ile Gln Lys Glu His
Arg Val Asn Phe220 225 230 235cca cgc tcc aag cac ctg aca ggc gag
tgc aag gac ctc atc tac cac 890Pro Arg Ser Lys His Leu Thr Gly Glu
Cys Lys Asp Leu Ile Tyr His 240 245 250atg ctg cag ccc gac gtc aac
cgg cgg ctc cac atc gac gag atc ctc 938Met Leu Gln Pro Asp Val Asn
Arg Arg Leu His Ile Asp Glu Ile Leu 255 260 265agc cac tgc tgg atg
cag ccc aag gca cgg gga tct ccc tct gtg gcc 986Ser His Cys Trp Met
Gln Pro Lys Ala Arg Gly Ser Pro Ser Val Ala 270 275 280atc aac aag
gag ggg gag agt tcc cgg gga act gaa ccc ttg tgg acc 1034Ile Asn Lys
Glu Gly Glu Ser Ser Arg Gly Thr Glu Pro Leu Trp Thr 285 290 295ccc
gaa cct ggc tct gac aag aag tct gcc acc aag ctg gag cct gag 1082Pro
Glu Pro Gly Ser Asp Lys Lys Ser Ala Thr Lys Leu Glu Pro Glu300 305
310 315gga gag gca cag ccc cag gca cag cct gag aca aaa ccc gag ggg
aca 1130Gly Glu Ala Gln Pro Gln Ala Gln Pro Glu Thr Lys Pro Glu Gly
Thr 320 325 330gca atg caa atg tcc agg cag tcg gag atc ctg ggt ttc
ccc agc aag 1178Ala Met Gln Met Ser Arg Gln Ser Glu Ile Leu Gly Phe
Pro Ser Lys 335 340 345ccg tcg act atg gag aca gag gaa ggg ccc ccc
caa cag cct cca gag 1226Pro Ser Thr Met Glu Thr Glu Glu Gly Pro Pro
Gln Gln Pro Pro Glu 350 355 360acg cgg gcc cag tgagcttctt
gcggcccagg gaatgagatg gagctcacgg 1278Thr Arg Ala Gln 365cttaaagccc
aagctctgaa gaagtcaagg gtggagccag agaaggaagg cagtcccaga
1338tgagcctcta ttttcatcag cttcttctct ctccccttga acttggtaac
ccacatggtt 1398ctcccgtggc ccctaggtgg atgaggccaa agtcaaatcc
aaggctgaga cagtcgtgcg 1458actcctactc ccccagagcg tgacccggag
caggtgctgg acacagagcc tgtctcagca 1518gagggtcccc actggccgca
acggctcagt gacagcaaga gcaggaagag cagcaggaag 1578gcaccgctgt
ccaccttggg caccatttat cctcctttca tcgtccccgg ggcagttgcg
1638tgaccctgct gggaggccag accgggccag actgagggtc agggggacca
ggctgggttg 1698gggggt 170415367PRTHomo sapiens 15Met Asp Asp Ala
Ala Val Leu Lys Arg Arg Gly Tyr Leu Leu Gly Ile 1 5 10 15Asn Leu
Gly Glu Gly Ser Tyr Ala Lys Val Lys Ser Ala Tyr Ser Glu 20 25 30Arg
Leu Lys Phe Asn Val Ala Ile Lys Ile Ile Asp Arg Lys Lys Ala 35 40
45Pro Ala Asp Phe Leu Glu Lys Phe Leu Pro Arg Glu Ile Glu Ile Leu
50 55 60Ala Met Leu Asn His Cys Ser Ile Ile Lys Thr Tyr Glu Ile Phe
Glu65 70 75 80Thr Ser His Gly Lys Val Tyr Ile Val Met Glu Leu Ala
Val Gln Gly 85 90
95Asp Leu Leu Glu Leu Ile Lys Thr Arg Gly Ala Leu His Glu Asp Glu
100 105 110Ala Arg Lys Lys Phe His Gln Leu Ser Leu Ala Ile Lys Tyr
Cys His 115 120 125Asp Leu Asp Val Val His Arg Asp Leu Lys Cys Asp
Asn Leu Leu Leu 130 135 140Asp Lys Asp Phe Asn Ile Lys Leu Ser Asp
Phe Ser Phe Ser Lys Arg145 150 155 160Cys Leu Arg Asp Asp Ser Gly
Arg Met Ala Leu Ser Lys Thr Phe Cys 165 170 175Gly Ser Pro Ala Tyr
Ala Ala Pro Glu Val Leu Gln Gly Ile Pro Tyr 180 185 190Gln Pro Lys
Val Tyr Asp Ile Trp Ser Leu Gly Val Ile Leu Tyr Ile 195 200 205Met
Val Cys Gly Ser Met Pro Tyr Asp Asp Ser Asn Ile Lys Lys Met 210 215
220Leu Arg Ile Gln Lys Glu His Arg Val Asn Phe Pro Arg Ser Lys
His225 230 235 240Leu Thr Gly Glu Cys Lys Asp Leu Ile Tyr His Met
Leu Gln Pro Asp 245 250 255Val Asn Arg Arg Leu His Ile Asp Glu Ile
Leu Ser His Cys Trp Met 260 265 270Gln Pro Lys Ala Arg Gly Ser Pro
Ser Val Ala Ile Asn Lys Glu Gly 275 280 285Glu Ser Ser Arg Gly Thr
Glu Pro Leu Trp Thr Pro Glu Pro Gly Ser 290 295 300Asp Lys Lys Ser
Ala Thr Lys Leu Glu Pro Glu Gly Glu Ala Gln Pro305 310 315 320Gln
Ala Gln Pro Glu Thr Lys Pro Glu Gly Thr Ala Met Gln Met Ser 325 330
335Arg Gln Ser Glu Ile Leu Gly Phe Pro Ser Lys Pro Ser Thr Met Glu
340 345 350Thr Glu Glu Gly Pro Pro Gln Gln Pro Pro Glu Thr Arg Ala
Gln 355 360 365161104DNAHomo sapiens 16atggatgacg ctgctgtcct
caagcgacga ggctacctcc tggggataaa tttaggagag 60ggctcctatg caaaagtaaa
atctgcttac tctgagcgcc tgaagttcaa tgtggcgatc 120aagatcatcg
accgcaagaa ggcccccgca gacttcttgg agaaattcct tccccgggaa
180attgagattc tggccatgtt aaaccactgc tccatcatta agacctacga
gatctttgag 240acatcacatg gcaaggtcta catcgtcatg gagctcgcgg
tccagggcga cctcctcgag 300ttaatcaaaa cccggggagc cctgcatgag
gacgaagctc gcaagaagtt ccaccagctt 360tccttggcca tcaagtactg
ccacgacctg gacgtcgtcc accgggacct caagtgtgac 420aaccttctcc
ttgacaagga cttcaacatc aagctgtccg acttcagctt ctccaagcgc
480tgcctgcggg atgacagtgg tcgaatggca ttaagcaaga ccttctgtgg
gtcaccagcg 540tatgcggccc cagaggtgct gcagggcatt ccctaccagc
ccaaggtgta cgacatctgg 600agcctaggcg tgatcctcta catcatggtc
tgcggctcca tgccctacga cgactccaac 660atcaagaaga tgctgcgtat
ccagaaggag caccgcgtca acttcccacg ctccaagcac 720ctgacaggcg
agtgcaagga cctcatctac cacatgctgc agcccgacgt caaccggcgg
780ctccacatcg acgagatcct cagccactgc tggatgcagc ccaaggcacg
gggatctccc 840tctgtggcca tcaacaagga gggggagagt tcccggggaa
ctgaaccctt gtggaccccc 900gaacctggct ctgacaagaa gtctgccacc
aagctggagc ctgagggaga ggcacagccc 960caggcacagc ctgagacaaa
acccgagggg acagcaatgc aaatgtccag gcagtcggag 1020atcctgggtt
tccccagcaa gccgtcgact atggagacag aggaagggcc cccccaacag
1080cctccagaga cgcgggccca gtga 110417277PRTArtificial
Sequenceconsensus sequence 17Tyr Glu Leu Leu Glu Lys Leu Gly Glu
Gly Ser Phe Gly Lys Val Tyr 1 5 10 15Lys Ala Lys His Lys Thr Gly
Lys Ile Val Ala Val Lys Ile Leu Lys 20 25 30Lys Glu Ser Leu Ser Arg
Glu Ile Gln Ile Leu Lys Arg Leu Ser His 35 40 45Pro Asn Ile Val Arg
Leu Leu Gly Val Phe Glu Asp Thr Asp Asp His 50 55 60Leu Tyr Leu Val
Met Glu Tyr Met Glu Gly Gly Asp Leu Phe Asp Tyr65 70 75 80Leu Arg
Arg Asn Gly Pro Leu Ser Glu Lys Glu Ala Lys Lys Ile Ala 85 90 95Leu
Gln Ile Leu Arg Gly Leu Glu Tyr Leu His Ser Asn Gly Ile Val 100 105
110His Arg Asp Leu Lys Pro Glu Asn Ile Leu Leu Asp Glu Asn Gly Thr
115 120 125Val Lys Ile Ala Asp Phe Gly Leu Ala Arg Leu Leu Glu Lys
Leu Thr 130 135 140Thr Phe Val Gly Thr Pro Trp Tyr Met Met Ala Pro
Glu Val Ile Leu145 150 155 160Glu Gly Arg Gly Tyr Ser Ser Lys Val
Asp Val Trp Ser Leu Gly Val 165 170 175Ile Leu Tyr Glu Leu Leu Thr
Gly Gly Pro Leu Phe Pro Gly Ala Asp 180 185 190Leu Pro Ala Phe Thr
Gly Gly Asp Glu Val Asp Gln Leu Ile Ile Phe 195 200 205Val Leu Lys
Leu Pro Phe Ser Asp Glu Leu Pro Lys Thr Arg Ile Asp 210 215 220Pro
Leu Glu Glu Leu Phe Arg Ile Lys Lys Arg Arg Leu Pro Leu Pro225 230
235 240Ser Asn Cys Ser Glu Glu Leu Lys Asp Leu Leu Lys Lys Cys Leu
Asn 245 250 255Lys Asp Pro Ser Lys Arg Pro Gly Ser Ala Thr Ala Lys
Glu Ile Leu 260 265 270Asn His Pro Trp Phe 27518231PRTArtificial
Sequenceconsensus sequence 18Tyr Glu Leu Leu Lys Lys Leu Gly Lys
Gly Ala Phe Gly Lys Val Tyr 1 5 10 15Leu Ala Arg Asp Lys Lys Thr
Gly Arg Leu Val Ala Ile Lys Val Ile 20 25 30Lys Glu Arg Ile Leu Arg
Glu Ile Lys Ile Leu Lys Lys Asp His Pro 35 40 45Asn Ile Val Lys Leu
Tyr Asp Val Phe Glu Asp Asp Lys Leu Tyr Leu 50 55 60Val Met Glu Tyr
Cys Glu Gly Asp Leu Gly Asp Leu Phe Asp Leu Leu65 70 75 80Lys Lys
Arg Gly Arg Arg Gly Leu Arg Lys Val Leu Ser Glu Glu Ala 85 90 95Arg
Phe Tyr Phe Arg Gln Ile Leu Ser Ala Leu Glu Tyr Leu His Ser 100 105
110Gln Gly Ile Ile His Arg Asp Leu Lys Pro Glu Asn Ile Leu Leu Asp
115 120 125Ser His Val Lys Leu Ala Asp Phe Gly Leu Ala Arg Gln Leu
Thr Thr 130 135 140Phe Val Gly Thr Pro Glu Tyr Met Ala Pro Glu Val
Leu Gly Tyr Gly145 150 155 160Lys Pro Ala Val Asp Ile Trp Ser Leu
Gly Cys Ile Leu Tyr Glu Leu 165 170 175Leu Thr Gly Lys Pro Pro Phe
Pro Gln Leu Asp Leu Ile Phe Lys Lys 180 185 190Ile Gly Ser Pro Glu
Ala Lys Asp Leu Ile Lys Lys Leu Leu Val Lys 195 200 205Asp Pro Glu
Lys Arg Leu Thr Ala Glu Ala Leu Glu Asp Glu Leu Asp 210 215 220Ile
Lys Ala His Pro Phe Phe225 2301913PRTArtificial Sequencesite
signiture motif 19Xaa Xaa Xaa Xaa Asp Xaa Lys Xaa Xaa Asn Xaa Xaa
Xaa 1 5 10203552DNAHomo sapiensCDS(208)...(2505) 20ctcggcgctg
cggacacttt tagctgaggg cgcgggcggg tcggctcctc cgcggctcct 60cggccccacc
tgcgcggaga gggcgggatg ccagagccag gtgtcccggc gcgttaaggg
120ccctcgcagt cagacgtccc tgcaccggcg ctcgcaccct tagtcggccc
ggaacgtctt 180tttgcggacg ccctcggagc agccgcg atg gcc agc acc agg agt
atc gag ctg 234 Met Ala Ser Thr Arg Ser Ile Glu Leu 1 5gag cac ttt
gag gaa cgg gac aaa agg ccg cgg ccg ggg tcg cgg aga 282Glu His Phe
Glu Glu Arg Asp Lys Arg Pro Arg Pro Gly Ser Arg Arg 10 15 20 25ggg
gcc ccc agc tcc tcc ggg ggc agc agc agc tcg ggc ccc aag ggg 330Gly
Ala Pro Ser Ser Ser Gly Gly Ser Ser Ser Ser Gly Pro Lys Gly 30 35
40aac ggg ctc atc ccc agt ccg gcg cac agt gcc cac tgc agc ttc tac
378Asn Gly Leu Ile Pro Ser Pro Ala His Ser Ala His Cys Ser Phe Tyr
45 50 55cgc acg cgg acc ctg cag gcc ctc agc tcg gag aag aag gcc aag
aag 426Arg Thr Arg Thr Leu Gln Ala Leu Ser Ser Glu Lys Lys Ala Lys
Lys 60 65 70gcg cgc ttc tac cgg aac ggg gac cgc tac ttc aag ggc ctg
gtg ttt 474Ala Arg Phe Tyr Arg Asn Gly Asp Arg Tyr Phe Lys Gly Leu
Val Phe 75 80 85gcc atc tcc agc gac cgc ttc cgg tcc ttc gat gcg ctc
ctc ata gag 522Ala Ile Ser Ser Asp Arg Phe Arg Ser Phe Asp Ala Leu
Leu Ile Glu 90 95 100 105ctc acc cgc tcc ctg tcg gac aac gtg aac
ctg ccc cag ggt gtc cgc 570Leu Thr Arg Ser Leu Ser Asp Asn Val Asn
Leu Pro Gln Gly Val Arg 110 115 120act atc tac acc atc gac ggc agc
cgg aag gtc acc agc ctg gac gag 618Thr Ile Tyr Thr Ile Asp Gly Ser
Arg Lys Val Thr Ser Leu Asp Glu 125 130 135ctg ctg gaa ggt gag agt
tac gtg tgt gca tcc aat gaa cca ttt cgt 666Leu Leu Glu Gly Glu Ser
Tyr Val Cys Ala Ser Asn Glu Pro Phe Arg 140 145 150aaa gtc gat tac
acc aaa aat att aat cca aac tgg tct gtg aac atc 714Lys Val Asp Tyr
Thr Lys Asn Ile Asn Pro Asn Trp Ser Val Asn Ile 155 160 165aag ggt
ggg aca tcc cga gcg ctg gct gct gcc tcc tct gtg aaa agt 762Lys Gly
Gly Thr Ser Arg Ala Leu Ala Ala Ala Ser Ser Val Lys Ser170 175 180
185gaa gta aaa gaa agt aaa gat ttc atc aaa ccc aag tta gtg act gtg
810Glu Val Lys Glu Ser Lys Asp Phe Ile Lys Pro Lys Leu Val Thr Val
190 195 200att cga agt gga gtg aag cct aga aaa gcc gtg cgg atc ctt
ctg aat 858Ile Arg Ser Gly Val Lys Pro Arg Lys Ala Val Arg Ile Leu
Leu Asn 205 210 215aaa aag act gct cat tcc ttt gaa caa gtc tta aca
gat atc acc gaa 906Lys Lys Thr Ala His Ser Phe Glu Gln Val Leu Thr
Asp Ile Thr Glu 220 225 230gcc att aaa cta gac tca gga gtc gtc aag
agg ctc tgc acc ctg gat 954Ala Ile Lys Leu Asp Ser Gly Val Val Lys
Arg Leu Cys Thr Leu Asp 235 240 245gga aag cag gtt act tgt ctg caa
gac ttt ttt ggt gat gac gat gtt 1002Gly Lys Gln Val Thr Cys Leu Gln
Asp Phe Phe Gly Asp Asp Asp Val250 255 260 265ttt att gca tgt gga
cca gaa aaa ttt cgt tat gcc caa gat gac ttt 1050Phe Ile Ala Cys Gly
Pro Glu Lys Phe Arg Tyr Ala Gln Asp Asp Phe 270 275 280gtc ctg gat
cat agt gaa tgt cgt gtc ctg aag tca tct tat tct cga 1098Val Leu Asp
His Ser Glu Cys Arg Val Leu Lys Ser Ser Tyr Ser Arg 285 290 295tcc
tca gct gtt aag tat tct gga tcc aaa agc cct ggg ccc tct cga 1146Ser
Ser Ala Val Lys Tyr Ser Gly Ser Lys Ser Pro Gly Pro Ser Arg 300 305
310cgc agc aaa tca cca gct tca gtt aat gga act ccc agc agc caa ctt
1194Arg Ser Lys Ser Pro Ala Ser Val Asn Gly Thr Pro Ser Ser Gln Leu
315 320 325tct act cct aaa tct acg aaa tcc tcc agt tcc tct cca act
agt cca 1242Ser Thr Pro Lys Ser Thr Lys Ser Ser Ser Ser Ser Pro Thr
Ser Pro330 335 340 345gga agt ttc aga gga tta aag cag att tct gct
cat ggc aga tct tct 1290Gly Ser Phe Arg Gly Leu Lys Gln Ile Ser Ala
His Gly Arg Ser Ser 350 355 360tcc aat gta acc ggt gga cct gag ctt
gac cgt tgc ata agt cct gaa 1338Ser Asn Val Thr Gly Gly Pro Glu Leu
Asp Arg Cys Ile Ser Pro Glu 365 370 375ggt gtg aat gga aac aga tgc
tct gaa tca tca act ctt ctt gag aaa 1386Gly Val Asn Gly Asn Arg Cys
Ser Glu Ser Ser Thr Leu Leu Glu Lys 380 385 390tac aaa att gga aag
gtc att ggt gat ggc aat ttt gca gta gtc aaa 1434Tyr Lys Ile Gly Lys
Val Ile Gly Asp Gly Asn Phe Ala Val Val Lys 395 400 405gag tgt ata
gac agg tcc act gga aag gag ttt gcc cta aag att ata 1482Glu Cys Ile
Asp Arg Ser Thr Gly Lys Glu Phe Ala Leu Lys Ile Ile410 415 420
425gac aaa gcc aaa tgt tgt gga aag gaa cac ctg att gag aat gaa gtg
1530Asp Lys Ala Lys Cys Cys Gly Lys Glu His Leu Ile Glu Asn Glu Val
430 435 440tca ata ctg cgc cga gtg aaa cat ccc aat atc att atg ctg
gtc gag 1578Ser Ile Leu Arg Arg Val Lys His Pro Asn Ile Ile Met Leu
Val Glu 445 450 455gag atg gaa aca gca act gag ctc ttt ctg gtg atg
gaa ttg gtc aaa 1626Glu Met Glu Thr Ala Thr Glu Leu Phe Leu Val Met
Glu Leu Val Lys 460 465 470ggt gga gat ctc ttt gat gca att act tcg
tcg acc aag tac act gag 1674Gly Gly Asp Leu Phe Asp Ala Ile Thr Ser
Ser Thr Lys Tyr Thr Glu 475 480 485aga gat ggc agt gcc atg gtg tac
aac tta gcc aat gcc ctc agg tat 1722Arg Asp Gly Ser Ala Met Val Tyr
Asn Leu Ala Asn Ala Leu Arg Tyr490 495 500 505ctc cat ggc ctc agc
atc gtg cac aga gac atc aaa cca gag aat ctc 1770Leu His Gly Leu Ser
Ile Val His Arg Asp Ile Lys Pro Glu Asn Leu 510 515 520ttg gtg tgt
gaa tat cct gat gga acc aag tct ttg aaa ctg gga gac 1818Leu Val Cys
Glu Tyr Pro Asp Gly Thr Lys Ser Leu Lys Leu Gly Asp 525 530 535ttt
ggg ctt gcg act gtg gta gaa ggc cct tta tac aca gtc tgt ggc 1866Phe
Gly Leu Ala Thr Val Val Glu Gly Pro Leu Tyr Thr Val Cys Gly 540 545
550aca ccc act tat gtg gct cca gaa atc att gct gaa act ggc tat ggc
1914Thr Pro Thr Tyr Val Ala Pro Glu Ile Ile Ala Glu Thr Gly Tyr Gly
555 560 565ctg aag gtg gac att tgg gca gct ggt gtg atc aca tac ata
ctt ctc 1962Leu Lys Val Asp Ile Trp Ala Ala Gly Val Ile Thr Tyr Ile
Leu Leu570 575 580 585tgt gga ttc cca cca ttc cga agt gag aac aat
ctc cag gaa gat ctc 2010Cys Gly Phe Pro Pro Phe Arg Ser Glu Asn Asn
Leu Gln Glu Asp Leu 590 595 600ttc gac cag atc ttg gct ggg aag ctg
gag ttt ccg gcc ccc tac tgg 2058Phe Asp Gln Ile Leu Ala Gly Lys Leu
Glu Phe Pro Ala Pro Tyr Trp 605 610 615gat aac atc acg gac tct gcc
aag gaa tta atc agt caa atg ctt cag 2106Asp Asn Ile Thr Asp Ser Ala
Lys Glu Leu Ile Ser Gln Met Leu Gln 620 625 630gta aat gtt gaa gct
cgg tgt acc gcg gga caa atc ctg agt cac ccc 2154Val Asn Val Glu Ala
Arg Cys Thr Ala Gly Gln Ile Leu Ser His Pro 635 640 645tgg gtg tca
gat gat gcc tcc cag gag aat aac atg caa gct gag gtg 2202Trp Val Ser
Asp Asp Ala Ser Gln Glu Asn Asn Met Gln Ala Glu Val650 655 660
665aca ggt aaa cta aaa cag cac ttt aat aat gcg ctc ccc aaa cag aac
2250Thr Gly Lys Leu Lys Gln His Phe Asn Asn Ala Leu Pro Lys Gln Asn
670 675 680agc act acc acc ggg gtc tcc gtc atc atg aac acg gct cta
gat aag 2298Ser Thr Thr Thr Gly Val Ser Val Ile Met Asn Thr Ala Leu
Asp Lys 685 690 695gag ggg cag att ttc tgc agc aag cac tgt caa gac
agc ggc agg cct 2346Glu Gly Gln Ile Phe Cys Ser Lys His Cys Gln Asp
Ser Gly Arg Pro 700 705 710ggg atg gag ccc atc tct cca gtt cct ccc
tca gtg gag gag atc cct 2394Gly Met Glu Pro Ile Ser Pro Val Pro Pro
Ser Val Glu Glu Ile Pro 715 720 725gtg cct ggg gaa gca gtc ccg gcc
ccc acc cct ccg gaa tct ccc acc 2442Val Pro Gly Glu Ala Val Pro Ala
Pro Thr Pro Pro Glu Ser Pro Thr730 735 740 745ccc cac tgt cct ccc
gct gcc ccg ggt ggt gag cgg gca gga acc tgg 2490Pro His Cys Pro Pro
Ala Ala Pro Gly Gly Glu Arg Ala Gly Thr Trp 750 755 760cgc cgc cac
cga gac tgagcctcct gcagacgggc gaagccgcct gctgccgccc 2545Arg Arg His
Arg Asp 765aggaagccag ccctctgctc ggcctcgccg gcctccctgc tgcaggcctc
cctctcttca 2605ccgcctgcgc ctgagttcgc gggtcctccg caggccgcct
gggaaccgga gcctggcgtg 2665ccggagcctg gcctggtgct ctgggctctg
ccttctggtt cctggaggca tcaaaggctg 2725catccgttct gccaacagct
gttcggagag actcgttcca gatcatcccg tcattttcag 2785tttgttggac
attttacagc ttcaccagga gaatgtgcaa ctttattcca gcattcgatg
2845catttttata gaaacacttt ggaaacactt tggatgaacc aaggcctttt
ccttatttaa 2905gtagactcag aacactccct ttcttttctt ttctctctct
ctcttttttt tttacgaaag 2965acttagaatt gcatttgtcc ttttgtgggt
gtcctgtgag aggtgatatg ggggctaaga 3025ggactggctt tctaatagaa
gaagtgagcg cctgagagga caatttggtc attggacacg 3085gattgcaggc
tttgagaagc gctcagaggc ccagggcggc gggctcagcc attcggcttg
3145gggcaccagg ctccccagag acaatgctca gtattcattc atacacagac
gatggaagaa 3205gccacttctt ccctgggcgg tgtgggtttc ccccagctct
tcccacacgt gtgttaggaa 3265atgcccgtga acttgccctc tgggcttttt
aatgagaggc ttggcgcatg cggcacccag 3325cggctgcttc cctgcaagcc
agcgacttgc cgagcagaat gagctctgct cctgagcccc 3385ggtagctgct
tcctcatctg ctctttttaa taattgtaca taatccgtgt atttgtttta
3445cctgctcatc ttctaaactg gcgagcccta tagttcgttc tcattgttag
attttgcctt 3505ttacaagtgt ccccaacctg caataaactt ttccctcttg aaaaaaa
355221766PRTHomo sapiens 21Met Ala Ser Thr Arg Ser Ile Glu Leu Glu
His Phe Glu Glu Arg Asp 1 5 10
15Lys Arg Pro Arg Pro Gly Ser Arg Arg Gly Ala Pro Ser Ser Ser Gly
20 25 30Gly Ser Ser Ser Ser Gly Pro Lys Gly Asn Gly Leu Ile Pro Ser
Pro 35 40 45Ala His Ser Ala His Cys Ser Phe Tyr Arg Thr Arg Thr Leu
Gln Ala 50 55 60Leu Ser Ser Glu Lys Lys Ala Lys Lys Ala Arg Phe Tyr
Arg Asn Gly65 70 75 80Asp Arg Tyr Phe Lys Gly Leu Val Phe Ala Ile
Ser Ser Asp Arg Phe 85 90 95Arg Ser Phe Asp Ala Leu Leu Ile Glu Leu
Thr Arg Ser Leu Ser Asp 100 105 110Asn Val Asn Leu Pro Gln Gly Val
Arg Thr Ile Tyr Thr Ile Asp Gly 115 120 125Ser Arg Lys Val Thr Ser
Leu Asp Glu Leu Leu Glu Gly Glu Ser Tyr 130 135 140Val Cys Ala Ser
Asn Glu Pro Phe Arg Lys Val Asp Tyr Thr Lys Asn145 150 155 160Ile
Asn Pro Asn Trp Ser Val Asn Ile Lys Gly Gly Thr Ser Arg Ala 165 170
175Leu Ala Ala Ala Ser Ser Val Lys Ser Glu Val Lys Glu Ser Lys Asp
180 185 190Phe Ile Lys Pro Lys Leu Val Thr Val Ile Arg Ser Gly Val
Lys Pro 195 200 205Arg Lys Ala Val Arg Ile Leu Leu Asn Lys Lys Thr
Ala His Ser Phe 210 215 220Glu Gln Val Leu Thr Asp Ile Thr Glu Ala
Ile Lys Leu Asp Ser Gly225 230 235 240Val Val Lys Arg Leu Cys Thr
Leu Asp Gly Lys Gln Val Thr Cys Leu 245 250 255Gln Asp Phe Phe Gly
Asp Asp Asp Val Phe Ile Ala Cys Gly Pro Glu 260 265 270Lys Phe Arg
Tyr Ala Gln Asp Asp Phe Val Leu Asp His Ser Glu Cys 275 280 285Arg
Val Leu Lys Ser Ser Tyr Ser Arg Ser Ser Ala Val Lys Tyr Ser 290 295
300Gly Ser Lys Ser Pro Gly Pro Ser Arg Arg Ser Lys Ser Pro Ala
Ser305 310 315 320Val Asn Gly Thr Pro Ser Ser Gln Leu Ser Thr Pro
Lys Ser Thr Lys 325 330 335Ser Ser Ser Ser Ser Pro Thr Ser Pro Gly
Ser Phe Arg Gly Leu Lys 340 345 350Gln Ile Ser Ala His Gly Arg Ser
Ser Ser Asn Val Thr Gly Gly Pro 355 360 365Glu Leu Asp Arg Cys Ile
Ser Pro Glu Gly Val Asn Gly Asn Arg Cys 370 375 380Ser Glu Ser Ser
Thr Leu Leu Glu Lys Tyr Lys Ile Gly Lys Val Ile385 390 395 400Gly
Asp Gly Asn Phe Ala Val Val Lys Glu Cys Ile Asp Arg Ser Thr 405 410
415Gly Lys Glu Phe Ala Leu Lys Ile Ile Asp Lys Ala Lys Cys Cys Gly
420 425 430Lys Glu His Leu Ile Glu Asn Glu Val Ser Ile Leu Arg Arg
Val Lys 435 440 445His Pro Asn Ile Ile Met Leu Val Glu Glu Met Glu
Thr Ala Thr Glu 450 455 460Leu Phe Leu Val Met Glu Leu Val Lys Gly
Gly Asp Leu Phe Asp Ala465 470 475 480Ile Thr Ser Ser Thr Lys Tyr
Thr Glu Arg Asp Gly Ser Ala Met Val 485 490 495Tyr Asn Leu Ala Asn
Ala Leu Arg Tyr Leu His Gly Leu Ser Ile Val 500 505 510His Arg Asp
Ile Lys Pro Glu Asn Leu Leu Val Cys Glu Tyr Pro Asp 515 520 525Gly
Thr Lys Ser Leu Lys Leu Gly Asp Phe Gly Leu Ala Thr Val Val 530 535
540Glu Gly Pro Leu Tyr Thr Val Cys Gly Thr Pro Thr Tyr Val Ala
Pro545 550 555 560Glu Ile Ile Ala Glu Thr Gly Tyr Gly Leu Lys Val
Asp Ile Trp Ala 565 570 575Ala Gly Val Ile Thr Tyr Ile Leu Leu Cys
Gly Phe Pro Pro Phe Arg 580 585 590Ser Glu Asn Asn Leu Gln Glu Asp
Leu Phe Asp Gln Ile Leu Ala Gly 595 600 605Lys Leu Glu Phe Pro Ala
Pro Tyr Trp Asp Asn Ile Thr Asp Ser Ala 610 615 620Lys Glu Leu Ile
Ser Gln Met Leu Gln Val Asn Val Glu Ala Arg Cys625 630 635 640Thr
Ala Gly Gln Ile Leu Ser His Pro Trp Val Ser Asp Asp Ala Ser 645 650
655Gln Glu Asn Asn Met Gln Ala Glu Val Thr Gly Lys Leu Lys Gln His
660 665 670Phe Asn Asn Ala Leu Pro Lys Gln Asn Ser Thr Thr Thr Gly
Val Ser 675 680 685Val Ile Met Asn Thr Ala Leu Asp Lys Glu Gly Gln
Ile Phe Cys Ser 690 695 700Lys His Cys Gln Asp Ser Gly Arg Pro Gly
Met Glu Pro Ile Ser Pro705 710 715 720Val Pro Pro Ser Val Glu Glu
Ile Pro Val Pro Gly Glu Ala Val Pro 725 730 735Ala Pro Thr Pro Pro
Glu Ser Pro Thr Pro His Cys Pro Pro Ala Ala 740 745 750Pro Gly Gly
Glu Arg Ala Gly Thr Trp Arg Arg His Arg Asp 755 760
765222301DNAHomo sapiens 22atggccagca ccaggagtat cgagctggag
cactttgagg aacgggacaa aaggccgcgg 60ccggggtcgc ggagaggggc ccccagctcc
tccgggggca gcagcagctc gggccccaag 120gggaacgggc tcatccccag
tccggcgcac agtgcccact gcagcttcta ccgcacgcgg 180accctgcagg
ccctcagctc ggagaagaag gccaagaagg cgcgcttcta ccggaacggg
240gaccgctact tcaagggcct ggtgtttgcc atctccagcg accgcttccg
gtccttcgat 300gcgctcctca tagagctcac ccgctccctg tcggacaacg
tgaacctgcc ccagggtgtc 360cgcactatct acaccatcga cggcagccgg
aaggtcacca gcctggacga gctgctggaa 420ggtgagagtt acgtgtgtgc
atccaatgaa ccatttcgta aagtcgatta caccaaaaat 480attaatccaa
actggtctgt gaacatcaag ggtgggacat cccgagcgct ggctgctgcc
540tcctctgtga aaagtgaagt aaaagaaagt aaagatttca tcaaacccaa
gttagtgact 600gtgattcgaa gtggagtgaa gcctagaaaa gccgtgcgga
tccttctgaa taaaaagact 660gctcattcct ttgaacaagt cttaacagat
atcaccgaag ccattaaact agactcagga 720gtcgtcaaga ggctctgcac
cctggatgga aagcaggtta cttgtctgca agactttttt 780ggtgatgacg
atgtttttat tgcatgtgga ccagaaaaat ttcgttatgc ccaagatgac
840tttgtcctgg atcatagtga atgtcgtgtc ctgaagtcat cttattctcg
atcctcagct 900gttaagtatt ctggatccaa aagccctggg ccctctcgac
gcagcaaatc accagcttca 960gttaatggaa ctcccagcag ccaactttct
actcctaaat ctacgaaatc ctccagttcc 1020tctccaacta gtccaggaag
tttcagagga ttaaagcaga tttctgctca tggcagatct 1080tcttccaatg
taaccggtgg acctgagctt gaccgttgca taagtcctga aggtgtgaat
1140ggaaacagat gctctgaatc atcaactctt cttgagaaat acaaaattgg
aaaggtcatt 1200ggtgatggca attttgcagt agtcaaagag tgtatagaca
ggtccactgg aaaggagttt 1260gccctaaaga ttatagacaa agccaaatgt
tgtggaaagg aacacctgat tgagaatgaa 1320gtgtcaatac tgcgccgagt
gaaacatccc aatatcatta tgctggtcga ggagatggaa 1380acagcaactg
agctctttct ggtgatggaa ttggtcaaag gtggagatct ctttgatgca
1440attacttcgt cgaccaagta cactgagaga gatggcagtg ccatggtgta
caacttagcc 1500aatgccctca ggtatctcca tggcctcagc atcgtgcaca
gagacatcaa accagagaat 1560ctcttggtgt gtgaatatcc tgatggaacc
aagtctttga aactgggaga ctttgggctt 1620gcgactgtgg tagaaggccc
tttatacaca gtctgtggca cacccactta tgtggctcca 1680gaaatcattg
ctgaaactgg ctatggcctg aaggtggaca tttgggcagc tggtgtgatc
1740acatacatac ttctctgtgg attcccacca ttccgaagtg agaacaatct
ccaggaagat 1800ctcttcgacc agatcttggc tgggaagctg gagtttccgg
ccccctactg ggataacatc 1860acggactctg ccaaggaatt aatcagtcaa
atgcttcagg taaatgttga agctcggtgt 1920accgcgggac aaatcctgag
tcacccctgg gtgtcagatg atgcctccca ggagaataac 1980atgcaagctg
aggtgacagg taaactaaaa cagcacttta ataatgcgct ccccaaacag
2040aacagcacta ccaccggggt ctccgtcatc atgaacacgg ctctagataa
ggaggggcag 2100attttctgca gcaagcactg tcaagacagc ggcaggcctg
ggatggagcc catctctcca 2160gttcctccct cagtggagga gatccctgtg
cctggggaag cagtcccggc ccccacccct 2220ccggaatctc ccacccccca
ctgtcctccc gctgccccgg gtggtgagcg ggcaggaacc 2280tggcgccgcc
accgagactg a 230123278PRTArtificial Sequenceconsensus sequence
23Tyr Glu Leu Leu Glu Lys Leu Gly Glu Gly Ser Phe Gly Lys Val Tyr 1
5 10 15Lys Ala Lys His Lys Thr Gly Lys Ile Val Ala Val Lys Ile Leu
Lys 20 25 30Lys Glu Ser Leu Ser Leu Arg Glu Ile Gln Ile Leu Lys Arg
Leu Ser 35 40 45His Pro Asn Ile Val Arg Leu Leu Gly Val Phe Glu Asp
Thr Asp Asp 50 55 60His Leu Tyr Leu Val Met Glu Tyr Met Glu Gly Gly
Asp Leu Phe Asp65 70 75 80Tyr Leu Arg Arg Asn Gly Pro Leu Ser Glu
Lys Glu Ala Lys Lys Ile 85 90 95Ala Leu Gln Ile Leu Arg Gly Leu Glu
Tyr Leu His Ser Asn Gly Ile 100 105 110Val His Arg Asp Leu Lys Pro
Glu Asn Ile Leu Leu Asp Glu Asn Gly 115 120 125Thr Val Lys Ile Ala
Asp Phe Gly Leu Ala Arg Leu Leu Glu Lys Leu 130 135 140Thr Thr Phe
Val Gly Thr Pro Trp Tyr Met Met Ala Pro Glu Val Ile145 150 155
160Leu Glu Gly Arg Gly Tyr Ser Ser Lys Val Asp Val Trp Ser Leu Gly
165 170 175Val Ile Leu Tyr Glu Leu Leu Thr Gly Gly Pro Leu Phe Pro
Gly Ala 180 185 190Asp Leu Pro Ala Phe Thr Gly Gly Asp Glu Val Asp
Gln Leu Ile Ile 195 200 205Phe Val Leu Lys Leu Pro Phe Ser Asp Glu
Leu Pro Lys Thr Arg Ile 210 215 220Asp Pro Leu Glu Glu Leu Phe Arg
Ile Lys Lys Arg Arg Leu Pro Leu225 230 235 240Pro Ser Asn Cys Ser
Glu Glu Leu Lys Asp Leu Leu Lys Lys Cys Leu 245 250 255Asn Lys Asp
Pro Ser Lys Arg Pro Gly Ser Ala Thr Ala Lys Glu Ile 260 265 270Leu
Asn His Pro Trp Phe 2752496PRTArtificial Sequenceconsensus sequence
24Ser Leu Val Lys Pro Lys Arg Ile Arg Val Tyr Arg Asn Gly Asp Arg 1
5 10 15Phe Phe Lys Gly Val Arg Leu Val Val Asn Arg Lys Arg Gln Phe
Lys 20 25 30Ser Phe Glu Ala Leu Leu Gln Asp Leu Thr Glu Leu Lys Leu
Val Val 35 40 45Lys Leu Asp Leu Pro Phe Ala Val Arg Lys Leu Tyr Thr
Leu Asp Gly 50 55 60Gly Lys Lys Val Thr Ser Leu Asp Glu Leu Glu Asp
Gly Asp Gly Val65 70 75 80Tyr Val Ala Ser Gly Thr Glu Glu Lys Phe
Lys Lys Val Asp Tyr Gly 85 90 9525231PRTArtificial
Sequenceconsensus sequence 25Tyr Glu Leu Leu Lys Lys Leu Gly Lys
Gly Ala Phe Gly Lys Val Tyr 1 5 10 15Leu Ala Arg Asp Lys Lys Thr
Gly Arg Leu Val Ala Ile Lys Val Ile 20 25 30Lys Glu Arg Ile Leu Arg
Glu Ile Lys Ile Leu Lys Lys Asp His Pro 35 40 45Asn Ile Val Lys Leu
Tyr Asp Val Phe Glu Asp Asp Lys Leu Tyr Leu 50 55 60Val Met Glu Tyr
Cys Glu Gly Asp Leu Gly Asp Leu Phe Asp Leu Leu65 70 75 80Lys Lys
Arg Gly Arg Arg Gly Leu Arg Lys Val Leu Ser Glu Glu Ala 85 90 95Arg
Phe Tyr Phe Arg Gln Ile Leu Ser Ala Leu Glu Tyr Leu His Ser 100 105
110Gln Gly Ile Ile His Arg Asp Leu Lys Pro Glu Asn Ile Leu Leu Asp
115 120 125Ser His Val Lys Leu Ala Asp Phe Gly Leu Ala Arg Gln Leu
Thr Thr 130 135 140Phe Val Gly Thr Pro Glu Tyr Met Ala Pro Glu Val
Leu Gly Tyr Gly145 150 155 160Lys Pro Ala Val Asp Ile Trp Ser Leu
Gly Cys Ile Leu Tyr Glu Leu 165 170 175Leu Thr Gly Lys Pro Pro Phe
Pro Gln Leu Asp Leu Ile Phe Lys Lys 180 185 190Ile Gly Ser Pro Glu
Ala Lys Asp Leu Ile Lys Lys Leu Leu Val Lys 195 200 205Asp Pro Glu
Lys Arg Leu Thr Ala Glu Ala Leu Glu Asp Glu Leu Asp 210 215 220Ile
Lys Ala His Pro Phe Phe225 23026253PRTArtificial Sequenceconsensus
sequence 26Asn Gly Leu Pro Ser Pro Thr His Ser Ala His Cys Ser Phe
Tyr Arg 1 5 10 15Thr Arg Thr Leu Gln Thr Leu Ser Asn Glu Lys Lys
Ala Lys Lys Val 20 25 30Arg Phe Tyr Arg Asn Gly Asp Arg Tyr Phe Lys
Gly Ile Val Tyr Ala 35 40 45Val Ser Pro Asp Arg Phe Arg Ser Phe Asp
Ala Leu Leu Ala Asp Leu 50 55 60Thr Arg Thr Leu Ser Asp Asn Ile Asn
Leu Pro Gln Gly Val Arg Tyr65 70 75 80Ile Tyr Thr Ile Asp Gly Ser
Arg Lys Ile Gly Ser Met Asp Glu Leu 85 90 95Glu Glu Gly Glu Ser Tyr
Val Cys Gly Ser Asp Asn Pro Phe Lys Lys 100 105 110Val Glu Tyr Thr
Lys Asn Val Asn Pro Asn Trp Ser Val Asn Val Lys 115 120 125Thr Thr
Ala Asn Met Lys Ala Pro Gln Ser Leu Ala Thr Ser Asn Gly 130 135
140Ala Pro Ser Gln Ala Arg Glu Asn Lys Asp Phe Val Arg Pro Lys
Leu145 150 155 160Val Thr Ile Ile Arg Ser Gly Val Lys Pro Arg Lys
Ala Val Arg Val 165 170 175Leu Leu Asn Lys Lys Thr Ala His Ser Phe
Glu Gln Val Leu Thr Asp 180 185 190Ile Thr Asp Ala Ile Lys Leu Asp
Thr Gly Val Val Lys Lys Leu Tyr 195 200 205Thr Leu Asp Gly Lys Gln
Val Thr Cys Leu His Asp Phe Phe Gly Asp 210 215 220Asp Asp Val Phe
Ile Ala Cys Gly Pro Glu Lys Phe Arg Tyr Ala Gln225 230 235 240Asp
Asp Phe Ser Leu Asp Glu Asn Glu Cys Arg Val Met 245
250273669DNAHomo sapiensCDS(106)...(2856) 27ccacgcgtcc ggcctggact
ggaagcgtgc aacactccag agtcgtagga gtgaacactg 60cacaggaatc tctgcccatc
tcaggagaaa ccaaacttgg ggaaa atg ttt gcg gtc 117 Met Phe Ala Val
1cac ttg atg gca ttt tac ttc agc aag ctg aag gag gac cag atc aag
165His Leu Met Ala Phe Tyr Phe Ser Lys Leu Lys Glu Asp Gln Ile Lys
5 10 15 20aag gtg gac agg ttc ctg tat cac atg cgg ctc tcc gat gac
acc ctt 213Lys Val Asp Arg Phe Leu Tyr His Met Arg Leu Ser Asp Asp
Thr Leu 25 30 35ttg gac atc atg agg cgg ttc cgg gct gag atg gag aag
ggc ctg gca 261Leu Asp Ile Met Arg Arg Phe Arg Ala Glu Met Glu Lys
Gly Leu Ala 40 45 50aag gac acc aac ccc acg gct gca gtg aag atg ttg
ccc acc ttc gtc 309Lys Asp Thr Asn Pro Thr Ala Ala Val Lys Met Leu
Pro Thr Phe Val 55 60 65agg gcc att ccc gat ggt tcc gaa aat ggg gag
ttc ctt tcc ctg gat 357Arg Ala Ile Pro Asp Gly Ser Glu Asn Gly Glu
Phe Leu Ser Leu Asp 70 75 80ctc gga ggg tcc aag ttc cga gtg ctg aag
gtg caa gtc gct gaa gag 405Leu Gly Gly Ser Lys Phe Arg Val Leu Lys
Val Gln Val Ala Glu Glu 85 90 95 100ggg aag cga cac gtg cag atg gag
agt cag ttc tac cca acg ccc aat 453Gly Lys Arg His Val Gln Met Glu
Ser Gln Phe Tyr Pro Thr Pro Asn 105 110 115gaa atc atc cgc ggg aac
ggc ata gag ctg ttt gaa tat gta gct gac 501Glu Ile Ile Arg Gly Asn
Gly Ile Glu Leu Phe Glu Tyr Val Ala Asp 120 125 130tgt ctg gca gat
ttc atg aag acc aaa gat tta aag cat aag aaa ttg 549Cys Leu Ala Asp
Phe Met Lys Thr Lys Asp Leu Lys His Lys Lys Leu 135 140 145ccc ctt
ggc cta act ttt tct ttc ccc tgt cga cag act aaa ctg gaa 597Pro Leu
Gly Leu Thr Phe Ser Phe Pro Cys Arg Gln Thr Lys Leu Glu 150 155
160gag ggt gtc cta ctt tcg tgg aca aaa aag ttt aag gca cga gga gtt
645Glu Gly Val Leu Leu Ser Trp Thr Lys Lys Phe Lys Ala Arg Gly
Val165 170 175 180cag gac acg gat gtg gtg agc cgt ctg acc aaa gcc
atg aga aga cac 693Gln Asp Thr Asp Val Val Ser Arg Leu Thr Lys Ala
Met Arg Arg His 185 190 195aag gac atg gac gtg gac atc ctg gcc ctg
gtc aat gac acc gtg ggg 741Lys Asp Met Asp Val Asp Ile Leu Ala Leu
Val Asn Asp Thr Val Gly 200 205 210acc atg atg acc tgt gcc tat gac
gac ccc tac tgc gaa gtt ggt gtc 789Thr Met Met Thr Cys Ala Tyr Asp
Asp Pro Tyr Cys Glu Val Gly Val 215 220 225atc atc gga act ggc acc
aat gcg tgt tac atg gag gac atg agc aac 837Ile Ile Gly Thr Gly Thr
Asn Ala Cys Tyr Met Glu Asp Met Ser Asn 230 235 240att gac ctg gtg
gag ggc gac gag ggc agg atg tgc atc aac aca gag 885Ile Asp Leu Val
Glu Gly Asp Glu Gly Arg Met Cys Ile Asn Thr Glu245 250 255 260tgg
ggg gcc ttc
ggg gac gac ggg gcc ctg gag gac att cgc act gag 933Trp Gly Ala Phe
Gly Asp Asp Gly Ala Leu Glu Asp Ile Arg Thr Glu 265 270 275ttc gac
agg gag ctg gac ctc ggc tct ctc aac cca gga aag caa ctg 981Phe Asp
Arg Glu Leu Asp Leu Gly Ser Leu Asn Pro Gly Lys Gln Leu 280 285
290ttc gag aag atg atc agt ggc ctg tac ctg ggg gag ctt gtc agg ctt
1029Phe Glu Lys Met Ile Ser Gly Leu Tyr Leu Gly Glu Leu Val Arg Leu
295 300 305atc ttg ctg aag atg gcc aag gct ggc ctc ctg ttt ggt ggt
gag aaa 1077Ile Leu Leu Lys Met Ala Lys Ala Gly Leu Leu Phe Gly Gly
Glu Lys 310 315 320tct tct gct ctc cac act aag ggc aag atc gaa aca
cgg cac gtg gct 1125Ser Ser Ala Leu His Thr Lys Gly Lys Ile Glu Thr
Arg His Val Ala325 330 335 340gcc atg gag aag tat aaa gaa ggc ctt
gct aat aca aga gag atc ctg 1173Ala Met Glu Lys Tyr Lys Glu Gly Leu
Ala Asn Thr Arg Glu Ile Leu 345 350 355gtg gac ctg ggt ctg gaa ccg
tct gag gct gac tgc att gcc gtc cag 1221Val Asp Leu Gly Leu Glu Pro
Ser Glu Ala Asp Cys Ile Ala Val Gln 360 365 370cat gtc tgt acc atc
gtc tcc ttc cgc tcg gcc aat ctc tgt gca gca 1269His Val Cys Thr Ile
Val Ser Phe Arg Ser Ala Asn Leu Cys Ala Ala 375 380 385gct ctg gcg
gcc atc ctg aca cgc ctc cgg gag aac aag aag gtg gaa 1317Ala Leu Ala
Ala Ile Leu Thr Arg Leu Arg Glu Asn Lys Lys Val Glu 390 395 400cgg
ctc cgg acc aca gtg ggc atg gac ggc acc ctc tac aag ata cac 1365Arg
Leu Arg Thr Thr Val Gly Met Asp Gly Thr Leu Tyr Lys Ile His405 410
415 420cct cag tac cca aaa cgc ctg cac aag gtg gtg agg aaa ctg gtc
cca 1413Pro Gln Tyr Pro Lys Arg Leu His Lys Val Val Arg Lys Leu Val
Pro 425 430 435agc tgt gat gtc cgc ttc ctc ctg tca gag agt ggc agc
acc aag ggg 1461Ser Cys Asp Val Arg Phe Leu Leu Ser Glu Ser Gly Ser
Thr Lys Gly 440 445 450gcc gcc atg gtg acc gcg gtg gcc tcc cgc gtg
cag gcc cag cgg aag 1509Ala Ala Met Val Thr Ala Val Ala Ser Arg Val
Gln Ala Gln Arg Lys 455 460 465cag atc gac agg gtg ctg gct ttg ttc
cag ctg acc cga gag cag ctc 1557Gln Ile Asp Arg Val Leu Ala Leu Phe
Gln Leu Thr Arg Glu Gln Leu 470 475 480gtg gac gtg cag gcc aag atg
cgg gct gag ctg gag tat ggg ctg aag 1605Val Asp Val Gln Ala Lys Met
Arg Ala Glu Leu Glu Tyr Gly Leu Lys485 490 495 500aag aag agc cac
ggg ctg gcc acg gtc agg atg ctg ccc acc tac gtc 1653Lys Lys Ser His
Gly Leu Ala Thr Val Arg Met Leu Pro Thr Tyr Val 505 510 515tgc ggg
ctg ccg gac ggc aca gag aaa gga aag ttt ctc gcc ctg gat 1701Cys Gly
Leu Pro Asp Gly Thr Glu Lys Gly Lys Phe Leu Ala Leu Asp 520 525
530ctt ggg gga acc aac ttc cgg gtc ctc ctg gtg aag atc aga agt gga
1749Leu Gly Gly Thr Asn Phe Arg Val Leu Leu Val Lys Ile Arg Ser Gly
535 540 545cgg agg tca gtg cga atg tac aac aag atc ttc gcc atc ccc
ctg gag 1797Arg Arg Ser Val Arg Met Tyr Asn Lys Ile Phe Ala Ile Pro
Leu Glu 550 555 560atc atg cag ggc act ggt gag gag ctc ttt gat cac
att gtg cag tgc 1845Ile Met Gln Gly Thr Gly Glu Glu Leu Phe Asp His
Ile Val Gln Cys565 570 575 580atc gcc gac ttc ctg gac tac atg ggc
ctc aag gga gcc tcc cta cct 1893Ile Ala Asp Phe Leu Asp Tyr Met Gly
Leu Lys Gly Ala Ser Leu Pro 585 590 595ttg ggc ttc aca ttc tca ttt
ccc tgc agg cag atg agc att gac aag 1941Leu Gly Phe Thr Phe Ser Phe
Pro Cys Arg Gln Met Ser Ile Asp Lys 600 605 610gga aca ctc ata ggg
tgg acc aaa ggt ttc aag gcc act gac tgt gaa 1989Gly Thr Leu Ile Gly
Trp Thr Lys Gly Phe Lys Ala Thr Asp Cys Glu 615 620 625ggg gag gac
gtg gtg gac atg ctc agg gaa gcc atc aag agg aga aac 2037Gly Glu Asp
Val Val Asp Met Leu Arg Glu Ala Ile Lys Arg Arg Asn 630 635 640gag
ttt gac ctg gac att gtt gca gtc gtg aat gat aca gtg ggg acc 2085Glu
Phe Asp Leu Asp Ile Val Ala Val Val Asn Asp Thr Val Gly Thr645 650
655 660atg atg acc tgt ggc tat gaa gat cct aat tgt gag att ggc ctg
att 2133Met Met Thr Cys Gly Tyr Glu Asp Pro Asn Cys Glu Ile Gly Leu
Ile 665 670 675gca gga aca ggc agc aac atg tgc tac atg gag gac atg
agg aac atc 2181Ala Gly Thr Gly Ser Asn Met Cys Tyr Met Glu Asp Met
Arg Asn Ile 680 685 690gag atg gtg gag ggg ggt gaa ggg aag atg tgc
atc aat aca gag tgg 2229Glu Met Val Glu Gly Gly Glu Gly Lys Met Cys
Ile Asn Thr Glu Trp 695 700 705gga gga ttt gga gac aat ggc tgc ata
gat gac atc cgg acc cga tac 2277Gly Gly Phe Gly Asp Asn Gly Cys Ile
Asp Asp Ile Arg Thr Arg Tyr 710 715 720gac acg gag gtg gat gag ggg
tcc ttg aat cct ggc aag cag aga tac 2325Asp Thr Glu Val Asp Glu Gly
Ser Leu Asn Pro Gly Lys Gln Arg Tyr725 730 735 740gag aaa atg acc
agt ggg atg tac ttg ggg gag att gtg cgg cag atc 2373Glu Lys Met Thr
Ser Gly Met Tyr Leu Gly Glu Ile Val Arg Gln Ile 745 750 755ctg atc
gac ctg acc aag cag ggt ctc ctc ttc cga ggg cag att tca 2421Leu Ile
Asp Leu Thr Lys Gln Gly Leu Leu Phe Arg Gly Gln Ile Ser 760 765
770gag cgt ctc cgg acc agg ggc atc ttc gaa acc aag ttc ctg tcc cag
2469Glu Arg Leu Arg Thr Arg Gly Ile Phe Glu Thr Lys Phe Leu Ser Gln
775 780 785atc gaa agc gat cgg ctg gcc ctt ctc cag gtc agg agg att
ctg cag 2517Ile Glu Ser Asp Arg Leu Ala Leu Leu Gln Val Arg Arg Ile
Leu Gln 790 795 800cag ctg ggc ctg gac agc acg tgt gag gac agc atc
gtg gtg aag gag 2565Gln Leu Gly Leu Asp Ser Thr Cys Glu Asp Ser Ile
Val Val Lys Glu805 810 815 820gtg tgc gga gcc gtg tcc cgg cgg gcg
gcc cag ctc tgc ggt gct ggc 2613Val Cys Gly Ala Val Ser Arg Arg Ala
Ala Gln Leu Cys Gly Ala Gly 825 830 835ctg gcc gct ata gtg gaa aaa
agg aga gaa gac cag ggg cta gag cac 2661Leu Ala Ala Ile Val Glu Lys
Arg Arg Glu Asp Gln Gly Leu Glu His 840 845 850ctg agg atc act gtg
ggt gtg gac ggc acc ctg tac aag ctg cac cct 2709Leu Arg Ile Thr Val
Gly Val Asp Gly Thr Leu Tyr Lys Leu His Pro 855 860 865cac ttt tct
aga ata ttg cag gaa act gtg aag gaa cta gcc cct cga 2757His Phe Ser
Arg Ile Leu Gln Glu Thr Val Lys Glu Leu Ala Pro Arg 870 875 880tgt
gat gtg aca ttc atg ctg tca gaa gat ggc agt gga aaa ggg gca 2805Cys
Asp Val Thr Phe Met Leu Ser Glu Asp Gly Ser Gly Lys Gly Ala885 890
895 900gca ctg atc act gct gtg gcc aag agg tta cag cag gca cag aag
gag 2853Ala Leu Ile Thr Ala Val Ala Lys Arg Leu Gln Gln Ala Gln Lys
Glu 905 910 915aac taggaacccc tgggattgga cctgatgcat cttggatact
gaacagcttt 2906Asntcctctggca gatcagttgg tcagagacca atgggcaccc
tcctggctga cctcaccttc 2966tggatggccg aaagagaacc ccaggttctc
gggtactctt agtatcttgt actggatttg 3026cagtgacatt acatgacatc
tctatttggt atatttgggc caaaatgggc caacttatga 3086aatcaaagtg
tctgtcctga gagatcccct ttcaacacat tgttcaggtg aggcttgagc
3146tgtcaattct ctatggcttt cagtcttgtg gctgcgggac ttggaaatat
atagaatctg 3206cccatgtggc tggcaggctg tttccccatt gggatgctta
agccatctct tataggggat 3266tggaccctgt acttgtggat gaacattgga
gagcaagagg aactcacgtt atgaactagg 3326gggatctcat ctaacttgtc
cttaacttgc catgttgact tcaaacctgt taagagaaca 3386aagactttga
agtatccagc cccagggtgc agagaggttg attgccaggg agcactgcag
3446gaatcattgc atgcttaaag cgagttatgt cagcaccctg taggattttg
ttccttatta 3506agtgtgtgcc atgtggtggg gtgctgtctg gggcatctgt
ttttcatttt gcctgtggtt 3566tgtgttgcag stgttgatag ttgttttaag
gattgttagg tataggaaat ccagtaaatt 3626aataaaaaaa ttttgatttt
ccaataaaaa aaaaaaaaaa aaa 366928917PRTHomo sapiens 28Met Phe Ala
Val His Leu Met Ala Phe Tyr Phe Ser Lys Leu Lys Glu 1 5 10 15Asp
Gln Ile Lys Lys Val Asp Arg Phe Leu Tyr His Met Arg Leu Ser 20 25
30Asp Asp Thr Leu Leu Asp Ile Met Arg Arg Phe Arg Ala Glu Met Glu
35 40 45Lys Gly Leu Ala Lys Asp Thr Asn Pro Thr Ala Ala Val Lys Met
Leu 50 55 60Pro Thr Phe Val Arg Ala Ile Pro Asp Gly Ser Glu Asn Gly
Glu Phe65 70 75 80Leu Ser Leu Asp Leu Gly Gly Ser Lys Phe Arg Val
Leu Lys Val Gln 85 90 95Val Ala Glu Glu Gly Lys Arg His Val Gln Met
Glu Ser Gln Phe Tyr 100 105 110Pro Thr Pro Asn Glu Ile Ile Arg Gly
Asn Gly Ile Glu Leu Phe Glu 115 120 125Tyr Val Ala Asp Cys Leu Ala
Asp Phe Met Lys Thr Lys Asp Leu Lys 130 135 140His Lys Lys Leu Pro
Leu Gly Leu Thr Phe Ser Phe Pro Cys Arg Gln145 150 155 160Thr Lys
Leu Glu Glu Gly Val Leu Leu Ser Trp Thr Lys Lys Phe Lys 165 170
175Ala Arg Gly Val Gln Asp Thr Asp Val Val Ser Arg Leu Thr Lys Ala
180 185 190Met Arg Arg His Lys Asp Met Asp Val Asp Ile Leu Ala Leu
Val Asn 195 200 205Asp Thr Val Gly Thr Met Met Thr Cys Ala Tyr Asp
Asp Pro Tyr Cys 210 215 220Glu Val Gly Val Ile Ile Gly Thr Gly Thr
Asn Ala Cys Tyr Met Glu225 230 235 240Asp Met Ser Asn Ile Asp Leu
Val Glu Gly Asp Glu Gly Arg Met Cys 245 250 255Ile Asn Thr Glu Trp
Gly Ala Phe Gly Asp Asp Gly Ala Leu Glu Asp 260 265 270Ile Arg Thr
Glu Phe Asp Arg Glu Leu Asp Leu Gly Ser Leu Asn Pro 275 280 285Gly
Lys Gln Leu Phe Glu Lys Met Ile Ser Gly Leu Tyr Leu Gly Glu 290 295
300Leu Val Arg Leu Ile Leu Leu Lys Met Ala Lys Ala Gly Leu Leu
Phe305 310 315 320Gly Gly Glu Lys Ser Ser Ala Leu His Thr Lys Gly
Lys Ile Glu Thr 325 330 335Arg His Val Ala Ala Met Glu Lys Tyr Lys
Glu Gly Leu Ala Asn Thr 340 345 350Arg Glu Ile Leu Val Asp Leu Gly
Leu Glu Pro Ser Glu Ala Asp Cys 355 360 365Ile Ala Val Gln His Val
Cys Thr Ile Val Ser Phe Arg Ser Ala Asn 370 375 380Leu Cys Ala Ala
Ala Leu Ala Ala Ile Leu Thr Arg Leu Arg Glu Asn385 390 395 400Lys
Lys Val Glu Arg Leu Arg Thr Thr Val Gly Met Asp Gly Thr Leu 405 410
415Tyr Lys Ile His Pro Gln Tyr Pro Lys Arg Leu His Lys Val Val Arg
420 425 430Lys Leu Val Pro Ser Cys Asp Val Arg Phe Leu Leu Ser Glu
Ser Gly 435 440 445Ser Thr Lys Gly Ala Ala Met Val Thr Ala Val Ala
Ser Arg Val Gln 450 455 460Ala Gln Arg Lys Gln Ile Asp Arg Val Leu
Ala Leu Phe Gln Leu Thr465 470 475 480Arg Glu Gln Leu Val Asp Val
Gln Ala Lys Met Arg Ala Glu Leu Glu 485 490 495Tyr Gly Leu Lys Lys
Lys Ser His Gly Leu Ala Thr Val Arg Met Leu 500 505 510Pro Thr Tyr
Val Cys Gly Leu Pro Asp Gly Thr Glu Lys Gly Lys Phe 515 520 525Leu
Ala Leu Asp Leu Gly Gly Thr Asn Phe Arg Val Leu Leu Val Lys 530 535
540Ile Arg Ser Gly Arg Arg Ser Val Arg Met Tyr Asn Lys Ile Phe
Ala545 550 555 560Ile Pro Leu Glu Ile Met Gln Gly Thr Gly Glu Glu
Leu Phe Asp His 565 570 575Ile Val Gln Cys Ile Ala Asp Phe Leu Asp
Tyr Met Gly Leu Lys Gly 580 585 590Ala Ser Leu Pro Leu Gly Phe Thr
Phe Ser Phe Pro Cys Arg Gln Met 595 600 605Ser Ile Asp Lys Gly Thr
Leu Ile Gly Trp Thr Lys Gly Phe Lys Ala 610 615 620Thr Asp Cys Glu
Gly Glu Asp Val Val Asp Met Leu Arg Glu Ala Ile625 630 635 640Lys
Arg Arg Asn Glu Phe Asp Leu Asp Ile Val Ala Val Val Asn Asp 645 650
655Thr Val Gly Thr Met Met Thr Cys Gly Tyr Glu Asp Pro Asn Cys Glu
660 665 670Ile Gly Leu Ile Ala Gly Thr Gly Ser Asn Met Cys Tyr Met
Glu Asp 675 680 685Met Arg Asn Ile Glu Met Val Glu Gly Gly Glu Gly
Lys Met Cys Ile 690 695 700Asn Thr Glu Trp Gly Gly Phe Gly Asp Asn
Gly Cys Ile Asp Asp Ile705 710 715 720Arg Thr Arg Tyr Asp Thr Glu
Val Asp Glu Gly Ser Leu Asn Pro Gly 725 730 735Lys Gln Arg Tyr Glu
Lys Met Thr Ser Gly Met Tyr Leu Gly Glu Ile 740 745 750Val Arg Gln
Ile Leu Ile Asp Leu Thr Lys Gln Gly Leu Leu Phe Arg 755 760 765Gly
Gln Ile Ser Glu Arg Leu Arg Thr Arg Gly Ile Phe Glu Thr Lys 770 775
780Phe Leu Ser Gln Ile Glu Ser Asp Arg Leu Ala Leu Leu Gln Val
Arg785 790 795 800Arg Ile Leu Gln Gln Leu Gly Leu Asp Ser Thr Cys
Glu Asp Ser Ile 805 810 815Val Val Lys Glu Val Cys Gly Ala Val Ser
Arg Arg Ala Ala Gln Leu 820 825 830Cys Gly Ala Gly Leu Ala Ala Ile
Val Glu Lys Arg Arg Glu Asp Gln 835 840 845Gly Leu Glu His Leu Arg
Ile Thr Val Gly Val Asp Gly Thr Leu Tyr 850 855 860Lys Leu His Pro
His Phe Ser Arg Ile Leu Gln Glu Thr Val Lys Glu865 870 875 880Leu
Ala Pro Arg Cys Asp Val Thr Phe Met Leu Ser Glu Asp Gly Ser 885 890
895Gly Lys Gly Ala Ala Leu Ile Thr Ala Val Ala Lys Arg Leu Gln Gln
900 905 910Ala Gln Lys Glu Asn 915292754DNAHomo sapiens
29atgtttgcgg tccacttgat ggcattttac ttcagcaagc tgaaggagga ccagatcaag
60aaggtggaca ggttcctgta tcacatgcgg ctctccgatg acaccctttt ggacatcatg
120aggcggttcc gggctgagat ggagaagggc ctggcaaagg acaccaaccc
cacggctgca 180gtgaagatgt tgcccacctt cgtcagggcc attcccgatg
gttccgaaaa tggggagttc 240ctttccctgg atctcggagg gtccaagttc
cgagtgctga aggtgcaagt cgctgaagag 300gggaagcgac acgtgcagat
ggagagtcag ttctacccaa cgcccaatga aatcatccgc 360gggaacggca
tagagctgtt tgaatatgta gctgactgtc tggcagattt catgaagacc
420aaagatttaa agcataagaa attgcccctt ggcctaactt tttctttccc
ctgtcgacag 480actaaactgg aagagggtgt cctactttcg tggacaaaaa
agtttaaggc acgaggagtt 540caggacacgg atgtggtgag ccgtctgacc
aaagccatga gaagacacaa ggacatggac 600gtggacatcc tggccctggt
caatgacacc gtggggacca tgatgacctg tgcctatgac 660gacccctact
gcgaagttgg tgtcatcatc ggaactggca ccaatgcgtg ttacatggag
720gacatgagca acattgacct ggtggagggc gacgagggca ggatgtgcat
caacacagag 780tggggggcct tcggggacga cggggccctg gaggacattc
gcactgagtt cgacagggag 840ctggacctcg gctctctcaa cccaggaaag
caactgttcg agaagatgat cagtggcctg 900tacctggggg agcttgtcag
gcttatcttg ctgaagatgg ccaaggctgg cctcctgttt 960ggtggtgaga
aatcttctgc tctccacact aagggcaaga tcgaaacacg gcacgtggct
1020gccatggaga agtataaaga aggccttgct aatacaagag agatcctggt
ggacctgggt 1080ctggaaccgt ctgaggctga ctgcattgcc gtccagcatg
tctgtaccat cgtctccttc 1140cgctcggcca atctctgtgc agcagctctg
gcggccatcc tgacacgcct ccgggagaac 1200aagaaggtgg aacggctccg
gaccacagtg ggcatggacg gcaccctcta caagatacac 1260cctcagtacc
caaaacgcct gcacaaggtg gtgaggaaac tggtcccaag ctgtgatgtc
1320cgcttcctcc tgtcagagag tggcagcacc aagggggccg ccatggtgac
cgcggtggcc 1380tcccgcgtgc aggcccagcg gaagcagatc gacagggtgc
tggctttgtt ccagctgacc 1440cgagagcagc tcgtggacgt gcaggccaag
atgcgggctg agctggagta tgggctgaag 1500aagaagagcc acgggctggc
cacggtcagg atgctgccca cctacgtctg cgggctgccg 1560gacggcacag
agaaaggaaa gtttctcgcc ctggatcttg ggggaaccaa cttccgggtc
1620ctcctggtga agatcagaag tggacggagg tcagtgcgaa tgtacaacaa
gatcttcgcc 1680atccccctgg agatcatgca gggcactggt gaggagctct
ttgatcacat tgtgcagtgc 1740atcgccgact tcctggacta catgggcctc
aagggagcct ccctaccttt gggcttcaca 1800ttctcatttc cctgcaggca
gatgagcatt gacaagggaa cactcatagg gtggaccaaa 1860ggtttcaagg
ccactgactg tgaaggggag gacgtggtgg acatgctcag ggaagccatc
1920aagaggagaa acgagtttga cctggacatt gttgcagtcg tgaatgatac
agtggggacc 1980atgatgacct gtggctatga agatcctaat tgtgagattg
gcctgattgc aggaacaggc 2040agcaacatgt gctacatgga ggacatgagg
aacatcgaga tggtggaggg gggtgaaggg 2100aagatgtgca tcaatacaga
gtggggagga tttggagaca atggctgcat agatgacatc 2160cggacccgat
acgacacgga ggtggatgag gggtccttga atcctggcaa
gcagagatac 2220gagaaaatga ccagtgggat gtacttgggg gagattgtgc
ggcagatcct gatcgacctg 2280accaagcagg gtctcctctt ccgagggcag
atttcagagc gtctccggac caggggcatc 2340ttcgaaacca agttcctgtc
ccagatcgaa agcgatcggc tggcccttct ccaggtcagg 2400aggattctgc
agcagctggg cctggacagc acgtgtgagg acagcatcgt ggtgaaggag
2460gtgtgcggag ccgtgtcccg gcgggcggcc cagctctgcg gtgctggcct
ggccgctata 2520gtggaaaaaa ggagagaaga ccaggggcta gagcacctga
ggatcactgt gggtgtggac 2580ggcaccctgt acaagctgca ccctcacttt
tctagaatat tgcaggaaac tgtgaaggaa 2640ctagcccctc gatgtgatgt
gacattcatg ctgtcagaag atggcagtgg aaaaggggca 2700gcactgatca
ctgctgtggc caagaggtta cagcaggcac agaaggagaa ctag
275430482PRTArtificial Sequenceconsensus sequence 30Ala Asp Leu Leu
Gln Ala Val Glu Glu Leu Leu Asp Asp Phe Thr Val 1 5 10 15Ser Thr
Glu Thr Leu Arg Glu Val Thr Lys Arg Phe Ile Lys Glu Met 20 25 30Glu
Lys Gly Leu Ser Pro Pro Lys Glu Gly Gly Asn Thr Ala Ser Val 35 40
45Val Lys Met Leu Pro Thr Phe Val Arg Ser Thr Pro Thr Gly Thr Glu
50 55 60Lys Gly Asp Phe Leu Ala Leu Asp Leu Gly Gly Thr Asn Phe Arg
Val65 70 75 80Leu Leu Val Lys Leu Gly Gly Asn Gly Lys Gly Val Glu
Met Thr Gln 85 90 95Ser Lys Tyr Arg Ile Pro Glu Glu Leu Met Thr Gly
Glu Asn Val Thr 100 105 110Gly Glu Gln Leu Phe Asp Phe Ile Ala Glu
Cys Ile Lys Asp Phe Met 115 120 125Asp Glu Gln Phe Pro Lys Gly Lys
Lys Glu Pro Leu Pro Leu Gly Phe 130 135 140Thr Phe Ser Phe Pro Cys
Ser Gln Thr Ser Ile Asn Glu Gly Ile Leu145 150 155 160Ile Arg Trp
Thr Lys Gly Phe Lys Ile Gly Arg Ala Thr Asn Ser Gly 165 170 175Val
Glu Gly His Asp Val Val Gln Leu Leu Arg Glu Ala Ile Lys Arg 180 185
190Arg Gly Ala Phe Pro Ile Asp Val Val Ala Val Val Asn Asp Thr Val
195 200 205Gly Thr Leu Met Ser Cys Ala Tyr Thr Lys Gly Arg Gly Asp
Pro Glu 210 215 220Cys Glu Thr Val Ile Gly Leu Ile Val Gly Thr Gly
Thr Asn Ala Cys225 230 235 240Tyr Met Glu Glu Met Arg Asn Ile Glu
Lys Leu Glu Gly Lys Leu Lys 245 250 255Asp Asp Ile Pro Asp Glu Gly
Arg Met Cys Ile Asn Met Glu Trp Gly 260 265 270Ala Phe Gly Asp Asn
Gly His Leu Asp Leu Pro Arg Thr Lys Tyr Asp 275 280 285Val Val Ile
Asp Glu Glu Ser Pro Asn Pro Gly Gln Gln Leu Phe Glu 290 295 300Lys
Met Ile Ser Gly Met Tyr Leu Gly Glu Ile Val Arg Leu Ile Leu305 310
315 320Leu Asp Leu Thr Lys Glu Gly Leu Leu Phe Lys Gly Gln Asp Ser
Pro 325 330 335Lys Leu Lys Thr Arg Gly Ser Phe Glu Thr Ser Val Leu
Ser Arg Ile 340 345 350Glu Ser Asp Pro Ser Glu Asn Leu Glu Asp Val
Arg Ala Ile Leu Gln 355 360 365Thr Ala Leu Gly Leu Glu Thr Thr Asp
Glu Glu Arg Lys Leu Val Arg 370 375 380Arg Val Cys Glu Ala Val Ser
Thr Arg Ala Ala Arg Leu Cys Ala Ala385 390 395 400Gly Leu Ala Ala
Ile Leu Lys Lys Ile Arg Glu Asn Arg Gly Arg Glu 405 410 415Arg Leu
Lys Val Thr Val Gly Val Asp Gly Ser Val Tyr Lys Leu Tyr 420 425
430Pro Gly Phe Lys Glu Arg Leu Ala Glu Ala Leu Arg Asp Leu Leu Pro
435 440 445Asp Cys Glu Gly Ser Glu Glu Asp Lys Lys Val Ser Ile Ile
Pro Ala 450 455 460Glu Asp Gly Ser Gly Lys Gly Ala Ala Leu Val Ala
Ala Val Ala Ala465 470 475 480Lys Leu3126PRTArtificial
Sequenceexemplary motif 31Leu Gly Phe Thr Phe Ser Phe Pro Cys Xaa
Gln Xaa Ser Ile Xaa Xaa 1 5 10 15Gly Xaa Leu Ile Xaa Trp Thr Lys
Gly Phe 20 25322838DNAHomo
sapiensCDS(462)...(2072)misc_feature(1)...(2838)n = A,T,C or G
32ggttttccac gttttgcntg accctgtttg ctcaactrwc ktytktktyk ykttytstkt
60trygcssykw yamrakmymm rmkttkaaaa amcmrraaag ttaaytggta agtttagtct
120ttttgtcttt tatttcaagg tcccggatcc ggtggtggtg caaatcaaag
aactgctcct 180cagtggatgt tgcctttact tctaggcctg tacggaagtg
ttacttctgc tctaaaagct 240gcggaattct aatacgactc actataggga
gtcgacccac gcgtccggtg ggcaggccgg 300gggtgagggc tcgcgctccg
ggagctgcac ggggctgcgt ggaaagagcg ccgagcggtg 360gcgtcgttgt
cgccccctcc tcgtcgggaa gaatcgtttg gtctcctgcc gtgcccggaa
420tcccagtcag aagttccagc ctgccactgt tctctgatgc c atg cca gca cca
act 476 Met Pro Ala Pro Thr 1 5caa ctg ttt ttt cct ctc atc cgt aac
tgt gaa ctg agc agg atc tat 524Gln Leu Phe Phe Pro Leu Ile Arg Asn
Cys Glu Leu Ser Arg Ile Tyr 10 15 20ggc act gca tgt tac tgc cac cac
aaa cat ctc tgt tgt tcc tca tcg 572Gly Thr Ala Cys Tyr Cys His His
Lys His Leu Cys Cys Ser Ser Ser 25 30 35tac att cct cag agt cga ctg
aga tac aca cct cat cca gca tat gct 620Tyr Ile Pro Gln Ser Arg Leu
Arg Tyr Thr Pro His Pro Ala Tyr Ala 40 45 50acc ttt tgc agg cca aag
gag aac tgg tgg cag tac acc caa gga agg 668Thr Phe Cys Arg Pro Lys
Glu Asn Trp Trp Gln Tyr Thr Gln Gly Arg 55 60 65aga tat gct tcc aca
cca cag aaa ttt tac ctc aca cct cca caa gtc 716Arg Tyr Ala Ser Thr
Pro Gln Lys Phe Tyr Leu Thr Pro Pro Gln Val 70 75 80 85aat agc atc
ctt aaa gct aat gaa tac agt ttc aaa gtg cca gaa ttt 764Asn Ser Ile
Leu Lys Ala Asn Glu Tyr Ser Phe Lys Val Pro Glu Phe 90 95 100gac
ggc aaa aat gtc agt tct atc ctt gga ttt gac agc aat cag ctg 812Asp
Gly Lys Asn Val Ser Ser Ile Leu Gly Phe Asp Ser Asn Gln Leu 105 110
115cct gca aat gca ccc att gag gac cgg aga agt gca gca acc tgc ttg
860Pro Ala Asn Ala Pro Ile Glu Asp Arg Arg Ser Ala Ala Thr Cys Leu
120 125 130cag acc aga ggg atg ctt ttg ggg gtt ttt gat ggc cat gca
ggt tgt 908Gln Thr Arg Gly Met Leu Leu Gly Val Phe Asp Gly His Ala
Gly Cys 135 140 145gct tgt tcc cag gca gtc agt gaa aga ctc ttt tat
tat att gct gtc 956Ala Cys Ser Gln Ala Val Ser Glu Arg Leu Phe Tyr
Tyr Ile Ala Val150 155 160 165tct ttg tta ccc cat gag act ttg cta
gag att gaa aat gca gtg gag 1004Ser Leu Leu Pro His Glu Thr Leu Leu
Glu Ile Glu Asn Ala Val Glu 170 175 180agc ggc cgg gca ctg cta ccc
att ctc cag tgg cac aag cac ccc aat 1052Ser Gly Arg Ala Leu Leu Pro
Ile Leu Gln Trp His Lys His Pro Asn 185 190 195gat tac ttt agt aag
gag gca tcc aaa ttg tac ttt aac agc ttg agg 1100Asp Tyr Phe Ser Lys
Glu Ala Ser Lys Leu Tyr Phe Asn Ser Leu Arg 200 205 210act tac tgg
caa gag ctt ata gac ctc aac act ggt gag tcg act gat 1148Thr Tyr Trp
Gln Glu Leu Ile Asp Leu Asn Thr Gly Glu Ser Thr Asp 215 220 225att
gat gtt aag gag gct cta att aat gcc ttc aag agg ctt gat aat 1196Ile
Asp Val Lys Glu Ala Leu Ile Asn Ala Phe Lys Arg Leu Asp Asn230 235
240 245gac atc tcc ttg gag gcg caa gtt ggt gat cct aat tct ttt ctc
aac 1244Asp Ile Ser Leu Glu Ala Gln Val Gly Asp Pro Asn Ser Phe Leu
Asn 250 255 260tac ctg gtg ctt cga gtg gca ttt tct gga gcc act gct
tgt gtg gcc 1292Tyr Leu Val Leu Arg Val Ala Phe Ser Gly Ala Thr Ala
Cys Val Ala 265 270 275cat gtg gat ggt gtt gac ctt cat gtg gcc aat
act ggc gat agc aga 1340His Val Asp Gly Val Asp Leu His Val Ala Asn
Thr Gly Asp Ser Arg 280 285 290gcc atg ctg ggt gtg cag gaa gag gac
ggc tca tgg tca gca gtc acg 1388Ala Met Leu Gly Val Gln Glu Glu Asp
Gly Ser Trp Ser Ala Val Thr 295 300 305ctg tct aat gac cac aat gct
caa aat gaa aga gaa cta gaa cgg ctg 1436Leu Ser Asn Asp His Asn Ala
Gln Asn Glu Arg Glu Leu Glu Arg Leu310 315 320 325aaa ttg gaa cat
cca aag agt gag gcc aag agt gtc gtg aaa cag gat 1484Lys Leu Glu His
Pro Lys Ser Glu Ala Lys Ser Val Val Lys Gln Asp 330 335 340cgg ctg
ctt ggc ttg ctg atg cca ttt agg gca ttt gga gat gta aag 1532Arg Leu
Leu Gly Leu Leu Met Pro Phe Arg Ala Phe Gly Asp Val Lys 345 350
355ttc aaa tgg agc att gac ctt caa aag aga gtg ata gaa tct ggc cca
1580Phe Lys Trp Ser Ile Asp Leu Gln Lys Arg Val Ile Glu Ser Gly Pro
360 365 370gac cag ttg aat gac aat gaa tat acc aag ttt att cct cct
aat tat 1628Asp Gln Leu Asn Asp Asn Glu Tyr Thr Lys Phe Ile Pro Pro
Asn Tyr 375 380 385cac aca cct cct tat ctc act gct gag cca gag gta
act tac cac cga 1676His Thr Pro Pro Tyr Leu Thr Ala Glu Pro Glu Val
Thr Tyr His Arg390 395 400 405tta agg cca cag gat aag ttt ctg gtg
ttg gct act gat ggg ttg tgg 1724Leu Arg Pro Gln Asp Lys Phe Leu Val
Leu Ala Thr Asp Gly Leu Trp 410 415 420gag act atg cat agg cag gat
gtg gtt agg att gtg ggt gag tac cta 1772Glu Thr Met His Arg Gln Asp
Val Val Arg Ile Val Gly Glu Tyr Leu 425 430 435act ggc atg cat cac
caa cag cca ata gct gtt ggt ggc tac aag gtg 1820Thr Gly Met His His
Gln Gln Pro Ile Ala Val Gly Gly Tyr Lys Val 440 445 450act ctg gga
cag atg cat ggc ctt tta aca gaa agg aga acc aaa atg 1868Thr Leu Gly
Gln Met His Gly Leu Leu Thr Glu Arg Arg Thr Lys Met 455 460 465tcc
tcg gta ttt gag gat cag aac gca gca acc cat ctc att cgc cac 1916Ser
Ser Val Phe Glu Asp Gln Asn Ala Ala Thr His Leu Ile Arg His470 475
480 485gct gtg ggc aac aac gag ttt ggg act gtt gat cat gag cgc ctc
tct 1964Ala Val Gly Asn Asn Glu Phe Gly Thr Val Asp His Glu Arg Leu
Ser 490 495 500aaa atg ctt agt ctt cct gaa gag ctt gct cga atg tac
aga gat gac 2012Lys Met Leu Ser Leu Pro Glu Glu Leu Ala Arg Met Tyr
Arg Asp Asp 505 510 515att aca atc att gta gtt cag ttc aat tct cat
gtt gta ggg gcg tat 2060Ile Thr Ile Ile Val Val Gln Phe Asn Ser His
Val Val Gly Ala Tyr 520 525 530caa aac caa gaa tagtgagtgg
ctctttcact ggcaattctc aaatgatata 2112Gln Asn Gln Glu 535catttaaagg
gcagattttt taaaaagata ctactataat aaacatttcc agttggtcat
2172tctaagcatt tacccttttg atactctagc tagtcaggta ctccaaattg
actttgcagc 2232agggtggcag ggtcaggaga gtctggtcct gcctagctca
gatttcatgg cacctgcact 2292tgaagcaagt cacttcttta tcacaggtgt
cttgaaacat tagcttcttt taccaacctg 2352agaaaattag gatgacctgg
caaataagat cttgaatagg ccaaaagcaa gtatcttgct 2412gtgtgtagtc
tcttggttaa agtgaagaaa cagtactgtt cacacctttc ttcactgaga
2472ttccagtgta catgagaaca tatatttatt ksmwkrwttt yywrrtacac
agtctatgca 2532ttwttcataw wmawttattt twgcctaaat aargtkkttw
wcamatcyag tthwtcmatc 2592matraacras mamcaascaa tctrtatktr
tttttktkwk trwttrwytg rmakgmwtsy 2652twaktrrrak ramtawmcwc
mstyatccay ccgmyykmyt wmykwaaktr attgaaatat 2712tttttwtttt
gcccccccct tggagtcaag aagggttttt agttttatct tctyttctat
2772tgaagttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaag 2832ggcgaa 283833537PRTHomo sapiens 33Met Pro Ala Pro
Thr Gln Leu Phe Phe Pro Leu Ile Arg Asn Cys Glu 1 5 10 15Leu Ser
Arg Ile Tyr Gly Thr Ala Cys Tyr Cys His His Lys His Leu 20 25 30Cys
Cys Ser Ser Ser Tyr Ile Pro Gln Ser Arg Leu Arg Tyr Thr Pro 35 40
45His Pro Ala Tyr Ala Thr Phe Cys Arg Pro Lys Glu Asn Trp Trp Gln
50 55 60Tyr Thr Gln Gly Arg Arg Tyr Ala Ser Thr Pro Gln Lys Phe Tyr
Leu65 70 75 80Thr Pro Pro Gln Val Asn Ser Ile Leu Lys Ala Asn Glu
Tyr Ser Phe 85 90 95Lys Val Pro Glu Phe Asp Gly Lys Asn Val Ser Ser
Ile Leu Gly Phe 100 105 110Asp Ser Asn Gln Leu Pro Ala Asn Ala Pro
Ile Glu Asp Arg Arg Ser 115 120 125Ala Ala Thr Cys Leu Gln Thr Arg
Gly Met Leu Leu Gly Val Phe Asp 130 135 140Gly His Ala Gly Cys Ala
Cys Ser Gln Ala Val Ser Glu Arg Leu Phe145 150 155 160Tyr Tyr Ile
Ala Val Ser Leu Leu Pro His Glu Thr Leu Leu Glu Ile 165 170 175Glu
Asn Ala Val Glu Ser Gly Arg Ala Leu Leu Pro Ile Leu Gln Trp 180 185
190His Lys His Pro Asn Asp Tyr Phe Ser Lys Glu Ala Ser Lys Leu Tyr
195 200 205Phe Asn Ser Leu Arg Thr Tyr Trp Gln Glu Leu Ile Asp Leu
Asn Thr 210 215 220Gly Glu Ser Thr Asp Ile Asp Val Lys Glu Ala Leu
Ile Asn Ala Phe225 230 235 240Lys Arg Leu Asp Asn Asp Ile Ser Leu
Glu Ala Gln Val Gly Asp Pro 245 250 255Asn Ser Phe Leu Asn Tyr Leu
Val Leu Arg Val Ala Phe Ser Gly Ala 260 265 270Thr Ala Cys Val Ala
His Val Asp Gly Val Asp Leu His Val Ala Asn 275 280 285Thr Gly Asp
Ser Arg Ala Met Leu Gly Val Gln Glu Glu Asp Gly Ser 290 295 300Trp
Ser Ala Val Thr Leu Ser Asn Asp His Asn Ala Gln Asn Glu Arg305 310
315 320Glu Leu Glu Arg Leu Lys Leu Glu His Pro Lys Ser Glu Ala Lys
Ser 325 330 335Val Val Lys Gln Asp Arg Leu Leu Gly Leu Leu Met Pro
Phe Arg Ala 340 345 350Phe Gly Asp Val Lys Phe Lys Trp Ser Ile Asp
Leu Gln Lys Arg Val 355 360 365Ile Glu Ser Gly Pro Asp Gln Leu Asn
Asp Asn Glu Tyr Thr Lys Phe 370 375 380Ile Pro Pro Asn Tyr His Thr
Pro Pro Tyr Leu Thr Ala Glu Pro Glu385 390 395 400Val Thr Tyr His
Arg Leu Arg Pro Gln Asp Lys Phe Leu Val Leu Ala 405 410 415Thr Asp
Gly Leu Trp Glu Thr Met His Arg Gln Asp Val Val Arg Ile 420 425
430Val Gly Glu Tyr Leu Thr Gly Met His His Gln Gln Pro Ile Ala Val
435 440 445Gly Gly Tyr Lys Val Thr Leu Gly Gln Met His Gly Leu Leu
Thr Glu 450 455 460Arg Arg Thr Lys Met Ser Ser Val Phe Glu Asp Gln
Asn Ala Ala Thr465 470 475 480His Leu Ile Arg His Ala Val Gly Asn
Asn Glu Phe Gly Thr Val Asp 485 490 495His Glu Arg Leu Ser Lys Met
Leu Ser Leu Pro Glu Glu Leu Ala Arg 500 505 510Met Tyr Arg Asp Asp
Ile Thr Ile Ile Val Val Gln Phe Asn Ser His 515 520 525Val Val Gly
Ala Tyr Gln Asn Gln Glu 530 535341611DNAHomo sapiens 34atgccagcac
caactcaact gttttttcct ctcatccgta actgtgaact gagcaggatc 60tatggcactg
catgttactg ccaccacaaa catctctgtt gttcctcatc gtacattcct
120cagagtcgac tgagatacac acctcatcca gcatatgcta ccttttgcag
gccaaaggag 180aactggtggc agtacaccca aggaaggaga tatgcttcca
caccacagaa attttacctc 240acacctccac aagtcaatag catccttaaa
gctaatgaat acagtttcaa agtgccagaa 300tttgacggca aaaatgtcag
ttctatcctt ggatttgaca gcaatcagct gcctgcaaat 360gcacccattg
aggaccggag aagtgcagca acctgcttgc agaccagagg gatgcttttg
420ggggtttttg atggccatgc aggttgtgct tgttcccagg cagtcagtga
aagactcttt 480tattatattg ctgtctcttt gttaccccat gagactttgc
tagagattga aaatgcagtg 540gagagcggcc gggcactgct acccattctc
cagtggcaca agcaccccaa tgattacttt 600agtaaggagg catccaaatt
gtactttaac agcttgagga cttactggca agagcttata 660gacctcaaca
ctggtgagtc gactgatatt gatgttaagg aggctctaat taatgccttc
720aagaggcttg ataatgacat ctccttggag gcgcaagttg gtgatcctaa
ttcttttctc 780aactacctgg tgcttcgagt ggcattttct ggagccactg
cttgtgtggc ccatgtggat 840ggtgttgacc ttcatgtggc caatactggc
gatagcagag ccatgctggg tgtgcaggaa 900gaggacggct catggtcagc
agtcacgctg tctaatgacc acaatgctca aaatgaaaga 960gaactagaac
ggctgaaatt ggaacatcca aagagtgagg ccaagagtgt cgtgaaacag
1020gatcggctgc ttggcttgct gatgccattt agggcatttg gagatgtaaa
gttcaaatgg 1080agcattgacc ttcaaaagag agtgatagaa tctggcccag
accagttgaa tgacaatgaa 1140tataccaagt ttattcctcc taattatcac
acacctcctt atctcactgc tgagccagag 1200gtaacttacc accgattaag
gccacaggat aagtttctgg tgttggctac tgatgggttg 1260tgggagacta
tgcataggca ggatgtggtt aggattgtgg gtgagtacct aactggcatg
1320catcaccaac agccaatagc tgttggtggc tacaaggtga ctctgggaca
gatgcatggc 1380cttttaacag aaaggagaac caaaatgtcc tcggtatttg
aggatcagaa cgcagcaacc 1440catctcattc gccacgctgt gggcaacaac
gagtttggga ctgttgatca tgagcgcctc 1500tctaaaatgc ttagtcttcc
tgaagagctt gctcgaatgt acagagatga cattacaatc 1560attgtagttc
agttcaattc tcatgttgta ggggcgtatc aaaaccaaga a
161135300PRTArtificial Sequenceconsensus sequence 35Leu Asp Val Gly
Val Ser Arg Met Gln Gly Trp Arg Lys Ser Met Glu 1 5 10 15Asp Ala
His Ile Ala Leu Lys Asn Leu Asn Ser Ser Ser Ser Gly Lys 20 25 30Asp
Ser Trp Ser Phe Phe Ala Val Phe Asp Gly His Gly Ser Gln Ala 35 40
45Ala Lys Tyr Ala Gly Lys His Leu His Lys Thr Ile Leu Ala Glu Arg
50 55 60Lys Ser Phe Pro Glu Gly Asp Pro Trp Glu Met Lys Leu Ser Asp
Leu65 70 75 80Glu Asp Ala Leu Lys Glu Ser Phe Leu Glu Ala Asp Thr
Asp Glu Glu 85 90 95Leu Arg Ser Ala Glu Ala Ser Ala Ala Asn Lys Val
Leu Thr Lys Glu 100 105 110Asp Leu Ser Ser Gly Ser Thr Ala Val Val
Ala Leu Ile Arg Gly Asn 115 120 125Lys Leu Tyr Val Ala Asn Val Gly
Asp Ser Arg Ala Val Leu Cys Arg 130 135 140Asn Gly Asn Ala Ile Lys
Trp Ala Val Thr Leu Thr Glu Asp His Lys145 150 155 160Pro Ser Asn
Glu Asp Glu Arg Glu Arg Ile Glu Ala Ala Gly Gly Phe 165 170 175Val
Ser Arg Val Ser Asn Gly Arg Val Asn Gly Val Leu Ala Val Ser 180 185
190Arg Ala Phe Gly Asp Phe Glu Leu Lys Pro Gly Ser Lys Leu Gly Pro
195 200 205Glu Glu Ser Leu Glu Ala Asn Tyr Glu Tyr Ile Lys Ser Pro
Glu Gln 210 215 220Leu Val Thr Ala Glu Pro Asp Val Thr Ser Ser Thr
Asp Leu Thr Pro225 230 235 240Asp Lys Asp Glu Phe Leu Ile Leu Ala
Cys Asp Gly Leu Trp Asp Val 245 250 255Val Ser Asp Gln Glu Val Val
Asp Ile Val Arg Ser Glu Leu Ser Asp 260 265 270Gly Asn Lys Ser Ala
Glu Asp Pro Met Glu Ala Ala Glu Lys Leu Val 275 280 285Asp Glu Ala
Ile Ala Arg Gly Ser Glu Asp Asn Ile 290 295 30036338PRTArtificial
Sequenceconsensus sequence 36Glu Ser Ser Gly Lys Asn Leu Gly Leu
Arg Tyr Gly Leu Gly Glu Ser 1 5 10 15Ser Met Gln Gly Trp Arg Lys
Pro Met Glu Asp Ala His Val Ile Arg 20 25 30Pro Phe Phe Gly Val Phe
Asp Gly His Gly Gly Ser Glu Ala Ala Lys 35 40 45Phe Leu Ser Lys Asn
Leu His Glu Ile Leu Ala Glu Glu Leu Ser Phe 50 55 60Asp Lys Asp Glu
Ser Leu Lys Glu Asn Glu Glu Leu Lys Asp Glu Pro65 70 75 80Glu Ser
Ser Glu Arg Leu Asn Gly Asp Lys Ser Leu Glu Asp Val Glu 85 90 95Glu
Ala Leu Arg Lys Ala Phe Leu Arg Thr Asp Glu Glu Ile Ser Thr 100 105
110Ala Val Val Ala Leu Ile Arg Gly Asn Lys Leu Tyr Val Ala Asn Val
115 120 125Gly Asp Ser Arg Ala Val Leu Cys Arg Asn Gly Lys Asp Ser
Trp Glu 130 135 140Gly Val Arg Thr Tyr Ser Ala Val Gln Leu Thr Glu
Asp His Lys Pro145 150 155 160Ser Asn Glu Asp Glu Arg Glu Arg Ile
Glu Ala Ala Gly Gly Glu Val 165 170 175Glu Pro Ile Asp Arg Glu Phe
Val Ser Asn Gly Gly Gly Val Val Trp 180 185 190Arg Val Asn Gly Val
Val Ile Ser Leu Ala Val Ser Arg Ala Leu Gly 195 200 205Asp Phe Glu
Leu Lys Lys Lys Glu Asp Glu Leu Ile Glu Glu Asn Arg 210 215 220Leu
Tyr Glu Lys Phe Asp Pro Arg Leu Pro Gly Lys Glu Pro Tyr Val225 230
235 240Ser Ala Glu Pro Glu Val Thr Val Val Glu Leu Ser Gln Thr Leu
Val 245 250 255Pro Thr Glu Asp Asp Asp Phe Leu Ile Leu Ala Ser Asp
Gly Leu Trp 260 265 270Asp Val Leu Ser Asn Gln Glu Ala Val Asp Ile
Val Arg Lys His Leu 275 280 285Arg Lys Gly Asp Asp Lys Glu Val Lys
Ser Ala Ala Gln Glu Leu Ala 290 295 300Arg Ala Asp Ser Leu Arg Ser
Lys Lys His Asn Asp Pro Lys Glu Ala305 310 315 320Ala Lys Leu Leu
Val Asp Leu Ala Leu Lys Asp Asn Ile Thr Val Val 325 330 335Val
Val373143DNAHomo sapiensCDS(229)...(2874) 37ctatagggag tcgcccacgc
gtccggcctc cgaggccaag gccgctgcta ctgccgccgc 60tgcttcttag tgccgcgttc
gccgcctggg ttgtcaccgg cgccgccgcc gaggaagcca 120ctacaaccag
gaccggagtg gaggcggcgc agcatgaagc ggcgcaggcc cgctccatag
180cgcacgtcgg gacggtccgg gcggggccgg ggggaaggaa aatgcaac atg gca gca
237 Met Ala Ala 1gca atg gaa aca gaa cag ctg ggt gtt gag ata ttt
gaa act gcg gac 285Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe
Glu Thr Ala Asp 5 10 15tgt gag gag aat att gaa tca cag gat cgg cct
aaa ttg gag cct ttt 333Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro
Lys Leu Glu Pro Phe 20 25 30 35tat gtt gag cgg tat tcc tgg agt cag
ctt aaa aag ctg ctt gcc gat 381Tyr Val Glu Arg Tyr Ser Trp Ser Gln
Leu Lys Lys Leu Leu Ala Asp 40 45 50acc aga aaa tat cat ggc tac atg
atg gct aag gca cca cat gat ttc 429Thr Arg Lys Tyr His Gly Tyr Met
Met Ala Lys Ala Pro His Asp Phe 55 60 65atg ttt gtg aag agg aat gat
cca gat gga cct cat tca gac aga atc 477Met Phe Val Lys Arg Asn Asp
Pro Asp Gly Pro His Ser Asp Arg Ile 70 75 80tat tac ctt gcc atg tct
ggt gag aac aga gaa aat aca ctg ttt tat 525Tyr Tyr Leu Ala Met Ser
Gly Glu Asn Arg Glu Asn Thr Leu Phe Tyr 85 90 95tct gaa att ccc aaa
act atc aat aga gca gca gtc tta atg ctc tct 573Ser Glu Ile Pro Lys
Thr Ile Asn Arg Ala Ala Val Leu Met Leu Ser100 105 110 115tgg aag
cct ctt ttg gat ctt ttt cag gca aca ctg gac tat gga atg 621Trp Lys
Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp Tyr Gly Met 120 125
130tat tct cga gaa gaa gaa cta tta aga gaa aga aaa cgc att gga aca
669Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg Ile Gly Thr
135 140 145gtc gga att gct tct tac gat tat cac caa gga agt gga aca
ttt ctg 717Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly Thr
Phe Leu 150 155 160ttt caa gcc ggt agt gga att tat cac gta aaa gat
gga ggg cca caa 765Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp
Gly Gly Pro Gln 165 170 175gga ttt acg caa caa cct tta agg ccc aat
cta gtg gaa act agt tgt 813Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn
Leu Val Glu Thr Ser Cys180 185 190 195ccc aac ata cgg atg gat cca
aaa tta tgc cct gct gat cca gac tgg 861Pro Asn Ile Arg Met Asp Pro
Lys Leu Cys Pro Ala Asp Pro Asp Trp 200 205 210att gct ttt ata cat
agc aac gat att tgg ata tct aac atc gta acc 909Ile Ala Phe Ile His
Ser Asn Asp Ile Trp Ile Ser Asn Ile Val Thr 215 220 225aga gaa gaa
agg aga ctc act tat gtg cac aat gag cta gcc aac atg 957Arg Glu Glu
Arg Arg Leu Thr Tyr Val His Asn Glu Leu Ala Asn Met 230 235 240gaa
gaa gat gcc aga tca gct gga gtc gct acc ttt gtt ctc caa gaa 1005Glu
Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val Leu Gln Glu 245 250
255gaa ttt gat aga tat tct ggc tat tgg tgg tgt cca aaa gct gaa aca
1053Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys Ala Glu
Thr260 265 270 275act ccc agt ggt ggt aaa att ctt aga att cta tat
gaa gaa aat gat 1101Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr
Glu Glu Asn Asp 280 285 290gaa tct gag gtg gaa att att cat gtt aca
tcc cct atg ttg gaa aca 1149Glu Ser Glu Val Glu Ile Ile His Val Thr
Ser Pro Met Leu Glu Thr 295 300 305agg agg gca gat tca ttc cgt tat
cct aaa aca ggt aca gca aat cct 1197Arg Arg Ala Asp Ser Phe Arg Tyr
Pro Lys Thr Gly Thr Ala Asn Pro 310 315 320aaa gtc act ttt aag atg
tca gaa ata atg att gat gct gaa gga agg 1245Lys Val Thr Phe Lys Met
Ser Glu Ile Met Ile Asp Ala Glu Gly Arg 325 330 335atc ata gat gtc
ata gat aag gaa cta att caa cct ttt gag att cta 1293Ile Ile Asp Val
Ile Asp Lys Glu Leu Ile Gln Pro Phe Glu Ile Leu340 345 350 355ttt
gaa gga gtt gaa tat att gcc aga gct gga tgg act cct gag gga 1341Phe
Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr Pro Glu Gly 360 365
370aaa tat gct tgg tcc atc cta cta gat cgc tcc cag act cgc ctg cag
1389Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr Arg Leu Gln
375 380 385ata gtg ttg atc tca cct gaa tta ttt atc cca gta gaa gat
gat gtt 1437Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu Asp
Asp Val 390 395 400atg gaa agg cag aga ctc att gag tca gtg cct gat
tct gtg acg cca 1485Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp
Ser Val Thr Pro 405 410 415cta att atc tat gaa gaa aca aca gac atc
tgg ata aat atc cat gac 1533Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile
Trp Ile Asn Ile His Asp420 425 430 435atc ttt cat gtt ttt ccc caa
agt cac gaa gag gaa att gag ttt att 1581Ile Phe His Val Phe Pro Gln
Ser His Glu Glu Glu Ile Glu Phe Ile 440 445 450ttt gcc tct gaa tgc
aaa aca ggt ttc cgt cat tta tac aaa att aca 1629Phe Ala Ser Glu Cys
Lys Thr Gly Phe Arg His Leu Tyr Lys Ile Thr 455 460 465tct att tta
aag gaa agc aaa tat aaa cga tcc agt ggt ggg ctg cct 1677Ser Ile Leu
Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly Gly Leu Pro 470 475 480gct
cca agt gat ttc aag tgt cct atc aaa gag gag ata gca att acc 1725Ala
Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile Ala Ile Thr 485 490
495agt ggt gaa tgg gaa gtt ctt ggc cgg cat gga tct aat atc caa gtt
1773Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn Ile Gln
Val500 505 510 515gat gaa gtc aga agg ctg gta tat ttt gaa ggc acc
aaa gac tcc cct 1821Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr
Lys Asp Ser Pro 520 525 530tta gag cat cac ctg tac gta gtc agt tac
gta aat cct gga gag gtg 1869Leu Glu His His Leu Tyr Val Val Ser Tyr
Val Asn Pro Gly Glu Val 535 540 545aca agg ctg act gac cgt ggc tac
tca cat tct tgc tgc atc agt cag 1917Thr Arg Leu Thr Asp Arg Gly Tyr
Ser His Ser Cys Cys Ile Ser Gln 550 555 560cac tgt gac ttc ttt ata
agt aag tat agt aac cag aag aat cca cac 1965His Cys Asp Phe Phe Ile
Ser Lys Tyr Ser Asn Gln Lys Asn Pro His 565 570 575tgt gtg tcc ctt
tac aag cta tca agt cct gaa gat gac cca act tgc 2013Cys Val Ser Leu
Tyr Lys Leu Ser Ser Pro Glu Asp Asp Pro Thr Cys580 585 590 595aaa
aca aag gaa ttt tgg gcc acc att ttg gat tca gca ggt cct ctt 2061Lys
Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala Gly Pro Leu 600 605
610cct gac tat act cct cca gaa att ttc tct ttt gaa agt act act gga
2109Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser Thr Thr Gly
615 620 625ttt aca ttg tat ggg atg ctc tac aag cct cat gat cta cag
cct gga 2157Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu Gln
Pro Gly 630 635 640aag aaa tat cct act gtg ctg ttc ata tat ggt ggt
cct cag gtg cag 2205Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly
Pro Gln Val Gln 645 650 655ttg gtg aat aat cgg ttt aaa gga gtc aag
tat ttc cgc ttg aat acc 2253Leu Val Asn Asn Arg Phe Lys Gly Val Lys
Tyr Phe Arg Leu Asn Thr660 665 670 675cta gcc tct cta ggt tat gtg
gtt gta gtg ata gac aac agg gga tcc 2301Leu Ala Ser Leu Gly Tyr Val
Val Val Val Ile Asp Asn Arg Gly Ser 680 685 690tgt cac cga ggg ctt
aaa ttt gaa ggc gcc ttt aaa tat aaa atg ggt 2349Cys His Arg Gly Leu
Lys Phe Glu Gly Ala Phe Lys Tyr Lys Met Gly 695 700 705caa ata gaa
att gac gat cag gtg gaa gga ctc caa tat cta gct tct 2397Gln Ile Glu
Ile Asp Asp Gln Val Glu Gly Leu Gln Tyr Leu Ala Ser 710 715 720cga
tat gat ttc att gac tta gat cgt gtg ggc atc cac ggc tgg tcc 2445Arg
Tyr Asp Phe Ile Asp Leu Asp Arg Val Gly Ile His Gly Trp Ser 725 730
735tat gga gga tac ctc tcc ctg atg gca tta atg cag agg tca gat atc
2493Tyr Gly Gly Tyr Leu Ser Leu Met Ala Leu Met Gln Arg Ser Asp
Ile740 745 750 755ttc agg gtt gct att gct ggg gcc cca gtc act ctg
tgg atc ttc tat 2541Phe Arg Val Ala Ile Ala Gly Ala Pro Val Thr Leu
Trp Ile Phe Tyr 760 765 770gat aca gga tac acg gaa cgt tat atg ggt
cac cct gac cag aat gaa 2589Asp Thr Gly Tyr Thr Glu Arg Tyr Met Gly
His Pro Asp Gln Asn Glu 775 780 785cag ggc tat tac tta gga tct gtg
gcc atg caa gca gaa aag ttc ccc 2637Gln Gly Tyr Tyr Leu Gly Ser Val
Ala Met Gln Ala Glu Lys Phe Pro 790 795 800tct gaa cca aat cgt tta
ctg ctc tta cat ggt ttc ctg gat gag aat 2685Ser Glu Pro Asn Arg Leu
Leu Leu Leu His Gly Phe Leu Asp Glu Asn 805 810 815gtc cat ttt gca
cat acc agt ata tta ctg agt ttt tta gtg agg gct 2733Val His Phe Ala
His Thr Ser Ile Leu Leu Ser Phe Leu Val Arg Ala820 825 830 835gga
aag cca tat gat tta cag atc tat cct cag gag aga cac agc ata 2781Gly
Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg His Ser Ile 840 845
850aga gtt cct gaa tcg gga gaa cat tat gaa ctg cat ctt ttg cac tac
2829Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu Leu His Tyr
855 860 865ctt caa gaa aac ctt gga tca cgt att gct gct cta aaa gtg
ata 2874Leu Gln Glu Asn Leu Gly Ser Arg Ile Ala Ala Leu Lys Val Ile
870 875 880taattttgac ctgtgtagaa ctctctggta tacactggct atttaaccaa
atgaggaggt 2934ttaatcaaca gaaaacacag aattgatcat cacattttga
tacctgccat gtaacatcta 2994ctcctgaaaa taaatgtggt gccatgcagg
ggtctacggt ttgtggtagt aatctaatac 3054cttaacccca catgctcaaa
atcaaatgat acatattcct gagagaccca gcaataccat 3114aagaattact
aaaaaaaaaa aaaaaaaaa 314338882PRTHomo sapiens 38Met Ala Ala Ala Met
Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu 1 5 10 15Thr Ala Asp
Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu 20 25 30Glu Pro
Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu 35 40 45Leu
Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro 50 55
60His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser65
70 75 80Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn
Thr 85 90 95Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala
Val Leu 100 105 110Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln
Ala Thr Leu Asp 115 120 125Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu
Leu Arg Glu Arg Lys Arg 130 135 140Ile Gly Thr Val Gly Ile Ala Ser
Tyr Asp Tyr His Gln Gly Ser Gly145 150 155 160Thr Phe Leu Phe Gln
Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly 165 170 175Gly Pro Gln
Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu 180 185 190Thr
Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp 195 200
205Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
210 215 220Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn
Glu Leu225 230 235 240Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly
Val Ala Thr Phe Val 245 250 255Leu Gln Glu
Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys 260 265 270Ala
Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu 275 280
285Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
290 295 300Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr
Gly Thr305 310 315 320Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu
Ile Met Ile Asp Ala 325 330 335Glu Gly Arg Ile Ile Asp Val Ile Asp
Lys Glu Leu Ile Gln Pro Phe 340 345 350Glu Ile Leu Phe Glu Gly Val
Glu Tyr Ile Ala Arg Ala Gly Trp Thr 355 360 365Pro Glu Gly Lys Tyr
Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr 370 375 380Arg Leu Gln
Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu385 390 395
400Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
405 410 415Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp
Ile Asn 420 425 430Ile His Asp Ile Phe His Val Phe Pro Gln Ser His
Glu Glu Glu Ile 435 440 445Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr
Gly Phe Arg His Leu Tyr 450 455 460Lys Ile Thr Ser Ile Leu Lys Glu
Ser Lys Tyr Lys Arg Ser Ser Gly465 470 475 480Gly Leu Pro Ala Pro
Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile 485 490 495Ala Ile Thr
Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn 500 505 510Ile
Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys 515 520
525Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
530 535 540Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser
Cys Cys545 550 555 560Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys
Tyr Ser Asn Gln Lys 565 570 575Asn Pro His Cys Val Ser Leu Tyr Lys
Leu Ser Ser Pro Glu Asp Asp 580 585 590Pro Thr Cys Lys Thr Lys Glu
Phe Trp Ala Thr Ile Leu Asp Ser Ala 595 600 605Gly Pro Leu Pro Asp
Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser 610 615 620Thr Thr Gly
Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu625 630 635
640Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Pro
645 650 655Gln Val Gln Leu Val Asn Asn Arg Phe Lys Gly Val Lys Tyr
Phe Arg 660 665 670Leu Asn Thr Leu Ala Ser Leu Gly Tyr Val Val Val
Val Ile Asp Asn 675 680 685Arg Gly Ser Cys His Arg Gly Leu Lys Phe
Glu Gly Ala Phe Lys Tyr 690 695 700Lys Met Gly Gln Ile Glu Ile Asp
Asp Gln Val Glu Gly Leu Gln Tyr705 710 715 720Leu Ala Ser Arg Tyr
Asp Phe Ile Asp Leu Asp Arg Val Gly Ile His 725 730 735Gly Trp Ser
Tyr Gly Gly Tyr Leu Ser Leu Met Ala Leu Met Gln Arg 740 745 750Ser
Asp Ile Phe Arg Val Ala Ile Ala Gly Ala Pro Val Thr Leu Trp 755 760
765Ile Phe Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met Gly His Pro Asp
770 775 780Gln Asn Glu Gln Gly Tyr Tyr Leu Gly Ser Val Ala Met Gln
Ala Glu785 790 795 800Lys Phe Pro Ser Glu Pro Asn Arg Leu Leu Leu
Leu His Gly Phe Leu 805 810 815Asp Glu Asn Val His Phe Ala His Thr
Ser Ile Leu Leu Ser Phe Leu 820 825 830Val Arg Ala Gly Lys Pro Tyr
Asp Leu Gln Ile Tyr Pro Gln Glu Arg 835 840 845His Ser Ile Arg Val
Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu 850 855 860Leu His Tyr
Leu Gln Glu Asn Leu Gly Ser Arg Ile Ala Ala Leu Lys865 870 875
880Val Ile392649DNAHomo sapiens 39atggcagcag caatggaaac agaacagctg
ggtgttgaga tatttgaaac tgcggactgt 60gaggagaata ttgaatcaca ggatcggcct
aaattggagc ctttttatgt tgagcggtat 120tcctggagtc agcttaaaaa
gctgcttgcc gataccagaa aatatcatgg ctacatgatg 180gctaaggcac
cacatgattt catgtttgtg aagaggaatg atccagatgg acctcattca
240gacagaatct attaccttgc catgtctggt gagaacagag aaaatacact
gttttattct 300gaaattccca aaactatcaa tagagcagca gtcttaatgc
tctcttggaa gcctcttttg 360gatctttttc aggcaacact ggactatgga
atgtattctc gagaagaaga actattaaga 420gaaagaaaac gcattggaac
agtcggaatt gcttcttacg attatcacca aggaagtgga 480acatttctgt
ttcaagccgg tagtggaatt tatcacgtaa aagatggagg gccacaagga
540tttacgcaac aacctttaag gcccaatcta gtggaaacta gttgtcccaa
catacggatg 600gatccaaaat tatgccctgc tgatccagac tggattgctt
ttatacatag caacgatatt 660tggatatcta acatcgtaac cagagaagaa
aggagactca cttatgtgca caatgagcta 720gccaacatgg aagaagatgc
cagatcagct ggagtcgcta cctttgttct ccaagaagaa 780tttgatagat
attctggcta ttggtggtgt ccaaaagctg aaacaactcc cagtggtggt
840aaaattctta gaattctata tgaagaaaat gatgaatctg aggtggaaat
tattcatgtt 900acatccccta tgttggaaac aaggagggca gattcattcc
gttatcctaa aacaggtaca 960gcaaatccta aagtcacttt taagatgtca
gaaataatga ttgatgctga aggaaggatc 1020atagatgtca tagataagga
actaattcaa ccttttgaga ttctatttga aggagttgaa 1080tatattgcca
gagctggatg gactcctgag ggaaaatatg cttggtccat cctactagat
1140cgctcccaga ctcgcctgca gatagtgttg atctcacctg aattatttat
cccagtagaa 1200gatgatgtta tggaaaggca gagactcatt gagtcagtgc
ctgattctgt gacgccacta 1260attatctatg aagaaacaac agacatctgg
ataaatatcc atgacatctt tcatgttttt 1320ccccaaagtc acgaagagga
aattgagttt atttttgcct ctgaatgcaa aacaggtttc 1380cgtcatttat
acaaaattac atctatttta aaggaaagca aatataaacg atccagtggt
1440gggctgcctg ctccaagtga tttcaagtgt cctatcaaag aggagatagc
aattaccagt 1500ggtgaatggg aagttcttgg ccggcatgga tctaatatcc
aagttgatga agtcagaagg 1560ctggtatatt ttgaaggcac caaagactcc
cctttagagc atcacctgta cgtagtcagt 1620tacgtaaatc ctggagaggt
gacaaggctg actgaccgtg gctactcaca ttcttgctgc 1680atcagtcagc
actgtgactt ctttataagt aagtatagta accagaagaa tccacactgt
1740gtgtcccttt acaagctatc aagtcctgaa gatgacccaa cttgcaaaac
aaaggaattt 1800tgggccacca ttttggattc agcaggtcct cttcctgact
atactcctcc agaaattttc 1860tcttttgaaa gtactactgg atttacattg
tatgggatgc tctacaagcc tcatgatcta 1920cagcctggaa agaaatatcc
tactgtgctg ttcatatatg gtggtcctca ggtgcagttg 1980gtgaataatc
ggtttaaagg agtcaagtat ttccgcttga ataccctagc ctctctaggt
2040tatgtggttg tagtgataga caacagggga tcctgtcacc gagggcttaa
atttgaaggc 2100gcctttaaat ataaaatggg tcaaatagaa attgacgatc
aggtggaagg actccaatat 2160ctagcttctc gatatgattt cattgactta
gatcgtgtgg gcatccacgg ctggtcctat 2220ggaggatacc tctccctgat
ggcattaatg cagaggtcag atatcttcag ggttgctatt 2280gctggggccc
cagtcactct gtggatcttc tatgatacag gatacacgga acgttatatg
2340ggtcaccctg accagaatga acagggctat tacttaggat ctgtggccat
gcaagcagaa 2400aagttcccct ctgaaccaaa tcgtttactg ctcttacatg
gtttcctgga tgagaatgtc 2460cattttgcac ataccagtat attactgagt
tttttagtga gggctggaaa gccatatgat 2520ttacagatct atcctcagga
gagacacagc ataagagttc ctgaatcggg agaacattat 2580gaactgcatc
ttttgcacta ccttcaagaa aaccttggat cacgtattgc tgctctaaaa
2640gtgatataa 26494072PRTArtificial Sequenceconsensus sequence
40Val Ala Ser Leu Leu Asn His Arg Gly Gly Ile Tyr Ala Val Val Asp 1
5 10 15Ile Arg Gly Gly Gly Glu Tyr Gly Gln Lys Trp His Glu Ala Gly
Thr 20 25 30Arg Arg Leu Lys Lys Asn Glu Phe Asn Asp Phe Ile Ala Ala
Ala Glu 35 40 45Tyr Leu Ser Lys Leu Gly Tyr Thr Ser Pro Lys Arg Ile
Ala Ile Phe 50 55 60Gly Gly Ser Asn Gly Gly Leu Leu65
7041710PRTArtificial Sequenceconsensus sequence 41Met Leu Ser Phe
Gln Tyr Pro Asp Val Tyr Arg Asp Glu Thr Ala Val 1 5 10 15Gln Asp
Tyr His Gly His Lys Ile Cys Asp Pro Tyr Ala Trp Leu Glu 20 25 30Asp
Pro Asp Ser Glu Gln Thr Lys Ala Phe Val Glu Ala Gln Asn Lys 35 40
45Ile Thr Val Pro Phe Leu Glu Gln Cys Pro Ile Arg Gly Leu Tyr Lys
50 55 60Glu Arg Met Thr Glu Leu Tyr Asp Tyr Pro Lys Tyr Ser Cys His
Phe65 70 75 80Lys Lys Gly Lys Arg Tyr Phe Tyr Phe Tyr Asn Thr Gly
Leu Gln Asn 85 90 95Gln Arg Val Leu Tyr Val Gln Asp Ser Leu Glu Gly
Glu Ala Arg Val 100 105 110Phe Leu Asp Pro Asn Ile Leu Ser Asp Asp
Gly Thr Val Ala Leu Arg 115 120 125Gly Tyr Ala Phe Ser Glu Asp Gly
Glu Tyr Phe Ala Tyr Gly Leu Ser 130 135 140Ala Ser Gly Ser Asp Trp
Val Thr Ile Lys Phe Met Lys Val Asp Gly145 150 155 160Ala Lys Glu
Leu Pro Asp Val Leu Glu Arg Val Lys Phe Ser Cys Met 165 170 175Ala
Trp Thr His Asp Gly Lys Gly Met Phe Tyr Asn Ser Tyr Pro Gln 180 185
190Gln Asp Gly Lys Ser Asp Gly Thr Glu Thr Ser Thr Asn Leu His Gln
195 200 205Lys Leu Tyr Tyr His Val Leu Gly Thr Asp Gln Ser Glu Asp
Ile Leu 210 215 220Cys Ala Glu Phe Pro Asp Glu Pro Lys Trp Met Gly
Gly Ala Glu Leu225 230 235 240Ser Asp Asp Gly Arg Tyr Val Leu Leu
Ser Ile Arg Glu Gly Cys Asp 245 250 255Pro Val Asn Arg Leu Trp Tyr
Cys Asp Leu Gln Gln Glu Ser Ser Gly 260 265 270Ile Ala Gly Ile Leu
Lys Trp Val Lys Leu Ile Asp Asn Phe Glu Gly 275 280 285Glu Tyr Asp
Tyr Val Thr Asn Glu Gly Thr Val Phe Thr Phe Lys Thr 290 295 300Asn
Arg Gln Ser Pro Asn Tyr Arg Val Ile Asn Ile Asp Phe Trp Asp305 310
315 320Pro Glu Glu Ser Lys Trp Lys Val Leu Val Pro Glu His Glu Lys
Asp 325 330 335Val Leu Glu Trp Ile Ala Cys Val Arg Ser Asn Phe Leu
Val Leu Cys 340 345 350Tyr Leu His Asp Val Lys Asn Ile Leu Gln Leu
His Asp Leu Thr Thr 355 360 365Gly Ala Leu Leu Lys Thr Phe Pro Leu
Asp Val Gly Ser Ile Val Gly 370 375 380Tyr Ser Gly Gln Lys Lys Asp
Thr Glu Ile Phe Tyr Gln Phe Thr Ser385 390 395 400Phe Leu Ser Pro
Gly Ile Ile Tyr His Cys Asp Leu Thr Lys Glu Glu 405 410 415Leu Glu
Pro Arg Val Phe Arg Glu Val Thr Val Lys Gly Ile Asp Ala 420 425
430Ser Asp Tyr Gln Thr Val Gln Ile Phe Tyr Pro Ser Lys Asp Gly Thr
435 440 445Lys Ile Pro Met Phe Ile Val His Lys Lys Gly Ile Lys Leu
Asp Gly 450 455 460Ser His Pro Ala Phe Leu Tyr Gly Tyr Gly Gly Phe
Asn Ile Ser Ile465 470 475 480Thr Pro Asn Tyr Ser Val Ser Arg Leu
Ile Phe Val Arg His Met Gly 485 490 495Gly Ile Leu Ala Val Ala Asn
Ile Arg Gly Gly Gly Glu Tyr Gly Glu 500 505 510Thr Trp His Lys Gly
Gly Ile Leu Ala Asn Lys Gln Asn Cys Phe Asp 515 520 525Asp Phe Gln
Cys Ala Ala Glu Tyr Leu Ile Lys Glu Gly Tyr Thr Ser 530 535 540Pro
Lys Arg Leu Thr Ile Asn Gly Gly Ser Asn Gly Gly Leu Leu Val545 550
555 560Ala Ala Cys Ala Asn Gln Arg Pro Asp Leu Phe Gly Cys Val Ile
Ala 565 570 575Gln Val Gly Val Met Asp Met Leu Lys Phe His Lys Tyr
Thr Ile Gly 580 585 590His Ala Trp Thr Thr Asp Tyr Gly Cys Ser Asp
Ser Lys Gln His Phe 595 600 605Glu Trp Leu Val Lys Tyr Ser Pro Leu
His Asn Val Lys Leu Pro Glu 610 615 620Ala Asp Asp Ile Gln Tyr Pro
Ser Met Leu Leu Leu Thr Ala Asp His625 630 635 640Asp Asp Arg Val
Val Pro Leu His Ser Leu Lys Phe Ile Ala Thr Leu 645 650 655Gln Tyr
Ile Val Gly Arg Ser Arg Lys Gln Ser Asn Pro Leu Leu Ile 660 665
670His Val Asp Thr Lys Ala Gly His Gly Ala Gly Lys Pro Thr Ala Lys
675 680 685Val Ile Glu Glu Val Ser Asp Met Phe Ala Phe Ile Ala Arg
Cys Leu 690 695 700Asn Val Asp Trp Ile Pro705 710422219DNAHomo
sapiensCDS(103)...(1758)misc_feature(1)...(2219)n = A,T,C or G
42gaagtgttac ttntgctcta aaagctgcgg aattctaata cgactcacta tagggagtcg
60acccacgcgt ccgagccgga gcactgagtg gcctggagca gc atg agg cag agc
114 Met Arg Gln Ser 1tgg aga cca gag ctg ctt att gtg gga gct gtg
gtc gtg ata gag ggt 162Trp Arg Pro Glu Leu Leu Ile Val Gly Ala Val
Val Val Ile Glu Gly 5 10 15 20ctt caa gca gct cag cgt gca tgc ggg
cag cgt ggc cct ggc cct cca 210Leu Gln Ala Ala Gln Arg Ala Cys Gly
Gln Arg Gly Pro Gly Pro Pro 25 30 35gag ccc cag gaa ggc aac aca tta
cct ggt gaa tgg ccc tgg cag gcc 258Glu Pro Gln Glu Gly Asn Thr Leu
Pro Gly Glu Trp Pro Trp Gln Ala 40 45 50agt gtg agg cga cag ggt gta
cac atc tgc agt ggc tcc ttg gtg gca 306Ser Val Arg Arg Gln Gly Val
His Ile Cys Ser Gly Ser Leu Val Ala 55 60 65gac act tgg gtc ctc aca
gct gct cac tgc ttt gaa aag atg gcc aca 354Asp Thr Trp Val Leu Thr
Ala Ala His Cys Phe Glu Lys Met Ala Thr 70 75 80gca gaa ctg agc tcc
tgg tcc gtg gtc ctg ggt tct ctc aag cag gag 402Ala Glu Leu Ser Ser
Trp Ser Val Val Leu Gly Ser Leu Lys Gln Glu 85 90 95 100ggg cag agc
ccg ggg gct gag gag gtg gga gtt gct gcc ctg cag ttg 450Gly Gln Ser
Pro Gly Ala Glu Glu Val Gly Val Ala Ala Leu Gln Leu 105 110 115ccc
aag gcc tat aac cac tat agc cag gga tca gat ctg gcc ctg ctc 498Pro
Lys Ala Tyr Asn His Tyr Ser Gln Gly Ser Asp Leu Ala Leu Leu 120 125
130cag ctc acc cac ccc acc gtt cag aca acc ctc tgc ttg ccc caa ccc
546Gln Leu Thr His Pro Thr Val Gln Thr Thr Leu Cys Leu Pro Gln Pro
135 140 145acc tac cac ttc ccc ttt gga gct tct tgc tgg gcc act ggc
tgg gac 594Thr Tyr His Phe Pro Phe Gly Ala Ser Cys Trp Ala Thr Gly
Trp Asp 150 155 160cag aac acc agt gat gtt tcc aga acc cta cgg aat
ctg cgc ctc cgt 642Gln Asn Thr Ser Asp Val Ser Arg Thr Leu Arg Asn
Leu Arg Leu Arg165 170 175 180ctc atc agc cgc ccc act tgt aac tgt
ctc tac aat cgg ttg cac cag 690Leu Ile Ser Arg Pro Thr Cys Asn Cys
Leu Tyr Asn Arg Leu His Gln 185 190 195agg ttg ctg tcc aac cca gca
aga cct ggg atg ctc tgt ggg ggt gca 738Arg Leu Leu Ser Asn Pro Ala
Arg Pro Gly Met Leu Cys Gly Gly Ala 200 205 210cag cct ggg gaa cag
ggg ccc tgc cag gga gat tct ggg gga cct gtg 786Gln Pro Gly Glu Gln
Gly Pro Cys Gln Gly Asp Ser Gly Gly Pro Val 215 220 225atg tgc cgt
gag cct gat gga cac tgg gtc cag gtt gga atc att agt 834Met Cys Arg
Glu Pro Asp Gly His Trp Val Gln Val Gly Ile Ile Ser 230 235 240ttc
aca tca aaa tgt gcc caa gag gac acc cct gtg ctg ttg act gac 882Phe
Thr Ser Lys Cys Ala Gln Glu Asp Thr Pro Val Leu Leu Thr Asp245 250
255 260atg gca gta cac agt tca tgg ctg cag gcc cat gtt cac gag gca
gct 930Met Ala Val His Ser Ser Trp Leu Gln Ala His Val His Glu Ala
Ala 265 270 275ttc ttg gtg cag gcc cca gga gtt gtg aag atg agc gac
gag aac agc 978Phe Leu Val Gln Ala Pro Gly Val Val Lys Met Ser Asp
Glu Asn Ser 280 285 290tgt gta gca tgt ggc tcc ttg agg agt gca gga
ccc cag gca gga gcg 1026Cys Val Ala Cys Gly Ser Leu Arg Ser Ala Gly
Pro Gln Ala Gly Ala 295 300 305ctc tct cag tgg ccc tgg gat gcc agg
ctg aag cac cac ggg aag ctg 1074Leu Ser Gln Trp Pro Trp Asp Ala Arg
Leu Lys His His Gly Lys Leu 310 315 320gct tgt ggt gga gct ctg gta
tcg gag gtg gtg gtg ctg acg gct gct 1122Ala Cys Gly Gly Ala Leu Val
Ser Glu Val Val Val Leu Thr Ala Ala325 330 335 340cac tgc ttt atc
ggg cgc caa acc cta gag gaa tgg agc gta gga ctg 1170His Cys Phe Ile
Gly Arg Gln Thr Leu Glu Glu Trp Ser Val Gly Leu 345
350 355ggg gct gga cca gag gaa tgg ggc ctg aag caa ctc att ctg cac
ggg 1218Gly Ala Gly Pro Glu Glu Trp Gly Leu Lys Gln Leu Ile Leu His
Gly 360 365 370gcc tac acc cac cca gaa ggc ggc tat gat gtg gcc ttc
ctg ctg ctg 1266Ala Tyr Thr His Pro Glu Gly Gly Tyr Asp Val Ala Phe
Leu Leu Leu 375 380 385gct cag cct gtg aca ttg ggc cct ggc cta agg
ccc ctc tgc ttg ccc 1314Ala Gln Pro Val Thr Leu Gly Pro Gly Leu Arg
Pro Leu Cys Leu Pro 390 395 400tat gct gac cac cac ctg cct gat ggt
gaa cat ggc tgg gtt ctt ggg 1362Tyr Ala Asp His His Leu Pro Asp Gly
Glu His Gly Trp Val Leu Gly405 410 415 420ctg acc caa aaa gca ggc
atc aac tac ccc cag aca gta cct gtg aca 1410Leu Thr Gln Lys Ala Gly
Ile Asn Tyr Pro Gln Thr Val Pro Val Thr 425 430 435gtc ctg ggg ccg
atg gcc tgt agc aga cag cat gca gct cct ggg ggc 1458Val Leu Gly Pro
Met Ala Cys Ser Arg Gln His Ala Ala Pro Gly Gly 440 445 450aca ggc
atc ccc atc ctg cca ggg atg gta tgc acc act gtc gtg ggt 1506Thr Gly
Ile Pro Ile Leu Pro Gly Met Val Cys Thr Thr Val Val Gly 455 460
465gag ccc cct cac tgt gag ggc ctc tct ggg gcg cca ctt gta cat gag
1554Glu Pro Pro His Cys Glu Gly Leu Ser Gly Ala Pro Leu Val His Glu
470 475 480atc agg ggc aca tgg ttc ctg gtt gga ctg cac agc ttt gga
gac acc 1602Ile Arg Gly Thr Trp Phe Leu Val Gly Leu His Ser Phe Gly
Asp Thr485 490 495 500tgt caa agc tct gca aag cct gca gtt ttt gca
gca ctc tct gcc tac 1650Cys Gln Ser Ser Ala Lys Pro Ala Val Phe Ala
Ala Leu Ser Ala Tyr 505 510 515gag gac tgg atc agc aat cta gac tgg
cag gtc tac ttc gct gag gag 1698Glu Asp Trp Ile Ser Asn Leu Asp Trp
Gln Val Tyr Phe Ala Glu Glu 520 525 530cca gag cct gag gct gag act
gga agc tgc ttg gtc aac tcg agc caa 1746Pro Glu Pro Glu Ala Glu Thr
Gly Ser Cys Leu Val Asn Ser Ser Gln 535 540 545cca gcc agt tgt
tgactggtga ctctagttta ctcacaggac gccagaaacg 1798Pro Ala Ser Cys
550ccagacaact cccacgtcaa cacccagtty tacactcctg cccctcccct
cccggtcttg 1858tggttcccag ccctgaggca ggtccaacag ctggctggct
ggctgagaat gagcctgccc 1918agagatgctt ttcatgtgtg ccatggcccc
gcccccaagt tytgctttcc aacagagatg 1978tctccagtat tccctagcca
atccttcaga tataaccaca ccagtagctg ttgtgaaaaa 2038aaaagttgtt
tttttttttc cttgggggtg gggggtttgg ggagcaattt ccttttttaa
2098aacttaaatt gktacaaaat agattttaga aaataagttc caaactatag
taaaaggctc 2158ccctgtccca ggcaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaaaaaaag 2218g 221943552PRTHomo sapiens 43Met Arg Gln
Ser Trp Arg Pro Glu Leu Leu Ile Val Gly Ala Val Val 1 5 10 15Val
Ile Glu Gly Leu Gln Ala Ala Gln Arg Ala Cys Gly Gln Arg Gly 20 25
30Pro Gly Pro Pro Glu Pro Gln Glu Gly Asn Thr Leu Pro Gly Glu Trp
35 40 45Pro Trp Gln Ala Ser Val Arg Arg Gln Gly Val His Ile Cys Ser
Gly 50 55 60Ser Leu Val Ala Asp Thr Trp Val Leu Thr Ala Ala His Cys
Phe Glu65 70 75 80Lys Met Ala Thr Ala Glu Leu Ser Ser Trp Ser Val
Val Leu Gly Ser 85 90 95Leu Lys Gln Glu Gly Gln Ser Pro Gly Ala Glu
Glu Val Gly Val Ala 100 105 110Ala Leu Gln Leu Pro Lys Ala Tyr Asn
His Tyr Ser Gln Gly Ser Asp 115 120 125Leu Ala Leu Leu Gln Leu Thr
His Pro Thr Val Gln Thr Thr Leu Cys 130 135 140Leu Pro Gln Pro Thr
Tyr His Phe Pro Phe Gly Ala Ser Cys Trp Ala145 150 155 160Thr Gly
Trp Asp Gln Asn Thr Ser Asp Val Ser Arg Thr Leu Arg Asn 165 170
175Leu Arg Leu Arg Leu Ile Ser Arg Pro Thr Cys Asn Cys Leu Tyr Asn
180 185 190Arg Leu His Gln Arg Leu Leu Ser Asn Pro Ala Arg Pro Gly
Met Leu 195 200 205Cys Gly Gly Ala Gln Pro Gly Glu Gln Gly Pro Cys
Gln Gly Asp Ser 210 215 220Gly Gly Pro Val Met Cys Arg Glu Pro Asp
Gly His Trp Val Gln Val225 230 235 240Gly Ile Ile Ser Phe Thr Ser
Lys Cys Ala Gln Glu Asp Thr Pro Val 245 250 255Leu Leu Thr Asp Met
Ala Val His Ser Ser Trp Leu Gln Ala His Val 260 265 270His Glu Ala
Ala Phe Leu Val Gln Ala Pro Gly Val Val Lys Met Ser 275 280 285Asp
Glu Asn Ser Cys Val Ala Cys Gly Ser Leu Arg Ser Ala Gly Pro 290 295
300Gln Ala Gly Ala Leu Ser Gln Trp Pro Trp Asp Ala Arg Leu Lys
His305 310 315 320His Gly Lys Leu Ala Cys Gly Gly Ala Leu Val Ser
Glu Val Val Val 325 330 335Leu Thr Ala Ala His Cys Phe Ile Gly Arg
Gln Thr Leu Glu Glu Trp 340 345 350Ser Val Gly Leu Gly Ala Gly Pro
Glu Glu Trp Gly Leu Lys Gln Leu 355 360 365Ile Leu His Gly Ala Tyr
Thr His Pro Glu Gly Gly Tyr Asp Val Ala 370 375 380Phe Leu Leu Leu
Ala Gln Pro Val Thr Leu Gly Pro Gly Leu Arg Pro385 390 395 400Leu
Cys Leu Pro Tyr Ala Asp His His Leu Pro Asp Gly Glu His Gly 405 410
415Trp Val Leu Gly Leu Thr Gln Lys Ala Gly Ile Asn Tyr Pro Gln Thr
420 425 430Val Pro Val Thr Val Leu Gly Pro Met Ala Cys Ser Arg Gln
His Ala 435 440 445Ala Pro Gly Gly Thr Gly Ile Pro Ile Leu Pro Gly
Met Val Cys Thr 450 455 460Thr Val Val Gly Glu Pro Pro His Cys Glu
Gly Leu Ser Gly Ala Pro465 470 475 480Leu Val His Glu Ile Arg Gly
Thr Trp Phe Leu Val Gly Leu His Ser 485 490 495Phe Gly Asp Thr Cys
Gln Ser Ser Ala Lys Pro Ala Val Phe Ala Ala 500 505 510Leu Ser Ala
Tyr Glu Asp Trp Ile Ser Asn Leu Asp Trp Gln Val Tyr 515 520 525Phe
Ala Glu Glu Pro Glu Pro Glu Ala Glu Thr Gly Ser Cys Leu Val 530 535
540Asn Ser Ser Gln Pro Ala Ser Cys545 550441659DNAHomo sapiens
44atgaggcaga gctggagacc agagctgctt attgtgggag ctgtggtcgt gatagagggt
60cttcaagcag ctcagcgtgc atgcgggcag cgtggccctg gccctccaga gccccaggaa
120ggcaacacat tacctggtga atggccctgg caggccagtg tgaggcgaca
gggtgtacac 180atctgcagtg gctccttggt ggcagacact tgggtcctca
cagctgctca ctgctttgaa 240aagatggcca cagcagaact gagctcctgg
tccgtggtcc tgggttctct caagcaggag 300gggcagagcc cgggggctga
ggaggtggga gttgctgccc tgcagttgcc caaggcctat 360aaccactata
gccagggatc agatctggcc ctgctccagc tcacccaccc caccgttcag
420acaaccctct gcttgcccca acccacctac cacttcccct ttggagcttc
ttgctgggcc 480actggctggg accagaacac cagtgatgtt tccagaaccc
tacggaatct gcgcctccgt 540ctcatcagcc gccccacttg taactgtctc
tacaatcggt tgcaccagag gttgctgtcc 600aacccagcaa gacctgggat
gctctgtggg ggtgcacagc ctggggaaca ggggccctgc 660cagggagatt
ctgggggacc tgtgatgtgc cgtgagcctg atggacactg ggtccaggtt
720ggaatcatta gtttcacatc aaaatgtgcc caagaggaca cccctgtgct
gttgactgac 780atggcagtac acagttcatg gctgcaggcc catgttcacg
aggcagcttt cttggtgcag 840gccccaggag ttgtgaagat gagcgacgag
aacagctgtg tagcatgtgg ctccttgagg 900agtgcaggac cccaggcagg
agcgctctct cagtggccct gggatgccag gctgaagcac 960cacgggaagc
tggcttgtgg tggagctctg gtatcggagg tggtggtgct gacggctgct
1020cactgcttta tcgggcgcca aaccctagag gaatggagcg taggactggg
ggctggacca 1080gaggaatggg gcctgaagca actcattctg cacggggcct
acacccaccc agaaggcggc 1140tatgatgtgg ccttcctgct gctggctcag
cctgtgacat tgggccctgg cctaaggccc 1200ctctgcttgc cctatgctga
ccaccacctg cctgatggtg aacatggctg ggttcttggg 1260ctgacccaaa
aagcaggcat caactacccc cagacagtac ctgtgacagt cctggggccg
1320atggcctgta gcagacagca tgcagctcct gggggcacag gcatccccat
cctgccaggg 1380atggtatgca ccactgtcgt gggtgagccc cctcactgtg
agggcctctc tggggcgcca 1440cttgtacatg agatcagggg cacatggttc
ctggttggac tgcacagctt tggagacacc 1500tgtcaaagct ctgcaaagcc
tgcagttttt gcagcactct ctgcctacga ggactggatc 1560agcaatctag
actggcaggt ctacttcgct gaggagccag agcctgaggc tgagactgga
1620agctgcttgg tcaactcgag ccaaccagcc agttgttga
165945251PRTArtificial Sequenceconsensus sequence 45Pro Gly Ser Phe
Gly Ser Pro Trp Gln Val Ser Leu Gln Val Arg Ser 1 5 10 15Gly Gly
Gly Ser Arg Lys His Phe Cys Gly Gly Ser Leu Ile Ser Glu 20 25 30Asn
Trp Val Leu Thr Ala Ala His Cys Val Ser Gly Ala Ala Ser Ala 35 40
45Pro Ala Ser Ser Val Arg Val Ser Leu Ser Val Arg Leu Gly Glu His
50 55 60Asn Leu Ser Leu Thr Glu Gly Thr Glu Gln Lys Phe Asp Val Lys
Lys65 70 75 80Thr Ile Ile Val His Pro Asn Tyr Asn Pro Asp Thr Leu
Asp Asn Gly 85 90 95Ala Tyr Asp Asn Asp Ile Ala Leu Leu Lys Leu Lys
Ser Pro Gly Val 100 105 110Thr Leu Gly Asp Thr Val Arg Pro Ile Cys
Leu Pro Ser Ala Ser Ser 115 120 125Asp Leu Pro Val Gly Thr Thr Cys
Thr Val Ser Gly Trp Gly Arg Arg 130 135 140Pro Thr Lys Asn Leu Gly
Leu Ser Asp Thr Leu Gln Glu Val Val Val145 150 155 160Pro Val Val
Ser Arg Glu Thr Cys Arg Ser Ala Tyr Glu Tyr Gly Gly 165 170 175Thr
Asp Asp Lys Val Glu Phe Val Thr Asp Asn Met Ile Cys Ala Gly 180 185
190Ala Leu Gly Gly Lys Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu
195 200 205Val Cys Ser Asp Gly Asn Arg Asp Gly Arg Trp Glu Leu Val
Gly Ile 210 215 220Val Ser Trp Gly Ser Tyr Gly Cys Ala Arg Gly Asn
Lys Pro Gly Val225 230 235 240Tyr Thr Arg Val Ser Ser Tyr Leu Asp
Trp Ile 245 25046249PRTArtificial Sequenceconsensus sequence 46Ser
Phe Gly Ser Pro Trp Gln Val Ser Leu Gln Val Arg Ser Gly Gly 1 5 10
15Gly Ser Arg Lys His Phe Cys Gly Gly Ser Leu Ile Ser Glu Asn Trp
20 25 30Val Leu Thr Ala Ala His Cys Val Ser Gly Ala Ala Ser Ala Pro
Ala 35 40 45Ser Ser Val Arg Val Ser Leu Ser Val Arg Leu Gly Glu His
Asn Leu 50 55 60Ser Leu Thr Glu Gly Thr Glu Gln Lys Phe Asp Val Lys
Lys Thr Ile65 70 75 80Ile Val His Pro Asn Tyr Asn Pro Asp Thr Leu
Asp Asn Gly Ala Tyr 85 90 95Asp Asn Asp Ile Ala Leu Leu Lys Leu Lys
Ser Pro Gly Val Thr Leu 100 105 110Gly Asp Thr Val Arg Pro Ile Cys
Leu Pro Ser Ala Ser Ser Asp Leu 115 120 125Pro Val Gly Thr Thr Cys
Thr Val Ser Gly Trp Gly Arg Arg Pro Thr 130 135 140Lys Asn Leu Gly
Leu Ser Asp Thr Leu Gln Glu Val Val Val Pro Val145 150 155 160Val
Ser Arg Glu Thr Cys Arg Ser Ala Tyr Glu Tyr Gly Gly Thr Asp 165 170
175Asp Lys Val Glu Phe Val Thr Asp Asn Met Ile Cys Ala Gly Ala Leu
180 185 190Gly Gly Lys Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu
Val Cys 195 200 205Ser Asp Gly Asn Arg Asp Gly Arg Trp Glu Leu Val
Gly Ile Val Ser 210 215 220Trp Gly Ser Tyr Gly Cys Ala Arg Gly Asn
Lys Pro Gly Val Tyr Thr225 230 235 240Arg Val Ser Ser Tyr Leu Asp
Trp Ile 24547226PRTArtificial Sequenceconsensus sequence 47Arg Ile
Val Gly Gly Ser Glu Ala Lys Ile Gly Ser Phe Pro Trp Gln 1 5 10
15Val Ser Leu Gln Cys Gly Gly Ser Leu Ile Ser Pro Arg Trp Val Leu
20 25 30Thr Ala Ala His Cys Arg Val Arg Leu Gly Ser His Asp Leu Ser
Ser 35 40 45Gly Glu Glu Thr Glu Gly Gly Pro Arg Leu Asp Ser Pro Gly
Gly Gln 50 55 60Val Ile Lys Val Ser Lys Ile Ile Glu Val His Pro Asn
Tyr Asn Asn65 70 75 80Asp Ile Ala Leu Leu Lys Leu Lys Glu Pro Val
Thr Leu Ser Asp Ser 85 90 95Asn Thr Val Arg Pro Ile Cys Leu Pro Ser
Ser Asn Glu Ile Lys Thr 100 105 110Ser Glu Gly Asn Thr Val Pro Ala
Gly Thr Thr Cys Thr Val Ser Gly 115 120 125Trp Gly Arg Thr Ser Glu
Gly Pro Glu Glu Ser Gly Gly Gly Ser Leu 130 135 140Pro Asp Val Leu
Gln Glu Val Asn Val Pro Ile Val Ser Asn Glu Thr145 150 155 160Cys
Arg Met Leu Cys Ala Gly Tyr Leu Glu Gly Gly Asn Thr Pro Gly 165 170
175Gly Lys Asp Ala Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Val
180 185 190Leu Val Gly Ile Val Ser Trp Gly Ser Ser Ser Leu Tyr Gly
Cys Ala 195 200 205Arg Pro Asn Lys Pro Gly Val Tyr Thr Arg Val Ser
Ser Tyr Leu Asp 210 215 220Trp Ile225485PRTArtificial
Sequenceactivation and cleavage site 48Arg Ile Val Gly Gly 1
5496PRTHomo sapiens 49Leu Thr Ala Ala His Cys 1 5505PRTHomo sapiens
50Gly Asp Ser Gly Gly 1 551957DNAHomo sapiensCDS(136)...(858)
51atttggccct cgaggccaag aattcggcac gaggcaaaaa ggagaccaga caggaggcgt
60ctgtagagat atcatgaact tcaacttagc tttgttttcc agagactgga gctaaactgg
120gctttcaaca tcatc atg aag ttt atc ctc ctc tgg gcc ctc ttg aat ctg
171 Met Lys Phe Ile Leu Leu Trp Ala Leu Leu Asn Leu 1 5 10act gtt
gct ttg gcc ttt aat cca gat tac aca gtc agc tcc act ccc 219Thr Val
Ala Leu Ala Phe Asn Pro Asp Tyr Thr Val Ser Ser Thr Pro 15 20 25cct
tac ttg gtc tat ttg aaa tct gac tac ttg ccc tgc gct gga gtc 267Pro
Tyr Leu Val Tyr Leu Lys Ser Asp Tyr Leu Pro Cys Ala Gly Val 30 35
40ctg atc cac ccg ctt tgg gtg atc aca gct gca cac tgc aat tta cca
315Leu Ile His Pro Leu Trp Val Ile Thr Ala Ala His Cys Asn Leu Pro
45 50 55 60aag ctt cgg gtg ata ttg ggg gtt aca atc cca gca gac tct
aat gaa 363Lys Leu Arg Val Ile Leu Gly Val Thr Ile Pro Ala Asp Ser
Asn Glu 65 70 75aag cat ctg caa gtg att ggc tat gag aag atg att cat
cat cca cac 411Lys His Leu Gln Val Ile Gly Tyr Glu Lys Met Ile His
His Pro His 80 85 90ttc tca gtc act tct att gat cat gac atc atg cta
atc aag ctg aaa 459Phe Ser Val Thr Ser Ile Asp His Asp Ile Met Leu
Ile Lys Leu Lys 95 100 105aca gag gct gaa ctc aat gac tat gtg aaa
tta gcc aac ctg ccc tac 507Thr Glu Ala Glu Leu Asn Asp Tyr Val Lys
Leu Ala Asn Leu Pro Tyr 110 115 120caa act atc tct gaa aat acc atg
tgc tct gtc tct acc tgg agc tac 555Gln Thr Ile Ser Glu Asn Thr Met
Cys Ser Val Ser Thr Trp Ser Tyr125 130 135 140aat gtg tgt gat atc
tac aaa gag ccc gat tca ctg caa act gtg aac 603Asn Val Cys Asp Ile
Tyr Lys Glu Pro Asp Ser Leu Gln Thr Val Asn 145 150 155atc tct gta
atc tcc aag cct cag tgt cgc gat gcc tat aaa acc tac 651Ile Ser Val
Ile Ser Lys Pro Gln Cys Arg Asp Ala Tyr Lys Thr Tyr 160 165 170aac
atc acg gaa aat atg ctg tgt gtg ggc att gtg cca gga agg agg 699Asn
Ile Thr Glu Asn Met Leu Cys Val Gly Ile Val Pro Gly Arg Arg 175 180
185cag ccc tgc aag gaa gtt tct gct gcc ccg gca atc tgc aat ggg atg
747Gln Pro Cys Lys Glu Val Ser Ala Ala Pro Ala Ile Cys Asn Gly Met
190 195 200ctt caa gga atc ctg tct ttt gcg gat gga tgt gtt ttg aga
gcc gat 795Leu Gln Gly Ile Leu Ser Phe Ala Asp Gly Cys Val Leu Arg
Ala Asp205 210 215 220gtt ggc atc tat gcc aaa att ttt tac tat ata
ccc tgg att gaa aat 843Val Gly Ile Tyr Ala Lys Ile Phe Tyr Tyr Ile
Pro Trp Ile Glu Asn 225 230 235gta atc caa aat aac tgagctgtgg
cagttgtgga ccatatgaca cagcttgtcc 898Val Ile Gln Asn Asn
240ccatcgttca cctttagaat taaatataaa ttaactcctc aaaaaaaaaa aaaaaaaaa
95752241PRTHomo sapiens 52Met Lys Phe Ile Leu Leu Trp Ala Leu Leu
Asn Leu Thr Val Ala Leu 1 5 10 15Ala Phe Asn Pro Asp Tyr Thr Val
Ser Ser Thr Pro Pro Tyr Leu Val
20 25 30Tyr Leu Lys Ser Asp Tyr Leu Pro Cys Ala Gly Val Leu Ile His
Pro 35 40 45Leu Trp Val Ile Thr Ala Ala His Cys Asn Leu Pro Lys Leu
Arg Val 50 55 60Ile Leu Gly Val Thr Ile Pro Ala Asp Ser Asn Glu Lys
His Leu Gln65 70 75 80Val Ile Gly Tyr Glu Lys Met Ile His His Pro
His Phe Ser Val Thr 85 90 95Ser Ile Asp His Asp Ile Met Leu Ile Lys
Leu Lys Thr Glu Ala Glu 100 105 110Leu Asn Asp Tyr Val Lys Leu Ala
Asn Leu Pro Tyr Gln Thr Ile Ser 115 120 125Glu Asn Thr Met Cys Ser
Val Ser Thr Trp Ser Tyr Asn Val Cys Asp 130 135 140Ile Tyr Lys Glu
Pro Asp Ser Leu Gln Thr Val Asn Ile Ser Val Ile145 150 155 160Ser
Lys Pro Gln Cys Arg Asp Ala Tyr Lys Thr Tyr Asn Ile Thr Glu 165 170
175Asn Met Leu Cys Val Gly Ile Val Pro Gly Arg Arg Gln Pro Cys Lys
180 185 190Glu Val Ser Ala Ala Pro Ala Ile Cys Asn Gly Met Leu Gln
Gly Ile 195 200 205Leu Ser Phe Ala Asp Gly Cys Val Leu Arg Ala Asp
Val Gly Ile Tyr 210 215 220Ala Lys Ile Phe Tyr Tyr Ile Pro Trp Ile
Glu Asn Val Ile Gln Asn225 230 235 240Asn53726DNAHomo sapiens
53atgaagttta tcctcctctg ggccctcttg aatctgactg ttgctttggc ctttaatcca
60gattacacag tcagctccac tcccccttac ttggtctatt tgaaatctga ctacttgccc
120tgcgctggag tcctgatcca cccgctttgg gtgatcacag ctgcacactg
caatttacca 180aagcttcggg tgatattggg ggttacaatc ccagcagact
ctaatgaaaa gcatctgcaa 240gtgattggct atgagaagat gattcatcat
ccacacttct cagtcacttc tattgatcat 300gacatcatgc taatcaagct
gaaaacagag gctgaactca atgactatgt gaaattagcc 360aacctgccct
accaaactat ctctgaaaat accatgtgct ctgtctctac ctggagctac
420aatgtgtgtg atatctacaa agagcccgat tcactgcaaa ctgtgaacat
ctctgtaatc 480tccaagcctc agtgtcgcga tgcctataaa acctacaaca
tcacggaaaa tatgctgtgt 540gtgggcattg tgccaggaag gaggcagccc
tgcaaggaag tttctgctgc cccggcaatc 600tgcaatggga tgcttcaagg
aatcctgtct tttgcggatg gatgtgtttt gagagccgat 660gttggcatct
atgccaaaat tttttactat ataccctgga ttgaaaatgt aatccaaaat 720aactga
72654227PRTArtificial Sequenceconsensus sequence 54Cys Gly Gly Ser
Leu Ile Ser Glu Asn Trp Val Leu Thr Ala Ala His 1 5 10 15Cys Val
Ser Gly Ala Ala Ser Ala Pro Ala Ser Ser Val Arg Val Ser 20 25 30Leu
Ser Val Arg Leu Gly Glu His Asn Leu Ser Leu Thr Glu Gly Thr 35 40
45Glu Gln Lys Phe Asp Val Lys Lys Thr Ile Ile Val His Pro Asn Tyr
50 55 60Asn Pro Asp Thr Leu Asp Asn Gly Ala Tyr Asp Asn Asp Ile Ala
Leu65 70 75 80Leu Lys Leu Lys Ser Pro Gly Val Thr Leu Gly Asp Thr
Val Arg Pro 85 90 95Ile Cys Leu Pro Ser Ala Ser Ser Asp Leu Pro Val
Gly Thr Thr Cys 100 105 110Thr Val Ser Gly Trp Gly Arg Arg Pro Thr
Lys Asn Leu Gly Leu Ser 115 120 125Asp Thr Leu Gln Glu Val Val Val
Pro Val Val Ser Arg Glu Thr Cys 130 135 140Arg Ser Ala Tyr Glu Tyr
Gly Gly Thr Asp Asp Lys Val Glu Phe Val145 150 155 160Thr Asp Asn
Met Ile Cys Ala Gly Ala Leu Gly Gly Lys Asp Ala Cys 165 170 175Gln
Gly Asp Ser Gly Gly Pro Leu Val Cys Ser Asp Gly Asn Arg Asp 180 185
190Gly Arg Trp Glu Leu Val Gly Ile Val Ser Trp Gly Ser Tyr Gly Cys
195 200 205Ala Arg Gly Asn Lys Pro Gly Val Tyr Thr Arg Val Ser Ser
Tyr Leu 210 215 220Asp Trp Ile22555226PRTArtificial
Sequenceconsensus sequence 55Arg Ile Val Gly Gly Ser Glu Ala Lys
Ile Gly Ser Phe Pro Trp Gln 1 5 10 15Val Ser Leu Gln Cys Gly Gly
Ser Leu Ile Ser Pro Arg Trp Val Leu 20 25 30Thr Ala Ala His Cys Arg
Val Arg Leu Gly Ser His Asp Leu Ser Ser 35 40 45Gly Glu Glu Thr Glu
Gly Gly Pro Arg Leu Asp Ser Pro Gly Gly Gln 50 55 60Val Ile Lys Val
Ser Lys Ile Ile Glu Val His Pro Asn Tyr Asn Asn65 70 75 80Asp Ile
Ala Leu Leu Lys Leu Lys Glu Pro Val Thr Leu Ser Asp Ser 85 90 95Asn
Thr Val Arg Pro Ile Cys Leu Pro Ser Ser Asn Glu Ile Lys Thr 100 105
110Ser Glu Gly Asn Thr Val Pro Ala Gly Thr Thr Cys Thr Val Ser Gly
115 120 125Trp Gly Arg Thr Ser Glu Gly Pro Glu Glu Ser Gly Gly Gly
Ser Leu 130 135 140Pro Asp Val Leu Gln Glu Val Asn Val Pro Ile Val
Ser Asn Glu Thr145 150 155 160Cys Arg Met Leu Cys Ala Gly Tyr Leu
Glu Gly Gly Asn Thr Pro Gly 165 170 175Gly Lys Asp Ala Cys Gln Gly
Asp Ser Gly Gly Pro Leu Val Cys Val 180 185 190Leu Val Gly Ile Val
Ser Trp Gly Ser Ser Ser Leu Tyr Gly Cys Ala 195 200 205Arg Pro Asn
Lys Pro Gly Val Tyr Thr Arg Val Ser Ser Tyr Leu Asp 210 215 220Trp
Ile22556191PRTArtificial Sequenceconsensus sequence 56Ser Asn Asn
Glu Glu Gly Ser Glu Gln Val Ile Ser Val Ser Lys Val 1 5 10 15Ile
Val His Pro Asn Tyr Tyr Asn Ser Ser Ser Thr Tyr Asp Asn Asp 20 25
30Ile Ala Leu Leu Lys Leu Ser Ser Pro Val Ser Phe Thr Ser Ser Ala
35 40 45Phe Ser Asp Asn Val Gln Pro Ile Cys Leu Pro Ser Ser Asn Glu
Thr 50 55 60Phe Pro Lys Pro Pro Gly Thr Thr Cys Thr Val Ser Gly Trp
Gly Arg65 70 75 80Thr Ser Ser Ser Gly Ser Ser Ser Ser Tyr Pro Asp
Thr Leu Gln Gln 85 90 95Val Asn Ile Pro Ile Ile Ser Asn Glu Glu Cys
Lys Ser Ser Tyr Tyr 100 105 110Ser Asn Gly Asn Lys Ser Thr Ile Thr
Asp Asn Met Ile Cys Ala Gly 115 120 125Tyr Tyr Ser Glu Gly Gly Lys
Asp Ser Cys Gln Gly Asp Ser Gly Gly 130 135 140Pro Leu Val Cys Lys
Asp Gln Lys Asn Gly Asn Trp Val Leu Val Gly145 150 155 160Ile Val
Ser Trp Gly Ser Ser Gly Cys Gly Cys Pro Ala Gln Pro Asn 165 170
175Lys Pro Gly Val Tyr Thr Arg Val Ser Ser Tyr Leu Asp Trp Ile 180
185 1905781PRTArtificial Sequenceconsensus sequence 57Cys Gly Gly
Ser Leu Ile Asn Glu Gln Trp Val Leu Thr Ala Ala His 1 5 10 15Cys
Phe Gln Asn Asn Gly Ser Ser Ser Thr Ser Ser Tyr Gln Val Thr 20 25
30Leu Gly Glu His Asn Thr Ser Glu Asn Ser Asn Asn Glu Glu Gly Ser
35 40 45Glu Gln Val Ile Ser Val Ser Lys Val Ile Val His Pro Asn Tyr
Tyr 50 55 60Asn Ser Ser Ser Thr Tyr Asp Asn Asp Ile Ala Leu Leu Lys
Leu Ser65 70 75 80Ser582446DNAHomo sapiensCDS(243)...(1697)
58ccacgcgtcc ggcgggcgcg gggtgtgtcg ggtgtcgacg gcggcgcttt gcggccggtc
60gtgcgggtcg ggcgcgggcg ggcgcggcgg cagtggcgcg cacaggtgat tgactggcca
120gctgcctgaa ggagcgccag gtcctccttg ctggcaggtg gcgaagccca
ttggggcggc 180ggtgcagacc gcggcggcgg ctgcggcggt ctggctcggg
aggcgttcct ggggccaagg 240cc atg gcc ccg cgg ctg cag ctg gag aag gcg
gcc tgg cgc tgg gcg 287 Met Ala Pro Arg Leu Gln Leu Glu Lys Ala Ala
Trp Arg Trp Ala 1 5 10 15gag acg gtg cgg ccc gag gag gtg tcg cag
gag cac atc gag acc gct 335Glu Thr Val Arg Pro Glu Glu Val Ser Gln
Glu His Ile Glu Thr Ala 20 25 30tac cgc atc tgg ctg gag ccc tgc att
cgc ggc gtg tgc aga cga aac 383Tyr Arg Ile Trp Leu Glu Pro Cys Ile
Arg Gly Val Cys Arg Arg Asn 35 40 45tgc aaa gga aat ccg aat tgc ttg
gtt ggt att ggt gag cat att tgg 431Cys Lys Gly Asn Pro Asn Cys Leu
Val Gly Ile Gly Glu His Ile Trp 50 55 60tta gga gaa ata gat gaa aat
agt ttt cat aac atc gat gat ccc aac 479Leu Gly Glu Ile Asp Glu Asn
Ser Phe His Asn Ile Asp Asp Pro Asn 65 70 75tgt gag agg aga aaa aag
aac tca ttt gtg ggc ctg act aac ctt gga 527Cys Glu Arg Arg Lys Lys
Asn Ser Phe Val Gly Leu Thr Asn Leu Gly80 85 90 95gcc act tgt tat
gtc aac aca ttt ctt caa gtg tgg ttt ctc aac ttg 575Ala Thr Cys Tyr
Val Asn Thr Phe Leu Gln Val Trp Phe Leu Asn Leu 100 105 110gag ctt
cgg cag gca ctc tac tta tgt cca agc act tgt agt gac tac 623Glu Leu
Arg Gln Ala Leu Tyr Leu Cys Pro Ser Thr Cys Ser Asp Tyr 115 120
125atg ctg gga gac ggc atc caa gaa gaa aaa gat tat gag cct caa aca
671Met Leu Gly Asp Gly Ile Gln Glu Glu Lys Asp Tyr Glu Pro Gln Thr
130 135 140att tgt gag cat ctc cag tac ttg ttt gcc ttg ttg caa aac
agt aat 719Ile Cys Glu His Leu Gln Tyr Leu Phe Ala Leu Leu Gln Asn
Ser Asn 145 150 155agg cga tac att gat cca tca gga ttt gtt aaa gcc
ttg ggc ctg gac 767Arg Arg Tyr Ile Asp Pro Ser Gly Phe Val Lys Ala
Leu Gly Leu Asp160 165 170 175act gga caa cag cag gat gct caa gaa
ttt tca aag ctc ttt atg tct 815Thr Gly Gln Gln Gln Asp Ala Gln Glu
Phe Ser Lys Leu Phe Met Ser 180 185 190cta ttg gaa gat act ttg tct
aaa caa aag aat cca gat gtg cgc aat 863Leu Leu Glu Asp Thr Leu Ser
Lys Gln Lys Asn Pro Asp Val Arg Asn 195 200 205att gtt caa cag cag
ttc tgt gga gaa tat gcc tat gta act gtt tgc 911Ile Val Gln Gln Gln
Phe Cys Gly Glu Tyr Ala Tyr Val Thr Val Cys 210 215 220aac cag tgt
ggc aga gag tct aag ctt ttg tca aaa ttt tat gag ctg 959Asn Gln Cys
Gly Arg Glu Ser Lys Leu Leu Ser Lys Phe Tyr Glu Leu 225 230 235gag
tta aat atc caa ggc cac aaa cag tta aca gat tgt atc tcg gaa 1007Glu
Leu Asn Ile Gln Gly His Lys Gln Leu Thr Asp Cys Ile Ser Glu240 245
250 255ttt ttg aag gaa gaa aaa tta gaa gga gac aat cgc tat ttt tgc
gag 1055Phe Leu Lys Glu Glu Lys Leu Glu Gly Asp Asn Arg Tyr Phe Cys
Glu 260 265 270aac tgt caa agc aaa cag aat gca aca aga aag att cga
ctt ctt agc 1103Asn Cys Gln Ser Lys Gln Asn Ala Thr Arg Lys Ile Arg
Leu Leu Ser 275 280 285ctt cct tgc act ctg aac ttg cag cta atg cgt
ttt gtc ttt gac agg 1151Leu Pro Cys Thr Leu Asn Leu Gln Leu Met Arg
Phe Val Phe Asp Arg 290 295 300caa act gga cat aag aaa aag ctg aat
acc tac att ggc ttc tca gaa 1199Gln Thr Gly His Lys Lys Lys Leu Asn
Thr Tyr Ile Gly Phe Ser Glu 305 310 315att ttg gat atg gag cct tat
gtg gaa cat aaa ggt ggg tcc tac gtg 1247Ile Leu Asp Met Glu Pro Tyr
Val Glu His Lys Gly Gly Ser Tyr Val320 325 330 335tat gaa ctc agc
gca gtc ctc ata cac aga gga gtg agt gct tat tct 1295Tyr Glu Leu Ser
Ala Val Leu Ile His Arg Gly Val Ser Ala Tyr Ser 340 345 350ggc cac
tac atc gcc cac gtg aaa gat cca cag tct ggt gaa tgg tat 1343Gly His
Tyr Ile Ala His Val Lys Asp Pro Gln Ser Gly Glu Trp Tyr 355 360
365aag ttt aat gat gaa gac ata gaa aag atg gag ggg aag aaa tta caa
1391Lys Phe Asn Asp Glu Asp Ile Glu Lys Met Glu Gly Lys Lys Leu Gln
370 375 380cta ggg att gag gaa gat cta gca gaa cct tct aag tct cag
aca cgt 1439Leu Gly Ile Glu Glu Asp Leu Ala Glu Pro Ser Lys Ser Gln
Thr Arg 385 390 395aaa ccc aag tgt ggc aaa gga act cat tgc tct cga
aat gca tat atg 1487Lys Pro Lys Cys Gly Lys Gly Thr His Cys Ser Arg
Asn Ala Tyr Met400 405 410 415ttg gtt tat aga ctg caa act caa gaa
aag ccc aac act act gtt caa 1535Leu Val Tyr Arg Leu Gln Thr Gln Glu
Lys Pro Asn Thr Thr Val Gln 420 425 430gtt cca gcc ttt ctt caa gag
ctg gta gat cgg gat aat tcc aaa ttt 1583Val Pro Ala Phe Leu Gln Glu
Leu Val Asp Arg Asp Asn Ser Lys Phe 435 440 445gag gag tgg tgt att
gaa atg gct gag atg cgt aag caa agt gtg gat 1631Glu Glu Trp Cys Ile
Glu Met Ala Glu Met Arg Lys Gln Ser Val Asp 450 455 460aaa gga aaa
gca aaa cac gaa gag gtt aag gag ctg tac caa agg tta 1679Lys Gly Lys
Ala Lys His Glu Glu Val Lys Glu Leu Tyr Gln Arg Leu 465 470 475cct
gct gga gct ggt ctg taagatattc tgggacagca ctgttgccat 1727Pro Ala
Gly Ala Gly Leu480 485taagtgcctt gtttttttat gttcacaaat gtatatgaag
aaactttctc aaacttactc 1787tttctaataa cccactaaag ccagcttaaa
cactctaaaa gtactttgta aaccaacaat 1847aacttgatgt gtagcattcc
atattatttc attacgttgt actcctaaaa atgggaagct 1907gttaataaat
tataacattt aggtcagcac tctgcatcca tgagtattgt agatatttat
1967attttgtgag atattaactt gtttaagaaa aatccgattg gattactatg
gaaaaagcaa 2027cttgcctgtt ctgtttcttt gcatactttg tgacctaaca
gttttaacag acattctatt 2087atatgaatac agtttttttg atactattag
attaacttga agtttaatac caaatattat 2147gctaagagta gaaaagcttt
ctgctgaccc ctgatttctt agaaatatcc cacataatcc 2207agcttatccc
ttttctgtat atgtttattc aggtttacct gatgtctcaa aatgaaacca
2267aattaagcct ttttaaaggc tgatgtgcca tttgtattaa gttatctttg
tcattttaaa 2327gacatgaatt ccccaagcct aattcctact taaggaagag
agacaattta gtccttactt 2387tagaaaataa atacttaagc ataaaaaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 244659485PRTHomo sapiens 59Met Ala
Pro Arg Leu Gln Leu Glu Lys Ala Ala Trp Arg Trp Ala Glu 1 5 10
15Thr Val Arg Pro Glu Glu Val Ser Gln Glu His Ile Glu Thr Ala Tyr
20 25 30Arg Ile Trp Leu Glu Pro Cys Ile Arg Gly Val Cys Arg Arg Asn
Cys 35 40 45Lys Gly Asn Pro Asn Cys Leu Val Gly Ile Gly Glu His Ile
Trp Leu 50 55 60Gly Glu Ile Asp Glu Asn Ser Phe His Asn Ile Asp Asp
Pro Asn Cys65 70 75 80Glu Arg Arg Lys Lys Asn Ser Phe Val Gly Leu
Thr Asn Leu Gly Ala 85 90 95Thr Cys Tyr Val Asn Thr Phe Leu Gln Val
Trp Phe Leu Asn Leu Glu 100 105 110Leu Arg Gln Ala Leu Tyr Leu Cys
Pro Ser Thr Cys Ser Asp Tyr Met 115 120 125Leu Gly Asp Gly Ile Gln
Glu Glu Lys Asp Tyr Glu Pro Gln Thr Ile 130 135 140Cys Glu His Leu
Gln Tyr Leu Phe Ala Leu Leu Gln Asn Ser Asn Arg145 150 155 160Arg
Tyr Ile Asp Pro Ser Gly Phe Val Lys Ala Leu Gly Leu Asp Thr 165 170
175Gly Gln Gln Gln Asp Ala Gln Glu Phe Ser Lys Leu Phe Met Ser Leu
180 185 190Leu Glu Asp Thr Leu Ser Lys Gln Lys Asn Pro Asp Val Arg
Asn Ile 195 200 205Val Gln Gln Gln Phe Cys Gly Glu Tyr Ala Tyr Val
Thr Val Cys Asn 210 215 220Gln Cys Gly Arg Glu Ser Lys Leu Leu Ser
Lys Phe Tyr Glu Leu Glu225 230 235 240Leu Asn Ile Gln Gly His Lys
Gln Leu Thr Asp Cys Ile Ser Glu Phe 245 250 255Leu Lys Glu Glu Lys
Leu Glu Gly Asp Asn Arg Tyr Phe Cys Glu Asn 260 265 270Cys Gln Ser
Lys Gln Asn Ala Thr Arg Lys Ile Arg Leu Leu Ser Leu 275 280 285Pro
Cys Thr Leu Asn Leu Gln Leu Met Arg Phe Val Phe Asp Arg Gln 290 295
300Thr Gly His Lys Lys Lys Leu Asn Thr Tyr Ile Gly Phe Ser Glu
Ile305 310 315 320Leu Asp Met Glu Pro Tyr Val Glu His Lys Gly Gly
Ser Tyr Val Tyr 325 330 335Glu Leu Ser Ala Val Leu Ile His Arg Gly
Val Ser Ala Tyr Ser Gly 340 345 350His Tyr Ile Ala His Val Lys Asp
Pro Gln Ser Gly Glu Trp Tyr Lys 355 360 365Phe Asn Asp Glu Asp Ile
Glu Lys Met Glu Gly Lys Lys Leu Gln Leu 370 375 380Gly Ile Glu Glu
Asp Leu Ala Glu Pro Ser Lys Ser Gln Thr Arg Lys385 390 395 400Pro
Lys Cys Gly Lys Gly Thr His Cys Ser Arg Asn Ala Tyr Met Leu 405 410
415Val Tyr Arg Leu Gln Thr Gln Glu Lys Pro Asn Thr Thr Val Gln Val
420
425 430Pro Ala Phe Leu Gln Glu Leu Val Asp Arg Asp Asn Ser Lys Phe
Glu 435 440 445Glu Trp Cys Ile Glu Met Ala Glu Met Arg Lys Gln Ser
Val Asp Lys 450 455 460Gly Lys Ala Lys His Glu Glu Val Lys Glu Leu
Tyr Gln Arg Leu Pro465 470 475 480Ala Gly Ala Gly Leu
485601455DNAHomo sapiens 60atggccccgc ggctgcagct ggagaaggcg
gcctggcgct gggcggagac ggtgcggccc 60gaggaggtgt cgcaggagca catcgagacc
gcttaccgca tctggctgga gccctgcatt 120cgcggcgtgt gcagacgaaa
ctgcaaagga aatccgaatt gcttggttgg tattggtgag 180catatttggt
taggagaaat agatgaaaat agttttcata acatcgatga tcccaactgt
240gagaggagaa aaaagaactc atttgtgggc ctgactaacc ttggagccac
ttgttatgtc 300aacacatttc ttcaagtgtg gtttctcaac ttggagcttc
ggcaggcact ctacttatgt 360ccaagcactt gtagtgacta catgctggga
gacggcatcc aagaagaaaa agattatgag 420cctcaaacaa tttgtgagca
tctccagtac ttgtttgcct tgttgcaaaa cagtaatagg 480cgatacattg
atccatcagg atttgttaaa gccttgggcc tggacactgg acaacagcag
540gatgctcaag aattttcaaa gctctttatg tctctattgg aagatacttt
gtctaaacaa 600aagaatccag atgtgcgcaa tattgttcaa cagcagttct
gtggagaata tgcctatgta 660actgtttgca accagtgtgg cagagagtct
aagcttttgt caaaatttta tgagctggag 720ttaaatatcc aaggccacaa
acagttaaca gattgtatct cggaattttt gaaggaagaa 780aaattagaag
gagacaatcg ctatttttgc gagaactgtc aaagcaaaca gaatgcaaca
840agaaagattc gacttcttag ccttccttgc actctgaact tgcagctaat
gcgttttgtc 900tttgacaggc aaactggaca taagaaaaag ctgaatacct
acattggctt ctcagaaatt 960ttggatatgg agccttatgt ggaacataaa
ggtgggtcct acgtgtatga actcagcgca 1020gtcctcatac acagaggagt
gagtgcttat tctggccact acatcgccca cgtgaaagat 1080ccacagtctg
gtgaatggta taagtttaat gatgaagaca tagaaaagat ggaggggaag
1140aaattacaac tagggattga ggaagatcta gcagaacctt ctaagtctca
gacacgtaaa 1200cccaagtgtg gcaaaggaac tcattgctct cgaaatgcat
atatgttggt ttatagactg 1260caaactcaag aaaagcccaa cactactgtt
caagttccag cctttcttca agagctggta 1320gatcgggata attccaaatt
tgaggagtgg tgtattgaaa tggctgagat gcgtaagcaa 1380agtgtggata
aaggaaaagc aaaacacgaa gaggttaagg agctgtacca aaggttacct
1440gctggagctg gtctg 14556132PRTArtificial Sequenceconsensus
sequence 61Thr Gly Leu Ile Asn Leu Gly Asn Thr Cys Tyr Met Asn Ser
Val Leu 1 5 10 15Gln Cys Leu Phe Ser Ile Pro Pro Leu Arg Asp Tyr
Leu Leu Asp Ile 20 25 306269PRTArtificial Sequenceconsensus
sequence 62Gly Pro Gly Lys Tyr Glu Leu Tyr Ala Val Val Val His Ser
Gly Ser 1 5 10 15Ser Leu Ser Gly Gly His Tyr Thr Ala Tyr Val Lys
Lys Glu Asn Trp 20 25 30Tyr Lys Phe Asp Asp Asp Lys Val Ser Arg Val
Thr Glu Glu Glu Val 35 40 45Leu Lys Glu Ser Gly Gly Glu Ser Gly Asp
Thr Ser Ser Ala Tyr Ile 50 55 60Leu Phe Tyr Glu
Arg656319PRTArtificial Sequencemotif 63Tyr Xaa Leu Xaa Xaa Xaa Xaa
Xaa His Xaa Gly Xaa Xaa Xaa Xaa Xaa 1 5 10 15Gly His Tyr
* * * * *